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Abstract 
 
The phosphatidylinositol polyphosphates play a fundamental role in intracellular 
signalling. Of particular importance is phosphatidylinositol 3,4,5-trisphosphate 
[PtdIns(3,4,5)P3], which acts by recruiting effector proteins to the cell membrane. 
PtdIns(3,4,5)P3 interacts with its protein targets through selective binding domains that 
include the pleckstrin homology (PH) domain. The PH-domain-containing kinase, protein 
kinase B (PKB/Akt), which interacts with PtdIns(3,4,5)P3, is upregulated in ~15 human 
malignancies. Significantly, inhibition of the PtdIns(3,4,5)P3-PKB interaction has proved 
viable as a point of therapeutic intervention. 
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There is currently a lack of small molecule probes that selectively interact with a given 
PH domain. Consequently, it is impossible to dissect the cellular function of PH-domain-
containing proteins at a molecular level. To address this problem, we have designed and 
synthesised a number of derivatives of the PtdIns(3,4,5)P3 inositol head-group – 
Ins(1,3,4,5)P4. Replacement of the 5-position phosphate with a range of phosphate 
bioisosteres afforded compounds that displayed no binding affinity for the PH-domain of 
general receptor for phosphoinositides 1 (GRP1). However, it was shown that the 5-
position sulfamate analogue displayed selectivity for the PH-domain of PKB.  The 
methylphosphate biosiostere at the 1-position displayed binding for both the GRP1 PH-
domain as well as the PKB PH-domain. These results demonstrate that subtle 
modification of the Ins(1,3,4,5)P4 structure allows the synthesis of compounds that 
interact selectively with a given PH domain.  We will now use these results for the 
synthesis of a second generation of compounds with improved PH-domain affinity and 
selectivity. 
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1. Introduction Part 1 
 
1.1. Inositol Structure and Nomenclature 
Small natural products and bio-molecules are often of great interest to scientists 
due to their discrete functions in biochemical systems and their specific 
interactions with biological macromolecules. Their small size makes them an 
attractive target for organic chemists, because of the potential for making 
synthetic analogues, which can, in turn, provide useful tools for probing and 
investigating biochemical systems. 
 
One such natural product of interest is myo-inositol 1, which is one of 9 naturally 
occurring and unnatural inositol isomers (Fig 1.1).  Inositol consists of a six 
membered carbocyclic ring that bears a single hydroxyl group at each carbon of 
the ring.  The stereochemistry possessed by each hydroxyl group around the ring 
dictates the isomer of inositol.  myo-Inositol 1 is the most abundant of the five 
naturally occurring inositols (myo-inositol 1, neo-inositol 3, D-(+)-chiro-inositol 8, 
L-(-)-chiro-inositol 9, and scyllo-inositol 2). 
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Figure 1.1.  All nine possible stereoisomers of inositol. 
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L-myo-inositol-3-phosphate D-numbered ‘Turtle’ 
myo-Inositol is a meso compound meaning that it is an achiral member of a set of 
diastereomers that also possesses chiral members.  This property causes 
confusion when naming myo-inositol derivatives, using IUPAC rules, in some 
early publications.  Different substitutions across the plane of symmetry 
sometimes changed the priorities of the substituents, thus causing the 
compounds to change between D- and L-numbering.  Therefore, in order to bring 
some continuity to the naming, a relaxation of the lowest-locant rule was 
recommended, allowing all biologically related myo-inositols to possess the 
D-numbering.1  Even though this allowed greater consistency within the scientific 
community, the numbering of the atoms in myo-inositol can still be confusing; 
therefore a useful mnemonic known as ‘Agranoff’s turtle’ can be used to avoid 
uncertainty.2,3 
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P OH
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Figure 1.2. Bernard W. Agranoff’s turtle mnemonic for the numbering of myo-inositol compounds 
and the structures of D-myo-inositol-1-phosphate and L-myo-inositol-3-phosphate.3 
 
In the mnemonic, the turtle’s head always represents the axial 2-position 
hydroxyl group (fig. 1.2).  When using the D- numbering system one counts 
anticlockwise.  Thus the head is the 2-position, the front left flipper is the 3-
position, the front right flipper is the 1-position, the rear flippers are the 4- and 6-
positions and the tail represents the 5-position.  If one were to use the L- 
numbering system, one would count clockwise, thus the front right flipper would 
be the 3-position and the front left flipper would be the 1-position etc.  
D-myo-inositol-1-phosphate 
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1.2. History of myo-inositol and introducing the phosphoinositides 
myo-Inositol was first isolated from cardiac muscle tissue in 1850 by Scherer,4 
but little progress regarding its purpose or function within the body was made 
until 1942, when inositol-containing phospholipids were discovered in the brain.5  
At the time it was widely considered that phospholipids were purely inert 
structural components of membranes.  However, a series of papers by Lowell 
and Mabel Hokin between 1953 and 1964, implicated phosphoinositides (PI) in 
receptor stimulated lipid turnover; a process that became known as the ‘PI 
effect’.6-11  Ultimately, this work paved the way for the seminal discovery 
published in 1983, by Berridge and co workers, that highlighted D-myo-inositol 
1,4,5-trisphosphate [Ins(1,4,5)P3] as a key second messenger molecule 
responsible for the release of Ca2+ from intracellular stores.12  This discovery 
triggered considerable interest in the study of inositol phosphates and their role in 
signalling pathways.11,13,14 
 
It is now known that Ins(1,4,5)P3 is formed by the action of phospholipase C 
(PLC) on PI, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2 10).15  
PtdIns(4,5)P2 is part of a family of phosphoinositides, that regulate an 
increasingly complex network of cell signalling pathways concerned with an array 
of important cellular processes (fig. 1.3).13,16,17   
 
 
 
PtdIns(4,5)P2 Ins(1,4,5)P3 + DAG
HO O
O lipid
O
lipid
O
DAG =
PLC
10 11 12
12  
Figure 1.3. Enzyme catalysed hydrolysis of PtdIns(4,5)P2 to give second messengers 
Ins(1,4,5)P3 and DAG. 
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The PIs form a minor component of membrane phospholipids, and are bound to 
the membrane through their diacylglycerol (DAG) unit (fig. 1.4), itself an 
important second messenger,18 which is attached to the 1-position phosphate.   
At present, there are eight known phosphoinositides (fig. 1.4), each bears the 
myo-inositol ring, with a cell membrane bound phosphatidyl moiety attached at 
the 1-position.  They then vary in the amount and position of phosphorylation at 
the 3- 4- and 5-position hydroxyl groups.  
 
HO O
R1O
OR2
OR3
OH
P
O
O-Na+
O O
O lipid
O
lipid
O
3
2
4 5
1 6
 
 
Figure 1.4. Structure of the eight naturally occurring PIs.  The lipid side chains vary depending on 
the source of the PI.19,20 
 
PIs are thought to mainly exert their activity through binding of their head groups 
to specific structural protein domains.  The PIs both regulate the function of 
integral membrane proteins, as well as induce membrane translocation of 
cytoskeletal components, and cell signalling proteins.13,16,17 
The site and degree of phosphorylation often allows for a remarkable selectivity 
in binding of these compounds with their respective effector proteins.  For 
example, the general receptor for phosphoinositides 1 (GRP1) binds 
PtdIns(3,4,5)P3 19 strongly with Kd $ 100 nM, but binds PtdIns(3,4)P2 17 and 
PtdIns(4,5)P2 10 with about 2-3 orders of magnitude lower affinity.21  
 
The subcellular concentration and distribution of the different PIs is strictly 
mediated by a variety of enzymes, such as phospholipases, lipid kinases, and 
lipid phosphatases.16  These enzymes are located in different cell membranes 
and organelles, this, coupled with the intrinsic selectivity each PI expresses for its 
effector protein, allows for extraordinary spatio-temporal control of PI 
 Hydroxyl 
substitution 
Compound Name 
13 R1=R2=R3=H PtdIns 
14 R1=PO(OH)2, R2=R3=H PtdIns(3)P 
15 R2=PO(OH)2, R1=R3=H PtdIns(4)P 
16 R3=PO(OH)2, R1=R2=H PtdIns(5)P 
17 R1=R2=PO(OH)2, R3=H PtdIns(3,4)P2 
18 R1=R3=PO(OH)2, R2=H PtdIns(3,5)P2 
10 R2=R3=PO(OH)2, R1=H PtdIns(4,5)P2 
19 R1=R2=R3=PO(OH)2 PtdIns(3,4,5)P3 
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concentration (fig. 1.5); which is presumably why the PIs are so ubiquitous within 
many important cellular events. 
 
PtdIns(4,5)P2 PtdIns(3,4,5)P3
PtdIns(3,4)P2
PtdIns(4)P
PtdIns(5)P
PtdIns(4)P PtdIns(4,5)P2PtdIns
PtdIns PtdIns(4)P2
PtdIns(3)PPtdIns PtdIns(3,5)P2
PtdIns(4)P PtdIns(4,5)P2 PtdIns(3,4)P2
PtdIns(3,5)P2PtdIns(3)P PtdIns(5)P
PtdIns(3)P
PA
Plasma membrane
Golgi complex Early endosome
Late endosomeEndoplasmic reticulum
PI5K(I)
5-ppase(II)
PI5K(I)
PI3K(I)
PTEN
SHIP
PI4K
4-ppase
PI3K(III)
PI5K(I)
5-ppase(II)
PI4K
4-ppase
PI3K(III)
4-ppase
5-ppase(II)
MTM
MTM
4-ppase
PI5K(III) MTM(R)
MTM PI3K
 
Figure 1.5. Subcellular localisations of the PIs.  The PI colour matches its predominant locaton 
within the cell.  Examples of the various enzymes that convert each PI are given. 
 
Phosphatidyl inositol (PtdIns 13) constitutes less than 15% of all the 
phospholipids within a eukaryotic cell, and is synthesised mainly at the 
endoplasmic reticulum.  The phosphorylated derivatives of PtdIns (PtdInsPn) 
typically exist in about one order of magnitude lower abundance. PtdIns(4)P 15 
and PdtIns(4,5)P2 10 comprise the bulk of the phosphoinositides, with 
PtdIns(4,5)P2 being the central precursor for the important second messengers 
Ins(1,4,5)P3 11 and DAG 12.  However, PtdIns(4,5)P2, which resides mainly in 
the plasma membrane (fig 1.5), acts as a messenger in its own right playing an 
important role in a number of processes such as exo- and endocytosis, 
potassium channel regulation, and cytosketetal organisation.16,22 
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The action of the type I phosphoinositide-3 kinase [PI3K(I)] phosphorylates the 
3-position of PtdIns(4,5)P2 10 to form PtdIns(3,4,5)P3 19.23  PtdIns(3,4,5)P3 is 
normally present in negligible amounts when cells are in a rested state, but 
increases significantly in response to growth factor stimulation.  PtdIns(3,4,5)P3 
along with PtdIns(3,4)P2 17, are again most abundant in the plasma membrane 
(fig 1.5); they act as second messengers in signalling pathways associated with 
cell growth, cell survival and metabolism.13 
PtdIns(3)P 14 is formed primarily by the action of type III phosphoinositide-3 
kinase [PI3K(III)] on PtdIns.  It is concentrated mainly in the endosome (fig 1.5) 
and participates in most aspects of endosomal activity, such as membrane 
fusion, interaction with the cytoskeleton, signalling and motility.16,22  PtdIns(3)P 
can undergo phosphorylation by phosphoinosidite-5 kinase (PI5K) to form 
PtdIns(3,5)P2 18, which is found mainly in the late endosome, and is thought to 
trigger vesicle budding.24 
PtdIns(4)P 15 is concentrated at the Golgi complex (fig 1.5), its function is less 
well characterised, but a deficiency of this PI effects the Golgi’s structure and 
function.16  PtdIns(4)P is also thought to be the principal source of PtdIns(4,5)P2. 
There is very little PtdIns(5)P 16 present in cells and its location and function 
remain poorly characterised.16 
 
1.3. PtdIns(3,4,5)P3 and the PI3K/PKB pathway 
Our interest in the PIs was at first centred around the study of PtdIns(3,4,5)P3, 
and more specifically its role within the PI3K / protein kinase B (PKB) signalling 
cascade.  Initially, looking at the interaction between PtdIns(3,4,5)P3 and PKB.  
PtdIns(3,4,5)P3 targets it’s effector proteins by binding to specific structural 
domains within the protein. Its principal target is the plekstrin homology (PH) 
domain, although it is known to interact other non-catalytic sub-domains such as 
phosphotyrosine-binding (PTB) domain and phox homology (PX) domain.13  The 
PH domain is the 11th most abundant domain class in the human genome.25  It is 
a stretch of between 100-120 amino acids, and although there is very little 
sequence homology between the PH domains of different proteins, they all 
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convey a conserved structural fold.26,27  This fold consists of a seven-stranded !-
sandwich with one end capped with a C-terminal "-helix; the other end consists 
of three variable loops that interconnect the different ! strands. 
 
The PI3K/PKB signalling cascade is represented in fig. 1.6.28  As was previously 
mentioned, PtdIns(3,4,5)P3 concentrations exist at a very low level when the cells 
are at rest, however, stimulation of the cells by external growth factors lead to 
increases in PtdIns(3,4,5)P3 concentrations of between 2- and 100-fold, through 
the action of type I PI3K on PtdIns(4,5)P2.  This increase leads to the 
accumulation of PKB to the plasma membrane, through the selective binding of 
the PKB-PH domain to the PtdIns(3,4,5)P3 head group.  Two other proteins, 
phosphoinositide dependant kinases 1 and 2 (PDK 1 and 2), also bind to 
PtdIns(3,4,5)P3 via their PH domains, which brings them in close proximity to 
PKB.  PDK 1 and 2 phosphorylate PKB, which results in several downstream 
events associated with cell survival and proliferation, growth, translation and 
transcription. 
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Figure 1.6. Outline of the PI3K signalling pathway and PKB activation of down stream events.28 
 
Significantly, upregulation of the PI3K/PKB signalling pathway has been shown in 
numerous human cancer types.28  As a consequence this upregulation promotes 
greater PKB activity thus allowing an increase in the processes associated with 
cell survival and DNA repair, and a decrease in processes associated with cell 
apoptosis.  Thus allowing the cancer cells to subsist and thrive within tumours, 
which are intrinsically stressful environments for cells to live in.  The central role 
that the PtdIns(3,4,5)P3-PKB PH domain interaction plays within these important 
cellular events linked with cancer, makes it an attractive proposition to develop 
an inhibitor of PKB that will disrupt that PtdIns(3,4,5)P3-PKB PH domain 
interaction.  These inhibitors might provide an effective therapeutic for the 
treatment of several types of human cancer; Kozikowski and co-workers 
subsequently provided a proof of this concept.29,30  They synthesised a range of 
3-position modified PtdIns-lipid ether analogues (fig. 1.7) and showed that these 
inhibited PKB with low µM activity, causing a reduction in the growth of colon and 
breast cancer cell lines in mouse studies.  They also suggested that the active 
components were likely to be the 4- and 5-position phosphorylated versions of 
their inhibitors, through the in vivo action of PI4K and PI5K. They have yet to 
synthesise the phosphorylated analogues to confirm this hypothesis. 
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22 X=CH2OH, Y=H  
Figure 1.7.  Kozikowski’s anti-cancer 3-position modified PtdIns-lipid ether analogues.29,30 
 
Previous work conducted within the group, by Nemeth,31 was aimed at the design 
and synthesis of PtdIns(3,4,5)P3 analogues, as potential inhibitors of the PKB PH 
domain.  These analogues were proposed to act as small molecule probes for 
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the further study of the PI3K / PKB pathway.  Nemeth successfully synthesised of 
a number of analogues based on Ins(1,3,4,5)P4, which is the head group of 
PtdIns(3,4,5)P3 (fig. 1.8), and they were subsequently submitted for biological 
analysis.  The results showed that both sets of analogues 24 – 29 (fig. 1.8) 
exhibit no binding affinity for the PKB PH domain. 
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Figure 1.8. The structures of PtdIns(3,4,5)P3, Ins(1,3,4,5)P4, and Nemeth’s Ins(1,3,4,5)P4 
derivatives 24-29. 
 
However, in addition to PKB, these analogues were also tested for their binding 
affinity towards the general receptor for phosphoinositides 1 (GRP1) PH domain.  
It was found that the 1-position modified Ins(1,3,4,5)P4 derivatives, 24 and 25, 
exhibited binding at concentrations over #0.1 µM, and that derivatives modified at 
the 4-position (26-29) expressed no binding affinity for the GRP1 PH domain.  
This observed selectivity prompted us to postulate the potential for expanding the 
project, broadening the scope to include the design of inhibitors for the other PH 
domain containing proteins that interact with the phosphoinositides.  In this way, 
we might be able to develop a tool kit of PH domain selective inhibitors for the 
study of not only the PKB signalling cascade (which is linked with cancer),28 but 
also for the signalling pathways associated with GRP1, Bruton’s tyrosine kinase 
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(Btk), and ARF nucleotide-binding-site opener (ARNO) all of which bind to 
PtdIns(3,4,5)P3 through their respective PH domains.32 
GRP1 has been shown to be involved in insulin signalling and cytoskeletal 
rearrangements.11,33  Btk plays an important role in lymphocyte development; but 
importantly, X-linked agammaglobulinemia (XLA), which is a hereditary 
immunodeficiency disease, is caused by a mutation in Btk.34,35  ARNO is involved 
in cytoskeletal rearrangements and membrane trafficking.36  Selective inhibitors 
targeted specifically for their PH domains will be able to shed light on a number 
of important cellular and disease linked processes. 
 
This dissertation describes the development, synthesis and biological analysis of 
PtdIns(3,4,5)P3 analogues.  The development of a robust and flexible synthetic 
route to PtdIns(3,4,5)P3 analogues is certainly one of the key features when 
attempting to synthesise a range of these compound.  But in the first instance, it 
is vital to impliment a logical design of potential inhibitors.  Our approach towards 
our initial range of compounds will be a very minimalist one.  Our structures will 
be based around the head group of PtdIns(3,4,5)P3, Ins(1,3,4,5)P4 (known to 
bind stongly with the PH domains of PKB, GRP1 and Btk),21,37,38 and will initially 
bear only a single substitution of a phosphate group with an isosteric phosphate 
replacement, retaining as much structural similarity to Ins(1,3,4,5)P4 as possible, 
without being identical (fig. 1.9). 
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Figure 1.9. General target structures of Ins(1,3,4,5)P4 derviatives.  R = phosphate bioisosteric 
replacement. 
 
The synthesis of a range of Ins(1,3,4,5)P4 derivatives with a mono-substitution of 
each phosphate, will allow us to ascertain, in detail, the importance that each 
phosphate possesses for each PH domain’s recognition of PtdIns(3,4,5)P3.  Then 
we will be able to use our findings in the design and synthesis of a new 
generation of analogues that will hopefully be more targeted for their respective 
PH domains.  Thus, the design of the PH-domain ligands becomes a problem of 
finding good phosphate bioisosteres.  Herein, the range of moieties that have 
been used as phosphate mimics is critically reviewed. 
 
1.4. Phosphate Bioisosteres Review 
It is clear that the addition and removal of the phosphate group in 
phosphoinositide and inositol phosphate function, controlled by the vast array of 
inositol kinases and phosphatases, plays a hugely important role in the regulation 
of many cellular processes.  The importance of the phosphate group, however, 
extends far beyond its role in inositol-containing compounds.  It is one of the 
major structural constituents of DNA and RNA, and is the cellular unit of energy 
in ATP, the main energy source of innumerable biological processes.  Indeed, 
the reversible phosphorylation of proteins to transmit signalling information is one 
of the most ubiquitous and fundamental processes within the cell. 
Protein kinases bind ATP to phosphorylate their specific substrates at certain 
amino acids (typically serine, threonine or tyrosine).  In medicinal chemistry, 
inhibitors of protein kinases commonly target the ATP binding domain; they, 
however, pay little attention to the phosphate group, as the phosphorylated 
products usually display little affinity for the kinase domain and diffuse away.  So 
in this case, the phosphate moiety only plays the role of passenger and is not 
generally involved in the recognition of either ATP or the substrate protein.  
However, in the case of phosphinositide second messenger activity, the 
phosphate is crucial for substrate recognition, and so for inhibitors that target the 
protein – phosphoinositide interaction, consideration of the phosphate moieties 
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must be paramount to their design.  This recognition of a non-catalytic domain by 
a phosphorylated species is not restricted to the PH domain – phosphoinositide 
interactions.  Another important example of this recognition is of phosphotyrosine 
(pTyr) residues with Src homology 2 (SH2) and pTyr binding (PTB) domains, and 
is the target of a many inhibitors bearing isosteric phosphate replacements.39,40 
The amount and significance of phosphate recognition within so many important 
cellular processes, renders the development of inhibitors that target phosphate-
recognising enzymes is an increasingly vital and diverse area of research.   
 
To design an exogenous ligand that targets a phosphate recognition domain 
(such pTyr) with high selectivity and recognition, a simple approach might be to 
incorporate a phosphate group to achieve the desired effect.  However, the major 
disadvantage of an approach such as this is the prevalence of in vivo 
phosphatases, which will likely hydrolyse the phosphate group, diminishing the 
ligand’s activity.  In addition, the dianionic nature of the phosphate at 
physiological pH, might compromise the bioavailability of the inhibitor.  As a 
result, isosteric phosphate replacements have been used in order to avoid these 
problems.  These replacements are usually designed to be hydrolytically stable, 
often bearing reduced or even neutral charge. 
 
The following is a review of structures designed to mimic the role of a phosphate 
group.  However, it is beyond the scope of this review to highlight ‘good’ 
isosteres over ‘bad’ isosteres, as all the examples given are from a variety of 
different studies, for a variety of different targets, and for a variety of different 
purposes.  The aim of this review is to indicate some of the different types of 
isostere used, based on broad structural characteristics, highlighting the logic 
behind some of the modifications used and contex (where appropriate) in which 
they were used. 
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1.5. Phosphorus-based Isosteres 
A logical start point, when designing phosphate replacements, is to retain the 
phosphorus atom and modify the substituents (oxygen) that surround it.  The first 
and most commonly used, phosphate isoster is the methylene phosphonate, in 
which the bridging oxygen is replaced with a methlyene (CH2) group.  The 
reduced electronegativity, due to the carbon atom, lowers the acidity of the 
group, resulting in differing ionisation states at physiological pH.  In addition to 
slightly inceasing the   
! 
pKa  from 7.1 to 8.4 (figure 1.10), the inclusion of carbon 
also removes a hydrogen bond acceptor.  This group was successfully use in the 
mid 1960s, by Myers and co-workers,41,42 whereby they synthesised a methylene 
phosphonate derivative of ATP (AMPPCP, 31, [fig. 1.10]), showing that it was 
both metabolically stable and acted as an ATP inhibitor.  This analogue 
possessed certain drawbacks, as it was a poor agonist at some ATP receptors, 
and as a result, triggered research to improve the utility of ATP analogues.   
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Figure 1.10. ATP analogues 31-35 bearing terminal phosphate isosteres and their respective 
  
! 
pKa  values.
41-44 
 
One of the first logical changes to the methylene phosphonate structure, was to 
substitute the terminal bridging oxygen with an NH to give AMPPNP 32 (fig. 
1.10),43 this alteration increases the   
! 
pKa
4  from 7.1 for 30 to 7.7 for 32.  This 
modification was met with moderate success in early studies but the highly labile 
 R   
! 
pKa
4  
30 O 7.1 
31 CH2 8.4 
32 NH 7.7 
33 CHF 7.4 
34 CF2 6.7 
35 CCl2 7.0 
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P-N-P linkage meant it suffered rapid hydrolysis, and thus limiting its use.  In 
order to retain the hydrolytic stability of AMPPCP and introduce the required 
electronegativity at the terminal bridging atom, derivatives bearing P-CCl2-P (35), 
P-CFH-P (33) and P-CF2-P (34) were synthesised by Blackburn and co-workers 
(fig. 1.10).44  These analogues showed   
! 
pKa
4  values close to that of the natural 
ATP, with the dichloro 35   
! 
pKa
4 =7.0, monofluoro 33   
! 
pKa
4 =7.4, and difluoro 34 
  
! 
pKa
4 =6.7, and subsequently the hydrolytically stable difluoromethylene 
phosphonate is now used widely as an isosteric phosphate replacement. 
 
More recently, Grimes and co-workers synthesised a range of acyl phosphate 
mimics as inhibitors of PIsY,45 an essential acyltransferase for the biosynthesis of 
phosphatidic acid in bacteria.  They showed that the methylene phosphonate 
analogue 36 (fig. 1.11) exhibited activity against B. anthracis (BaPIsY1) with an 
IC50 = 90 µM.  The more acidic difluoromethylene phosphonate analogue of 37 
(fig. 1.11), was more potent (IC50 = 50 µM) against BaPIsY1 and was also highly 
potent against S. pneumoniae (SpPIsY) with an IC50 = 39 µM.  In addition to the 
methylene and difluoromethylene containing isosteres, Grimes also synthesised 
the phosphoramide 38 (fig. 1.11).  This analogue was the most potent against 
SpPIsY with an IC50 = 11 µM, which was four times more potent than the 
equivalent methylene phosphonate analogue.  The substitution of O with NH will 
give the isostere a slightly increased   
! 
pKa  compared to that of the native 
phosphate.  However, the isostere retains the hydrogen bond acceptor activity, 
compared with the methylene phosponate, as well as contributes an additional 
hydrogen bond donor, in the form of N-H. 
 
 31 
 
Phosphate Isostere
P
O
OH
OH
C
F2
P
O
OH
OH
N
H
P
O
OH
OH
R' R
O
P
O
OHOH
O
O
O
 
Figure 1.11.  Acyl phosphate mimics 36-38 bearing phosphate isosteres.45 
 
A study conducted by Kim and co-workers46 into some highly potent anti-viral 
agents explored the effect of methylene phosphonate, the extended, ethylene 
phosphonate and the isoelectronic thiomethylene phosphonate (fig. 1.12).  
Comparing the second dissociation constants they found that the methylene 
phosphonate 39, ethylene phosphonate 40 and the thiomethylene phosphonate 
41 all exhibited   
! 
pKa
2  values very close to one another (6.52, 6.76 and 6.59, 
respectively).  It is interesting to note that 39 was the only active compound of 
the three and in addition to this, ethylene phosphonate 40 did not undergo 
phosphorylation by bovine brain guanylate, whereas methylene phosphonate 39 
did. 
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Figure 1.12. Purine based analogues 39-41 bearing phosphate isosteres and their respective 
  
! 
pKa values.
46 
 
 R 
36 CH2 
37 CF2 
38 NH 
R’ = various aliphatic side chains 
 R   
! 
pKa  
39 OCH2 6.52 
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 32 
An interesting evolution of the methylene phosphonate isostere, was highlighted 
by Shakespeare in 2001.39,47  He incorporated a diphosphonomethyl isostere 42 
(fig. 1.13) as a pTyr mimetic, for the inhibition of the SH2 domain of Src.  This 
highly charged isostere, showed a sevenfold increase in affinity, compared to 
that of the native pTyr analogue.  This isostere is one of the only examples of 
pTyr substitution that demonstrates an increased affinity over pTyr, however, its 
highly charged nature will undoubtedly give the isostere poor bioavailablity. 
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Figure 1.13. pTyr mimetic bearing phosphate isostere that displays higher affinity that the natural 
phosphate.39,47 
 
1.6. Monocharged Phosphorus-based Isosteres 
Instead of changing the bridging oxygen as with those mentioned above, another 
logical modification is to change one of the acidic or charge-bearing oxygen 
atoms.  van Boom and co-workers successfully demonstrated the utility of this 
approach,48 by the synthesis of a racemic methyl phosphonate analogue of 
Ins(1,4,5)P3 43 and a racemic difluoromethyl phosphonate analogue of 
Ins(1,3,4,5)P4 45 (fig. 1.14).  These isosteric phosphate replacements bear only 
a single charge and, in the case of the methylphosphate, a reduced   
! 
pKa .  Their 
biological results indicated that 43 acted as an antagonist for Ins(1,4,5)P3 
stimulated Ca2+ release, indicating that the methylphosonate moiety was 
tolerated by Ins(1,4,5)P3 receptors, no biological discussion was given for 
analogue 45 (fig. 1.14).  Recently, work within the Conway group by Aslam and 
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Keddie,49 successfully synthesised 44 in an enantiomerically pure fashion and 
demonstrated that it is an Ins(1,4,5)P3 receptor antagonist. 
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Figure 1.14. Methylphosphonate and difluoromethylphosphonate bearing Ins(1,4,5)P3 and 
Ins(1,3,4,5)P4 analogues.48,49 
 
Raushel et al. demonstrated an interesting use of this methyl substitution.50  They 
synthesised two methylphosphonamidate-bearing analogues, one on amino-
glucose 46, and the other on aspartic acid 47 (fig. 1.15).  They demonstrated 
that these analogues where extremely potent inhibitors of two deacetylases 
belonging to the amidohydrolase superfamily.  Sugar 46 showed inhibition of 
NagA at 34 nM, whereas amino acid 47 inhibited DGD at 460 pM.  Strictly 
speaking the methyl phosphonamidates, are acting as mimics of the tetrahedral 
acetyl intermediate, during the enzymatic hydrolysis of an N-acylated substrate.  
However, this paper does demonstrate the potential for the group to be used as a 
true phosphate mimetic. 
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Figure 1.15. Methylphosphonate and difluoromethylphosphonate bearing Ins(1,4,5)P3 and 
Ins(1,3,4,5)P4 analogues.50 
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Burke and co-workers synthesised a range of macrocyclic tetrapeptides (fig. 
1.16),51 bearing different pTyr mimics as potent SH2 domain-binding antagonists.  
Their results showed that the hydrolytically stable methylene phosphonate 
derivative 48 exhibited the highest affinity (KD = 1.47 nM).  They also explored 
mono charged phosphorus base mimics 49 and 50, varying the size of the side 
group installed.  These compounds also displayed nanomolar affinities. 
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Figure 1.16. Cyclic peptide pTyr analogues 48-50 bearing phosphate isosteres.51 
 
 
1.6. More Unusual Phosphorus-based Isosteres  
Another successful phosphorus-containing mimetic is the use of 
phosphorothioates.  Phosphorothioates are phosphates in which one or more of 
the oxygon atoms have been replaced by an isoelectronic sulfur atom.  This 
isostere has been put to good use in inositol chemistry.  Potter et al. synthesised 
racemic Ins(1,4,5)P3 with each phosphate replaced by a phosphorothioate 51 
(fig. 1.17).52  51 was subsequently shown to stimulate Ca2+ release via binding to 
Ins(1,4,5)P3 receptors.  Not only was agonist activity observed, but the 
phosphorothioates also proved to be more metabolically stable than Ins(1,4,5)P3. 
 
 R 
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Figure 1.17. Ins(1,4,5)P3 analogue 51 bearing phosphorothioate replacements for each 
phosphate.52 
 
Introducing metabolic stability to phosphate isosteres has always been of 
paramount importance, and so has been approached in a variety of ways.  
Recently, Prestwich and co-workers have described a novel set of metabolically 
stabilised analogues of lysophosphatidic acid (LPA)[fig. 1.18].53  LPA is an 
important phospholipid involved in a diverse array of biological processes, such 
as platelet aggregation, cell survival, and cell migration.  They synthesised a 
range of cyclic phosphonates 52-55 (fig. 1.18), exploring the isoelectronic nature 
of cyclic methylenephosphonate 52 and cyclic methylenephosphonothioate 53.  
In addition to this, they also explored the effect of   
! 
pKa  by the synthesis of cyclic 
mono- and difluoromethylenephosphonates 54 and 55.  They measured   
! 
pKa  
values (fig. 1.18) of each analogue and found that the methylenephosphonate 52 
and the methylenephosphonothioate 53 values are well matched (  
! 
pKa = 6.58 and 
6.76, respectively) and that the monofluoromethylenephosphonate 54 and the 
difluoromethylenephosphonate 55 exhibit reduced   
! 
pKa s (5.60 and 4.62, 
respectively).  The biological activity expressed by each isostere, however, was 
quite intriguing, in that all analogues showed strikingly different results.  No 
activity for the three G-protein coupled receptors (LPA1, LPA2 and LPA3) was 
exhibited by cyclic methylene phosphonate 52.  However, the cyclic methylene 
phosphonothioate 53 and cyclic monofluoromethylenephosphonate 54 both 
exhibited anatagonist activity towards LPA1 and LPA3.  But the addition of an 
extra fluorine atom in the cyclic difluoromethylene phosphonate 55 showed a flip 
in activity, being weak agonist activity towards LPA2 and LPA3.  These examples 
clearly indicate that there is intricate complexity in the nature of receptor and 
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ligand interactions that stretch beyond the effects that isosteres express on 
compound conformation and   
! 
pKa  values. 
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Figure 1.18. Cyclic phosphatidic acid analogues 52-55, and their respective   
! 
pKa values; anogists 
of lysophosphatidic acid receptors.53 
 
An interesting and unusual phosphate isostere, has recently been demonstrated 
by Fischer et al.54  They synthesised a range of ATP analogues bearing a 1-
boranophosphate 56 (fig. 1.19).  These compounds were shown to behave as 
P2Y1 receptor agonists, but also displayed remarkable hydrolytic stability under 
physiological and gastric juice pH values at 37 ºC (t1/2 1395 h and t1/2 59 h, 
respectively).  They applied this isostere to the synthesis of dinucleoside 
polyphosphates (NpnN).55 NpnNs are a diverse group of biomolecules,56 their 
function is still largely unknown although they have been implicated in DNA 
replication.57,58  The NpnNs extracellular effects are better characterised, having 
been shown to stimulate NO release,59 and inhibit platelet aggregation.60 In 
addition to the continuing investigations of NpnNs biological roles, NpnN 
analogues are also undergoing clinical trials for a number of therapeutic 
targets.61  However, some of the endogenous NpnN analogues exhibit short in 
vivo half-lives, e.g. Up4U t1/2 = 50 min.  Their Ap3(!-B)A analogue 57 (fig. 1.19) 
 X R   
! 
pKa  
52 O CH2 6.58 
53 S CH2 6.76 
54 O CHF 5.60 
55 O CF2 4.62 
R’=alkyl chain 
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was a potent P2Y1-R agonist and showed 40% and 59% slower hydrolysis 
compared to Ap3A, when submitted to human nucleotide pyrophosphatase 
phosphodiesterases, NPP1 and NPP3, respectively. 
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Figure 1.19. Borano triphospate analogue of ATP 56, general structure of borano phosphate 
analogues of NpnN’ (n=0 or 1, B=A or U).55 
 
1.7. Sulfur-based Isosteres 
When considering phosphate isosteres that are not based around phosphorus, 
one of the most logical moves is to consider sulfur, which is the focus of a 
significant number of phosphate replacements.  Like phosphorus, sulfur can exist 
in a number of stable oxidation states as well as possess different coordination 
numbers, giving sulfur great flexibility in synthesis.  However, phosphorus is at its 
highest stable oxidation state [P(V)] in a phosphate and thus the sulfur based 
phosphate equivalents are also oxidatively saturated. 
 
A simple and widely used sulfur-based phosphate isostere is the sulfate moiety.  
The sulfate (  
! 
pKa! -3.0) is mono charged at physiological pH, but like a 
phosphate it is tetrahedral and contains multiple hydrogen bond acceptors.  
However, this brings with it drawbacks akin to phosphates, such as hydrolytic 
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instability and poor bioavailability.  Despite these issues the sulfate is still a 
widely employed phosphate isostere. 
 
A study by Larsen and co-workers, on a novel class of low molecular weight 
protein tyrosine phosphatase (PTP) inhibitors,62 demonstrated that the sulfate 58 
(fig. 1.20) was an excellent pTry mimetic, exhibiting 80% inhibition of PTP1.  In 
this study the effects of non-charged sulfate analogues methylsulfonate 59 and 
trifluoromethylsulfonate 60 (fig. 1.20), were compared.  However, work by Taylor 
et al. on the same target,63 compared a different range of pTyr mimics.  Their 
results showed that the difluoromethylenesulfonic acid isostere 62 exhibited a 
1000-fold reduction in activity, compared to the difluoromethylenephosphonate 
isostere.  It is interesting to note was that the methylenesulfonic acid 61 and the 
difluoromethylenesulfonic acid 62 showed remarkably similar activities, indicating 
that the fluorine atoms have little impact in this case.  Further pTyr mimics, 
published by Seto and co-workers,64 were installed on a short oligo-peptide and 
their inhibitory action towards two PTPs evaluated.  Their methylene sulfonamide 
analogue 63 (fig. 1.20) inhibited Yersinia PTP with an IC50 of 370 µM.  
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Figure 1.20. Sulfate-based pTyr mimics 58-63.62-64 
 
Early work by van Boeckel et al.,65 as well as recent work by Prestwich et al.,66 
show the syntheses of novel Ins(1,4,5)P3 dervatives in which both sulfate and 
sulfamate phosphate isosteres replace the phosphates of Ins(1,4,5)P3, and a 
derivative 64, 65 (fig. 1.21).  It was subsequently shown that this much 
modification led to the compounds having no binding affinity for Ins(1,4,5)P3 
receptors. 
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Figure 1.21. Sulfur-based Ins(1,4,5)P3 mimics. 64, 65 R=OH or NH2.65,66 
 
 R 
58 OSO3- 
59 OSO2CH3 
60 OSO2CH3 
 
 R’ 
61 CH2SO3- 
62 CF2SO3- 
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In the previous section, a comparison of the antimicrobial acylphosphate mimics 
36-38 was made.45  In addition to these compounds, Grimes also synthesised a 
range of analogues containing sulfur-based acylphosphate isosteres.  In this 
paper she compared the effect of acyl sulfamate esters 66 and acyl sulfamide 
esters 67 (fig. 1.22).  The sulfamate-bearing analogues, 66, all showed good 
activity against B. anthracis, with IC50 values ranging from 35-65 µM.  The 
sulfamide 67, which bears an additional hydrogen bond donor (NH), exhibited 
lower activity (IC50 = 200 µM), but nonetheless is clearly well tolerated within their 
targets. 
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Figure 1.22. Sulfate-based acylphosphate mimics 66 and 67.45 
 
1.8. Carboxylate-based Isosteres 
The difluoromethylene phosphonate is one of the most successful metabolically 
stable phosphate isosteres, its high affinity can be attributed to the closely 
matched   
! 
pKa  values with the native phosphate as well as direct hydrogen 
bonding between the fluorines and the enzyme active site.67  The major 
drawback is, however, its poor bioavailability.  As a result attention has been 
drawn to the development of hydrolytically stable and more bioavailable 
phosphate isosteres.  One of the most abundant areas researched is the use of 
carboxylate-based isosteric phosphate replacements, and this is the subject of 
the next part of this review. 
 
 R 
66 O 
67 NH 
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As with many isosteric phosphate replacements, pTyr mimics have included a 
vast array of carboxylate derivatives.  Grove and co-workers synthesised a large 
range of carboxylate based pTyr mimics in order to explore alternatives for their 
difluoromethylene phosphonate analogue, which displays excellent activity but 
poor bioavailability.68  A list of their phosphate replacements is shown in fig. 
1.23.  A direct comparison of each carboxylate derivative purely as a phosphate 
replacement is meaningless in a study such as this, as the measure of 
effectiveness relies on many variables such as the substitutions on the phenyl 
ring and the conformations it can adopt within the receptor.  However, what this 
paper highlights are the logical progressions used when trying to find a 
phosphate, or in this case, a methylene phosphonate, replacement.  Included are 
groups such as the O-methylene carboxylate 68, the O-difluoromethylene 
carboxylate 69, and the S-methylene carboxylate 70, these will all display similar 
spatial arrangements, but possess different   
! 
pKa  values and electronic properties.  
In order to address possible steric constraints the truncated difluoromethylene 
carboxylate 76 was also synthesised.  Extra hydrogen-bond acceptor character 
was introduced through the inclusion of sulfoxide 71, sulfone 72, and ketone 75.  
Hydrogen-bond donor character was added through the addition of alcohol 77 
and a mixture of hydrogen-bond donor and acceptor character was introduced 
through the inclusion of amide 73.  Aliphatic and aromatic side chains were also 
explored by the synthesis of compounds 74, 79 and 80; as well as a di-charged 
analogue in the form of the malonate 78. 
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Figure 1.23. Carboxylate-based pTyr mimics 68 - 80.68 
 
A recent article by Auclair and co-workers,69 on the synthesis of inhibitors of 
aminoglycoside 6’-N-acetyltransferases, noted that the interactions between the 
coenzyme A (CoA) pyrophosphate and the enzyme contained mainly hydrogen 
bonds.  This led to the synthesis of two keto- carboxylates 81 and 82 (fig. 1.24), 
varying the size of linker, as basic pyrophosphate mimics.  Analogue 81 bearing 
the methylene linker showed activity over the ethylene linked analogue 82 in this 
case. 
 
 R 
68 OCH2CO2H 
69 OCF2CO2H 
70 SCH2CO2H 
71 S(O)CH2CO2H 
72 SO2CH2CO2H 
73 NHC(O)CO2H 
74 NPhC(O)CO2H 
75 C(O)CO2H 
76 CF2CO2H 
77 CH(OH)CO2H 
78 C(CO2H)2Me 
79 CH(CH3)CO2H 
80 CH(Bn)CO2H 
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Figure 1.24. Carboxylate-based phosphate mimics 81, 82.69 
 
In addition to the phosphorus base pTyr mimics, described above (by Larsen et 
al.),62 they also included a varied range of carboxylate based phosphate 
isosteres.  Here they examined many of the common carboxylate isosteres such 
as the methylene carboxylate.  However, they also included a number of 
dicarboxylic acid bearing pTyr derivatives.  They included the malonate 83 as 
well as a malonate containing a CH2 spacer 84 and a malonic ester 85 (fig. 
1.25).  They also varied the position of the CH2 spacer to include the 
dicarboxylate 86 and included unsaturated dicarboxylates in the form of 87 and 
88 (fig. 1.25). 
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Figure 1.25. Carboxylate-based pTyr mimics 83 – 88.62 
 
 
 R 
81 CH2 
82 CH2CH2 
 
 R 
83 OCH(CO2H)2 
84 OCH2CH(CO2H)2 
85 OC(O)CH2CO2H 
86 OCH(CO2H)CH2CO2H 
87 CHC(CO2H)2 
88 OC(CO2H)CHCO2H 
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1.9. Heterocyclic-based Isosteres 
As work continues in pursuit of phosphate isosteres with higher bioavailability, 
more and more analogues are appearing that bear a heterocyclic scaffold. 
 
A recent publication by Ma%i& and colleagues details the synthesis and biological 
evalutation of glutamic acid-based inhibitors of MurD ligase.70  Mur ligases 
catalyse the biosynthesis of important peptides for the cell-wall of bacteria.  
Docking studies of their lead compounds highlighted that its quinazoline ring was 
located in the same position as the diphosphate of UDP.  This prompted them to 
replace the quinazoline ring with a 2-thioxo-1,3-thiazolidin-4-one (rhodanine) 
moiety 89, 90 to act as a phosphate isostere (fig. 1.26).  This had the desired 
effect giving then their most potent inhibitors to date.  Docking studies of their 
new lead compound confirmed the rhodanine moiety binding in the same location 
as the diphosphate of UDP. 
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Figure 1.26. Rhodanine-based phosphate mimics 89 and 90.70 
 
A number of pharmaceutical companies have independently converged on the 
thiadiazolidinone based moieties, that act as pTyr mimics.40  The fact that they 
have all converged upon closely related structures speaks for the efficacy of the 
group as a phosphate isostere.  Novartis,71 AstraZeneca,72 and Incyte73 have all 
developed pTyr mimics containing this group as a phosphate isostere, which all 
exhibit low µM IC50s for PTP1B (fig. 1.27). 
 R 
89 S 
90 O 
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Figure 1.27. Thiadiazolidinone-based phosphate mimics.40 
 
Some preliminary work by Blaskovich et al.,74 incorporated several bicyclic 
moieties 91-96 (fig. 1.28) into a template structure and screened them against 
four phosphatases.  Some derivatives demonstrated moderate potency and 
selectivity, indicating the potential utility of these derivatives as non-charged 
phosphate isosteres with increased bioavailability. 
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Figure 1.28. Bicyclic-based phosphate mimics.74 
 
1.10. Miscellaneous Phosphate Isosters 
A very recent publication by Vasseur and co-workers,75 reports the synthesis of 
borono-analogues of all four nucleotide monophosphates 97-100 (fig. 1.29); the 
boronic acid in these structures, is acting as the isosteric phosphate 
 R 
91 CO 
92 SO2 
 
 X Y 
93 O CO 
94 S CO 
95 CMe2 CO 
96 O SO2 
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replacement.  They conducted semi-empirical calculations that indicated their 
new bioisosteres are close mimics of their natural counterparts and indicated the 
utility of this technology in the synthesis of unnatural DNA and RNA. 
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Figure 1.29. All four nucleotides bearing a boronic acid replacement of the phosphate.  
Borononucleotide T (97), borononucleotide C (98), borononucleotide G (99) and 
borononucleotide A (100).75 
 
A commonly overlooked element, in the design of novel phosphate isosteres, due 
its high toxicity and often unstable nature, is selenium.  However, Knapp and co-
workers synthesised analogue 101 (fig. 1.30) with the seleninate acting as a 
phosphate replacement in pTyr,76 and showed that it acted as an irreversible 
inhibitor of PTPs.  An X-ray crystal structure of PTP1B complexed with 101 was 
obtained, showing that 101 was covalently attached to PTP1B via a selenosulfide 
bond between Cys215 and the selenium atom. 
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Figure 1.30. Seleninate 101 acting as an irreversible pTyr mimic and the X-ray crystal structure, 
showing S-Se bond between 101 (Se=light orange, C=yellow, O=red, N=blue) and Cys215 
(S=orange, C=green, O=red, N=blue).76 
 
1.11. Summary 
The reversible phosphorylation of proteins to transmit signalling information is 
recognised as one of the most ubiquitous and fundamental processes within the 
cell.  Due to its prevalence within so many cellular processes, the recognition of 
receptors for phosphorylated cellular moieties has become the target for many 
small molecule probes.  However, due to the highly charged nature of the 
phosphate and its propensity for hydrolysis by in vivo phosphatases it is 
becoming a less desirable group to incorporate into exogenous ligands.  It has 
therefore become important to develop isosteric groups to replace the 
phosphate, inorder to increase the ligands metabolic stability and improve its 
bioavailability.  This review has detailed some of the structures that have been 
incorporated into small molecules as a replacement of the phosphate moiety.  
The diversity of ligand and targets, means that the phosphate isosteres have 
been ordered based on broad structural characteristics.  It is apparent that there 
are three main approaches used towards phosphate replacements, these are to 
base isosteres around phosphorus, sulfur and carboxylic acids.  However, there 
is an increasing shift towards hetrocyclic moieties, these compounds usually 
have improved pharmaco-kinetic properties, which is important for therapeutic 
applications.  However, highly novel approaches have been shown, that 
incorporate less common elements such as boron and selenium. 
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2. Introduction Part 2: PH Domain Targeted Ligand Design 
 
2.1. Introduction and Aims 
The primary aim of this project is the synthesis of PtdIns(3,4,5)P3 19 analogues.  
For both chemical and biological reasons, these analogues will be based on the 
structure of the PtdIns(3,4,5)P3 head group, Ins(1,3,4,5)P4 23 (fig. 2.1).  Although 
the lipid diester is undoubtedly important for PBK PH domain binding, and 
essential for routing PtdIns(3,4,5)P3 to the cell membrane in vivo, in vitro 
Ins(1,3,4,5)P4 binds to the PKB PH domain with an equivalent affinity.37  So for 
the purposes of assessing the contribution each phosphate of PtdIns(3,4,5)P3 
makes for PH domain recognition and binding, omitting the glycerol lipid diester 
unit is justified. 
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Figure 2.1. The structure of PtdIns(3,4,5)P3 and its head group InsP4. 
 
The publication of the X-ray crystal structures of PBK#PH-apo and PBK#PH-
Ins(1,3,4,5)P4 complex by van Aalten and co-workers, highlighted significant 
differences in the conformation of the PH domain when in the presence and 
absence of the ligand.38  Inspection of the ligand-binding site of PBK#PH-apo 
shows a complex hydrogen-bonding network located around key amino acid 
residues; Arg86, Lys14, Glu17 and Asn53, and several conserved water 
molecules (fig. 2.2).  Upon binding of Ins(1,3,4,5)P4, the acidic residue, Glu17, is 
repelled by the incoming acidic phosphates; it is postulated that this movement 
enables Arg86 to move 2.3 Å to bind strongly with the 4-position phosphate.  
Lys14 and Asn53 bind to the 3- and 4-position phosphates, Lys14 moves 1.2 Å 
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and Asn53 is in a similar position in both apo and complexed states.  In addition 
to the structures of PBK#PH-apo and PBK#PH-Ins(1,3,4,5)P4 complex, an X-ray 
crystal structure of PBK#PH-sulfate complex was obtained.  The PBK#PH-sulfate 
complex shows the sulfate located 2.2 Å from the position of the 4-position 
phosphate in the Ins(1,3,4,5)P4 complex.  The sulfate interacts in a comparable 
way to the 4-position phosphate binding to both Arg86 and Asn54.  It is apparent 
from our previous work that modification of the 4-position phosphate is not well 
tolerated for PBK#PH recognition.31  It was surprising, therefore, that compound 
28 (fig. 2.2) showed no binding affinity for PBK#PH given the sulfates hydrogen 
bonding ability. An explanation for this lack of binding maybe that the reduced 
charge cannot repel Glu17 enough to allow Arg86 to move and form the binding 
interactions to the conformationally restricted sulfate at the 4-positon. 
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Figure 2.2. 4-Position modified InsP4 sulfate derivative 28,31 and x-ray crystal structure of 
PBK#PH-Ins(1,3,4,5)P4 complex,38 with important residues highlighted. 
 
The 3-position phosphate of Ins(1,3,4,5)P4 shows hydrogen bonding to Asn53, 
Lys14 and a single hydrogen bond to Arg23.  A significant movement of Arg23 is 
observed upon binding of Ins(1,3,4,5)P4 moving 6.2 Å to form a hydrogen bond 
between the 1- and 3-position phosphates.  It can be postulated that an isosteric 
phosphate replacement of the 3-position phosphate bearing a reduced charge 
will reduce the interactions observed at this position, potentially with the effect of 
Lys-14 
Asn-53 
Arg-25 
Arg-23 
Glu-17 
Arg-86 
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preventing the observed conformational change.  The synthesis of a small 
molecule that binds selectively to PKB PH that prevents the conformational 
change, which appears crucial for PKB activity, and that potentially prevents 
membrane translocation of PKB will likely be a useful PKB ligand. 
It is, therefore, desirable to synthesise analogues of Ins(1,3,4,5)P4 modified at 
the 3-position with a phosphate mimic that occupies a similar spatial 
arrangement as a phosphate but possesses diminished hydrogen bonding, or 
salt-bridge forming, capability.  A moiety such as the sulfate, for example, 
contains multiple hydrogen bond acceptors, which is akin to a phosphate, but will 
only be mono charged at physiological pH, reducing its ionic strength.  Following 
on from this, it would be interesting to incorporate the sulfamate moiety, this 
again possesses good hydrogen-bonding ability, but unlike the sulfate, it will be 
neutral at physiological pH providing hydrogen bond donor activity as a result.  Of 
additional interest will be the inclusion of the methyl phosphonate moiety, this 
group will not only make the group mono-charged, but it will also reduce the pKa 
of the group with respect to that of the native phosphate.  It will therefore be of 
valuable comparison to synthesise the difluoromethyl phosphonate, as this will 
have a pKa closer to that of the native phosphate.  Additionally, the 3-position 
phosphate makes a hydrogen bond with a conserved water molecule within a 
polar pocket below Arg23 and next to Lys14.  Therefore, of interest would be the 
synthesis of an extended phosphate mimic such as a methylene phosphonate or 
methylene carboxylate.  These, one carbon unit, extended derivatives might 
favourably displace the water molecule resulting in increased affinity. 
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Figure 2.3. Primary synthetic targets, showing the phosphate isosteres that will provide 
interesting comparisons. 
 
In addition to the synthesis of 3-position modified Ins(1,3,4,5)P4 derivatives, it will 
be interesting to extend the group of compounds modified at the 1-position, as 
the modifications at this position appears to be better tolerated for the GRP1 PH 
domain than for the PKB PH domain.  Of particular interest would be the 
synthesis of a methyl phosphate ester (fig. 2.3) 1-position analogue, as this is 
more similar to PtdIns(3,4,5)P3 than any of the previous 1-position modified 
Ins(1,3,4,5)P4 derivatives.  It is, therefore, expected that this compound might 
show high affinity for the PKB-PH as well as be tolerated in the GRP1-PH 
domain.  A 1-position methyl phosphate ester analogue probably would not 
prevent the conformational change in PKB required for activity but instead would 
likely serve as an inhibitor by preventing membrane translocation. 
Synthesis of a range of 5-position-modified Ins(1,3,4,5)P4 derivatives (fig. 2.3) 
will complete mono-substitution of all the phosphate groups surrounding the 
inositol ring of Ins(1,3,4,5)P4.  With testing completed for all 1-, 3-, 4- and 5-
position analogues we will be able to build a picture of how important each 
phosphate is for binding to specific PH domains.  Knowing the positions where 
modification is well tolerated, we can then synthesise further PH domain targeted 
analogues hopefully improving the binding strength and selectivity. 
Another potential advantage for omitting the phospholipid portion is for co-
crystallisation of our analogues within the PH-domain of PKB or GRP1.  
Crystallisation of a PBK#PH-PtdIns(3,4,5)P3 complex or indeed a GRP1- 
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PtdIns(3,4,5)P3 complex have been unsuccessful, this has been attributed to the 
presence of the lipid diester, which is not thought to be essential for binding. 
The above set of compounds will initially be tested to ascertain whether they 
express any binding affinity for the different PH domains.  Once a potential 
inhibitor is found cell membrane permeant groups such as 102 (fig. 2.4), 
successfully employed for the synthesis of cell permeant Ins(1,4,5)P3 by Holmes 
et al.,77 could be introduced to enable in vivo studies of these compounds. 
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Figure 2.4. Potential cell pembrane permeant InsP4 derivative 102.77 
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3. Results and Discussion Part 1: Towards 3-position modified 
PtdIns(3,4,5)P3 analogues 
 
3.1. Synthetic Targets 
The first target is the synthesis of 3-position-modified Ins(1,3,4,5)P4 derivatives 
(fig 3.1).  It is essential that a robust synthesis be developed, as once the initial 
group of compounds have their biological activity evaluated, it will be necessary 
to expand the number of derivatives, based on the structure activity relationship 
that is observed. 
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Figure 3.1. 3-Position modified targets. 
 
3.2. Retrosynthesis 
Syntheses of inositol phosphates have been approached in a number of different 
ways.78,79  The most common approaches use myo-inositol as the starting point 
in their syntheses.  myo-Inositol is a cheap abundant starting material and 
benefits from having all the stereogenic centres around the ring correctly defined.  
The major hurdle to overcome when using myo-inositol,80 is that myo-inositol is a 
meso compound and therefore needs to be desymmetrised in order to synthesise 
enantiomerically pure inositol phosphates, such as our targets.  The 
desymmetrisation of myo-inositol has been achieved in a number of different 
ways, including asymmetric chiral catalysis,79,81-86 enzyme mediated 
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desymmetrisation,87,88 and the use of chiral auxiliaries.89,90  The use of chiral 
auxiliaries is the most widely employed technique for the desymmetrisation of 
myo-inositol and is the principle method that is used within our research group. 
 
With the chemistry already well established and heavily used within the group, it 
was decided that the approach towards the synthesis of 3-position Ins(1,3,4,5)P4 
derivatives would centre around the desymmetrisation of myo-inositol originally 
published by Holmes.89  This desymmetrisation provides a robust route to 
racemic triol 103, represented in scheme 3.1, and then employs the use of (S)-
camphor as the chiral auxiliary forming four diastereomers 104 (scheme 3.1).  
104a can then be isolated by column chromatography to yield it enantiomerically 
pure.  The use of compound 104a has already been shown in the development of 
enantiomerically pure 1-position modified Ins(1,3,4,5)P4 derivatives.31  It is hoped 
that using a similar approach, compound 104a will deliver robust routes to 
enantiomerically pure 3-, and 5-position Ins(1,3,4,5)P4 derivatives. 
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Scheme 3.1. Diastereomeric resolution of myo-inositol derivatives.89 
 
A general retrosynthesis for compound 110 for 3-position modified Ins(1,3,4,5)P4 
derivatives is presented in scheme 3.2.  It is desirable to achieve the requisite 
 57 
compounds 110 via a global de-protection of fully benzyl protected precursor 
compound 109, as it has been shown that hydrogenolysis of benzyl protected 
inositol phosphates generally proceed cleanly, in high yield and with no need for 
subsequent purification. 
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Scheme 3.2. General retrosynthesis for 3-position InsP4 derivatives. 
 
Additionally, derivatives containing benzyl protected phosphates are amenable to 
column chromatography and are soluble in a number of common organic 
solvents.  It is then hoped that 109 can be made from the corresponding alcohol 
108.  In the forward sense alcohol 108 can potentially undergo multiple 
derivations for the synthesis of a variety of precursor compounds.  Therefore, a 
reliable synthesis of 108 is certainly a central prerequisite for making a number of 
3-position Ins(1,3,4,5)P4 derivatives.  The key alcohol 108 can be obtained by 
de-protection of a suitable protected trisphosphate 107.  It has been shown that 
the de-protection of PMB ethers to give their corresponding alcohols in the 
presence of multiple benzyl protected phosphate esters is well tolerated.31,91,92 
Therefore we proposed the use of PMB-protected trisphosphate 107 which, in 
turn, could be obtained via a phosphitylation reaction from PMB-protected triol 
106.  The required 3-position orthogonality is then potentially introduced by regio-
selective alkylation, using stannylene acetal chemistry, on the vicinal diol 105 
(scheme 3.2) which itself can be afforded in 2 steps from enantiopure alcohol 
104.31 
 58 
3.3. Synthesis of alcohol 104 
The synthesis of alcohol 104 commences with the protection of myo-inositol with 
triethylorthoformate in the presence of a sub-stoichiometric quantity of 
4-toluenesulfonic acid monohydrate (PTSA) giving the adamantane-like inositol 
orthoformate 111 in 70% yield.  It is noteworthy that this reaction is highly 
consistent and is carried out regularly on scale of up to 50 g. 
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Scheme 3.3. Holmes synthesis of enantiomerically pure intermediate 104.89 Reagents and 
conditions: i. (EtO)3CH, TsOH·H2O, DMF, 100 °C, 70% yield; ii. NaH, PMBCl, DMF, 0 °C ' RT, 
90% yield; iii. NaH, BnBr, DMF, 0 °C ' RT, 98% yield; iv. DIBAL-H, CH2Cl2, 0 °C ' RT, 90% 
yield; v. NaH, AllBr, imidazole, DMF, 0 °C ' RT, 89% yield; vi. HCl, MeOH, reflux, 93% yield; vii. 
(-)-(S)-Camphor dimethyl acetal 118, TsOH·H2O, CH2Cl2, reflux, 24% yield. Synthesis of 
Camphor dimethyl acetal 118. Reagents and conditions: viii. HC(OMe)3, Montmorrillonite K10 
clay, hexane, 96% yield. 
 
The triol 111 was mono benzylated regioselectively at a single axial hydroxyl by 
the careful treatment with sodium hydride and 4-(methoxy)benzyl chloride 
(PMBCl) to give compound 112 in 90% yield.  The high yield and selectivity of 
this reaction can be attributed to careful formation of the alkoxide.  Portion-wise 
addition of sodium hydride to a solution of triol 111 in dimethylformamide (DMF) 
kept at -5 ºC ensures mono-deprotonation.  The axial alkoxide is favoured over 
the equatorial partially through a statistical advantage but also through 
stabilisation of the forming axial alkoxide through chelation of the sodium ion with 
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the neighbouring hydroxyl (scheme 3.4).  Evidence for this chelation effect was 
provided by Billington et al.,93 who observed that selectivity was lost upon 
changing either the counter ion or the reaction solvent.   
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Scheme 3.4. Regio selective PMB ether formation via favourable axial alkoxide formation. 
 
The mono-protected PMB ether is not the sole product of this reaction as some 
of the bis-substituted product is observed, however, these compounds are readily 
separated by column chromatography.  In addition, it should be noted that, 
although regioselective, the PMB ether formation is not stereoselective, therefore 
breaking the plane of symmetry of compound 111 in this manner yields a racemic 
mixture of chiral compounds.   
Per benzylation of diol 112 using sodium hydride and benzyl bromide provided 
the fully protected inositol orthoformate 113 in 98% yield.  The orthoformate 113 
is reduced by treatment with diisobutylaluminium hydride (DIBALH) in hexanes to 
exclusively give alcohol 114.  Studies of the reaction mechanism by Holmes et al. 
using deuterium-labelling experiments reveal the reason behind the exceptional 
selectivity.94-96  The mechanism is represented in scheme 3.5, it shows that at 
least 2 equivalents of DIBALH are required for the reaction.  The first DIBALH 
equivalent behaves as a Lewis acid coordinating preferentially to the 5-position 
oxygen of the orthoformate to give 113a.   
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Scheme 3.5. Proposed mechanism for the regioselective DIBAL reduction of orthoformate 113.96  
 
The 5-position oxygen is preferred over the 1- and 3-position oxygens most likely 
due to unfavourable steric interactions with the equatorial benzyl group at the 2-
position.  This coordination promotes formation of the oxacarbenium ion, which in 
order to relieve unfavourable 1,3-diaxial interactions flips to give a boat 
conformation 113b.  With the aluminate species now apart from the 
oxacarbenium ion, reduction occurs via a second equivalent of DIBALH attacking 
the exposed carbon to give 114.  Compound 114 is formed in excellent yield and 
without the need for purification by column chromatography. 
Alcohol 114 was treated with sodium hydride and allyl bromide to give the fully 
protected inositol 115.  One-pot methanolysis of both the methylene acetal and 
the PMB ether of compound 115, using conc. HCl in methanol, gave the racemic 
triol 116 in 93% yield. 
Here we performed the diastereomeric resolution making the synthesis 
enantiomerically pure.  The racemic triol 116 was reacted with the dimethyl 
acetal of (1S)-(-)-camphor 118, to protect the vicinal diol as the camphor acetal.  
(1S)-(-)-Camphor dimethyl acetal 118 was prepared in one step from (1S)-(-)-
camphor 117 by reaction with trimethyl orthoformate and Montmorillonite® K-10 
clay.  The crude reaction mixture gave an 87% conversion to the dimethyl acetal 
as shown by 1H NMR analysis, the reaction mixture was filtered and 
concentrated and no further purification was required.  The crude dimethyl acetal 
 61 
118 was reacted directly with triol 116 in the presence of 4-toluenesulfonic acid 
giving a presumed statistical mixture of the four possible diastereomers of 
compound 104 (scheme 3.1). 
With diastereomer 104a being slightly more polar than the other diastereomers, it 
is possible to isolate this compound using column chromatography furnishing the 
versatile, enantiomerically enriched, and orthogonally protected myo-inositol 104 
in 24% yield.  The other three diastereomers are inseparable and likely accounts 
for the remaining material. 
 
3.4. Synthesis of alcohol 122 
Having made enantiomerically pure alcohol 104, synthesis of the triisopropylsilyl 
(TIPS) ether 121 followed by methanolysis could be achieved following the 
reported synthesis of diol 121 (scheme 3.6).31 
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Scheme 3.6. Silyl protection of 1-position hydroxyl.31 Reagents and conditions: i. TIPSOTf, 2,6-
lutidine, CH2Cl2, RT, 94% yield; ii. TIPSOTF, Et3N, CH2Cl2, RT, 87% yield. 
 
Entry Conditions Yield of 121 
1 2,6-lutidine, TIPSOTf, CH2Cl2, RT Reaction did not go to 
completion 
2 Et3N, TIPSOTf, CH2Cl2, RT Reaction did not go to 
completion 
3 NaH, TIPSCl, DMF, 0 ºC to RT 51% 
4a Et3N, TIPSOTf, CH2Cl2, RT 87% 
 
Table 3.1. Summary of reaction conditions for the silyl protection of the 1-position hydroxyl of 
compound 104. aEt3N and TIPSOTf pre-stirred for 1 h prior to the addition of alcohol 104. 
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The reaction of alcohol 104 in the presence of 2,6-lutidine and triisopropylsilyl 
trifluoromethanesulfonate (TIPSOTf) was found to be very sluggish, with 
considerable starting material present, as shown by TLC analysis, after several 
days stirring at room temperature.  The reaction failed to proceed to completion, 
despite the addition of further amounts of TIPSOTf and 2,6-lutidine.  The same 
result was observed when changing the base to Et3N (entry 2, table 3.1).  With 
tertiary amines failing to effectively promote the reaction, the alkoxide of alcohol 
104 formed by NaH in DMF was reacted with triisopropylsilyl chloride (TIPSCl) to 
give the desired product in a 51% yield (entry 3, table 3.1).  It was subsequently 
found, however, that pre-stirring Et3N with TIPSOTf for 1 h prior to the addition of 
alcohol 104 gave complete consumption of starting material within 12 h.  A much 
simpler work-up procedure and easier purification gave an isolated yield of 87% 
for intermediate 121 (entry 4, table 3.1). 
Cleavage of the camphor auxiliary to give the vicinal diol 105 was achieved in 
91% yield via simple methanolysis using acetyl chloride in methanol and CH2Cl2 
(scheme 3.7). 
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Scheme 3.7. Cleavage of chiral auxiliary to give vicinal diol 105.  Reagents and conditions: i. 
AcCl, MeOH/CH2Cl2, RT, 91% yield. 
 
The subsequent synthetic step concerned the installation of an orthogonal 
protecting group onto the 3-position hydroxyl.  A selective protection of this kind 
was developed within the group where a benzoyl ester functionality was 
incorporated with exclusive selectivity for the 3-position hydroxyl, over the 4-
position hydroxyl, and in 76% yield (scheme 3.8).31,97  This protection involved 
the formation of a stannylene acetal complex of diol 105, by reaction with 
dibutyltin oxide in toluene under reflux, using a Soxhlet apparatus containing 3 Å 
molecular sieves for the removal of water.  Then subsequent reaction of this 
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complex with benzoyl chloride (BzCl) at room temperature, gave protection at the 
3-position with complete selectivity.   
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Scheme 3.8. Regioselective benzolyester formation using stannylene acetal chemistry.  
Reagents and conditions: i. (a) Bu2SnO, toluene, reflux; (b) benzoyl chloride, 0 ºC ' RT, 80% 
yield. 
 
The regiochemistry of the benzoylation was shown by X-ray crystallography.  It 
was therefore hoped that an analogous reaction using PMBCl as the electrophile 
would furnish the desired 3-position PMB ether 122. 
However, using the conditions described, PMBCl showed very little reaction with 
the stannylene acetal complex of 105 at room temperature after 24 h, showing 
little consumption of starting material. 
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Entry Conditions Reaction Time Yield of 122 
1 i. Bu2SnO, toluene, reflux 
ii. PMBCl, TBABr, toluene, 
reflux 
+72 h Complex mixture 
2 Bu2SnO, PMBCl, TBAI, toluene, 
reflux 
18 h 9% 
3 Bu2SnO, PMBCl, TBAI, MeCN, 
reflux 
24 h 33% 
4 i. Bu2SnO, toluene, reflux 
ii. PMBCl, TBAI, CsF, DMF, 
50 ºC 
48 h 43% 
5 NaH, PMBCl, DMF, 0 ºC to RT 18 h 18% 
6 i. Bu2SnO, toluene, reflux 
ii. PMBCl, NaI, CsF, DMF, 
50 ºC 
20 h Complex mixture 
7 i. Bu2SnO, MeOH, reflux 
ii. PMBCl, CsF, DMF, 50 ºC 
20 h Complex mixture 
8 Bu2SnO, PMBCl, TBABr, MeCN, 
reflux 
24 h Complex mixture 
Table 3.2. Summary of reaction conditions for the regioselective protection of diol 105 as the 
PMB ether. 
 
From published literature, it is apparent that reaction of allyl and benzyl halides 
with stannylene acetals in non-polar media is poor.97  Frequently, these reactions 
are conducted in polar solvents such as DMF with much greater success.  
However, the addition of quarternary ammonium halides has been shown to 
facilitate a number of reactions of this type in toluene or benzene.  Therefore 
tetrabutylammonium bromide (TBABr) was added to the above reaction 
conditions but several hours at room temperature failed to give any improvement.  
Finally, heating the reaction under reflux resulted in a complex mixture of 
products being formed (entry 1, table 3.2).  Heating the stannylene acetal under 
reflux in toluene with PMBCl and tetrabutylammonium iodide (TBAI), on the other 
hand, yielded 9% of the desired PMB ether with no trace of the undesired 4-
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position PMB ether.  It is apparent from these two results that PMBCl is much 
less reactive towards the stannylene than BzCl in non-polar media, despite the 
addition of quarternary ammonium halides.  Hence, further study of the reaction 
was required, the results of which are summarised in table 3.2.  Conditions 
developed within the group selectively benzylate the 3-position of a comparable 
protected myo-inositol 123 (scheme 3.9).91  This reaction involves heating a 
solution of dibutyltin oxide (1.1 equivalents), benzyl bromide (4.8 equivalents), 
and TBAI (1 equivalent) in acetonitrile under reflux, using a Soxhlet apparatus 
containing 3 Å molecular sieves to remove the water generated through 
stannylene acetal formation.  The reaction proceeds in 72% yield with a 5:1 
selectivity (as ajudged by 1H NMR analysis) in preference for the 3-position 
benzyl protected compound 124 over the 4-position 125 (scheme 3.9). 
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Scheme 3.9. Regioselective benzylation of vicinal diol 123 developed within the group.91  
Reagents and conditions:  i. Bu2SnO, TBAI, benzyl bromide, acetonitrile, reflux, 72% yield. 
 
The analogous reaction using intermediate 105 instead of compound 123 and 
PMBCl instead of benzyl bromide indeed gave a marked improvement, giving an 
isolated yield of 33% for desired compound 122 (entry 3, table 3.2).  The 
presence of a polar aprotic solvent clearly facilitates the reaction; this could be 
attributed to improved stabilisation of the presumed SN2 transition state.  The 
literature on reactions of this type have described a two-step procedure, initially 
the relatively stable stannylene acetal is pre-formed, in a non-polar solvent.  The 
second step involves replacement of the non-polar solvent with a polar solvent, in 
which the stannylene acetal is reacted with the appropriate electrophile.  Thus, 
diol 105 and dibutyltin oxide (1.1 equivalent) in toluene where heated under 
reflux together with a Soxhlet apparatus attached containing 3 Å molecular 
sieves.  After 12 h, the toluene was removed by distillation to give the stannylene 
acetal, as a wax, which was then dissolved in dry DMF at room temperature.  
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The solution of the stannylene acetal was treated with PMBCl at room 
temperature, but the reaction appeared to progress slowly and heating to 50 ºC 
showed no improvement in the reaction progress. Only upon the addition TBAI 
was significant consumption of starting material observed. 
Examination of the mechanisms associated with reactions of this type have been 
discussed in the literature.97  Using mass spectrometry and 119Sn NMR 
techniques it has been shown that in non-polar media the stannylene acetal 
exists as a dimer 126 of the type shown in scheme 3.10.  Here, the tin atom is 
five-coordinate, with one of the oxygen atoms tri-coordinate.  When all solvent is 
removed, the dimers are thought to possibly exist as oligomers or infinite ribbons 
with a six-coordinate tin atom.  In polar solvents a trigonal bipyramidal structure 
127 can be formed by coordination of one molecule of solvent to the central tin 
atom (scheme 3.10). 
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Scheme 3.10. Representation of stannylene acetals in solution.97 
 
In these complexes the apical oxygen possesses the longer O-Sn bond so 
typically has the greater reactivity.  A common technique for improving the 
reactivity of the apical oxygen is to add caesium fluoride to the reaction mixture.  
The fluoride is able to replace the coordinating solvent (105b, scheme 3.10) 
polarising the apical oxygen thus increasing its reactivity. 
For this reason, caesium fluoride was also added to the above reaction, 
subsequent work-up and isolation via column chromatography gave the desired 
3-position PMB ether 122 in 43% isolated yield, and a 2:1 ratio, as adjudged by 
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1H NMR analysis, in favour of the desired 3-position protected product over the 
4-position (entry 4, table 3.2).  The stereochemistry was assigned by 1D and 2D 
1H NMR techniques.  Subsequently, slow controlled diffusion of petroleum ether, 
as an anti-solvent, into a concentrated solution of 122 in ethyl acetate yielded a 
crystal of sufficient quality to obtain X-ray crystal analysis, which confirmed our 
initial NMR assignment by showing the relative configuration (fig. 3.2).   
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Figure 3.2. Single crystal X-ray structure of intermediate 122 confirming desired regiochemistry. 
 
Further attempts to optimise the reaction conditions failed to improve the 
selectivity or yield (table 3.2).  Interestingly, substitution of TBAI with NaI 
severely reduced the reactivity, which eventually led to a complex mixture of 
products (entry 6, table 3.2).  This indicates that the quaternary ammonium 
species plays an important role in the reaction.  In addition to this observation, 
work conducted within the group showed that an improvement in yield was 
obtained when adding TBABr to their reaction of stannylene acetal with benzyl 
bromide.  In this instance halide exchange cannot produce a more reactive 
electrophile and therefore the tetrabutyl ammonium species must be the 
contributing factor for the improvement in reaction.  It is postulated, therefore, 
1 
2 
3 4 
5 
6 
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that the tetrabutyl ammonium ion is able to improve solubility of the halide ion in 
the polar organic solvent. This improved solubility allows for increased Sn-halide 
coordination, which thus increases reaction rates, leading to less degradation of 
the stannylene, and consequently an improvement in yield. 
Following the successful isolation of intermediate 122, sequential removal of the 
allyl and TIPS protecting groups to furnish triol 106 was required prior to 
phosphitylation. 
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Scheme 3.11. Synthesis of triol 106.  Reagents and conditions: i. (a) Wilkinson’s catalyst, DIPEA, 
EtOH, reflux, (b) 4-TsOH·H2O, MeOH, RT, 76%; ii. TBAF, THF, RT. 
 
The allyl protecting group was removed by firstly treating 122 with Wilkinson’s 
catalyst, which after 3 h complete isomerisation of the allylic double bond to give 
the enol ether was shown by 1H NMR analysis.  Methanolysis of the enol ether 
using PTSA gave 128 initially isolated as a crude gum. 1H NMR analysis of this 
material indicated that the allyl group had been cleaved by the loss of signals 
corresponding to both the allylic and vinylic protons.  However, purification of 
intermediate 128 proved difficult, requiring exhaustive chromatography isolating 
128 in 76% yield (scheme 3.11). 
Having isolated intermediate 128, removal of the TIPS protecting group to furnish 
triol 106 was attempted using standard silyl deprotection conditions.  Thus diol 
128 was treated with tetrabutyl ammonium fluoride (TBAF) in THF at room 
temperature.  Consumption of the starting material was observed after stirring for 
18 h, correlating with the appearance of a new more polar product as adjudged 
by TLC analysis.  However, work-up followed by isolation via column 
chromatography yielded a very impure brown oil that corresponded to multiple 
products and only 30% of the required mass.  The reaction was repeated with 
fresh TBAF to rule out the possibility that the initial reagent used might have 
degraded, causing undesirable side reactions.  This yielded a sticky pale yellow 
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solid, which by 1H NMR suggested was the desired product.  However the 
material showed considerable impurities and also corresponded to only 12% of 
the desired mass. 
Therefore, due to the poor yield and exhaustive purification experienced with the 
regioselective PMB protection of diol 128 and the subsequent problems 
experienced with the TIPS deprotection of diol 128, a new approach towards the 
synthesis of 3-position modified Ins(1,3,4,5)P4 derivatives was envisaged. 
 
3.5. Synthesis of alcohol 131 
The potential othogonality obtained by the incorporation of the TIPS protecting 
group at the 1-position hydroxyl is desirable because it adds potential flexibility to 
the intermediates formed, which could be useful for synthesis of more complex 
inositol phosphates in the future.  However, for the initial target alcohol 108 this 
orthogonality is not required so a new retrosynthesis can be postulated (scheme 
3.12). 
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Scheme 3.12. Retrosynthesis of revised synthetic route to 3-position modified Ins(1,3,4,5)P4 
derivatives. 
 
As with the initial route, it is key to achieve orthogonality at the 3-position 
hydroxyl group.  The 1-, 4-, and 5-position hydroxyl groups will ultimately all need 
to be phosphorylated, it is simplest to do this in one step from the desired triol 
106. Therefore, orthogonality is not required at the 1-, 4- and 5-positions.  A 
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shorter synthesis is proposed by forming the 3-position PMB ether 106 from 
known diol 129.  With allyl being a considerably smaller group than TIPS it was 
hoped that the stanylene acetal of 129, formed during the regioselective 
alkylation step, might be more reactive towards PMBCl, because of the reduced 
steric bulk at the 1-position, leading to improved protection of the 3-position 
alcohol. 
 
In the first instance, synthesis of diol 129 was accomplished inaccordance with 
the literature procedure (scheme 3.13).91,92  Thus 104 was treated with NaH and 
allyl bromide in a mixture of THF and DMF with a sub-stoichiometric quantity of 
imidazole, giving the desired bis allyl protected intermediate 130 in 68% yield.  
The camphor acetal was cleaved in 95% yield by treatment of 130 with acetyl 
chloride in CH2Cl2 and MeOH. 
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Scheme 3.13. Synthesis of diol 129.  Reagents and conditions: i. NaH, AllBr, THF, imidazole, 
0°C to RT, 68% yield; ii. AcCl, CH2Cl2, MeOH, RT, 95% yield.  Improved synthesis.  Reagents 
and conditions: i. NaH, AllBr, DMF, TBAI, 0°C to RT, telescoped to following step; ii. AcCl, 
CH2Cl2, MeOH, RT, 93% over 2 steps. 
 
A subsequent improvement to the synthesis of diol 129 was found by simply 
adding NaH (2 eq), allyl bromide (2 eq) and TBAI (cat) to a cooled solution of 
alcohol 104 in DMF.  The reaction was allowed to warm to room temperature 
overnight, aqueous work up gave the crude product that was dissolved in CH2Cl2 
and MeOH and treated with acetyl chloride to effect methanolysis of the camphor 
acetal.  Isolation of the desired diol 129 was achieved by column 
chromatography giving the product in 93% yield over the two steps (scheme 
3.13). 
Having isolated diol 129 in excellent yield, it was important to achieve the 
subsequent regioselective protection of the 3-position hydroxyl in good yield to 
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provide enough material for the remaining steps of the synthesis.  Therefore, 
using the previously optimised conditions the stannylene acetal of diol 129 was 
formed by reaction with dibutyltin oxide in refluxing toluene with a Soxhlet 
apparatus containing 3 Å molecular sieves.  After 18 h, the reaction solution was 
concentrated then re-dissolved in DMF and treated with PMBCl, TBAI and CsF.  
As the reaction progress was monitored, formation of multiple products were 
observed on TLC analysis, and ultimately a complex mixture was formed.   
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Scheme 3.14. Regioselective PMB ether formation from vicinal diol 129.  Reagents and 
conditions: i. Bu2SnO, TBABr, PMBCl, acetonitrile, reflux, 25% yield. 
 
No isolation of products or further analysis was conducted, as a cleaner reaction 
was found by simply refluxing diol 129 with dibutyltin oxide, PMBCl and TBABr in 
acetonitrile with a Soxhlet apparatus containing 3 Å molecular sieves.  After the 
work-up procedure, 1H NMR analysis of the crude material indicated that a 5:2 
ratio of mono PMB-protected isomers was formed.  Separation of the isomers 
was troublesome, but after multiple chromatographic columns the major isomer 
was isolated in 25% yield and corresponded to the desired 3-position protected 
PMB ether 131 as assigned by 1H NMR analysis (scheme 3.14). 
A higher yield for the PMB ether formation is desirable for a more robust 
synthesis, however, the reduced number of synthetic steps over the initial route 
proposed might moderately compensate for the problematic step and still provide 
a viable synthetic route.  So, despite the poor yield of the PMB ether formation, 
removal of the allylic ethers to give the desired triol was attempted. 
The widely used and typically reliable method for removal of an allyl ether is to 
firstly use Wilkinson’s catalyst to isomerise the double bond to the enol ether and 
then cleave this by acid catalysed methanolysis.  This method was successfully 
employed for the synthesis of intermediate 128 reported above.  However, one of 
the major disadvantages of this method is the partial reduction of the allyl ether to 
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the propyl ether that occurs, usually only in a small proportion.  The propyl ether 
is not hydrolysable by methanolysis and as 131 contains two allyl ether groups 
there is a statistically increased chance for reduction taking place and thus 
potentially limiting the reaction yield.  However, a literature method developed by 
Boons et al.,98 treats Wilkinson’s catalyst with n-butyl lithium to form a catalyst 
that isomerises allyl ethers with no discernable reduction to the proply ether.  It is 
thought that the chloride ion in Wilkinson’s catalyst is replaced by an n-butyl ion 
that undergoes a !-hydride shift to form the new active catalyst, hydrido 
tris(triphenylphosphine) rhodium(I). 
This modified catalyst was put to good use within the group for the removal of 
two allyl ethers from a similar system (scheme 3.15).91,92 
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Scheme 3.15. Modified Wilkinson’s catalyst removal of allylic ethers.  Reagents and conditions: i. 
(a) Wilkinson’s catalyst, BuLi, THF, reflux; (b) AcCl, CH2Cl2/MeOH, RT, 89% yield. ii. (a) 
Wilkinson’s catalyst, BuLi, THF, reflux; (b) AcCl, CH2Cl2/MeOH, RT. 
 
Wilkinson’s catalyst was thus treated with n-butyl lithium at -78 °C and then 
allowed to stir at room temperature for 10 minutes, before the addition of bis 
allyic ether 131.  The reaction was heated under reflux and the isomerisation 
progress was followed by 1H NMR analysis.  However, after 6 h, analysis of the 
crude reaction mixture showed the allylic ether was still present and that no 
isomerisation had occurred.  The reaction was thus administered with fresh 
untreated Wilkinson’s catalyst, which led to the required isomerisation within 3 h.  
The crude material was then treated with acetyl chloride in methanol and CH2Cl2 
to methanolyse the enol ether.  Isolation of the product was attempted by silica 
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gel column chromatography, this gave a sticky blue gum and 1H NMR analysis 
was inconclusive as to whether the triol had formed. 
Given the problematic nature of the selective PMB ether formation and the 
subsequent loss of material experienced with the removal of the allyic ethers, it 
was decided that an improvement in the regioselective protection of the 3-
position hydroxyl was vital for a workable synthesis of 3-position modified 
Ins(1,3,4,5)P4 derivatives. 
 
3.6. Synthesis of Triol 106 
It had so far proved difficult to reliably install the desired PMB ether at the 3-
position using stannylene acetal chemistry; it was thought that an improvement 
might be achieved by using a different orthogonal protecting group.  However, 
two speculative methods were attempted prior to changing the protecting group.  
Firstly it is widely documented that 1,3-diols are condensed with anisaldehyde 
dimethyl acetal to give the corresponding anisylidene acetal, which readily 
undergo reduction with DIBALH to give the corresponding PMB ether, often with 
excellent selectivity.99  It was, therefore, hoped that triol 116, which can be 
formed in enantiopure form via acid hydrolysis of the camphor auxiliary of 104, 
might form the 5-membered anisylidene acetal 135 (scheme 3.16) which, in turn, 
might then undergo selective reduction with DIBALH to give the desired 3-
position PMB ether.  It was speculated that the 3-position PMB ether would be 
the favoured product based on a favourable steric environment provided by the 
axial 2-position benzyl ether over the equatorial 5-position allylic ether. 
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Scheme 3.16. Desired anisylidene acetal formation and reduction.  Reagents and conditions: i. 
anisaldehyde dimethylacetal, TsOH·H2O, DMF, 60 °C, 100 mbar pressure; ii. DIBAL-H. 
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A dry solution of racemic triol 116 in DMF was therefore treated with 
anisaldehyde dimethylacetal and PTSA, and heated to 60 °C under 100 mbar 
pressure in order to drive off the methanol produced with the new acetal 
formation.  But after 3 days under these conditions, no progression of the 
reaction was observed; and as a result the reaction was terminated. 
The second speculative reaction was to attempt using the stannylene acetal 
chemistry on racemic triol 116 (scheme 3.18), installing the PMB ether on the 
enantiopure version of triol 116 would have the benefit of reducing the length of 
the synthesis.  However the presence of the extra hydroxyl group might lead to 
the possible formation of the six membered stannylene acetal 116b, potentially 
leading to further undesired PMB ethers 137, 123, 138 and 139 (scheme 3.17). 
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Scheme 3.17. Possible products for reaction of triol 116 using stannylene acetal chemistry. 
 
Nevertheless, the stannylene acetal of triol 116 was formed by heating under 
reflux with dibutyltin oxide in toluene for 18 h through a Soxhlet apparatus 
containing 3 Å molecular sieves.  The toluene was removed under reduced 
pressure yielding a waxy solid, which was dissolved in DMF.  PMBCl, TBAI and 
CsF were added to the solution of stannylene acetal and the reaction heated to 
50 °C.  This reaction formed two major products, work-up and isolation of these 
products revealed two mono protected PMB ethers in a 2:1 ratio.  The major 
product was revealed as the desired 3-position PMB ether 136 isolated in 50% 
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yield and the stereochemistry was assigned by 1H, COSY, HSQC and HMBC 
NMR analysis (vide infra).  The minor 4-position PMB ether 137 was isolated in 
23%, the remaining mass can be accounted for as unreacted starting material, 
no other regioisomers were observed (scheme 3.18). 
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Scheme 3.18. Synthesis of racemic and enantiopure 3-position PMB ethers.  Reagents and 
conditions: i. (a) Bu2SnO, toluene, reflux, (b)TBAI, PMBCl, CsF, 50°C, 50% yield.  
Enantiomerically pure synthesis of 3-position PMB ethers.  Reagents and conditions: ii. AcCl, 
CH2Cl2, MeOH, RT, 76%; iii. (a) Bu2SnO, toluene, reflux, (b)TBAI, PMBCl, CsF, 50°C, 50% yield. 
 
The reaction proved reliable and repeatable on a large scale; the separation of 
the two observed regioisomers was readily achieved with a single silica gel 
chromatographic column.  In order to produce the enantiomerically enriched PMB 
ether of 138, a solution of alcohol 104 in CH2Cl2 and MeOH was treated with 
acetyl chloride to effect the methanolysis of the camphor acetal, this gave the 
enantiomerically pure triol 138 in 76% yield.  This reaction gave enantiomerically 
pure 139 using the conditions described above (scheme 3.18). 
It was important to correctly assign the regiochemistry observed in formation of 
compound 139, this was achieved using a combination of 1D and 2D 1H and 13C 
NMR techniques.  The 2-position proton expresses a very characteristic signal in 
the 1H NMR spectrum, as it is the only proton that has two equatorial-axial 
couplings, as a result this proton is easily assigned.  Using the 2D 1H-1H COSY 
the 2-position proton showed two correlations at 3.3 ppm and 3.5 ppm (fig. 3.3).  
The signal at 3.5 ppm showed correlation to an alcohol peak and the signal at 
3.3 ppm did not show correlation to an alcohol, this rules out the possibility of the 
compound being the 4-position PMB ether 140.  The signal at 3.5 ppm also 
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showed two correlations at 3.7 ppm and 4.0 ppm.  The signal at 4.0 ppm 
corresponds to the already assigned 2-position proton.  However, the signal at 
3.7 ppm does not show a correlation to an alcohol, this rules out the presence of 
a vicinal diol and so consequently rules out the possibility of the compound being 
the 1-position PMB ether 123.  This process of elimination provides strong 
evidence for the compound being substituted at the 3-position.  Using 1H-13C 2D 
HSQC and HMBC NMR techniques the 1H signal at 3.3 ppm (now firmly 
assigned as 3-position proton) showed a 13C HSQC correlation at 83 ppm (fig. 
3.4).  The 13C signal at 83 ppm showed a strong HMBC correlation to two 1H 
signals at 4.55 ppm and 4.65 ppm (fig. 3.4), these signals correspond to the AB 
quartet of the benzylic protons belonging to the PMB ether.  This confirms that 
the PMB ether has formed selectively at the 3-position. 
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Figure 3.3. 1H-1H NMR correlation spectrum (COSY) of diol 139, the dashed red lines indicate 
protons that couple to one another.  Structure of 139 and diagram showing the coupling of the 
ring protons and their coupling constants in Hz (J values were obtained from the 1D 1H NMR 
spectrum). 
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Figure 3.4. 1H-13C hetronuclear single quantum coherence (HSQC [multiplicity edited, CH2 
signals in green and CH and CH3 signals in blue]) overlayed with 1H-13C hetronuclear multiple 
bond coherence (HMBC [signals in red]) of diol 139. 
 
Having successfully installed the desired PMB ether reliably on the 3-position 
hydroxyl group, removal of the allylic ether to furnish triol 106 was attempted 
(table 3.3).  Initial conditions using Wilkinson’s catalyst to isomerise, followed by 
acidic cleavage gave the desired triol 106 in 49% yield (entry 1, table 3.3).  Loss 
of material was observed as the propyl ether which is formed by reduction of the 
double bond and which is not hydrolysable under standard acidic conditions.  
Therefore the BuLi modified method was attempted, however after 6 hours under 
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reflux in the presence of the modified catalyst no isomerisation to the enol ether 
was observed (entry 2, table 3.3). 
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Entry Conditions Reaction Time Yield 
1 i. Wilkinson’s catalyst, Hünig’s base, EtOH, 
reflux 
ii. AcCl, MeOH, CH2Cl2, RT 
8 h 49% 
2 i. Wilkinson’s catalyst, nBuLi, THF, -78 °C to 
reflux 
ii. AcCl, MeOH, CH2Cl2, RT 
No reaction n/a 
3 Pd(PPh3)4, AcOH, RT 48 h 93% 
4 Pd(PPh3)4, AcOH, 80 °C 6 h 89% 
Table 3.3. Summary of conditions for the removal of allylic ether from intermediate 139 
 
A literature search was conducted in order to find alternative conditions that 
might effect the allyl removal with improved yields.  Conditions published by 
Kusama and co workers in 1991,100 described a simple procedure where 
treatment of a number of allylic ethers with catalytic Pd(PPh3)4 in glacial acetic 
acid furnished the desired alcohol in less than 6 h at 80 °C with excellent yield.  
Therefore, a solution of allylic ether 139 in glacial acetic acid was treated with 
Pd(PPh3)4 but due to the possible acid sensitivity of the PMB ether present in the 
molecule the reaction was conducted at room temperature as opposed to 80 °C.  
The reaction proceeded smoothly but was sluggish at room temperature 
requiring 48 h and almost stoichiometric Pd(PPh3)4 to complete.  However, upon 
work up and chromatographic purification the desired triol 106 was achieved in 
93% yield (entry 3, table 3.3).  The reaction was repeated at 80 °C where 
completion was observed within 6 h and with an 89% isolated yield of triol 106.  
Almost stoichiometric amounts of Pd(PPh3)4 were still required but no hydrolysis 
of the PMB ether was observed under the heated conditions (entry 4, table 3.3). 
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Small quantities of triphenylphosphine impurities were observed in the 1H NMR 
of the product, although these were easily removed by re-crystallisation of triol 
106 from ethyl acetate and petroleum ether.  A further improvement in the purity 
of the reaction was found when using freshly made Pd(PPh3)4, which is made in 
one step from PdCl2 by treatment with triphenylphosphine and hydrazine hydrate 
in DMSO (scheme 3.19). 
i
PdCl2 Pd(PPh3)4  
Scheme 3.19. Synthesis of Pd(PPh3)4. Reagents and conditions: i. PdCl2, PPh3, DMSO, 
hydrazine hydrate, 140 °C ' 125 °C, quantitative yield. 
 
Although the regioselectivity of PMB ether 139 was fully assigned by NMR 
analysis, removal of the allylic ether gave triol 106 that was sufficiently crystalline 
enabling the acquisition of a single crystal X-ray structure (fig. 3.5).  This 
confirmed the initial NMR assignment by clearly showing the relative position of 
the PMB ether at the 3-position. 
 
Figure 3.5. Single crystal X-ray structure of the triol 106 (C=green, O=red). 
 
3.7. Synthesis of alcohol 108 
Having achieved a robust synthesis of the desired PMB ether 106, installation of 
the fully benzyl protected phosphates to give the PMB protected trisphosphate 
107 was required.  A reliable method for the installation of fully benzyl protected 
phosphates, and one successfully utilised within the group for the synthesis of 
Ins(1,3,4,5)P4 analogues, reacts the appropriate alcohol with bis(benzyloxy)-N,N-
diisopropylamino phosphine in the presence of catalytic 1H-tetrazole.  This 
reaction gives the corresponding inositol phosphine, which is subsequently 
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oxidised with 3-chloroperoxybenzoic acid (mCPBA) to yield the desired 
benzylphosphate ester. 
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Scheme 3.20. Synthesis of alcohol 108.  Reagents and conditions: i. (a) bis(Benzyloxy)-N,N-
diisopropylamino phosphine, 1H-tetrazole, CH2Cl2, RT, (b) 3-Chloroperoxybenzoic acid, -78°C 
89% yield; ii. TMSCl, anisole, SnCl2, CH2Cl2, RT, 19%-77% yield. Synthesis of bis(benzyloxy)-
N,N-diisopropylamino phosphine 142; iii. PCl3, pyridine, BnOH, diisopropylamine, Et2O, 81% 
yield; iv. 1H-tetrazole, BnOH, CH2Cl2, 88% yield. 
 
 
Thus, bis(benzyloxy)-N,N-diisopropylamino phosphine was successfully prepared 
using a literature procedure from phosphorus trichloride (PCl3) scheme 3.20.  
PCl3 was firstly cautiously reacted with 1 equivalent of BnOH followed by excess 
diisopropyl amine in diethyl ether and stoichiometric pyridine to give the desired 
benzyloxy bis(N,N-diisopropylamino)phosphine 141.  No purification of 141 was 
attempted so the crude material was carefully reacted with 1 equivalent of BnOH 
and 1H-tetrazole in CH2Cl2, purification by flash silica gel column 
chromatography gave the desired bis(benzyloxy)-N,N-diisopropylamino 
phosphine reagent 142 in 88% yield (scheme 3.20).  The triol 106 was reacted 
with excess bis(benzyloxy)-N,N-diisopropylamino phosphine 142 and catalytic 
1H-tetrazole in CH2Cl2 at room temperature for 18 h.  The crude reaction mixture 
was then oxidised with mCPBA at -78 °C and upon work up and chromatographic 
purification, the desired trisphosphate 107 was isolated in 89% yield (scheme 
3.20).  The subsequent step was to remove the PMB ether, furnishing the 
potentially versatile alcohol 108 (scheme 3.21).  Widely used and reliable 
procedures for this transformation use oxidative cleavage using either ceric 
ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). 
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Scheme 3.21. Common methods for the removal of PMB ethers. 
 
Work reported within the group successfully removed a PMB ether with CAN in 
the presence of multiple fully benzyl protected trisphosphates in high yield.31,91,92  
Therefore, 107 was treated with 2.5 eq of CAN at room temperature in 
MeCN/H2O, this appeared to cleave the PMB ether as adjudged by TLC analysis.  
The reaction was sluggish and required further equivalents of CAN after 12 h.  
Isolation of the major product gave a sticky solid in 42% yield (table 3.4).  1H 
NMR analysis indicated that the desired product had formed but both 1H and 31P 
NMR analysis showed impurities that could not be seen by TLC analysis.  The 
reaction was repeated using half the amount of solvent, this appeared to greatly 
increase the rate and yield (73 %) of reaction and eliminated the need for extra 
CAN (table 3.4).  Chromatographic purification followed by 1H and 31P NMR 
analysis showed an increase in the same impurities observed in the initial 
reaction.  On close inspection of the NMR data these impurities were attributed 
the migration of the sterically strained 4-position protected phosphate migrating 
to the less constricted 3-position of the inositol ring (fig. 3.6). 
 
• Oxidative cleavage 
• Brønsted acid 
• Lewis acid 
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Figure 3.6. 31P NMR spectrum of alcohol 108 after deprotection with CAN showing migration at a 
9:1 ratio of non-migrated to migrated product. 
 
Exhaustive silica gel column chromatography failed to separate the undesired 
regioisomer formed by the migration. 
A pH measurement showed that the addition of CAN lowers the reaction pH to 
around pH 1.  It was postulated that this strong acidity might be facilitating the 
migration.  Different work conducted within the group also encountered problems 
due to the acidity caused by CAN, the solution in this case was to buffer the 
reaction at neutral pH, this did not appear to affect the reactivity of CAN and 
prevented product degradation.  Therefore, a reaction was carried out where a 
pH 7 concentrated trisborate EDTA buffer was added to a solution of 107 prior to 
the addition of CAN, this proved to be effective in buffering the reaction to a pH 7, 
however, no reaction was observed.  Dilution of the buffer solution simply failed 
to effectively buffer the reaction and as a result a pH of 1 was observed.  This 
acidity, however, allowed the reaction to proceed but 1H and 31P NMR analysis of 
the products showed that migration had occurred. 
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As migration of the phosphates leads to inseparable regioisomers of 108, 
different reaction conditions were needed in order to obtain 108 pure, the results 
of this study are summarised in table 3.4. 
 
Type Conditions Conc. of 12 / 
mg ml-1 
Time Yield Migration 
CAN, MeCN/H2O, RT 10 24 h 42% Yes 
CAN, MeCN/H2O, RT 25 12 h 73% Yes 
CAN, conc. Trisborate 
EDTA pH 7 buffer, 
MeCN/H2O, RT 
10 48 h No reaction, 
staring material 
reclaimed 
N/A 
CAN, 5( diluted Trisborate 
EDTA pH 7 buffer, 
MeCN/H2O, RT 
25 24 Complex mixture Yes 
CAN, AcCN/H2O, 0 °C 15 12 h 30% Yes 
DDQ, CH2Cl2/H2O, RT, acid 
work-up 
10 12 h 70% Yes (moderate) 
DDQ, CH2Cl2/H2O, RT, 
basic work-up 
10 12 h - Yes 
(considerable) 
DDQ, CH2Cl2/H2O, RT, 
neutral work-up 
10 12 h - Yes 
O
xi
da
tiv
e 
I2, MeOH, reflux 30 12 h Complex mixture Complex 
mixture 
TMSI (2 eq), CHCl3, RT 78 24 h No reaction, 
staring material 
reclaimed 
N/A 
Ac
id
ic
 
AcOH, 90 °C 25 18 h Complex mixture Complex 
mixture 
ZrCl4, MeCN 10 24 h No reaction, 
staring material 
reclaimed 
N/A 
TMSCl, anisole, SnCl2, 
CH2Cl2, RT 
10 15 
min 
15% Yes 
Le
w
is
 A
ci
d 
TMSCl, anisole, SnCl2, 
CH2Cl2, RT 
5 3 h Variable 77%-19% No 
Table 2.4. Summary of conditions for the synthesis of 108. 
 
Cooling the reaction of CAN with PMB ether 107 had the effect of significantly 
slowing the reaction but unfortunately had negligible effect on the amount of 
phosphate migration observed.  DDQ effected the PMB cleavage more rapidly 
than CAN but the initial conditions gave considerable migrated products. The 
work-up procedure for this reaction washes the organic component with a 
NaHCO3 solution, this removes a large amount of the phenolic by-products as 
the phenolate salts.  Basic conditions, albeit strongly basic (such as NaH or 
NaOH), are known to cause considerable phosphate migrations.  By changing 
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the work-up procedure of the DDQ reaction to a weakly acidic one, purification 
was harder but migration was significantly reduced from an 18:1 ratio to a 4:1 
ratio of migrated to non-migrated product (fig. 3.7).  This result indicates that 
even weak base should be avoided.  Neutral work-up conditions for the DDQ 
cleavage still showed migration indicating that this is inherent in using DDQ. 
 
 
Figure 3.7. Showing the decreased migration from a basic work-up procedure A compared to an 
acid work-up B. 
 
With the oxidative cleavage of the PMB ether leading to phosphate migrations, 
another avenue had to be explored.  Many methods for the selective removal of 
A 
B 
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PMB ethers involve the activation of the PMB group via Lewis acid coordination 
followed by cleavage either hydrolytically or with a sacrificial nucleophile.  Of the 
Lewis acid catalysed methods known, a procedure described by Ozaki and co-
workers was attempted on this system.101  This method involved the reaction of 
PMB ether with TMSCl, anisole and a catalytic amount of SnCl2.  The reaction 
was very fast reaching completion within 15 minutes.  It did, however, only yield 
15% crude material and also showed migration.  Nevertheless, it was postulated 
that diluting the reaction might slow it enough to a controllable rate and also 
reduce the occurrence of phosphate group migration.  The reaction was, 
therefore, repeated with a two-fold dilution.  This dilution appeared to significantly 
reduce the reaction rate, which went to completion within 3 h, purification and 
isolation initially gave the desired product in 77% yield with no detectable 
migrated product.  Unfortunately, subsequent reactions using the same 
conditions on larger scale diminished the yield significantly, only isolating 19-40% 
of the clean product free from migration.  It was observed that the reaction time 
was also increased on the larger scale taking up to 6 h to complete.  TLC 
analysis showed the presence of baseline impurities, isolation and analysis, by 
1H and 31P NMR were of poor quality due to the amount of overlap so no firm 
structure could be postulated from the NMR alone.  However, mass spectrometry 
provided strong evidence that multiple de-benzylations were occurring during the 
reaction, showing a negative ion mass corresponding to M-Bn. 
The proposed mechanism for the PMB ether cleavage is the formation of a 
SnCl2-TMSCl complex that coordinates with the ether oxygen activating the 
benzylic position towards the formation of the cationic intermediate, which is 
stabilised in the case of PMB ether, this is then trapped out by the sacrificial 
nucleophile anisole (scheme 3.22).101 
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Scheme 3.22. Mechanism of PMB cleavage using TMSCl, SnCl2 and anisole.101 
 
The original paper reported benzyl ethers being stable under their conditions.  
This stability is presumably because the forming benzyl benzylic cation is not 
stabilised compared with PMB benzylic cation resulting in PMB groups reacting 
much faster.  However, in our system, because of the steric strain experienced 
by the vicinal phosphates, the loss of a benzyl group must be energetically 
favourable thus shifting the equilibrium of the process over to the more 
favourable debenzylated intermediate.  With extended reaction times on larger 
scale, the loss of material due to de-benzylation reduces the yield of the reaction.  
In addition, it was not possible to reliably repeat the reaction on the same scale 
that produced the initial high yield, therefore making this unsuitable for producing 
enough of the desired alcohol 108 for further elaboration to final compound 
precursors. 
 
3.8. Synthesis of benzoyl protected trisphosphate 145 
Given the poor yield and unreliable nature of the PMB deprotections, it was 
decided that an alternative protecting group strategy was required.  A literature 
search found a procedure whereby a benzoyl ester was removed using DIBALH 
from the 3-position hydroxy, in the presence of vicinal protected phosphates, in 
high yield and with no apparent phosphate migration (scheme 3.23).102 
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Scheme 3.23. Deprotection of benzoyl ester in the presence of vicinal phosphate diesters.102  
Reagents and conditions:  i. DIBALH, CH2Cl2, -78 °C, 84% yield. 
 
The vicinal phosphate esters in the published example are methyl protected, so it 
was a concern that DIBALH might react with the benzyl protected phosphates of 
the desired compound.  Hence, to check the stability of the bisbenzyl phosphate 
esters in the presence of DIBALH, a model system was used (scheme 3.24).  An 
additional concern is that DIBALH might facilitate migrations of the benzyl 
protected phosphates, however, the benefit of the method is that reactions are 
conducted at -78 °C so it was hoped that this temperature might prevent 
migration. 
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Scheme 3.24. Model system for the deprotection of benzoyl ester in the presence of fully benzyl 
protected phosphate ester.  Reagents and conditions: i. Bu2SnO, toluene, benzoyl chloride, 
reflux, 50% yield; ii. (a) bis(Benzyloxy)-N,N-diisopropylamino phosphine, 1H-tetrazole, CH2Cl2, 
RT, (b) 3-Chloroperoxybenzoic acid, -78°C, 56% yield; iii. DIBALH, CH2Cl2, -78°C, 87% yield. 
 
Thus trans-cyclohexane diol 146 was mono protected as the benzoylester by 
reaction with dibutyltin oxide and benzoyl chloride under reflux in toluene, with a 
Dean-Stark apparatus attached for the azeotropic removal of water.  This 
reaction gave the desired monobenzoyl ester 147 in 50% yield.  147 was then 
reacted with excess bis(benzyloxy)-N,N-diisopropylamino phosphine 142 and 
catalytic 1H-tetrazole in CH2Cl2 at room temperature for 18 h.  The crude reaction 
mixture was then oxidised with mCPBA at -78 °C and, upon work up and 
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chromatographic purification, the desired monophosphate 148 was isolated in 
56% yield.  A solution of monophosphate 148 in CH2Cl2 was cooled to -78 °C and 
treated with DIBALH, consumption of the starting material was observed within 
15 min, corresponding with the formation of a new product observed by TLC 
analysis.  The reaction was quenched at -78 °C and after work-up and 
purification, analysis showed that alcohol 149 was isolated in 87% yield.  No 
debenzylation of the protected phosphate ester was observed (scheme 3.24). 
As a result of the test reaction, it was desirable to attempt a reaction on the real 
substrate.  In order not to waste enantiomerically pure material the decision was 
made to conduct the synthesis of the desired benzoyl protected trisphosphate 
145 racemically (scheme 3.25). 
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Scheme 3.25. Synthesis of alcohol 108 using benzoyl protection of 3-position hydroxyl. Reagents 
and conditions: i. Bu2SnO, toluene, benzoyl chloride, reflux, 60% yield; ii. Pd(PPh3)4, AcOH, RT, 
86% yield; iii. (a) bis(Benzyloxy)-N,N-diisopropylamino phosphine, 1H-tetrazole, CH2Cl2, RT, (b) 
3-Chloroperbenzoic acid, -78°C, 56% yield; iv. DIBALH, CH2Cl2, -78°C. 
 
Therefore racemic triol 116 was mono protected in a similar fashion as before, by 
reaction of 116 with dibutyltin oxide and benzoyl chloride in refluxing toluene with 
a Soxhlet apparatus containing 3 Å molecular sieves for the removal of water.  
This gave the desired monobenzoyl ester 150 in 60% yield.  The regiochemistry 
was assigned by 1H NMR analysis as the 3-position benzoyl ester, no other 
regioisomers were observed from the reaction.  Removal of the allylic ether to 
furnish the triol 151 was achieved in 86% yield by stirring diol 150 with Pd(PPh3)4 
in glacial acetic acid at room temperature.  Reaction of 151 with excess 
bis(benzyloxy)-N,N-diisopropylamino phosphine 142 and 1H-tetrazole in CH2Cl2 
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at room temperature for 18 h gave the crude phosphine that was then oxidised 
with mCPBA at -78 °C.  Upon work up and chromatographic purification the 
desired trisphosphate 145 was isolated in 70% yield.  A solution of trisphosphate 
145 in CH2Cl2 was therefore cooled to -78 °C and treated with DIBALH, an 
attempt to monitor phosphate migration during the reaction by 31P NMR analysis 
failed to give clear phosphorus signals probably due to metal ion coordination by 
the aluminate species present in the reaction mixture.  Nevertheless 
consumption of the starting material was observed after 2.5 h.  Work-up and 
isolation of the product showed that removal of the benzoyl ester group had been 
achieved but a significant amount of phosphate group migration had also 
occurred. 
 
3.9. Summary 
The synthesis of 3-position modified Ins(1,3,4,5)P4 derivatives requires masking 
the 3-position hydroxyl group with an appropriate protecting group.  The 
protection of the 3-position hydroxyl group using stannylene acetal chemistry, 
with a PMB ether, was initially found to be difficult when protecting groups were 
present at the 1-position.  The poor reaction yields and difficult regioisomer 
separations, experienced with early reactions, were overcome when it was found 
that the stannylene acetal chemistry works well on triol 138.  It was found that the 
PMB protecting group, could be installed onto the 3-position hydroxyl of triol 138, 
in remarkably good yield and good selectivity.  The success of this reaction 
allowed for the reliable synthesis of PMB trisphosphate 107.  However, reaction 
conditions for the subsequent removal of the PMB group, to furnish the desired 
alcohol 108, were not reliable, often causing phosphate group migration or 
debenzylation.   This prompted the exploration for a different protecting group; 
the literature suggested that the benzoyl ester might be a good alternate.102  The 
installation of the benzoyl ester protecting group, onto the 3-position hydroxyl 
group of triol 116, worked in higher yield and better selectivity, compared with the 
PMB ether.  This successful reaction allowed for the reliable synthesis of benzoyl 
ester trisphosphate 145.  However, the published conditions for the DIBALH 
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mediated removal of the ester, to furnish alcohol 108, resulted in a significant 
amount of phosphate migration.   
It has become clear that in order to make multiple derivatives of Ins(1,3,4,5)P4 
modified at the 3-position, it is crucial to have a robust synthesis of alcohol 108.  
This requires protection of the 3-position hydroxyl group with a protecting group 
that is easily removed under mild conditions, avoiding strong acid or base.  There 
is seemingly a strong thermodynamically favourable arrangement of the 
benzylphosphate esters that surround the inositol ring.  Therefore, in order to 
minimise the steric strain experience by the vicinal phosphates of alcohol 108 it 
seems only to require moderately activating conditions to promote phosphate 
migration or de-benzylation. 
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4. Results and Discussion Part 2: The synthesis of 5-position 
modified Ins(1,3,4,5)P3 analogues 
 
4.1. Synthetic Targets 
With work on-going towards the synthesis of 3-position modified PtdIns(3,4,5)P3 
analogues, the focus of the project shifted towards the synthesis of 5-position 
modified PtdIns(3,4,5)P3 derivatives.  Again, completing mono-substitution of all 
the phosphate groups surrounding the inositol ring of Ins(1,3,4,5)P4 is desirable 
as it will allow us to assess the importance of each phosphate for binding to 
specific PH domains.  Knowing the positions where modification is well tolerated 
will allow us to synthesise more targeted analogues, hopefully giving extra 
binding affinity and improved selectivity towards specific PH domains. 
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Figure 4.1. 5-Position modified targets. 
 
As before, due to the basic nature of the PKB-PH domain it is desirable to install 
acidic isosteric phosphate mimics such as those outlined in fig. 4.1.  These 
isosteres should bear a reduced charge compared to that of the native 
phosphate.  It is also desirable to install 5-position phosphate replacements 
analogous to those already synthesised at the 1- and 4-positions, such as the 
methylene phosphonate 24, sulfate 25, and sulfate 28; this strategy will allow for 
the direct comparison between regioisomers. 
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4.2. Retrosynthesis 
A general retrosynthetic analysis for 5-position modified Ins(1,3,4,5)P4 
derivatives, is represented in scheme 4.1.  The approach that was used for the 
work towards 3-position derivatives was employed for the synthesis of 5-position 
derivatives.  Thus, the desired final compounds 155 would be achieved from a 
global de-protection of fully benzyl protected precursor compound 154.  
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Scheme 4.1. General retrosynthesis for 5-position InsP4 derivatives. 
 
It was desirable to synthesise the 5-position alcohol trisphosphate 153, which 
can potentially undergo multiple derivatisations to give a range of precursors 154.  
Masking the 5-position alcohol requires the presence of an appropriately 
orthogonal protecting group, the simplest way to achieve this is to preserve the 
allyl protecting group that is already present in enantiopure alcohol 104.  
Phosphitylation of enantiopure triol 138 would then give the orthogonally 
protected trisphosphate 152.  It was hoped that conditions for removal of the allyl 
protecting group from 152 would furnish alcohol 153 reliably, in high yield and, 
importantly, free from phosphate migration. 
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4.3. Synthesis of the trisphosphate 153 
The synthesis of enantiomerically pure alcohol 104 is described in chapter 2 and 
was conducted on multi-gram scale to provide material for the development of 
the 5-position synthesis. 
The synthesis of the allyl-protected trisphosphate 152 proved to be 
straightforward (scheme 4.2).  Firstly, removal of the camphor auxiliary from 
alcohol 104 was achieved by acidic methanolysis, to give the enantiomerically 
pure triol 138, in 76% yield.  Triol 138 was reacted with excess bis(benzyloxy)-
N,N-diisopropylamino phosphine 142 and catalytic 1H-tetrazole in CH2Cl2 at 
room temperature for 18 h.  The crude reaction mixture was oxidised with 
mCPBA at -78 °C and, upon work-up and chromatographic purification, the 
desired trisphosphate 152 was isolated in 89% yield (scheme 4.2). 
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Scheme 4.2. Synthesis of alcohol 153.  Reagents and conditions: i. AcCl, CH2Cl2/MeOH, RT, 
76% yield; ii. (a) bis(Benzyloxy)-N,N-diisopropylamino phosphine, 1H-tetrazole, CH2Cl2, RT, (b) 
3-Chloroperoxybenzoic acid, -78°C, 89% yield; iii. PdCl2, MeOH, RT, 65% yield. 
 
Having isolated trisphosphate 152, it was important to have optimal conditions for 
the removal of the allyl protecting group.  In the first instance, using the 
conditions optimised for allyl removal of 139 described in chapter 2, a solution of 
trisphosphate 152 in glacial acetic acid was treated with freshly prepared 
Pd(PPh3)4 at room temperature.  Complete consumption of the starting material 
was observed after 18 h, requiring over 2 equivalents of the catalyst. These 
conditions led to the appearance of new baseline products, as observed by TLC 
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analysis.  Work-up and isolation of the major product, however, gave the desired 
5-position alcohol in 55% yield assigned by 1H NMR analysis.  Gratifyingly, the 
1H and 31P NMR assignment showed that the product was free from phosphate 
migration (fig. 4.2). 
 
Figure 4.2. 31P NMR spectrum of 5-position alcohol 153 showing the three main signals 
corresponding to the phosphate groups and an additional triphenyl phosphine impurity. 
 
Due to the high polarity of the trisphosphate, purification via silica gel column 
chromatography failed to effectively remove all of the triphenyl phosphine from 
the catalyst.  A signal for this impurity can be seen in the 31P NMR spectrum at 
29.3 ppm (fig. 4.2).  Multiple chromatographic columns eventually yielded the 
pure substrate, however, this further diminished the yield of the product.  For a 
robust synthesis a higher yielding and more reliable allyl deprotection was 
desirable, therefore, some optimisation studies were conducted, the results of 
which are summarised in table 4.1.  As was observed with the synthesis of triol 
139 in chapter 3, it was hoped that heating might boost the rate of reaction and 
thus reduce the number of equivalents of Pd(PPh3)4 required, thus reducing the 
OPO(OBn)2BnO
(BnO)2OPO
(BnO)2OPO
OH
OBn
153
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amount of PPh3 impurity.  Indeed, by heating the reaction to 80 ºC complete 
consumption of starting material was observed within 6 h with only 0.5 
equivalents of Pd(PPh3)4 required.  However, equally lengthy column 
chromatography was required to remove the triphenyl phosphine impurities, 
ultimately with a reduction in the isolated yield (entry 2, table 4.1).  Stripping the 
chromatographic column with a high polarity flush obtained material present at 
the base-line of the TLC analysis.  Mass spectrometry of these products showed 
the presence of [M+NH4·MeCN]+ in positive ionisation mode (fig 4.3) and [M-H]- 
in the negative ionisation mode for the mono de-benzylated alcohol, indicating 
that at least some loss of material was due to de-benzylation of the product. 
 
 
Figure 4.3. Mass spectrum of baseline material.  Electrospray ionisation in positive mode, 
showing m/z 1109 [M+NH4·MeCN]+ corresponding to debenzylated material. 
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Entry Conditions Time Yield 
1 Pd(PPh3)4 (2 eq), AcOH, RT 18 h 55% 
2 Pd(PPh3)4 (0.5 eq), AcOH, 80 ºC 6 h 34% 
3 PdCl2 (8 eq), MeOH, RT 5 h 64% 
4 PdCl2 (2 eq), MeOH, RT (with oxidative work-up) 5 h 65% 
Table 4.1. Summary of condition for the removal of allylic ether from compound 152. 
 
A search of the literature to find alternative methods for a mild cleavage of allylic 
ethers was conducted.  This search found many conditions that use palladium 
chloride (PdCl2) for the removal of allylic ethers from various oligo-saccharides 
that contain diverse functionality.103-105  Initially, using the conditions reported by 
Mandai et al.,103 a solution of allyl ether 152 in methanol was treated with 8 
equivalents of PdCl2; the reaction proceeded smoothly to completion within 5 h.  
Purification, however, proved troublesome requiring three silica gel 
chromatographic columns to yield pure material.  It was subsequently found that 
only 2 equivalents of palladium were necessary to perform the deprotection with 
no increase in reaction time.  An oxidative work-up procedure for the removal of 
ruthenium residues is described (vide infra).  It was postulated that the same 
work-up procedure might help with the removal of palladium residues from this 
reaction.  Therefore, the organic fraction of the aqueous work-up was washed 
with an aqueous solution of hydrogen peroxide, this resulted in considerable 
effervescence and some dark precipitate, which was removed by filtration.  
However, this wash significantly reduced the colouration of the organic fraction 
and ultimately only a single flash chromatographic column was required to obtain 
the desired alcohol 153 in an equivalent yield (entry 4, table 4.1).  In the 
ruthenium example (vide infra), the hydrogen peroxide oxidises the metal to give 
the insoluble ruthenium(IV) oxide which is removed by filtration.  In this case it 
could be possible that palladium(II) chloride is oxidised to a water soluble 
palladium(IV) species or potentially the palladium(II) chloride could undergo 
hydrolysis to form hydrated palladium(II) oxide.  This reaction was repeatable; 
however, on a larger-scale the reaction time was extended and significant de-
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benzylation was observed.  Therefore, to produce larger quantities of the desired 
alcohol 153, several small-scale reactions were conducted in parallel; once 
complete they were combined for work-up and purification, which avoided 
significant loss of material through de-benzylation due to extended reaction time. 
 
4.4. Synthesis of the methyl phosphate ester 157 
Having developed a reliable synthesis of alcohol 153, studies could begin 
towards the incorporation of isosteric phosphate replacements.  As described in 
chapter 2, it was desirable to incorporate groups with a reduced charge.  It was 
also very important that conditions used to install the isosteres were mild.  The 
presence of the three protected phosphates in alcohol 153 provided challenges 
to overcome when installing the desired phosphate isosteres.  Firstly, steric 
crowding around the inositol ring would likely limit the size of the functionality that 
could be installed at the free hydroxyl.  Secondly, relief from the steric strain 
experienced by the trisphosphate might occur via phosphate migration or 
debenzylation, seen during the synthesis of both the 3-position and 5-position 
alcohols, 108 and 153.  Therefore, it was desirable to find mild reaction 
conditions that would avoid these potential tranformations.  From the work 
carried out for the synthesis of the 3- and 5-position alcohols it was known that 
strong base, strong Brønsted and Lewis acids should be avoided. 
It was, therefore, envisioned that a simple and mild method to synthesise an 
interesting isostere would be to incorporate the benzyl protected methyl 
phosphate ester.  This synthesis could be achieved by reaction with the 
appropriate phosphoramidite 159, followed by oxidation which, upon global 
deprotection, would yield the desired methyl phosphate ester 157 (scheme 4.3).  
Phosphoramidite 158 was, therefore, prepared from PCl3 using a modification of 
conditions published by Bannwarth in 1987.106  The benzyloxy bis(N,N-
diisopropylamino)phosphoramidite 141 was prepared as described in chapter 3, 
then treated with 1 equivalent methanol in the presence of 1H-tetrazole to give 
the desired phosphoramidite 158 in 76% yield (scheme 4.3). 
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Scheme 4.3. Synthesis of the 5-position methyl phosphate ester, Ins(1,3,4,5)P4 derivative.  
Reagents and conditions: i. (a) Phosphoramidite 158, 1H-tetrazole, CH2Cl2, RT, (b) 
3-Chloroperoxybenzoic acid, -78°C, 79% yield; ii. NaHCO3, Pd black, H2, tBuOH/H2O, RT, 83% 
yield.  Synthesis of phosphoramidite 158.  Reagents and conditions: iii. PCl3, Py, BnOH, 
diisopropylamine, Et2O, 81% yield; iv. 1H-tetrazole, MeOH, CH2Cl2, 76% yield. 
 
Phosphoramidite 158, in excess, was then reacted with alcohol 153 in the 
presence of 1H-tetrazole at room temperature.  Once consumption of the starting 
material was observed, the reaction was cooled to -78 °C and the crude 
phosphite oxidised, using mCPBA, to give the phosphate.  Work-up and 
purification gave the desired methyl phosphate ester 156 in 79% yield as a 1.3:1 
mixture of diastereomers and importantly without any phosphate migration, as 
adjudged by 1H and 31P NMR spectroscopy (fig. 4.4).  Figure 4.4 shows the four 
phosphorus signals of the 31P NMR spectrum, which correspond to each 
phosphate of 156, it can be seen that each signal is split into what look like 
doublets.  This splitting corresponds to the major and minor diastereomers of 
156, formed by the reaction of alcohol 153 with the racemic phosphoramidite 
158.  From the observed diastereomeric ratio, it can be seen that the reaction 
does not form a completely racemic mixture, indicating that the alcohol 153 
imparts some stereo-control on the formation of the phosphite. 
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Figure 4.5. 31P NMR of methylphosphate ester 156, showing the four phosphorus signals 
corresponding to each phospate of 156.  Each signal is split into two, corresponding to the major 
and minor compounds of the diastereomeric mixture. 
 
The global deprotection of the benzyl protecting groups proceeded smoothly. Pd-
black catalysed hydrogenolysis was conducted in the presence of NaHCO3 to 
give the presumed heptasodium salt.  Isolation of the product gave the final 
compound 157 in 83% yield without the need for further purification. 
 
4.5. Synthesis of Sulfamate 160 
A common isosteric replacement for phosphates is a sulfamate group.  This 
group can potentially act both as a hydrogen bond acceptor through the lone 
pairs of electrons on the oxygen and nitrogen atoms, or as a hydrogen bond 
donor through the hydrogens bonded to nitrogen.  Common methods for 
sulfamoylation use sulfamoyl chloride with excess base and, when conducted in 
DMF, can produce undesired side products.  However, an effective procedure for 
the sulfamoylation of a wide range of alcohols was reported by Okada et al. in 
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2000.107  This method simply involves treating the alcohol or phenol with 
sulfamoyl chloride in dimethyl acetamide (DMA); giving the desired sulfamate 
with excellent conversion and high isolated yields.  The DMA in this case acts as 
both reaction solvent and base. 
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Scheme 4.4. Synthesis of the 5-position sulfamate Ins(1,3,4,5)P4 derivative. Reagents and 
conditions: i. Sulfamoyl chloride 162, DMA, 0 °C ' RT, 50% yield; ii. NaHCO3, Pd black, H2, 
tBuOH/H2O, RT, 84%.  Synthesis of sulfamoyl chloride 162.  Reagents and conditions: iii. Formic 
acid, CH2Cl2, 0 °C, used as a 2.50 M solution in CH2Cl2. 
 
Sulfamoyl chloride is highly unstable, so sulfamoyl chloride was freshly prepared 
from chlorosulfonyl isocyanate (CSI), by treatment with formic acid at 0 °C.  This 
reaction gave the crude sulfamoyl chloride, which was used as a 2.50 M solution 
in CH2Cl2 without further purification (scheme 4.4).   
A solution of the trisphosphate 153 in DMA was cooled to 0 °C and treated with 
the freshly prepared sulfamoyl chloride 162.  The reaction proceeded smoothly to 
completion within 18 h, as adjudged by TLC analysis.  Isolation and purification 
of the major product gave the desired sulfamate 159 in 50% yield (scheme 4.4).  
The global deprotection by hydrogenolysis of precursor 159, using the conditions 
described previously but in the presence of 6 equivalents of NaHCO3, gave the 
desired final compound 160 in 84% yield, without the need for further purification. 
 
4.6. Attempted synthesis of sulfate 164 
Having successfully synthesised the 5-position sulfamate derivative 160 it was 
desirable to make the 5-position sulfate 164, for direct comparison.  With the 
sulfate bearing a more acidic O-H than the N-H of the sulfamate, interesting 
information regarding the importance of pKa towards PtdIns(3,4,5)P3 binding 
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could be gained from these derivatives.  In addition, it would be interesting to 
compare these compounds with the 4-position sulfate previously synthesised 
within the group.31 
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Scheme 4.4. Attempted synthesis of sulfate 5-position Ins(1,3,4,5)P4 derivative. Reagents and 
conditions: i. SO3·Pyridine complex, 50 °C, DMF; ii. NaHCO3, Pd black, H2, tBuOH/H2O, RT. 
 
Sulfation of alcohol 153 was attempted using conditions that were previously 
optimised within the group for the synthesis of the 4-position sulfate.  Thus, 
alcohol 153 was stirred with excess sulfur trioxide pyridine complex (SO3·Py) as 
a solution in DMF at 50 °C (scheme 4.4).  Consumption of the starting material 
was observed by TLC analysis coinciding with the formation of a new major 
product.  Mass spectrometry analysis found [M+H]+ and [M+NH4·MeCN]+ 
corresponding to the desired sulfate 163.  Unfortunately, isolation and purification 
proved difficult; silica gel column chromatography allowed isolation of the desired 
spot in 50% crude yield.  1H and  31P NMR analysis indicated that the desired 
sulfate had been formed; however, the product was not pure enough for the 
global deprotection step.  Further attempts to purify the sulfate, through 
additional chromatography and ion exchange resin, diminished the yield of the 
material and failed to improve the quality of the compound.  Compound 163 
proved to be intrinsically unstable even when refrigerated indicated by the 
observation of peaks corresponding to [M-SO3H]- and [M-Bn]- in the mass 
spectrum of the material as well as the observation of more polar impurities and 
starting material by TLC analysis.  This indicated the compound was breaking 
down both through the loss of the sulfate moiety and the debenzylation of the 
phosphate diesters. 
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4.7. Attempted Synthesis of Methyl Phosphonate 166 
Another interesting phosphate isostere is the methyl phosphonate group.  The 
methyl phosphonate was successfully utilised by van Boom and co-workers 
during the published synthesis of methyl phosphonate containing Ins(1,4,5)P3 
analogues.108,109   
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Figure 4.6. Methyl phosphonate containing Ins(1,4,5)P3 analogues 
 
Their work indicated that racemic analogue 43 (fig. 4.6) showed weak 
antagonistic activity against Ins(1,4,5)P3 receptors, however, no biological data 
were published to support their claim.  Subsequent unpublished work within our 
group successfully synthesised 43 in an enantiomerically pure fashion (44, fig. 
4.6).  Preliminary biological results suggest analogue 44, behaves as an 
antagonist for Ins(1,4,5)P3 receptors.  For this reason it would be interesting to 
assess whether a similar modification would be tolerated within PH-domains. 
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Scheme 4.5. Attempted synthesis of the 5-position methylphosphonate Ins(1,3,4,5)P4 derivative 
166. Reagents and conditions: i. (a) 169, Py, 20 °C, 10 min, (b) BnOH; ii. NaHCO3, Pd black, H2, 
tBuOH/H2O, RT.  Synthesis of phosphonating reagent 169.  Reagents and conditions: iii. 
Hydrazine hydrate, ethanol, RT, 48% yield; iv. Methyl phosphonic dichloride, HOBT 168, Py, 
dioxane, used crude as a 0.125M solution in dioxane. 
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To install the methyl phosphonate on alcohol 153, the highly reactive 
phosphonating reagent 169 was made, following van Boom’s original method 
(scheme 4.5).108  Firstly, trifluoromethyl hydroxybenzotriazole 168 was made by 
treating the trifluoromethyl nitrobenzene 167 with hydrazine hydrate in ethanol, 
giving the desired HOBT 168 in 48% yield.  The phosphonating reagent 169 was 
then made by reaction of methyl phosphonic dichloride with the HOBT 168 in the 
presence of pyridine.  Due to the high reactivity of the phosphonating reagent 
169 no purification was attempted and the material was used as a crude 0.125 M 
solution in dioxane. 
Alcohol 153 was dried over P2O5 for 18 h prior to reaction with phosphonating 
reagent 169.  This procedure ensured that as much water as possible was 
excluded from the reaction, thereby reducing any problematic side reactions.  Dry 
pyridine was added to alcohol 153 and kept at 20 °C for the addition of 
phosphonating reagent 169.  Once the reagent 169 was added, consumption of 
the starting alcohol 153 was observed almost instantly.  After 10 min, dry benzyl 
alcohol was added and the reaction stirred for a further 2 h.  TLC analysis 
indicated a new major product had formed and mass spectrometry showed 
[M+H]+ and [M+H·Py]+ for the desired product.  Unfortunately, as with the 5-
position sulfate precursor 163, the methylphosphonate 165 proved inherently 
unstable.  Purification by silica gel chromatography led to degradation of the 
product, and thus 165 could not be obtained with the required purity to perform 
the global deprotection. 
 
4.8. Synthesis of Carboxylate 173 
The synthesis of analogues using the 5-position alcohol as a handle for 
modification proved moderately successful.  However, problems experienced 
with the stability of the precursor compounds have so far limited the utility of this 
approach.  With work on-going regarding elaboration of alcohol 153, our attention 
was drawn towards alternative approaches towards 5-position derivatives. 
The precursor to alcohol 153 is the 5-position allyl protected ether 152.  It was 
postulated that the double bond of the allyl protecting group might be able to 
 106 
undergo some interesting chemistry to attain 5-position derivatives that might be 
difficult to obtain via alcohol 153.  The presence of the double bond presents 
numerous possibilities that are not easily available from the alcohol such as, 
Grubbs cross metathesis, epoxide formation, halogenation, oxidative or reductive 
cleavage, and dihydroxylation.  A literature search was conducted to find if 
reactions of this sort had been previously employed on inositol substrates.  This 
search highlighted one paper by Potter et al. in which oxidative cleavage of the 
allylic double bond to give the carboxylic acid was achieved in the presence of 
three cyanoethyl protected phosphates in good yield (scheme 4.6).110  It was 
hoped that using similar conditions would yield the carboxylic acid without 
affecting the benzyl protected phosphates. 
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Scheme 4.6. Published synthesis of carboxylic acid 171 from allylic ether.110 Reagents and 
conditions: i. RuCl3·H2O, NaIO4, CCl4, MeCN, H2O, RT, 64% yield. Synthesis of carboxylate 5-
position Ins(1,3,4,5)P4 derivative 173.  Reagents and conditions: ii. RuCl3·H2O, NaIO4, CCl4, 
MeCN, H2O, RT, 40% yield; iii. NaHCO3, Pd black, H2, tBuOH/H2O, RT, 85% yield. 
 
The allylic ether 152 was treated with sodium periodate and ruthenium(III) 
chloride at room temperature.  The reaction proceeded smoothly with 
consumption of starting material observed after 2 h.  Work-up and isolation of the 
major product gave an oil that was contaminated with ruthenium by-products.  1H 
and 31P NMR analysis showed that the desired carboxylate 172 had formed 
(scheme 4.6); unfortunately repeated silica gel chromatography, reverse phase 
and ion exchange chromatography all failed to remove the black colouration from 
the ruthenium adducts.  The compound also proved to be fairly unstable and 
ultimately decomposed during the various purification techniques attempted.  
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However, unpublished work conducted by Knight in Cardiff also experienced 
problems with ruthenium by-products.  It was discovered that by conducting an 
oxidative wash using H2O2 solution during the aqueous work-up procedure they 
could oxidise any remaining ruthenium(III) to ruthenium(IV) oxide.  The insoluble 
ruthenium(IV) oxide could be removed through filtration, giving sub PPM levels of 
ruthenium in their desired product.  Consequently the oxidative cleavage of allylic 
ether 152 was repeated which again smoothly proceeded to completion, giving 
the desired carboxylic acid 172.  An oxidative work-up procedure using a 15% 
aqueous solution of H2O2 was employed; after the copious effervescence 
subsided the phases were filtered through Celite.  Isolation of the major product 
by column chromatography gave the desired carboxylic acid 172, free from 
ruthenium impurities. 
Having successfully isolated carboxylic acid 172, global benzyl group 
deprotection was attempted under standard conditions in the presence of 7 
equivalents of NaHCO3.  This reaction proceeded smoothly to give the desired 
carboxylate 173 as the sodium salt in 85% yield, without the need for further 
purification. 
 
4.9. Summary 
A robust synthesis of the enantiomerically pure 5-position alcohol trisphosphate 
153 has been developed.  The utility of this approach was justified by the 
successful synthesis of two 5-position modified Ins(1,3,4,5)P4 derivatives, methyl 
phosphate ester 157 and sulfamate 160 (fig. 4.4).  However, the number of 
analogues produced was limited due to the instability of the final compound 
precursors for a number of potential 5-position Ins(1,3,4,5)P4 derivatives. 
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Figure 4.4. Summary of final comound 5-position modified Ins(1,3,4,5)P4 derivatives 
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An alternative approach was employed, making use of the chemistry available 
from reactions with the 5-position allyl ether 152.  Oxidative cleavage of the allylic 
ether double bond enabled the successful synthesis of the enantiomerically pure 
5-position carboxylate Ins(1,3,4,5)P4 derivative 173 (fig. 4.4). 
The three new 5-position derivatives 157, 160 and 173 were submitted to 
biological analysis to assess their binding affinity for both the PBK and GRP1 PH 
domains. 
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5. Results and Discussion Part 3: The synthesis of 1-position 
modified Ins(1,3,4,5)P4 analogues 
 
5.1. Synthetic targets 
Having successfully synthesised a collection of novel 5-position modified 
Ins(1,3,4,5)P4 analogues, our attention was drawn towards expanding the 
number of 1-position modified Ins(1,3,4,5)P4 analogues (fig. 5.1). 
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Figure 5.1. 1-Position modified targets. 
 
Work conducted within the group by Nemeth,31 successfully synthesised two 
novel 1-position modified Ins(1,3,4,5)P4 derivatives, the sulfate 175 and the 
racemic methylene phosphonate 174 (fig. 5.2).  These compounds were tested 
for their binding affinity towards the PKB and GRP1 PH domains.  Neither 
analogue was shown to possess any binding affinity towards the PKB PH 
domain, however, both modifications were well tolerated within the GRP1 PH 
domain. 
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Figure 5.2. 1-Position modified Ins(1,3,4,5)P4 analogues synthesised within the group.31 
 
In the first instance, it was desirable to resynthesise the methylene phosphonate 
174 in enantiomerically pure form.  This compound would be re-tested to assess 
whether any weak binding could be observed with the PKB-PH domain, as it is 
expected that in the enantiomerically pure form the compounds should be twice 
as potent, that is assuming that the L-enantiomer always shows no binding 
affinity.  The sulfate 175 and methylene phosphonate 174, showed almost 
equivalent binding affinity for the GRP1 PH domain.  It is, therefore, desirable to 
synthesise a greater range of 1-position derivatives, to assess the impact of the 
different phosphate isosteres towards GRP1 and PKB PH domain binding. 
 
5.2. Retrosynthesis 
A general retrosynthesis of the enantiopure 1-position derivatives of 
Ins(1,3,4,5)P4 178, is represented in scheme 5.1.  The strategy towards 1-
position derivatives was the same general approach that was used successfully 
for the synthesis of 5-position modified Ins(1,3,4,5)P4 derivatives.  In this 
approach, the final compounds 178, are obtained by a global debenzylation of 
the appropriate precursor compounds 177, which in-turn, are synthesised from 
the trisphosphate 176. 
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Scheme 5.1. A general retrosynthesis for 1-position modified ins(1,3,4,5)P4 derivatives. 
 
The desired alcohol trisphosphate 176 can be obtained from the enantiomerically 
pure alcohol 104 using the reliable synthetic route established by Nemeth.31 
 
5.3. Synthesis of Alcohol trisphosphate 176 
Commencing from the enantiomerically pure alcohol 104, the 1-position hydroxyl 
was protected using TIPSOTf and Et3N as opposed to TIPSOTf and 2,6-lutidine, 
which was utilised in the racemic synthesis of alcohol 176.  The modified 
conditions gave the TIPS ether 121 in 87% yield.  In the racemic synthesis of 
alcohol 176, triol 177 was made via sequential deprotection of intermediate 121.  
Firstly methanolysis of the camphor acetal gave diol 105; then methanolysis of 
the vinyl ether of 105, formed through isomerisation of the allylic ether with 
Wilkinson’s catalyst, gave the desired triol 177.  As both these deprotections 
utilise acid methanolysis it was postulated that both removal of the camphor 
acetal and the allylic ether could be accomplished in one pot. 
 
 112 
OHBnO
O
O
OAll
OBn
OTIPSBnO
O
O
OAll
OBn OTIPSBnO
HO
OH
OH
OBn
OTIPSBnO
(BnO)2OPO
OPO(OBn)2
OPO(OBn)2
OBn
OHBnO
(BnO)2OPO
OPO(OBn)2
OPO(OBn)2
OBn
i ii
iii
iv
104 121 177
178176  
Scheme 5.2. Synthesis of enantiopure alcohol 176. Reagents and conditions: i. TIPSOTF, Et3N, 
CH2Cl2, RT, 87% yield; ii. PdCl2, MeOH, RT, 81% yield; iii. (a) bis(Benzyloxy)-N,N-
diisopropylamino phosphine, 1H-tetrazole, CH2Cl2, RT, (b) 3-Chloroperoxybenzoic acid, -78°C 
86% yield; iv. TBAF, THF, RT, 81% yield. 
 
A solution of intermediate 121 in ethanol was treated with Hünig’s base and 
Wilkinson’s catalyst and heated under reflux.  These conditions effected the 
isomerisation of allylic ether 121 to the vinyl ether within 3 h, as adjudged by 1H 
NMR analysis.  After replacing the reaction solvent with methanol, the reaction 
was treated with 4-TsOH.  Acid-catalysed methanolysis of both the vinyl ether 
and the camphor acetal was indeed accomplished; with the desired triol 177 
isolated in 37% yield.  However, the low yield of the two simultaneous 
deprotections was not optimal, therefore, the Pd(PPh3)4 catalysed conditions for 
the removal of allyl groups published by Kusama and co-workers,100 
(successfully employed for the removal of allylic ether from diol 139 in chapter 3 
giving PMB-triol 106 in high yield) were investigated.  It was hoped that the same 
conditions might enhance the one-pot hydrolysis of 121 to give triol 177 in 
improved yield.  Therefore, a solution of intermediate 121 in glacial acetic acid at 
80 °C, was treated with Pd(PPh3)4.  These conditions completed the desired 
transformation within 3 h, however, work-up and purification gave the triol in only 
32% yield. In addition, 1H and 31P NMR analysis showed that some 
triphenylphosphine impurities were present.  The triphenylphosphine impurities 
were a problem during the synthesis of the 5-position alcohol 153, described in 
chapter 3, the answer to this problem was to use PdCl2 for the allyl removal.  
Therefore, a solution of intermediate 121 in methanol was treated with PdCl2 at 
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room temperature.  The reaction proceeded smoothly, going to completion within 
5 h; after work-up and simple purification the desired triol 177 was isolated in 
81% yield (scheme 5.1). 
Having developed a more robust and shorter synthesis of triol 177, the remaining 
synthetic steps were accomplished in accordance with the route developed by 
Nemeth.  Thus, triol 177 was reacted with excess bis(benzyloxy)-N,N-
diisopropylamino phosphine 142 and catalytic 1H-tetrazole in CH2Cl2 at room 
temperature for 18 h.  The crude reaction mixture was oxidised with mCPBA at 
-78 °C and upon work-up and chromatographic purification the desired 
trisphosphate 178 was isolated in 86% yield (scheme 5.1).  The TIPS protected 
trisphosphate 178 was treated with TBAF in THF to affect the deprotection, 
affording alcohol 176 in 81% yield (scheme 5.1). 
 
 
5.4. Attempted synthesis of methylene phosphonate 182 
The initial aim of this synthesis was to repeat the synthesis of 174 in 
enantiomerically pure form, using the previously established chemistry.  The 
methodology used involved reacting the dibenzyl phosphonomethyl triflate 185 
with alcohol 179 in the presence of sodium hydride.  These conditions gave the 
desired product, after exhaustive chromatography, in 24% yield.  In this reaction, 
the use of sodium hydride was unavoidable, and as a result one can presume 
migration of the phosphates did occur, which might account for the poor overall 
yield of the reaction. 
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Scheme 5.2. Synthesis of racemic methylenephosphonate Ins(1,3,4,5)P4 analogue 174. 
Reagents and conditions: i. Triflate 185, NaH, THF, -78 °C to RT, 24% yield; ii. NaHCO3, Pd 
black, H2, tBuOH/H2O, RT, 93% yield. Attempted synthesis of enantiomerically pure 
methylenephosphonate 182. Reagents and conditions: iii. Triflate 185, NaH, THF, -78 °C to RT. 
Synthesis of dibenzyl phosphonomethyl triflate 185. Reagents and Conditions: iv. 
Paraformaldehyde, Et3N, 130 °C, 25% yield; v. Trifluoromethanesulfonic anhydride, 2,6-lutidine, 
CH2Cl2, 75% yield. 
 
 
The dibenzyl(hydroxymethyl)phosphonate 184 was synthesised according to the 
literature procedure,111 by heating dibenzyl phosphite with paraformaldehyde and 
triethylamine at 130 °C for 20 min (scheme 5.2).  After silica gel chromatographic 
purification, dibenzyl(hydroxymethyl)phosphonate 184 was isolated in 24% yield.  
Despite the poor yield, enough material was made in order to synthesise the 
required dibenzyl phosphonomethyl triflate 185.  This synthesis was 
accomplished using the literature procedure,112 in which a solution of 
dibenzyl(hydroxymethyl)phosphonate 184 at -78 °C was treated with 
trifluromethane sulfonic anhydride and 2,6-lutidine.  After work-up and isolation, 
the desired triflate was obtained in 75% yield (scheme 5.2). 
Having made the required triflate, the same conditions used by Nemeth to make 
the racemic methylenephosphonate 180 were employed on the enantiomerically 
pure alcohol 176.  This reaction involved adding sodium hydride to a cooled 
solution of alcohol 176 and excess triflate 185.  It was hoped that having the 
triflate in excess and keeping the reaction cold, would reduce the chance of 
intermolecular phosphate migration, via attack of the alkoxide on a phosphate of 
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another molecule.  However, as was found with the racemic synthesis, in order 
for the reaction to progress the mixture needed to warm to room temperature.  
Upon being allowed to slowly warm to room temperature, complete consumption 
of the starting material was observed within 2 h.  After work-up the major product 
was isolated by silica gel column chromatography.  1H and 31P NMR analysis 
showed that the desired methylenephosphonate had indeed formed, however, a 
significant proportion of phosphate migration has also occurred.  Repeated 
attempts to purify the compound via silica gel column chromatography, failed to 
separate the regioisomers and so the required purity for the global deprotection 
was not achieved. 
Having been unsuccessful in repeating the methylenephosphonate synthesis 
using the established chemistry, alternative methods were considered.  The 
fundamental problem with the reaction is that, in order to condense alcohol 176 
with alcohol 184 to give ether 181 (scheme 5.3), alcohol 184 requires activation 
by formation of triflate 185, and alcohol 176 requires activation via the alkoxide, 
which promotes phosphate migration.  We therefore require milder conditions 
that avoid alkoxide formation.  A common method to avoid activation of an 
alcohol by alkoxide formation is to activate the donor alcohol as a highly reactive 
leaving group.  This activation is often achieved by the formation of the 
trichloroacetimidate (TCA) 186, then reacting this with the desired alcohol via 
Lewis acid activation (scheme 5.3). 
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Scheme 5.3. Mild ether formation via use of trichloroacetimidate 186. 
 
It was desirable to investigate whether the trichloroacetimidate of alcohol 184, 
would be reactive enough to undergo substitution without activation of alcohol 
176 via the alkoxide.  Hence, a study was conducted using model system 
whereby trichloroacetimidate 187 was synthesised and tested for reactivity 
against the simple model alcohol 188 with a range of Lewis acids. 
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Scheme 5.4. Model system for the mild synthesis of the methylenephosphonate 189. Reagents 
and conditions: i. Trichloroacetonitrile, DBU, CH2Cl2, 0 °C to RT, 58% yield. Synthesis of model 
alcohol 189. Reagents and conditions: ii. NaH, BnBr, DMF, 0 °C to RT, 48% yield. 
 
The model alcohol acceptor 188 was synthesised in one step from trans-
cyclohexane-1,2-diol by alkylation with benzyl bromide and sodium hydride.  This 
reaction gave the model alcohol 188 in 48% yield.  The trichloroacetimidate 187 
was synthesised using standard conditions, whereby a solution of alcohol 184 in 
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dry CH2Cl2 at 0 °C was treated with trichloroacetonitrile and DBU.  This reaction 
furnished the desired TCA-reagent in 58% yield.  Having successfully 
synthesised the required reagents for the study, the trichloroacetimidate 
reactions were setup in parallel to test both a range of Lewis acid activators and 
some different reaction solvents reaction solvents.  The results of the study are 
summarised in table 5.1. 
 
Entry Lewis Acid Solvent Temperature Reaction Observation 
1 TMSOTf THF RT Complex mixture, solvent polymerised 
2 BF3·Et2O THF RT Complex mixture, solvent polymerised 
3 SnCl4 THF RT Complex mixture, solvent polymerised 
4 AgBF4 THF RT Complex mixture, some TCA hydrolysis 
product 
5 TMSOTf CH2Cl2 RT No reaction after several days, starting 
material present 
6 BF3·Et2O CH2Cl2 RT Complex mixture of products 
7 SnCl4 CH2Cl2 RT No reaction after several days, starting 
material present 
8 AgBF4 CH2Cl2 RT No reaction after several days, starting 
material present 
Table 5.1. Summary of conditions used, for the reaction of TCA-reagent 187 with model alcohol 
acceptor 188. 
 
When designing the experiment the choice of solvent was based on the 
requirement that it needed to be a polar aprotic solvent; DMF was avoided in the 
study as it was thought that Lewis acid coordination with the carbonyl of DMF 
might lead to undesirable side reactions.  Therefore, THF and CH2Cl2 were 
chosen as reaction solvents.  For each test reaction a solution of alcohol 188 in 
the desired solvent, was treated with TCA reagent 187, followed by 0.1 molar 
equivalents of the appropriate Lewis acid.  The reactions were stirred at room 
temperature and monitored by both TLC analysis and mass spectrometry.  It 
quickly became apparent that THF was a poor choice of reaction solvent, as 
polymerisation of the solvent was observed, forming a thick gel that stalled all 
stirring (entries 1-3, table 5.1).  Presumably, the Lewis acids were coordinating 
with the lone pair on the oxygen of the THF ring activating it towards nucleophilic 
attack from another THF ring.  All the reactions using THF as a solvent formed 
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complex mixtures, no potential products were observed by either TLC or mass 
spectrometry. 
Switching the solvent to CH2Cl2 resolved the problem of solvent polymerisation, 
however, TMSOTf, SnCl4, and AgBF4 (entries 5,7 and 8, table 5.1) failed to 
promote any reaction with the alcohol acceptor even after several days and with 
extra Lewis acid equivalents added.  Ultimately, [M+H]+ for the hydrolysed TCA-
reagent and [M+H]+ for the starting alcohol were the only discernable mass ions 
observed in the mass spectrum of the reaction mixture.  BF3·Et2O (entry 6, table 
5.1) saw rapid consumption of starting material, unfortunately, many products 
were observed by TLC analysis and mass spectrometry showed none of the 
desired mass ions.  It became apparent that the trichloroacetimidate was too 
stable and that the secondary alcohol was too poor a nucleophile to react, even 
with the Lewis acid activated donor.  This result brought us to postulate 
alternative stratagies for increasing the reactivity of the methylene phosphonate 
donor. 
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Scheme 5.5. Model system for the mild synthesis of methylenephosphonate 189. Reagents and 
conditions: i. (a) Trifluoroacetamide, DMSO, oxalyl chloride, Et3N, CH2Cl2, -78 °C, (b) alcohol 
184, DBU, CH2Cl2, -78 °C to RT, 40% yield. 
 
A literature search found a report describing the use of trifluoroacetimidates 
(TFA) as an alternative to trichloroacetimidates.113,114  The CF3 unit has greater 
electronegativity and is thus, better able to stabilise the negative charge upon 
cleavage of the C-O bond, making it a better leaving group and a more reactive 
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species, often reacting via Brønsted acid catalysis rather than Lewis acid 
catalysis.  It was hoped that the trifluoroacetimidate 190 would, therefore, be 
reactive enough to undergo our desired transformation.  To synthesise the 
trifluoroacetimidate 190, the literature contained similar methods to the synthesis 
of TCA reagents, utilising trifluoroacetonitrile as opposed to trichloroacetonitrile.  
The drawbacks to using trifluoroacetonitrile are that it is relatively expensive and 
is a highly toxic gas that requires a complicated setup.  However, another 
method described in the literature makes use of trifluoroacetamide.114  This much 
cheaper starting material is converted to trifluoroacetonitrile, in situ, via a Swern-
type oxidation, which then reacts with the desired alcohol to give the required 
trifluoroacetimidate.  Thus, to a solution of trifluoroacetamide in CH2Cl2 at -78 °C 
was added DMSO followed by oxalyl chloride and triethylamine.  The reaction 
was stirred at -78 °C for 40 min before the addition of alcohol 184 as a solution in 
CH2Cl2.  After purification by flash silica gel column chromatography, the desired 
trifluoroacetimidate 190 was isolated in 40% yield.  Having successfully isolated 
the TFA reagent 190, the coupling was attempted using a literature procedure.  A 
solution of model alcohol 188 in CH2Cl2 was treated with TFA reagent 190 and 
pyridinium 4-toluenesulfonate (PPTS) at room temperature.  The reaction was 
monitored by mass spectrometry and TLC analysis, but after several days only 
starting materials remained and no sign of a new product was observed.  
Eventually, hydrolysis of the TFA reagent back to alcohol 184 was observed.  
The reaction was repeated using TMSOTf as opposed to PPTS, to see if Lewis 
acid catalysis would promote the reaction, but as before, only starting material 
was observed after several days. 
Both the TCA and TFA reagents were unreactive towards the secondary alcohol 
model compound 188.  One can tentatively explain this lack of reactivity when 
looking at the possible mechanism.  During the transition state there is nothing to 
stabilise the developing positive charge on the methylene carbon.  The electron 
withdrawing dibenzylphosphonate is # to the methylene carbon, thus formation of 
positive charge at this position is unfavourable. 
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Having failed to effectively activate the oxygen of alcohol 184 as a good leaving 
group, one more approach was considered before concentrating on other 
phosphate isosteres.  It has been shown that alkyl bromides can undergo 
substitution with alcohols at room temperature in the presence of silver(I) 
oxide,115 without the need of strong base to activate the alcohol.  For this reason, 
the bromide 191 was also made for testing with the model alcohol 146 (scheme 
5.6). 
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Scheme 5.6. Model system for the mild synthesis of methylenephosphonate 189. Reagents and 
conditions: i. PPh3, CBr4, Et2O, RT, 29% yield. Conditions: (a) Silver(I) oxide, DMF, RT; or (b) 
Silver(I) oxide (freshly prepared), DMF, RT. 
 
The bromide 191 was accessed via an Appel-like reaction,116 taking a solution of 
alcohol 184 in diethylether and treating this with carbon tetrabromide and 
triphenylphosphine gave the bromide 191 in 29% yield.  Using conditions 
described in the literature for a similar process, a solution of model alcohol 146 
and bromide 191 in DMF was treated with silver(I) oxide.  The reaction was 
stirred at room temperature and monitored by TLC and mass spectrometry 
analysis.  Due to the light sensitive nature of silver(I) oxide, the reaction was kept 
in the dark.  However, as before no reaction was observed even with further 
additions of bromide 191 and silver(I) oxide and with heating.  It was noted in the 
literature that reactions of this sort often require freshly prepared silver(I) oxide, 
because it’s intrinsic instability towards light. 
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Scheme 5.7. Synthesis of silver(I) oxide. Reagents and conditions: i. NaOH, H2O, RT, 48% yield. 
 
Silver(I) oxide was prepared by treating silver(I) nitrate with sodium hydroxide 
solution (scheme 5.7), the silver(I) oxide precipitate was isolated by filtration.  
The coupling reaction was repeated using the freshly prepared silver(I) oxide.  
However, this modification had no effect on the outcome of the reaction.  No 
reaction occurred after several days and with heating. 
 
5.5. Attempted synthesis of sulfamate 195 
The synthesis of the enantiomerically pure methylene phosphonate 182 using the 
established chemistry was unsuccessful, and the development of a new milder 
approach for its synthesis did not produce the desired results.  Consequently, our 
focus shifted towards expanding the range of 1-position Ins(1,3,4,5)P4 derivatives 
using chemistry that has been established for the installation of phosphate 
isosteres on similar derivatives.  The successful synthesis of a novel 5-position 
modified sulfamate derivative 160 was described in chapter 3.  It was hoped that 
using the same chemistry on the 1-position alcohol 176 would yield the sulfamate 
precursor 194 which would in-turn give the novel 1-position modified sulfamate 
final compound 195 (scheme 5.8). 
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Scheme 5.8. Attempted synthesis of sulfamate 195. Reagents and conditions: i. Sulfamoyl 
chloride 162, DMA, 0 °C ' RT. Synthesis of sulfamoyl chloride 162.  Reagents and conditions: ii. 
CSI, formic acid, CH2Cl2, 0 °C, used as a 2.50 M solution in CH2Cl2. 
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Alcohol 176 was treated with sulfamoyl chloride in the manner described in 
chapter 4.  As previously observed, the reaction proceeded smoothly to 
completion within 18 h.  After work-up and purification 1H NMR analysis showed 
that the desired sulfamate had indeed formed, with [M+NH4·MeCN]+ for the 
required mass ion being observed in the mass spectrum.  However, the 31P NMR 
revealed other phosphorus peaks shouldering the three major peaks, which is 
indicative of migration.  A higher resolution 1H NMR spectrum showed small 
peaks in the inositol region that had previously been over-lapped by the major 
inositol signals, which again provides evidence that phosphate migration had 
occurred.  Further attempts to purify the product, using column chromatography, 
failed to give any improvement in the quality of the material. 
 
5.6. Attempted synthesis of methylphosphonate 197 
The installation of the methylphosphonate isosteric phosphate replacement has 
been conducted successfully within the group for the synthesis of Ins(1,4,5)P3 
derivatives.49  Installation of the methylphosphonate onto the 5-position alcohol 
as described in chapter 3 was unsuccessful.  It was hoped, however, that 
because the 1-position neighbours the axial 2-position benzyl ether, the less 
sterically demanding environment might lend itself to easier substitution and 
more stable precursors. 
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Scheme 5.9. Attempted synthesis of methylphosphonate 197. Reagents and conditions: i. (a) 
Phosphonating reagent 169, Py, 20 °C, 10 min, (b) BnOH; Synthesis of phosphonating reagent 
197.  Reagents and conditions: ii. HOBT 168, Py, dioxane, used crude as a 0.125 M solution in 
dioxane. 
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A solution of alcohol 176 in dry pyridine was treated with the phosphonating 
reagent 169, as before, the starting material was consumed within 15 min.  After 
this time the reaction was quenched with the addition of dry benzyl alcohol in 
order to displace the second HOBT unit, and form the desired benzyl protected 
methylphosphonate.  A new major product was observed by TLC analysis and 
mass spectrometry found [M+NH4·MeCN]+ corresponding to the desired 
methylphosphonate 196.  However, the compound was found to be highly 
unstable towards column chromatography, giving rise to products corresponding 
both to the starting material and to highly polar impurities corresponding to 
debenzylation products.  Attempts to purify the compound using neutral alumina 
and reverse phase chromatography, both failed to give any separation of 
products, with the compound being particularly unstable with regard to reverse 
phase chromatography.  As a result of the inherent instability towards standard 
purification techniques, the desired precursor compound 196 could not be 
synthesised with the required purity to conduct the global deprotection. 
 
5.7. Synthesis of methylphosphate ester 198 
A particularly interesting analogue to access was methylphosphate ester (fig. 
5.3) 1-position derivative of Ins(1,3,4,5)P4 198, as this compound resembles 
PtdIns(3,4,5)P3, more than any of the previous 1-position modified Ins(1,3,4,5)P4 
derivatives.  It was, therefore, expected that this compound might show high 
affinity for the PKB PH domain as well as be tolerated in the GRP1 PH domain. 
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Figure 5.3. Desired methyl phosphate ester analogue 198 and PtdIns(3,4,5)P3. 
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The methylphosphate ester isostere was successfully installed on the 5-position 
alcohol using phosphorus(III) chemistry, as described in chapter 4.  It was hoped 
that by utilising these same mild phosphitylation conditions the 1-position 
methylphosphate ester precursor compound 199 could be obtained (scheme 
5.10). 
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Scheme 5.10. Synthesis of methylphosphate ester Ins(1,3,4,5)P4 derivative 198. Reagents and 
conditions: i. (a) Phosphoramidite 158, 1H-tetrazole, CH2Cl2, RT, (b) 3-Chloroperoxybenzoic acid, 
-78°C, 83% yield; ii. NaHCO3, Pd black, H2, tBuOH/H2O, RT, quantitative yield.  Synthesis of 
phosphoramidite 158.  Reagents and conditions: iii. Py, BnOH, diisopropylamine, Et2O, 81% 
yield; iv. 1H-tetrazole, MeOH, CH2Cl2, 76% yield. 
 
The racemic phosphoramidite 158 was made in two steps, as described in the 
previous chapter.  A solution of alcohol 176 in CH2Cl2 was subsequently treated 
with excess phosphoramidite 158 in the presence of 1H-tetrazole.  The reaction 
proceeded smoothly to completion within 18 h, as adjudged by TLC analysis.  
Mass spectrometry analysis showed [M+NH4·MeCN]+ corresponding to the 
phosphorus(III) intermediate.  mCPBA was added to the reaction mixture at 
-78 °C and then the mixture was allowed to warm to room temperature, after 
which time oxidation to the phosphorus(V) species was deemed complete by 
TLC analysis.  Work-up and purification gave the desired methyl phosphate ester 
199 in 83% yield as a 1.3:1 mixture of diastereomers as adjudged by 1H NMR 
spectroscopy.  Importantly, there was no sign of migration products and, 
gratifyingly, the intermediate appeared stable towards column chromatography.  
Having obtained the precursor 199 in a pure form the global deprotection of the 
benzyl protecting groups proceeded smoothly.  The hydrogenolysis was 
conducted in the presence of NaHCO3 to give, what is assumed to be, the 
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hepta-sodium salt.  Isolation of the product gave the final compound 198 in 
quantitative yield without the need for further purification. 
 
5.8. Summary 
A synthetic route towards novel 1-position modified enantiomerically pure 
Ins(1,3,4,5)P4 derivatives had previously been established within the group.  This 
route involved the synthesis of enantiomerically pure alcohol 176 in five steps 
from the versatile alcohol 104.  An improvement to this synthesis has been made 
by the development of a one-pot synthesis of triol 177 from intermediate 104.  
This modification shortened the synthetic route and provided a more reliable and 
higher yielding synthesis of alcohol 176. 
Attempts to expand the range of enantiomerically pure 1-position modified 
Ins(1,3,4,5)P4 derivatives proved difficult.  The initial attempt to synthesise the 
methylenephosphonate derivative 182 was unsuccessful due to significant 
migration of the phosphate esters.  The migration was attributed to the use of the 
strong base, NaH.  Model studies were conducted, in an effort to discover a 
milder method for the incorporation of the methylene phosphonate unit, these 
however proved unsuccessful.  Migration was also observed during the 
attempted synthesis of the sulfamate analogue 195 and the methylphosphonate 
precursor 197 was found to be very unstable towards standard purification 
techniques. 
Using the phosphorus(III) chemistry that was developed for the successful 
synthesis of the 5-position methylphosphate ester derivative 157 (chapter 4),  it 
was possible to conduct the analogous reaction with the 1-position alcohol.  This 
reaction gave the 1-position methylphosphate ester precursor 199 in excellent 
yield and purity.  The presursor 199 subsequently underwent global deprotection 
to give the desired 1-position methylphosphate ester derivative 198. 
Having been successful in expanding the range of 1-position modified 
Ins(1,3,4,5)P4 derivatives, compound 198 was subjected to biological analysis to 
assess its binding affinity for both the PBK and GRP1 PH domains. 
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6. Results and Discussion Part 4: Biological Analysis of Novel 
PtdIns(3,4,5)P3 Analogues 
 
6.1. Binding of PtdIns(3,4,5)P3 Analogues to GRP1 PH domain 
The biological evaluation of our novel PtdIns(3,4,5)P3 analogues was conducted 
by our collaborators Professor Pete Downes and Dr Alex Gray at the College of 
Life Sciences, University of Dundee. 
As described in chapter 1, previously unpublished biological analysis was 
conducted on the compounds synthesised by Nemeth (fig. 6.1). 
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Figure 6.1. Compounds synthesised by Dr Joseph Nemeth for testing with GRP1 and PBK PH 
domains. 
 
The compounds synthesised by Nemeth were tested for binding affinity towards 
both the GRP1 PH domain and the PKB PH domain.  The results of these tests 
showed that both the 1-position modified PtdIns(3,4,5)P3 analogues 24 and 25 
bound to the GRP1 PH domain selectively over the PKB PH domain and that 
substitution of the 4-position phosphate was not tolerated by either PH domain 
containing protein. 
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6.2. Evaluation of PtdIns(3,4,5)P3 Analogues for GRP1 PH Domain Binding 
Having successfully synthesised a range of novel 5-position modified 
PtdIns(3,4,5)P3 analogues and expanded on the range of 1-position modified 
PtdIns(3,4,5)P3 analogues, these compounds were sent for biological evaluation 
to our collaborators in Dundee. 
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Figure 6.2. Novel PtdIns(3,4,5)P3 analogues for testing with GRP1 and PBK PH domains. 
 
The initial testing of these compounds was for binding affinity towards the GRP1 
PH domain.  The results are shown in figure 6.3. 
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Figure 6.3. Graphical representation of the fluorescence quenching experiment, examining the 
binding affinity of compounds 157, 160, 173 and 198 for the GRP1 PH domain compared with 
PtdIns(3,4,5)P3. 
 
Figure 6.3 shows the relative binding affinities of each ligand with the GRP1 PH 
domain.  The plot in red shows the natural ligand PtdIns(3,4,5)P3 binds strongly 
at concentrations above 1 µM.  All the 5-position modified PtdIns(3,4,5)P3 
analogues 157, 160 and 173 (plotted in black) showed no binding affinity to the 
GRP1 PH domain up to concentrations of 1000 µM.  The plot in blue shows that 
the 1-position modified methylphosphate ester analogue 198 possesses strong 
binding at concentrations above 10 µM.  These results reinforce and complement 
the results obtained from the analysis of our previous 1-position analogues 24 
and 25, as both these analogues showed binding to the GRP1 PH domain with 
an equivalent affinity to that of 198.  It is interesting to see that modification at the 
5-position, as with the 4-position modification, is not well tolerated for GRP1 PH 
domain binding, this indicates that both 4- and 5-position phosphates are crucial 
for binding.  Additionally, it is interesting to note that the 1-position 
methylphosphate ester 198 shows a 10 fold reduction in binding compared to 
that of the natural PtdIns(3,4,5)P3.  The methylphosphate ester analogue 198 
most closely resembles PtdIns(3,4,5)P3 the difference being the lack of the 
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glycerol lipid diester unit, indicating that the glycerol diester moiety must 
contribute to the strength of PtdIns(3,4,5)P3 binding. 
 
6.3. Evaluation of PtdIns(3,4,5)P3 Analogues for PKB PH Domain Binding 
Having generated data for the GRP1 PH domain binding, testing was conducted 
for binding to the PKB PH domain.  Our previous results showed that both the 
PKB and GRP1 PH domains did not tolerate modifications at both the 1- and 4-
position phosphates. 
 
 
Figure 6.4. Graphical representation of the fluorescence quenching experiment, examining the 
binding affinity of compounds 198 and 160 for the PKB PH domain compared with 
PtdIns(3,4,5)P3. 
 
Figure 6.4 shows that the natural ligand PtdIns(3,4,5)P3 (plot in red) binds with 
the PKB PH domain strongly above concentrations of 1 µM.  The plot in blue 
represents the 1-position modified methylphosphate ester 198 this shows binding 
to the PKB PH domain at concentrations above 10 µM.  This is the first analogue 
that we have produced that shows binding to the PKB PH domain, although it 
may not be surprising that this analogue does bind as 198 very closely 
resembles PtdIns(3,4,5)P3. As with the binding of methylphosphate 198 to the 
GRP1 PH domain, there is a significant reduction in affinity compared to that of 
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PtdIns(3,4,5)P3, indicating that again the glycerol diester moiety contributes to 
the binding strength in the PKB PH domain as well as to binding within the GRP1 
PH domain.  The plot in black represents the 5-position modified sulfamate 
analogue 160, interestingly this compound also shows binding to the PKB PH 
domain at concentrations above 10 µM.  The remaining 5-position analogues are 
yet to be tested for PKB PH domain binding affinity, nevertheless, the sulfamate 
present at this position is well tolerated, it can be hypothesised that the more 
acidic carboxylate and methylphosphate ester analogues might also show good 
binding with PKB PH domain, given the basic nature of the residues close to the 
5-position phosphate of Ins(1,3,4,5)P4 bound to the PKB PH domain.  We have 
now shown that some of our analogues are able to discriminate between the 
GRP1 and PKB PH domains.  The sulfamate 160 shows binding to PKB PH 
domain but not to the GRP1 PH domain, whereas both the sulfate 25 and 
methylene phosphonate 24 show binding to the GRP1 PH domain but not to the 
PKB PH domain.  This mutual selectivity really highlights the potential for the 
development of PH domain selective inhibitors. 
 
6.4. SAR of PtdIns(3,4,5)P3 Analogues to GRP1 PH domain Binding 
Having obtained biological data we can now use the published X-ray crystal 
structures of Ins(1,3,4,5)P4 bound PKB PH domain and Ins(1,3,4,5)P4 bound 
GRP1 PH domain to interpret our findings and start drawing up some structure 
activity relationship (SAR). 
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Table 6.1. Summary of novel PtdIns(3,4,5)P3 analogues and their biological activity. 
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Figure 6.5. PyMOL representation of the X-ray crystal structure of Ins(1,3,4,5)P4 bound GRP1 
PH domain.21  Expanded view of Ins(1,3,4,5)P4 binding mode. 
 
The X-ray crystal structure of Ins(1,3,4,5)P4 bound GRP1 PH domain was 
obtained by Lambright et al.21  From inspecting the binding of Ins(1,3,4,5)P4 in 
the GRP1 PH domain (fig. 6.5), it can be seen that the 4-position phosphate is 
deeply embedded within the binding pocket, forming a complex hydrogen 
bonding network with several amino acids and at least two conserved water 
molecules.  It is evident from our results that the 4-position phosphate is crucial 
for binding, as even with the highly acidic sulfate moiety, no affinity for the GRP1 
PH domain is observed.  Similarly, the 5-position phosphate forms multiple 
hydrogen bonds with several amino acids and conserved water molecules.  One 
can see from the PyMOL representation (fig. 6.5) that basic residues surround 
the 5-position phosphate.  Modification of the 5-position was not tolerated, 
despite replacing the phosphate with acidic functionality.  Clearly the 4- and 5-
position phosphates are equally important for GRP1 PH domain recognition.  
Interestingly a report by Lemmon et al.,37 comparing the binding affinity of a 
variety of multiply phosphorylated myo-inositols showed that Ins(1,3,4,5)P4 
bound the GRP1 PH domain very strongly with a KD $ 27 nM, but that 
Ins(1,3,4)P3 bound with an approximate KD $ 2 µM.  Our 5-position modified 
derivatives showed no binding affinity at concentrations up to 1000 µM, 
4-position phosphate 
5-position phosphate 
1-position phosphate 
3-position phosphate 
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suggesting that our phosphate replacements were more detrimental to binding 
than having no phosphate present at all. 
 
Modification of the 1-position phosphate of Ins(1,3,4,5)P4 was well tolerated 
within the GRP1 PH domain.  From the X-ray crystal structure (fig. 6.5), it can be 
seen that the 1-position phosphate is a lot more solvent exposed and only makes 
one hydrogen bonding interaction with Thr-280 on the !1/!2 loop, indicating that 
the 1-position is less important for GRP1 PH domain recognition, and thus 
tolerates modification well.  It will be interesting to test 3-position modified 
derivatives, as the 3-position phosphate in the GRP1 PH domain makes an 
equivalent number of hydrogen bonding interactions as the 4- and 5-position 
phosphates.  From this one can hypothesise that 3-position modifications are 
likely to not be well tolerated. 
 
6.5. SAR of PtdIns(3,4,5)P3 Analogues to PKB PH domain Binding 
The X-ray crystal structure of Ins(1,3,4,5)P4 bound PKB# PH domain was 
obtained by van Aalten and co workers (fig. 6.6).38  Direct comparison of 
Ins(1,3,4,5)P4 bound PKB# PH domain with the Ins(1,3,4,5)P4 bound GRP1 PH 
domain, one can immediately see that the Ins(1,3,4,5)P4 binds in the same 
mode, with the axial 2-position hydroxyl pointing down into the binding pocket. 
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Figure 6.6. PyMOL representation of the X-ray crystal structure of Ins(1,3,4,5)P4 bound PKB PH 
domain.38  Expanded view of Ins(1,3,4,5)P4 binding mode. 
 
The 4-position phosphate makes considerable hydrogen bonding interactions 
between residues on the !-4 and !-5 strands and a number of conserved water 
molecules (fig. 6.6).  This extensive hydrogen bonding network is clearly very 
important for Ins(1,3,4,5)P4 binding.  Our results show that even substituting the 
4-position phosphate with an acidic sulfate, removes any significant affinity for 
the PKB PH domain. 
It is interesting to note that the 3-position phosphate of Ins(1,3,4,5)P4 makes an 
equivalent number of hydrogen bonding interactions as the 4-position phosphate. 
Indicating that the 3-position phosphate might play a very important role in 
binding.  This importance is perhaps exemplified by the fact that Arg23 moves 
6.2 Å to bind with the 3-phosphate.  This observation suggests that modification 
at this position would likely be poorly tolerated.  Conversely, however, the report 
by Lemmon et al. in 1998,37 showed that Ins(1,4,5)P3 bound to the PKB# PH 
domain with KD $ 12 µM, indicating that potentially 3-position modification might 
be weakly tolerated. 
The 1-position phosphate of Ins(1,3,4,5)P4 makes a number of hydrogen bonds 
between variable loop 1 of the PKB PH domain and two of the oxygen atoms on 
4-position phosphate 
5-position phosphate 1-position phosphate 
3-position phosphate 
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the phosphate.  The methyl phosphate ester 198, which showed binding the PKB 
PH domain, also contains two unsubstituted oxygen atoms at the methyl 
phosphate moiety, this is presumably why this modification was tolerated.  
However, the sulfate and methylene phosphonate modified derivatives, 25 and 
24, did not bind.  These compounds most likely could not form the required 
orientation for making the comparable hydrogen bonds at variable loop 1 that the 
methyl phosphate ester 198 and Ins(1,3,4,5)P4 can make.  If one looks at the 
differences in binding of the 1-position phosphate in the PKB PH domain, 
compared with that of the 1-position phosphate in the GRP1 PH domain.  The 1-
position phosphate makes only one direct hydrogen bond with Thr280 on the !3-
!4 loop of the GRP1 PH domain whereas in the PKB PH domain it makes five 
hydrogen bonding interactions with Tyr18, Ile19 and Arg23 on variable loop 1.  
This significant difference highlights the importance of the 1-position phosphate 
for PKB-PH domain binding as well as explaining the observed tolerance that the 
GRP1 PH domain has for 1-position modified derivatives. 
The 5-position phosphate of Ins(1,3,4,5)P4 makes no direct hydrogen bonding 
interactions with the PH domain of PKB (fig. 6.6), which explains why the 5-
position modified sulfamate 160 showed binding, as no key binding interactions 
will have been disturbed upon the binding of 160.  Comparison of how the 5-
position phosphate of Ins(1,3,4,5)P4 interacts with the PH domains of both PKB 
and GRP1 reveals significant differences.  One can see that the 5-phosphate 
makes five direct hydrogen bonds with residues in the GRP1 PH domain (fig. 
6.5) compared to zero in the PKB PH domain (fig. 6.6).  This observation 
highlights the importance of the 5-position phosphate for GRP1 PH domain 
binding and explains the selectivity observed between the two PH domains. 
 
6.6. Summary 
We have been able to develop a range of PtdIns(3,4,5)P3 analogues and have 
tested them for binding to both the PKB PH and GRP1 PH domains.  Our results 
have shown, that for binding to either PH domain, the 4-position phosphate 
appears crucial.  As analogues bearing highly acidic phosphate isosteres at this 
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position showed no binding affinity.  The 1-position phosphate appears to be less 
important for GRP1 PH domain binding compared to that of PKB PH domain 
binding, with all 1-position analogues binding to the GRP1 PH domain.  The 5-
position phosphate appears to be very important for GRP1 PH domain binding, 
but much less important for PKB PH domain binding.  Due to these intrinsic 
differences within their PH domains, we have successfully synthesised mutually 
selective PH domain binders, with the 1-position sulfate 25 and methylene 
phosphonate 24 selectively binding the GRP1 PH domain over the PKB PH 
domain.  But the 5-position sulfamate 160 binding to the PKB PH domain 
selectively, over the GRP1 PH domain. 
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7. Results and Discussion Part 5: The synthesis of 
Phosphatidylinositol 
 
7.1. Synthetic Target 
Although the primary aim of the project is the synthesis of PtdIns(3,4,5)P3 
analogues, another important inositol phosphate is phosphatidyl inositol (PtdIns) 
13.  PtdIns is the biosynthetic precursor to phosphatidylinositol 3-phosphate, 
phosphatidylinositol 4-phosphate and phosphatidyl inositol 5-phosphate, which 
are subsequently transformed into the many and important multiply 
phosphorylated PtdInsPns, which play important roles in cellular signalling.   
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Figure 7.1. A general structure of PtdIns derivatives 13 and the structure of target dioctanoyl 
PtdIns 300. 
 
The structure of the lipid chain in PtdIns isolated from natural sources (13, fig. 
7.1) varies depending on the source.  Many synthetic PtdIns also vary in the type 
of lipid chain used.  We were interested in developing a robust synthesis of 
dioctanoyl PtdIns 200 (fig. 7.1); this has superior water solubility than other 
PtdIns derivatives, which has advantages when used for biological assays or in 
crystallisation studies. 
 
7.2. Retrosynthesis 
A general retrosynthesis for PtdIns 200 is represented in scheme 7.1.  The 
retrosynthesis of PtdIns 200 follows a similar approach to the one used for the 
successful synthesis of 1- and 5-position Ins(1,3,4,5)P4 derivatives, described in 
chapters 3 and 4. 
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Scheme 7.1. General retrosynthesis for dioctanoyl PtdIns 
 
The final compound 200 would be obtained from a fully protected precursor 
compound 204, via a global deprotection step.  The precursor compound 204 
can be broken into two fragments, the inositol fragment 201 and the phospholipid 
fragment 203.  The coupling of the two fragments will be mediated via the reliable 
phosphorus(III) chemistry employed for the installation of the benzyl protected 
phosphate esters and the methyl phosphate esters.  The inositol fragment 201 
could hopefully be obtained reliably from the versatile enantiomerically pure 
intermediate 104, and the lipid phosphoramidite 203 could be obtained from the 
enantiomerically pure (+)-1,2-O-isopropylidene glycerol 202.  As only a single 
position around the inositol ring is substituted, the key for the synthesis of insitol 
fragment 201 is to obtain the required 1-position orthogonality.  It was envisioned 
that this would be accomplished using the same method as was utilised within 
the synthesis of 1-position modified Ins(1,3,4,5)P4 derivatives described in 
chapter 4. 
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7.3. Synthesis of Inositol Fragment 201 
The synthesis of the required inositol fragment 201 commences from the 
enantiomerically pure alcohol 104.89  The synthesis of alcohol 104 was described 
in chapter 3. 
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Scheme 5.2. Synthesis of enantiomerically pure alcohol 201. Reagents and conditions: i. 
TIPSOTF, Et3N, CH2Cl2, RT, 87% yield; ii. PdCl2, MeOH, RT, 81% yield; iii. BnBr, NaH, DMF, 0 
°C ' RT, 68% yield; iv. TBAF, THF, RT, 88% yield. 
 
TIPS protection of the 1-position hydroxyl group of alcohol 104 was conducted 
using the conditions optimised previously.  This reaction gave TIPS ether 121, 
which has the required othogonality at the 1-position.  Other syntheses have 
orthogonally protected the 1-position alcohol with a PMB ether, however, work 
within the group has found PMB ethers to be sensitive to certain acidic 
conditions.  We have found the TIPS ether can be added and removed very 
reliably in high yields, but is also stable to a multitude of conditions.  Both the 
camphor acetal and the allylic ether were removed using the one-pot PdCl2-
mediated procedure, to give the vicinal triol 177.  The triol 177 was treated with 
NaH and benzyl bromide to afford the perbenzylated intermediate 205 in 68% 
yield.  Reasonably forcing conditions were required for the benzylation, with an 
excess of both benzyl bromide and NaH required to push the reaction to 
completion.  The steric demands imposed by the benzylation, of three 
neighbouring hydroxyls, likely accounts for the moderate yield experienced.  The 
synthesis of the desired inositol fragment was completed by removal of the TIPS 
ether using TBAF in THF; this reaction gave the desired alcohol 201 in 88% 
yield. 
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7.4. Synthesis of Lipid Fragment 203 
The synthesis of the lipid fragment 203 was completed using conditions similar to 
those that have been previously reported.117-120  Nemeth completed the initial 3 
steps of the synthesis, whereby the (+)-1,2-O-isopropylidene glycerol 202 was 
protected as the benzyl ether 206, acidic methanolysis subsequently gave the 
diol 207, which was then reacted with octanoyl chloride in the presence of 
catalytic DMAP, to give the diester 208. 
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Scheme 7.3. Synthesis of enantiopure lipid fragment 203. Reagents and conditions: i. NaH, 
BnBr, DMF, RT, 92% yield; ii. conc. HCl, MeOH, reflux, 96% yield; iii. DMAP, pyridine, octanoyl 
chloride, RT, 92% yield; iv. Pd(OH)2, H2, THF, RT, 87% yield; v. Benzyloxybis(N,N-
diisopropylamino)phosphine 141, 1H-tetrazole, CH2Cl2, RT, 71% yield. 
 
The benzyl group of the protected diester 208 was then removed by Pd(OH)2 
catalysed hydrogenolysis, to give the desired alcohol 209 in 87% yield.  Reaction 
of alcohol 209 with benzyloxybis(N,N-diisopropylamino)phosphine 209 and 1H-
tetrazole in CH2Cl2, gave the desired phosphoramidite 203, in 71% yield.  This 
reaction completed the synthesis of the lipid fragment for coupling to the inositol 
fragment. 
 
7.5. Synthesis of Dioctanoyl PtdIns 
Having successfully synthesised the desired inositol fragment 201 and the 
desired lipid fragment 203, we could proceed with the coupling to give the 
precursor compound 204. 
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Scheme 7.4. Synthesis of enantiopure dioctanoyl PtdIns 200. Reagents and conditions: i. (a) 
phosphoramidite 203, 1H-tetrazole, CH2Cl2, RT, (b) 3-Chloroperoxybenzoic acid, -78 °C, 52% 
yield; ii. NaHCO3, Pd black, H2, tBuOH/H2O, RT, 64% yield. 
 
Thus, a solution of alcohol 201 in CH2Cl2 was treated with the lipid 
phosphoramidite 203 in the presence of 1H-tetrazole at room temperature.  The 
reaction proceeded smoothly; however, further equivalents of the 
phosphoramidite were required after 18 h.  Stirring the reaction mixture for an 
additional 3 h saw the complete consumption of starting material as adjudged by 
TLC analysis.  It is assumed the the phosphorus(III) intermediate had formed at 
this point.  Therefore, the reaction was cooled to -78 °C and treated with mCPBA 
in order to oxidise the phosphorus(III) to phosphorus(V).  The purification 
required exhaustive silica gel column chromatography in order to give the desired 
precursor 204 in 52% yield.  The troublesome purification was attributed to 
impurities arising from the lipid phosphoramidite.  The highly non-polar nature of 
both 204 and the lipid impurities made separation difficult, which accounts for the 
moderate isolated yield.  Nevertheless, the precursor 204 was isolated in the 
required purity to proceed with the global deprotection.  Palladium black-
mediated hydrogenolysis proceeded smoothly and was conducted in the 
presence of one equivalent of NaHCO3 to give the presumed sodium salt.  
Isolation of the product gave the final compound 200 in 64% yield, without the 
need for further purification. 
 
7.6. Summary 
The versatile enantiomerically pure alcohol 104 has allowed for the development 
of a very reliable and robust synthesis of dioctanoyl PtdIns.  The TIPS ether is 
not frequently used in inositol chemistry, but has certainly proved it can be added 
and removed very reliably in high yields, and is stable to a number of conditions 
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that we utilise regularly.  The use of the TIPS ether has allowed access to the 
useful intermediate alcohol 201 in high yield, which ultimately led to the 
successful synthesis of dioctanoyl PtdIns. 
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Scheme 7.5. The mono substitution of meso compound myo-inositol.121 
 
What initially appears to be a rather trivial transformation (a mono substitution of 
the inositol ring with a single phospholipid [scheme 7.5]), has taken us 20 steps 
of synthesis, with a 13 step longest linear sequence and with an overall yield of 
0.45%.121 With the cell being able to accomplish the same transformation in one-
step, this highlights the challenges faced when breaking the symmetry of a 
molecule like the meso compound myo-inositol and how important it is to develop 
robust methods for the desymmetrisation of compounds of this nature. 
 
7.7. Future Work and Summary 
This project has broadened the synthetic utility of the enantiomerically pure 
intermediate 104 by the successful synthesis of 1- and 5-position Ins(1,3,4,5)P4 
derivatives as well as the natural product PI.  The approach used within the 
group, has been to develop a robust synthesis to an alcohol trisphosphate, of the 
respective position around the inositol ring that requires modification.  Then using 
this alcohol as a handle for further reactions with a set of electrophiles, in order to 
incorporate the desired isosteric phosphate replacement.  This approach has met 
with success, however certain drawbacks to the method are becoming apparent.  
The secondary alcohol, for instance, is not a particularly good nucleophile, a 
simple way to activate the alcohol is to form the alkoxide, however, we have 
found that this cannot be formed in the presence of phosphate esters, as it 
causes a significant amount of phosphate migration.  Therefore, to avoid 
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activation of the alcohol, highly reactive electophiles are required.  This 
propensity for migration under forcing conditions has begun to limit the number of 
phosphate isosteres that can be easily incorporated onto the inositol ring, this 
limitation is exemplified by the attempted synthesis of the methylene 
phosphonate moiety in chapter 5.  It is, therefore, of interest to seek alternative 
approaches that reduce the susceptibility of phosphate migration and 
debenzylation pathways.  One approach could be the use of dimethyl 
phosphates 211 (fig. 7.2), commonly used by Prestwich and co-workers 210 (fig. 
7.2);102 these would be less sterically strained, however, the global deprotection 
of these is not as mild as the hydrogenolysis of benzyl groups, and further 
purification steps for the final compounds are a likely requirement. 
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Figure 7.2. Prestwich compound 210 and methyl-protected trisphosphate 211  as a potential 
alternative to the sterically strained benzyl-protected trisphosphates. 
 
Another approach would be to turn the inositol ring into the electrophile, and have 
the desired phosphate isostere behave as the attacking nucleophile.  For 
example it may be possible to perform an Appel-type reaction on alcohol 108 to 
form the bromide 212 (scheme 7.6).  In this way it may be possible to activate 
the desired nucleophile, with strong base for instance, in the absence of the 
benzyl-protected phosphates and then displace the bromide by the careful 
addition of the activated nucleophile.  With no free hydroxyl group on the inositol 
ring migration cannot occur; also, limiting the exposure of the trisphosphate 
electrophile 212 to the activated nucleophile, might reduce the propensity of 
debenzylation because of the milder environment. 
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Scheme 7.6. Potential use of bromide 212. Appel-type reaction: i. PPh3, CBr4; ii. Activated 
nucleophile. 
 
With reliable access to 1-, 4- and 5-position derivatives of Ins(1,3,4,5)P4 now  
developed, it is of continuing interest to research the synthesis of 3-position 
modified Ins(1,3,4,5)P4 analogues.  This will complete the substitution of all the 
phosphates of Ins(1,3,4,5)P4 and allow us to plan a second generation of PH 
domain-targeted analogues, aimed at increasing both selectivity and binding 
affinity towards a particular PH domain. 
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8. Experimental Section 
 
8.1. General Experimental 
 
1H NMR spectra were recorded on Bruker DPX250 (250 MHz); Bruker Avance 
300 (300 MHz); Bruker Avance 400 (400 MHz); Bruker Avance II 400 (400 MHz); 
Bruker DRX500 (500 MHz); Bruker Avance 500 (500 MHz); or Bruker Avance III 
(500 MHz) using deuterochloroform (unless indicated otherwise) as a reference 
for internal deuterium lock. The chemical shift data for each signal are given as 
)H in units of parts per million (ppm) relative to tetramethylsilane (TMS) where ) 
(TMS) = 0.00 ppm. The multiplicity of each signal is indicated by: s (singlet); br s 
(broad singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); ddd 
(doublet of doublet of doublets); dddd (doublet of doublet of doublet of doublets); 
ddt (doublet of doublet of triplets); sp (septet); or m (multiplet). The number of 
protons (n) for a given resonance signal is indicated by nH. Coupling constants 
(J) are quoted in Hz and are recorded to the nearest 0.1 Hz. Identical proton 
coupling constants (J) are averaged in each spectrum and reported to the 
nearest 0.1 Hz. The coupling constants are determined by analysis using Bruker 
TopSpin software. 
 
13C NMR spectra were recorded on Bruker Avance 300 (75 MHz); Bruker Avance 
II 400 (100 MHz); or Bruker Avance III (125 MHz) spectrometers using the 
PENDANT or DEPT Q pulse sequences with broadband proton decoupling and 
internal deuterium lock. The chemical shift data for each signal are given as ) in 
units of parts per million (ppm) relative to tetramethylsilane (TMS) where )C 
(TMS) = 0.00 ppm. Where appropriate, coupling constants (J) are quoted in Hz 
and are recorded to the nearest 0.1 Hz. 1H and 13C spectra were assigned using 
2D NMR experiments including COSY, HSQC, HMBC, DEPT-135, HMQC, and 
DEPT Q. 
 
31P NMR spectra were recorded on Bruker Avance II 400 (162 MHz) or Bruker 
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DRX500 (202 MHz) spectrometers using broadband proton decoupling pulse 
sequences and deuterium internal lock. The chemical shift data for each signal 
are given as )P in units of parts per million (ppm) relative to 85% phosphoric acid 
as an external reference. 
 
19F NMR spectra were recorded on a Bruker Avance II 400 (282 MHz) using a 
broadband proton decoupling pulse sequence and deuterium internal lock. The 
chemical shift data for each signal are given as )F in units of parts per million 
(ppm). Where appropriate, coupling constants (J) are quoted in Hz and are 
recorded to the nearest 0.1 Hz. 
 
Mass spectra were acquired on a VG platform spectrometer. For electron impact 
spectra, the instrument was operating at 70 eV. Chemical ionization spectra were 
obtained using isobutane as the ionising gas. Electrospray ionisation spectra 
were obtained on Micromass LCT; Micromass LCT Premier; and Bruker 
MicroTOF spectrometers, operating in positive or negative mode, from solutions 
of methanol, acetonitrile or water. m/z values are reported in Daltons and 
followed by their percentage abundance in parentheses. 
 
Melting points were determined using an Electrothermal 9100 melting point 
apparatus or Kofler hot stage microscope and are uncorrected. 
 
Microanalyses were obtained on a Carlo Erber EA1110 analyser by the St 
Andrews University microanalysis service. Certain samples were submitted to the 
Elemental Analysis Service, London Metropolitan University, London. 
 
Infrared Specta were obtained either as: a thin film on sodium chloride discs; b 
potassium bromide disc. The spectra were recorded on Perkin Elmer GX FT-IR 
or Bruker Tensor 27 spectrometers. Absorption maxima are reported in 
wavenumbers (cm-1). 
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Specific Optical Rotations were measured using Perkin Elmer Model 241 and 
341 polarimeters, in cells with a path length of 1 dm. The light source was 
maintained at 589 nm. The concentration (c) is expressed in g/100 mL 
(equivalent to g/0.1 dm3). Specific rotations are denoted 
! 
"[ ]D
T  and are given in 
implied units of 10-1 deg cm2 g-1 (T = ambient temperature in °C). 
 
Analytical thin layer chromatography (TLC) was carried out on Merck silica 
gel 60 F254 aluminum-supported thin layer chromatography sheets. Visualisation 
was by absorption of UV light (*max 254 or 365 nm), or thermal development after 
dipping in one of: a ethanolic solution of phosphomolybdic acid (PMA); b 
aqueous solution of potassium permanganate, potassium carbonate and sodium 
hydroxide; c ethanolic solution of 4-anisaldehyde, sulfuric acid and acetic acid. 
 
Flash Column chromatography was carried out on Apollo Scientific Ltd silica 
gel 40-63 micron or Merck silica gel 60 (240-400 mesh), eluting with solvents as 
supplied, under a positive pressure of compressed air (unless otherwise stated). 
 
Anhydrous solvents were obtained under the following conditions: dry 
acetonitrile was distilled from calcium hydride in a recycling still; dry N,N-
dimethylformamide was purchased from SigmaAldrich UK in a SureSeal™ bottle 
and used without further purification or was distilled under reduced pressure from 
activated 4 Å molecular sieves and stored over 4 Å molecular sieves under an N2 
atmosphere; dry dimethyl sulfoxide was pre-dried over activated alumina, then 
distilled from calcium hydride and stored over activated 4 Å molecular sieves 
under an N2 atmosphere; anhydrous 1,4-dioxane was distilled from sodium and 
benzophenone in a recycling still and stored over activated 3 Å molecular sieves 
under an Ar atmosphere. Anhydrous dichloromethane, diethyl ether, toluene, 
hexane and tetrahydrofuran were obtained using a MBRAUN GmbH MB SPS-
800 solvent purification system, where solvent was dried by passage through 
filter columns and dispensed under an atmosphere of N2 or Ar gas. 
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Chemicals were purchased from Acros UK, Sigma Aldrich UK, Alfa Aesar UK, 
Fisher UK, Fluka UK, Fluorochem, Merck or TCI-Europe. All solvents and 
reagents were purified, when necessary, by standard techniques. Where 
appropriate and if not stated otherwise, all non aqueous reactions were 
performed in a flame-dried flask under an inert atmosphere of nitrogen or argon, 
using a double vacuum manifold with the inert gas passing through a bed of 
activated 4 Å molecular sieves and self indicating silica gel. 
 
In vacuo refers to the use of a rotary evaporator attached to a diaphragm pump. 
Brine refers to a saturated aqueous solution of sodium chloride. Hexane refers to 
a mixture of hexane isomers and petroleum ether to the fraction boiling between 
40-60 °C. 
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8.2. Synthesis of Enantiopure Intermediate 104 
 
D-myo-Inositol 1,3,5-orthoformate 111 
 
O
O
O
OH
HO
HO
 
111 
 
To a stirred solution of myo-inositol 1 (10 g, 55.56 mmol, 1 eq), in dry DMF 
(40 mL) under an atmosphere of nitrogen, was added 4-toluenesulfonic acid 
monohydrate (4.23 g, 22.22 mmol, 0.4 eq) followed by triethyl orthoformate 
(51.86 g, 46.21 mL, 277.80 mmol, 5 eq). The solution was heated to 100 °C and 
stirred overnight. The reaction was shown to be complete by TLC analysis and 
cooled to RT. The reaction was quenched by addition of solid sodium hydrogen 
carbonate (~5 g). The solid was removed by filtration, washed with methanol and 
discarded. The filtrate was concentrated under reduced pressure affording a pale 
yellow oil. The oil was dissolved in methanol (100 mL), and cooled to promote 
crystallisation of the product, which was isolated by filtration. The filtrate 
concentrated under vacuum yielding a pale yellow oil, which was adsorbed onto 
silica gel and the product purified by silica gel column chromatography, eluting 
first with CH2Cl2, then with MeOH and CH2Cl2 (5:95) and finally MeOH/CH2Cl2 
(10:90). All product fractions were combined and the solvent removed under 
vacuum to yield D-myo-inositol 1,3,5-orthoformate 111  (6.66 g, 63% yield) as a 
colourless crystalline solid: Rf 0.5 (MeOH and CHCl3 20/80); mp 287-288 °C dec. 
(from MeOH/CH2Cl2, lit.122 300-302 °C sealed tube); )H (300 MHz, DMSO-D6) 
5.45 (2H, d, J 5.1, 2 ( OH), 5.44 (1H, s, 3-H), 5.30 (1H, d, J 6.2, equatorial OH), 
4.26 (2H, br s, 2 ( inositol ring), 4.07-4.04 (1H, m, inositol ring), 4.01-3.97 (1H, 
m, inositol ring), 3.95-3.92 (2H, m, 2 ( inositol ring). The data are in good 
agreement with literature values.89,93 
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(±)-D-4-O-(4-Methoxybenzyl)-myo-inositol 1,3,5-orthoformate 112 
 
O
O
O
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D-myo-Inositol 1,3,5-orthoformate 111 (21 g, 110.53 mmol, 1 eq) was dissolved 
in dry DMF (500 mL) under an atmosphere of nitrogen and cooled to 0 °C. With 
vigorous stirring, sodium hydride (60% dispersion in mineral oil, 4.86 g, 
121.58 mmol, 1.1 eq) was added portionwise over a period of 1 h. The resulting 
suspension was allowed to warm to room temperature and stirred for a further 
2 h, forming a thick white slurry. The slurry was cooled to 0 °C and 4-
(methoxy)benzyl chloride (19.04 g, 16.50 mL, 121.58 mmol, 1.1 eq) was added 
dropwise with vigorous stirring. The reaction mixture was warmed to room 
temperature and stirred overnight. The reaction was shown to be complete by 
TLC analysis and so was quenched with water (50 mL). The volatile components 
were removed under vacuum yielding a thick yellow oil, which was partitioned 
between ethyl acetate (200 mL) and water (200 mL). The layers were separated 
and the aqueous phase extracted with ethyl acetate (3 ( 100 mL). The combined 
organic components were washed with brine (200 mL) and dried over 
magnesium sulfate, filtered and the filtrate concentrated under vacuum, yielding 
a yellow oil. The oil was adsorbed onto silica gel and purified by silica gel column 
chromatography, eluting with ethyl acetate and petroleum ether (20:80, 30:70, 
40:60 and 50:50). The combined organic fractions were concentrated under 
vacuum yielding (±)-D-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-orthoformate 
112 as a fine, colourless crystalline solid (30.75 g, 90% yield): Rf 0.35 (ethyl 
acetate and petroleum ether 1:1); mp 97-100 °C (from ethyl acetate and 
petroleum ether, lit.123 99-100 °C); )H (300 MHz, CDCl3) 7.20-7.14 (2H, m, 
OCH2C6H4OCH3), 6.86-6.81 (2H, m, OCH2C6H4OCH3), 5.36 (1H, d, J 1.3, 3-H), 
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4.55 (1H, d, JAB 11.4, OCHAHB), 4.50 (1H, d, JAB 11.4, OCHAHB), 4.42-4.31 (2H, 
m, 2 ( inositol ring), 4.20-4.11 (3H, m, 3 ( inositol ring), 4.03-3.93 (1H, m, inositol 
ring),  3.75 (3H, s, OCH3), 3.71 (1H, d, J 10.2, OH), 3.09 (1H, d, J 11.8, OH). The 
data are in good agreement with the literature values.123 
 
 
(±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-
orthoformate 113 
 
O
O
O
OPMB
BnO
BnO
 
113 
 
(±)-D-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-orthoformate 112 (4.00 g, 12.09 
mmol, 1 eq) was dissolved in dry DMF (50 mL) under an atmosphere of nitrogen 
and cooled to 0 °C. Sodium hydride (60% dispersion in mineral oil, 1.30 g, 
32.23 mmol, 2.5 eq) was added portionwise and stirred for 30 minutes at 0 °C 
followed by 1 h at RT forming a thick green gel. The gel was cooled to 0 °C and 
benzyl bromide (5.51 g, 3.83 mL, 32.23 mmol, 2.5 eq) was added dropwise, 
loosening the thick gel, the resulting slurry was allowed to warm to room 
temperature and stirred overnight.  The reaction was shown to be complete by 
TLC analysis and the mixture was quenched with water (10 mL). The volatile 
components were removed under vacuum resulting in an oil, which was 
partitioned between ethyl acetate (20 mL) and water (20 mL). The layers were 
separated and the aqueous phase extracted with ethyl acetate (3 ( 10 mL). The 
combined organic components were washed with brine (20 mL) and dried over 
magnesium sulfate, filtered and the filtrate concentrated under vacuum yielding a 
yellow oil. The oil was adsorbed onto silica gel and purified by silica gel column 
chromatography, eluting with ethyl acetate and petroleum ether (20:80 then 
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30:70). The product fractions were combined and the solvent removed under 
vacuum to give (±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-
orthoformate 113 (5.42 g, 91% yield) as a colourless oil: Rf 0.43  (ethyl acetate 
and petroleum ether 40:60); )H (300 MHz, CDCl3) 7.42-7.20 (10H, m, 2 ( Ph), 
7.13 (2H, d, J 8.7, OCH2C6H4OCH3), 6.82 (2H, d, J 8.7, OCH2C6H4OCH3), 5.54 
(1H, d, J 1.3, 3-H), 4.65 (2H, s, OCH2Ph), 4.62 (1H, d, JAB 11.6, OCHAHBPh), 
4.55 (1H, d, JA'B' 11.2, OCHA'HB'-C6H4OCH3), 4.48 (1H, d, JAB 11.6, OCHAHBPh), 
4.42 (1H, d, JA'B' 11.2, OCHA'HB'-C6H4OCH3), 4.45-4.40 (1H, m, inositol ring), 
4.38-4.26 (4H, m, inositol ring), 4.06-4.03 (1H, m, inositol ring), 3.81 (3H, s, 
OCH3). The data are in good agreement with the literature values.123 
 
 
(±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-methylene 
114 
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(±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-orthoformate 
113 (14.23 g, 29.01 mmol, 1 eq) was dissolved in dry CH2Cl2 (140 mL) under a 
nitrogen atmosphere and cooled to 0 °C. With vigorous stirring, 
diisobutylaluminium hydride (72.52 mL of a 1 M solution in hexanes, 72.52 mmol, 
2.5 eq) was added slowly dropwise maintaining the temperature at 0 °C (±5 °C). 
The reaction mixture was allowed to warm to RT slowly and react, affording a 
colourless solution overnight. TLC analysis indicated the full consumption of the 
starting material. The reaction mixture was cooled to 0 °C and the 
diisobutylaluminium hydride quenched slowly with the addition of water (2.9 mL, 
0.04 mL per mmol of diisobutylaluminium hydride) (CAUTION: copious 
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effervescence and a slight exotherm is observed upon addition of water). The 
reaction mixture was treated with 15% (w/v) sodium hydroxide (aqueous) solution 
(2.9 mL, 0.04 mL per mmol of diisobutylaluminium hydride) followed by water 
(7.3 mL, 0.1 mL per mmol of diisobutylaluminium hydride). The solution was 
allowed to warm to RT and stirred for 1 h, yielding the aluminium salts as a 
colourless precipitate. The mixture was dried over magnesium sulfate and the 
solid components isolated via filtration. The filtrate was concentrated under 
vacuum to yield (±)-D-2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-
methylene 114 (13.18 g, 92% yield) as a thick colourless oil: Rf 0.34 (ethyl 
acetate and petroleum ether 40:60); )H (300 MHz, CDCl3) 7.30-7.20 (10H, m, 2 ( 
Ph), 7.12 (2H, d, J 8.7, OCH2C6H4OCH3), 6.75 (2H, d, J 8.7, OCH2C6H4OCH3), 
5.48 (1H, d, J 4.9, 3-H), 4.60 (1H, d, JAB 11.9, OCHAHB-Ph), 4.59 (1H, d, J 4.9, 3-
H), 4.53 (2H, s, OCH2-Ph), 4.53 (1H, d, JA'B' 9.5, OCHA'HB'-C6H4OCH3), 4.49 (1H, 
d, JA'B' 9.5, OCHA'HB'-C6H4OCH3), 4.43 (1H, d, JAB 11.9, OCHAHB-Ph),  4.38-4.31 
(2H, m, inositol ring), 4.22-4.20 (1H, m, inositol ring), 3.95-3.90 (2H, m, inositol 
ring), 3.87 (1H, d, J 10.2 inositol ring), 3.73 (3H, s, OCH3), 2.90 (1H, d, J 10.2 
OH). The data are in good agreement with the literature values.123 
 
 
(±)-D-5-O-Allyl-2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-
methylene 115 
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(±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-methylene 114 
(13.18 g, 26.76 mmol, 1 eq) was dissolved in dry DMF (150 mL) under an 
atmosphere of nitrogen and cooled to 0 °C.  With stirring, sodium hydride (1.6 g, 
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40.14 mmol, 1.5 eq) was added portionwise and the mixture allowed to warm to 
RT for 2 h before cooling to 0 °C. The resulting colourless slurry was treated with 
imidazole (sub stoichiometric) followed by the slow drop-wise addition of allyl 
bromide (4.85 g, 3.47 mL, 40.14 mmol, 1.5 eq). The resulting colourless solution 
was allowed to warm to RT and stir overnight. The reaction was shown to be 
complete by TLC analysis and subsequently quenched by the addition of water 
(15 mL). The volatile components were removed under vacuum and the residue 
formed was partitioned between ethyl acetate (50 mL) and water (50 mL). The 
layers were separated and the aqueous  phase extracted with ethyl acetate 
(3 ( 50 mL). The combined organic extracts were washed with brine, dried over 
magnesium sulfate, filtered and the filtrate concentrated under vacuum to give a 
thick yellow oil. The oil was purified by silica gel column chromatography eluting 
with ethyl acetate and hexane (30:70). The product fractions were combined and 
the solvent was removed under vacuum to yield (±)-D-5-O-allyl-2,6-bis-O-benzyl-
4-O-(4-methoxybenzyl)-myo-inositol 1,3-methylene 115 (12.7 g, 89% yield) as a 
thick colourless oil: Rf 0.45 (ethyl acetate and petroleum ether 40:60); )H (300 
MHz, CDCl3) 7.30-7.20 (10H, m, 2 ( Ph), 7.17 (2H, d, J 8.7, OCH2C6H4OCH3), 
6.79 (2H, d, J 8.7, OCH2C6H4OCH3), 5.80 (1H, ddt, J 17.1, 10.3, 5.6, CH=CH2), 
5.16 (1H, ddt, J 17.1, 1.8, 1.6, CH=CHxHy), 5.11 (1H, d, J 5.6, 3-H), 5.09 (1H, 
ddt, J 10.3, 1.8, 1.3, CH=CHxHy), 4.75 (1H, d, J 5.6, 3’-H), 4.58 (1H, d, JAB 11.7, 
OCHAHB-Ph), 4.57 (2H, s, OCH2-Ph), 4.61 (1H, d, JAB 11.7, OCHAHB-Ph), 4.52 
(1H, d, JA'B' 11.4, OCHA'HB'-C6H4OCH3), 4.45 (1H, d, JA'B' 11.4, OCHA'HB'-
C6H4OCH3), 4.18-4.15 (2H, m, inositol ring), 4.05 (2H, ddd, J 5.6, 1.4, 1.4 
OCH2CH=CH), 3.76-3.73 (1H, m, inositol ring), 3.73 (3H, s, OCH3), 3.45 (1H, dd, 
J 5.6, 5.6, inositol ring). The data are in good agreement with the literature 
values.123 
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(±)-5-O-Allyl-2,6-O-dibenzyl-myo-inositol 116 
 
BnO OH
OBn
OAll
OH
HO
 
116 
 
(±)-D-5-O-Allyl-2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-
methylene 115 (2.86 g, 5.37 mmol, 1 eq) was dissolved in methanol (5 mL) and 
to this solution was added conc. hydrochloric acid (5 mL). The mixture was 
heated under reflux and stirred overnight. TLC analysis indicated the reaction 
had gone to completion, so the solution was cooled to 0 °C and the acid 
quenched by the cautious addition of solid sodium hydrogen carbonate (Note: 
copious effervescence is observed upon addition of sodium hydrogen carbonate) 
until pH 7 was achieved. The solid precipitate was removed by filtration and the 
filtrate concentrated under vacuum to give a crude colourless solid.  This solid 
was purified by silica gel column chromatography eluting with ethyl acetate and 
hexane (30:70, then 40:60) to give (±)-5-O-allyl-2,6-O-dibenzyl-myo-inositol 116 
(2.0 g 93% yield) as a colourless solid. Rf 0.45 (ethyl acetate); )H (300 MHz, 
CDCl3) 7.33-7.18 (10H, m, 2 ( Ph) 5.90 (1H, ddt, J 17.2, 10.4, 5.7, CH=CH2), 
5.23 (1H, ddt, JAB 17.2, 1.7, 1.6, CH=CHAHB), 5.12 (1H, ddt, JAB 10.4, 1.7, 1.3, 
CH=CHAHB), 4.85 (1H, d, JAB 11.0, OCHAHB-Ph), 4.81 (1H, d, JA'B' 11.4, 
OCHA'HB'-Ph), 4.70 (1H, d, JA'B' 11.4, OCHA'HB'-Ph), 4.67 (1H, d, JAB 11.0, 
OCHAHB-Ph),  4.28 (2H, dddd, J 21.4, 12.6, 5.5, 1.4, 1.4, OCH2CH=CH2), 3.95 
(1H, t, J 2.8, 2-H), 3.73 (1H, t, J 9.5, inositol ring), 3.66 (1H, t, J 9.3, inositol ring), 
3.50 (1H, dd, J 9.7, 2.7, inositol ring), 3.39 (1H, dd, J 9.7, 2.9, inositol ring), 3.15 
(1H, dd, J 9.2, 9.2, inositol ring), 2.21 (3H, br s, OH). The data are in good 
agreement with the literature values.123 
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(1S)-(-)-Camphor dimethyl acetal 118 
 
MeO
MeO
 
118 
 
(1S)-(-)-Camphor 117 (10 g, 65.68 mmol, 1 eq) was dissolved in hexane 
(100 mL), to this solution was added Montmorillonite K-10 clay (18 g) followed by 
trimethyl orthoformate (27.88 g, 28.74 mL, 262.72 mmol, 4 eq). The resulting 
slurry was allowed to stir at RT overnight. The reaction was shown to be 
complete by TLC analysis and the mixture filtered through a pad of Celite®, 
washing with hexane (3 ( 50 mL).  The filtrate was concentrated under vacuum 
to yield (1S)-(-)-camphor dimethyl acetal 118 (12.3 g, 94% yield, 87% conversion 
to dimethyl acetal shown by 1H NMR analysis) as a crude colourless oil: Rf 0.64 
(diethyl ether and petroleum ether 30:70);  )H (300 MHz, CDCl3) 3.23 (3H, s, 
OCH3), 3.17 (3H, s, OCH3), 2.24-2.16 (1H, m, camphor ring), 1.80-1.63 (3H, m, 
camphor ring), 1.46-1.14 (3H, m, camphor ring), 0.97 (3H, s, 1-CH3), 0.92 (3H, s, 
7-CH3), 0.83 (3H, s, 7-CH3). The data are in good agreement with the literature 
values.124 
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(-)-1D-5-O-Allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-104 
 
BnO OH
OBn
OAll
O
O
 
(-)-104 
 
(±)-5-O-Allyl-2,6-O-dibenzyl-myo-inositol 116 (4.40 g, 11.00 mmol, 1 eq) was 
dissolved in dry CH2Cl2 (50 mL) under an atmosphere of nitrogen, to this was 
added (1S)-(-)-camphor dimethyl acetal 118 (7.52 g, 33.00 mmol, 3 eq, 87% 
converted to dimethyl acetal) and 4-toluenesulfonic acid monohydrate (105 mg, 
0.55 mmol, 0.05 eq). The solution was heated under reflux and allowed to stir 
overnight. TLC analysis indicated the reaction had gone to completion, so the 
solution was allowed to cool to RT, the volatile components were removed under 
vacuum to give a colourless oil. The crude material was purified by silica gel 
column chromatography eluting with ethyl acetate and petroleum ether (5:95, 
6:94, 7:93, 8:92, 9:91, 10:90). The product fractions were combined and the 
solvent removed to yield (-)-1D-5-O-allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-104 (500 mg, 19% yield) as 
a colourless oil:  Rf 0.37 (ethyl acetate/hexane 30:70); 
! 
"[ ]D
20-10.5, (c 1.0 in 
CHCl3) [(lit.123 
! 
"[ ]D
22-11.7, (c 1.3 in CHCl3)]; )H (300 MHz, CDCl3) 7.43-7.29 (10H, 
m, 2 ( Ph), 5.97 (1H, ddt, J 17.2, 10.4, 5.6, CH=CH2), 5.33 (1H, ddt, J 17.2, 1.8, 
1.7, CHC=CHH), 5.18 (1H, ddt, J 10.4, 1.7, 1.3, CHC=CHH), 5.03 (1H, d, JAB 
11.5, OCHAHB-Ph), 4.94 (1H, d, JA'B' 11.0, OCHA'HB'-Ph), 4.79 (1H, d, JA'B' 11.0, 
OCHA'HB'-Ph), 4.70 (1H, d, JAB 11.5, OCHAHB-Ph), 4.41 (1H, ddt, JAB 12.9, 5.6, 
1.3, CHAHB=CH2), 4.24-4.17 (2H, m, 1 ( CHAHB=CH2, 1 ( inositol ring), 3.99 (1H, 
dd, J 9.6, 9.6, inositol ring), 3.73-3.49 (3 H, m, inositol ring), 3.31 (1H, dd, J 9.8, 
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1.8, inositol ring), 2.46 (1H, br s, OH), 2.17 (1H, dt, J 13.5, 3.3, camphor ring), 
1.98-1.88 (1H, m, camphor ring), 1.79-1.69 (2H, m, 2 ( camphor ring), 1.47 (1H, 
d, J 13.5, camphor ring), 1.30-1.23 (2H, m, 2 ( camphor ring), 1.03 (3H, s, CH3), 
1.28-1.10 (3H, m, 3 ( camphor ring), 0.86 (3H, s, CH3 camphor bridge), 0.85 (3H, 
s, CH3 camphor bridge). The data are in good agreement with the literature 
values.123 
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8.3. Towards the synthesis of 3-O-position compounds 
 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 
 
BnO OTIPS
OBn
OAll
O
O
 
(-)-121 
 
To a stirred solution of triisopropylsilane trifluoromethanesulfonate (2.26 g, 
1.66 mL, 7.98 mmol, 4 eq) in dry CH2Cl2 (3 mL) under an atmosphere of 
nitrogen, was added triethylamine (944 mg, 1.3 mL, 9.35 mmol, 5 eq). The 
solution was allowed to stir for 1 h at RT, turning a dark orange colour, to this 
solution was added a solution of (-)-1D-5-O-allyl-2,6-di-O-benzyl-3-O-exo-(L-
1',7',7'-trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-104 (3.0 g, 5.61 
mmol, 1 eq) in dry CH2Cl2 (30 mL). The reaction mixture was stirred at RT 
overnight. TLC analysis indicated the reaction was complete, so it was diluted 
with CH2Cl2 (20 mL) and partitioned with the addition of water (50 mL). The 
layers were separated and the aqueous phase extracted with CH2Cl2 (3 ( 20 
mL). The combined organic phases were dried over magnesium sulfate, filtered 
and the filtrate concentrated under vacuum to yield a dark brown oil. The oil was 
adsorbed onto silica gel and purified by silica gel column chromatography eluting 
with diethyl ether and petroleum ether (2:98) to give (-)-1D-5-O-allyl-2,6-di-O-
benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-
ylidine)-myo-inositol (-)-121 as a colourless oil (1.12 g, 87%). Rf 0.51 (ethyl 
acetate and hexane 10/90); 
! 
"[ ]D
25= -1.54 (c 1.23 in CHCl3); !max (NaCl disc)/cm-1 
2943.5 (s), 2867.0 (s), 2362.9 (w), 1496.9 (w), 1454.2 (m), 1389.8 (m), 1369.4 
(w), 1308.9 (w), 1245.9 (w), 1202.3 (w), 1181.76 (m), 1113.7 (s), 1068.2 (s), 
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921.6 (w), 883.4 (m), 820.3 (m), 730.4 (m), 695.5 (m), 680.7 (w); )H (300 MHz, 
CDCl3) 7.38-7.12 (10H, m, ArH), 5.81 (1H, dddd, J 17.2, 10.4, 5.5, 5.5, 
CHX=CHYHZ), 5.17 (1H, dd, J 17.2, 1.5, CHX=CHYHZ), 5.03 (1H, d, J 10.4, 
CHX=CHYHZ), 4.92 (1H, d, J 11.5, OCHAHB-Ph), 4.85 (1H, d, J 11.1, OCHA’HB’-
Ph), 4.68 (1H, d, J 11.1, OCHA’HB’-Ph), 4.63 (1H, d, J 11.5, OCHAHB-Ph), 4.27 
(1H, dd, J 12.7, 5.5, OCHVHW-CH=CH2), 4.10 (1H, dd, J 2.7, 1.5, inositol ring, H-
2) 4.03 (1H, dd, J 12.7, 5.5, OCHVHW-CH=CH2), 3.94 (1H, dd, J 9.7, 9.7, inositol 
ring, H-6), 3.83 (1H, dd, J 9.0, 2.7, inositol ring, H-3), 3.67 (1H, dd, J 9.0, 9.0, 
inositol, H-4), 3.44 (1H, dd, J 9.7, 9.0, inositol ring, H-5), 3.21 (1H, dd, J 9.7, 1.5, 
inositol ring, H-5), 2.07 (1H, dt, J 13.4, 3.8, camphor ring), 1.89-1.77 (1H, m, 
camphor ring), 1.72-1.58 (2H, m, camphor ring), 1.43-1.36 (1H, m, camphor 
ring), 1.36-1.25 (1H, m, camphor ring), 1.18-1.09 (1H, m, camphor ring), 0.95-
0.93 (21H, m, Si-(CH(CH3)2)3), 0.93 (3H, s, CH-camphor ring), 0.77 (3H, s, CH3-
camphor bridge), 0.73 (3H, s, CH3-camphor bridge); )C (75 MHz; CDCl3), 139.9 
(ArC), 139.3 (ArC), 135.8 (CHX=CHYHZ), 128.5 (ArCH), 128.4 (ArCH), 127.9 
(ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.4 (ArCH), 120.7 (ketal carbon), 116.9 
(CHX=CHYHZ), 83.7 (inositol ring), 81.9 (inositol ring), 77.9 (inositol ring), 77.2 
(inositol ring), 76.4 (inositol ring), 76.3 (CH2), 75.3 (inositol ring), 74.2 (CH2), 72.1 
(CH2), 53.3 (Cq- camphor ring), 48.7 (Cq- camphor ring), 46.7 (CH2), 45.3 (CH), 
29.3 (CH2), 27.1 (CH2), 20.7 (CH3), 20.5 (CH3), 18.6 (CH3), 13.3 (CH3), 10.0 
(CH); m/z (ES+) [Found: (M+Na)+ 713.4209. C42H62O6SiNa requires M+, 
713.4213], m/z (ES+) 713 ([M+Na]+, 100%); Anal. Calcd. For C42H62O6Si: C, 73.0, 
H, 9.0; Found: C, 72.7, H, 9.3. 
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(-)-5-O-Allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl myo-inositol 105 
 
BnO OTIPS
OBn
OAll
OH
HO
 
(-)-105 
 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 (5.17 g, 7.48 mmol, 
1 eq) was dissolved in CH2Cl2 (90 mL) and methanol (60 mL) and stirred under 
an atmosphere of nitrogen. To this solution was added acetyl chloride (352 mg, 
320 +L, 0.43 mmol, 0.6 eq) and the mixture was allowed to stir at room 
temperature for 6 h after which the reaction was shown to be complete by TLC 
analysis. The reaction was quenched with the addition of triethylamine (8 mL) 
and the volatile components removed under vacuum, resulting in a dark brown 
oil. The oil was partitioned between CH2Cl2 (100 mL) and water (100 mL), the 
layers separated and the aqueous phase further extracted with CH2Cl2 (3 ( 50 
mL). The combined organic layers were dried (magnesium sulfate), filtered and 
the filtrate concentrated under vacuum yielding a brown oil. The oil was adsorbed 
onto silica gel and purified by silica gel column chromatography eluting with ethyl 
acetate and petroleum ether (20:80). The product fractions were combined and 
the solvent removed under vacuum to give (-)-5-O-allyl-2,6-bis-O-benzyl-1-O-
triisopropylsilyl myo-inositol (-)-105 (3.8 g, 91%) as a colourless oil: Rf 0.51 (ethyl 
acetate/petroleum ether 50/50); 
! 
"[ ]D
25= -11.9, (c 1.2 in CHCl3); )H (300 MHz, 
CDCl3) 7.42-7.27 (10H, m, ArH), 5.87 (1H, dddd, J 17.2, 10.5, 5.7, 5.7, 
CHX=CHYHZ), 5.19 (1H, dddd, J 17.2, 1.6, 1.4, 1.4, CHX=CHYHZ), 5.11 (1H, dddd, 
J 10.5, 1.6, 1.4, 1.4, CHX=CHYHZ), 5.10 (1H, d, J 11.2, OCHAHB-Ph), 4.90 (1H, d, 
J 11.7, OCHA’HB’-Ph), 4.84 (1H, d, J 11.7, OCHA’HB’-Ph), 4.73 (1H, d, J 11.2, 
OCHAHB-Ph), 4.31 (1H, dddd, J 12.3, 5.7, 1.4, 1.4, OCHVHW-CH=CH2), 4.24 (1H, 
dddd, J 12.3, 5.7, 1.4, 1.4, OCHVHW-CH=CH2), 4.00 (1H, dd, J 2.6, 1.2, inositol 
ring, H-2), 3.88-3.82 (2H, m, inositol ring, H-4 and 5), 3.81 (1H, dd, J 9.5, 9.5, 
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inositol ring, H-6), 3.47 (1H, dd, J 9.5, 2.6, inositol ring, H-1), 3.24-3.15 (1H, m, 
inositol, H-3), 2.83 (1H, br s, OH), 2.57 (1H, br s, OH), 1.02-0.93 (21H, m, Si-
[CH(CH3)2]3); )C (75 MHz; CDCl3), 139.1 (ArC), 138.9 (ArC), 135.0 
(CHX=CHYHZ), 128.4 (ArCH), 128.0 (ArCH), 127.6 (ArCH), 127.4 (ArCH), 127.1 
(ArCH), 117.0 (CHX=CHYHZ), 83.4 (inositol ring), 81.7 (inositol ring), 81.5 (inositol 
ring), 75.3 (OCH2-Ph), 75.2 (OCH2-Ph), 74.5 (inositol ring), 74.3 (inositol ring), 
74.3 (CH2CH=CH2), 72.3 (inositol ring), 18.3 (TIPS-CH3), 18.2 (TIPS-CH3), 12.9 
(TIPS-CH); m/z (ES+) [Found: (M+Na)+ 579.3116. C32H48O6SiNa requires M+, 
579.3118], m/z (ES+) 579 ([M+Na]+, 100%); Anal. Calcd. For C32H48O6Si: C, 69.0, 
H, 8.7; Found: C, 69.1, H, 8.8. The data are in good agreement with the literature 
values.31 
 
 
(-)-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl 
myo-inositol (-)-122 
 
BnO OTIPS
OBn
OAll
OH
PMBO
 
(-)-122 
 
Dibutyltin oxide (246 mg, 0.99 mmol, 1.1 eq) and cesium fluoride (273 mg, 1.80 
mmol, 2 eq) were added to a solution of (-)-5-O-allyl-2,6-bis-O-benzyl-1-O-
triisopropylsilyl myo-inositol (-)-105 (555 mg, 0.90 mmol, 1 eq) in dry toluene 
(20 mL). Soxhlet apparatus containing 3 Å molecular sieves was attached and 
the mixture was heated under reflux overnight to pre-form the tin acetal complex. 
The mixture was cooled to room temperature and the volatile components 
removed under vacuum. The resulting waxy yellow solid was dissolved in dry 
DMF and 4-(methoxy)benzyl chloride (155 mg, 134 +L, 0.99 mmol, 1.1 eq) 
added. The reaction mixture was allowed to stir at room temperature and 
monitored by TLC analysis. After 48 h, 4-(methoxy)benzyl chloride (141 mg, 122 
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+L, 0.90 mmol, 1 eq) was added and the reaction heated to 50 °C for 12 h before 
the addition of (tetrabutyl)ammonium iodide (332 mg, 0.90 mmol, 1 eq). After a 
further 6 h of stirring at 50 °C the reaction was adjudged to be complete by TLC 
analysis. The volatile components were removed under vacuum and the residue 
partitioned between ethyl acetate (50 mL) and water (50 mL). The partitioning 
produced a fine precipitate preventing separation of the layers. The emulsion 
was clarified by filtration through Celite and consequently easy separation of the 
layers was achieved. The aqueous phase was further extracted with ethyl 
acetate (3 ( 20 mL). The combined organic components were washed with brine 
and dried (magnesium sulfate), filtered and the solvent removed under vacuum. 
The crude brown oil was purified by silica gel column chromatography eluting 
with ethyl acetate and petroleum ether (20:80). The mixed fractions combined 
and re-columned eluting with ethyl acetate and petroleum ether (15:85 then 
20:80), this gave the major regioisomer (-)-5-O-allyl-2,6-bis-O-benzyl-3-O-(4-
methoxy)benzyl-1-O-triisopropylsilyl myo-inositol (-)-122 (267 mg, 43%) as a 
colourless solid: Rf 0.58 (ethyl acetate/petroleum ether 30/70); 
! 
"[ ]D
25= -6.3, (c 1.5 
in CHCl3); "max (NaCl disc)/cm-1 3556 (m), 3453 (m broad), 2943 (s), 2866 (s), 
1948 (w), 1879 (w), 1646 (m), 1514 (s), 1211 (s), 1015 (s); )H (300 MHz, CDCl3) 
7.32 (2H, d, J 8.7, OCH2C6H4OCH3), 7.29-7.12 (10H, m, ArH), 6.70 (2H, d, J 8.7, 
OCH2C6H4OCH3), 5.80 (1H, dddd, J 17.2, 10.6, 5.5, 5.5, CHX=CHYHZ), 5.11 (1H, 
dddd, J 17.2, 1.6, 1.6, 1.6, CHX=CHYHZ), 5.00 (1H, dddd, J 10.6, 1.6, 1.6, 1.6, 
CHX=CHYHZ), 4.79 (1H, d, J 11.6, OCHAHB-Ph), 4.78 (1H, d, J 11.4, OCHA’HB’-
Ph), 4.73 (1H, d, J 11.6, OCHAHB-Ph), 4.73 (1H, d, J 11.4, OCHA’HB’-Ph), 4.53 
(2H, s, OCH2-C6H4OCH3), 4.23 (1H, dddd, J 12.4, 5.5, 1.6, 1.6, OCHVHW-
CH=CH2), 4.17 (1H, dddd, J 12.4, 5.5, 1.6, 1.6, OCHVHW-CH=CH2), 4.00 (1H, dd, 
J 9.4, 9.4, inositol ring, H-4), 3.80 (1H, dd, J 2.1, 2.1, inositol ring, H-2), 3.78 (1H, 
dd, J 9.4, 9.4, inositol ring, H-6), 3.73 (3H, s, OCH2-C6H4OCH3), 3.62 (1H, dd, J 
9.4, 2.1, inositol ring, H-1), 3.14 (1H, dd, J 9.4, 9.4, inositol ring, H-5), 3.13 (1H, 
dd, J 9.4, 2.1, inositol ring, H-3), 2.41 (1H, br s, 4-OH), 0.99-0.93 (21H, m, Si-
[CH(CH3)2]3); )C (75 MHz; CDCl3), 159.8 (ArC), 139.7 (ArC), 135.7 
(CHA=CHBHC), 130.5 (ArC), 130.0 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 127.7 
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(ArCH), 127.6 (ArCH), 127.4 (ArCH), 117.1 (CH=CH2), 114.4 (PMB – ArCH), 
84.2 (inositol ring), 82.1 (inositol ring), 80.2 (inositol ring), 79.4 (inositol ring), 75.7 
(OCH2-Ph), 74.9 (OCH2CH=CH2), 74.6 (OCH2-Ph), 74.5 (inositol ring), 73.5 
(inositol ring), 72.6 (OCH2-C6H4OCH3), 55.7 (OCH2-C6H4OCH3), 18.6 (TIPS-
CH3), 18.6 (TIPS-CH3), 13.2 (TIPS-CH); m/z (ES+) [Found: (M+Na)+ 699.3680. 
C40H56O7SiNa requires M+, 699.3693], m/z (ES+) 699 ([M+Na]+, 100%); Anal. 
Calcd. For C40H56O7Si: C, 71.0, H, 8.3; Found: C, 70.9, H, 8.4. 
 
 
(-)-2,6-Bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl myo-
inositol (-)-128 
 
BnO OTIPS
OBn
OH
OH
PMBO
 
(-)-128 
 
(-)-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl myo-
inositol (-)-122 (100 mg, 0.15 mmol, 1 eq) was dissolved in absolute ethanol (2 
mL), to this (under an atmosphere of nitrogen) was added diisopropylethyl amine 
(19 mg, 26 +L, 0.15 mmol, 1 eq).  The solution was stirred at room temperature 
for 5 minutes and then Wilkinson’s catalyst (27 mg, 0.03 mmol, 0.2 eq) was 
added. The dark red slurry was heated under reflux for 3 h before being cooled to 
room temperature and filtered though Celite. The filtrate was concentrated under 
vacuum and the residue analysed by 1H NMR to confirm complete isomerisation 
of the allylic ether to the enol ether. The crude residue was dissolved in MeOH 
(2 mL) and 4-toluenesulfonic acid monohydrate (9 mg, 0.05 mmol, 0.3 eq) was 
added. The reaction was left to stir at room temperature for 4 h before the 
addition of triethylamine (0.5 mL) to quench the acid. The volatile components 
were removed under vacuum and the residue purified by silica gel column 
chromatography eluting with ethyl acetate and petroleum ether (30:70), to give 
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(-)-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl myo-inositol (-)-
128 (72 mg, 76%) as a pale yellow oil. )H (300 MHz, CDCl3) 7.33 (2H, d, J 8.7, 
OCH2C6H4OCH3), 7.30-7.17 (10H, m, 2 ( Ph), 6.80 (2H, d, J 8.7, 
OCH2C6H4OCH3), 4.84 (1H, d, J 11.8, OCHAHB-Ph), 4.79 (1H, d, J 11.5, 
OCHA’HB’-Ph), 4.74 (1H, d, J 11.5, OCHA’HB’-Ph), 4.66 (1H, d, J 11.8, OCHAHB-
Ph), 4.53 (2H, s, OCHAHB-C6H4OCH3), 3.91 (1H, dd, J 9.4, 9.4, inositol ring, H-4), 
3.83 (1H, dd, J 2.1, 2.1, inositol ring, H-2), 3.77-3.70 (4H, m, OCH2-C6H4OCH3 + 
inositol ring, H-6), 3.66 (1H, dd, J 9.5, 2.1, inositol ring, H-1), 3.31 (1H, dd, J 9.3, 
9.3, inositol ring, H-5), 3.15 (1H, dd, J 9.3, 2.1, inositol ring, H-3), 2.31 (2H, br s, 
2 ( OH), 1.04-0.98 (21H, m, Si-[CH(CH3)2]3).  Compound was not pure and could 
not be synthesised reliably for full characterisation. 
 
 
(-)-1D-1,5-bis-O-Allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-130 
 
BnO OAll
OBn
OAll
O
O
 
(-)-130 
 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-
ylidine)-myo-inositol (-)-104 (1.19 g, 2.22 mmol, 1 eq) was dissolved in dry THF 
(25 mL), the solution was cooled to 0 °C and sodium hydride (60% dispersion in 
mineral oil, 106 mg, 2.67 mmol, 1.2 eq) added. The resulting suspension was 
warmed to room temperature and stirred for 1 h, then re-cooled to 0 °C. 
Imidazole (substoichiometric), tetrabutylammonium iodide (substoichiometric) 
and allyl bromide (323 mg, 231 +L, 2.67 mmol, 1.2 eq) were added to the cold 
suspension and the reaction allowed to warm to room temperature with stirring. 
After 1 h, dry DMF (10 mL) was added and the reaction left overnight. TLC 
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analysis indicated the reaction had gone to completion, so the volatile 
components were removed under reduced pressure. The residue was partitioned 
between ethyl acetate (50 mL) and water (50 mL), the layers separated and the 
aqueous phase was further extracted with ethyl acetate (3( 50 mL). The 
combined organic layers were washed with brine, dried (magnesium sulfate) and 
filtered. The filtrate was concentrated under vacuum and the residue purified by 
silica gel column chromatography, eluting with ethyl acetate and petroleum ether 
(5/95). This afforded (-)-1D-1,5-bis-O-allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-130 (781 mg, 61% yield) as 
a colourless oil: Rf 0.46 (ethyl acetate/petroleum ether 20:80); 
! 
"[ ]D
25= -23.3, (c 1.4 
in CHCl3) [(Lit.91 
! 
"[ ]D
26= -23.0, (c 0.49 in CHCl3)]; )H (300 MHz, CDCl3) 7.49-7.26 
(10H, m, ArH), 6.06-5.84 (2H, m, CHX=CHYHZ, CHX’=CHY’HZ’), 5.35 (1H, dddd, J 
16.8, 1.5, 1.5, 1.5, CHX=CHYHZ), 5.29 (1H, dddd, J 16.7, 1.5, 1.5, 1.5, 
CHX’=CHY’HZ’), 5.18 (2H, dd, J 10.4, 1.5, CHX=CHYHZ + CHX’=CHY’HZ’), 4.93 (1H, 
d, J 12.3, OCHAHB-Ph), 4.87 (1H, d, J 10.5, OCHA’HB’-Ph), 4.86 (1H, d, J 12.3, 
OCHAHB-Ph), 4.83 (1H, d, J 10.5, OCHA’HB’-Ph), 4.40 (1H, dddd, J 13.1, 5.3, 1.5, 
1.5, OCHVHW-CH=CH2), 4.27-4.18 (2H, OCHVHW-CH=CH2 + OCHV’HW’-
CH=CH2), 4.09-4.00 (3H, m, OCHV’HW’-CH=CH2 + 2 ( inositol ring, H-2 and 4), 
3.84 (1H, dd, J 9.3, 8.6, inositol ring, H-5), 3.50 (1H, dd, J 9.5, 8.6, inositol ring, 
H-6), 3.42 (1H, dd, J 9.5, 3.2, inositol ring, H-1), 3.22 (1H, dd, J 9.8, 1.7, inositol 
ring, H-3), 2.15 (1H, dt, J 13.4, 3.5, camphor ring), 2.01-1.91 (1H, m, camphor 
ring), 1.80-1.68 (2H, m, camphor ring), 1.49-1.37 (2H, m, camphor ring), 1.29-
1.19 (1H, m, camphor ring), 1.04 (3H, s, CH3 camphor ring), 0.90 (3H, s, CH3- 
camphor bridge), 0.88 (3H, s, CH3 camphor bridge). The data are in good 
agreement with the literature values.91 
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(-)-1D-1,5-bis-O-Allyl-2,6-bis-O-benzyl-myo-inositol (-)-129 
 
 
BnO OAll
OBn
OAll
OH
HO
 
(-)-129 
Method 1 
(-)-1D-1,5-bis-O-Allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-trimethylbicyclo-[2.2.1]-
hept-2’-ylidine)-myo-inositol (-)-130 (781 mg, 1.36 mmol, 1 eq) was dissolved in 
CH2Cl2 (15 mL) and methanol (10 mL). To this solution was added acetyl chloride 
(64 mg, 58 +L, 0.82 mmol, 0.6 eq). The reaction was stirred at room temperature 
for 6 h before being quenched with the addition of triethylamine (0.5 mL). The 
volatile components were removed under reduced pressure and the resulting 
residue purified by silica gel column chromatography, eluting with ethyl acetate 
and petroleum ether (30:70). This afforded (-)-1D-1,5-bis-O-allyl-2,6-bis-O-
benzyl-myo-inositol (-)-129 (560 mg, 93% yield) as a colourless solid: Rf 0.56 
(ethyl acetate); )H (300 MHz, CDCl3) 7.42-7.29 (10H, m, ArH), 6.03-5.88 (2H, m, 
CHX=CHYHZ, CHX’=CHY’HZ’), 5.34 (1H, dddd, J 17.2, 1.5, 1.5, 1.5, CHX=CHYHZ), 
5.29 (1H, dddd, J 17.2, 1.5, 1.5, 1.5, CHX’=CHY’HZ’), 5.20 (1H, dddd, J 10.3, 1.4, 
1.4, 1.4, CHX=CHYHZ), 5.18 (1H, dddd, J 10.2, 1.5, 1.4, 1.4, CHX’=CHY’HZ’), 5.06 
(1H, d, J 11.5, OCHAHB-Ph), 4.90 (1H, d, J 12.5, OCHA’HB’-Ph), 4.79 (1H, d, J 
12.5, OCHA’HB’-Ph), 4.68 (1H, d, J 11.5, OCHAHB-Ph), 4.41 (1H, dddd, J 12.5, 
5.7, 1.3, 1.3, OCHVHW-CH=CH2), 4.27 (1H, dddd, J 12.5, 5.7, 1.3, 1.3, OCHVHW-
CH=CH2) 4.03-4.17 (2H, m, OCHV’HW’-CH=CH2), 4.03 (1H, dd, J 2.5, 2.5, inositol 
ring, H-2), 3.92 (1H, dd, J 9.6, 9.6, inositol ring, H-6), 3.79 (1H, ddd, J 9.6, 9.6, 
1.7, inositol ring, H-4), 3.40 (1H, ddd, J 9.6, 8.1, 2.5, inositol ring, H-3), 3.37 (1H, 
dd, J 9.6, 2.5, inositol ring, H-1), 3.19 (1H, dd, J 9.6, 9.6, inositol ring, H-5), 2.53 
(1H, d, J 1.7, 4-OH), 2.28 (1H, d, J 8.1, 3-OH). The data are in good agreement 
with the literature values.91 
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 Method 2 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-
ylidine)-myo-inositol (-)-130 (150 mg, 281 µmol, 1 eq) was dissolved in dry DMF 
(5 mL), the solution was cooled to 0 °C and sodium hydride (60% dispersion in 
mineral oil, 13 mg, 561 µmol, 2 eq), allyl bromide (67 mg, 49 µL, 561 µmol, 2 eq) 
and tetrabutylammonium iodide (substoichiometric) were added. The reaction 
allowed to warm to room temperature and allowed to stir overnight. TLC analysis 
indicated the reaction had gone to completion, methanol was added to quench 
the sodium hydride.  The volatile components were removed under reduced 
pressure and the residue partitioned between CH2Cl2 (5 mL) and water (5 mL).  
The layers separated and the aqueous phase was further extracted with CH2Cl2 
(3 ( 5 mL). The combined organic layers dried (magnesium sulfate), filtered and 
the filtrate was concentrated under vacuum.  The resulting residue was dissolved 
in CH2Cl2 (3 mL) and methanol (2 mL) and to this solution was added acetyl 
chloride (13 mg, 12 +L, 168 µmol, 0.6 eq).  The reaction was stirred at room 
temperature for 6 h before being quenched with the addition of triethylamine 
(0.5 mL). The volatile components were removed under reduced pressure and 
the resulting residue purified by silica gel column chromatography, eluting with 
ethyl acetate and petroleum ether (30:70). This afforded (-)-1D-1,5-bis-O-allyl-
2,6-bis-O-benzyl-myo-inositol (-)-129 (115 mg, 93% yield) as a colourless solid.  
The analysis of this material was consistent with that found for the method 1. 
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(+)-1D-1,5-bis-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol 
(+)-131 
 
BnO OAll
OBn
OAll
OH
PMBO
 
(+)-131 
 
(-)-1D-1,5-bis-O-Allyl-2,6-bis-O-benzyl-myo-inositol (-)-129 (100mg, 0.227mmol, 1 
eq) was dissolved in dry acetonitrile (30 mL). To this solution was added 
dibutyltin oxide (85 mg, 0.34 mmol, 1.5 eq) and TBABr (73 mg, 0.227 mmol, 1 
eq) and a Soxhlet apparatus containing 3 Å molecular sieves attached. The 
mixture was heated under reflux for 2 h before being cooled to room temperature 
and 4-(methoxy)benzyl chloride (170 mg, 148 +L, 1.1 mmol, 4.8 eq) added. The 
reaction was then heated under reflux overnight. The reaction was adjudged 
complete by TLC analysis so the volatile components were removed under 
reduced pressure. The residue was then partitioned between ethyl acetate 
(50 mL) and water (50 mL), the layers separated and the aqueous layer further 
extracted with ethyl acetate (3 ( 20 mL). The combined organic layers were 
washed with a saturated aqueous solution of sodium hydrogen carbonate (50 
mL) and then dried (magnesium sulfate) and filtered. The filtrate was 
concentrated under vacuum and residue purified by silica gel column 
chromatography eluting with ethyl acetate and petroleum ether (10:90 then 
20:80) to give (+)-1D-1,5-bis-O-allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-
myo-inositol (-)-129 (32 mg, 25% yield) as a colourless gum: Rf 0.46 (petroleum 
ether / ethyl acetate 70/30); 
! 
"[ ]D
25= +3.6, (c 0.9 in CHCl3); "max (KBr disc)/cm-1 
3548 (s), 3361 (s), 3083 (w), 3062 (w), 2913 (s), 2896 (s), 2868 (s), 1951 (w), 
1887 (w), 1818, (w), 1616 (m), 1516 (s), 1072 (s); )H (300 MHz, CDCl3) 7.46-7.23 
(12H, m, ArH), 6.92-6.86 (2H, m, OCH2C6H4OCH3), 5.97 (2H, dddd, J 17.2, 10.9, 
5.6, 5.6, CHX=CHYHZ and CHX’=CHY’HZ’), 5.33 (1H, dddd, J 17.2, 1.7, 1.7, 1.7, 
CHX=CHYHZ), 5.30 (1H, dddd, J 17.2, 1.7, 1.7, 1.7, CHX’=CHY’HZ’), 5.20 (1H, 
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dddd, J 10.9, 1.7, 1.4, 1.4, CHA=CHBHC), 5.18 (1H, dddd, J 10.4, 1.6, 1.3, 1.3, 
CHA’=CHB’HC’), 4.90 (1H, d, J 12.0, OCHAHB-Ph), 4.89 (1H, d, J 10.5, OCHA’HB’-
Ph), 4.80 (1H, d, J 12.0, OCHAHB-Ph), 4.80 (1H, d, J 10.5, OCHA’HB’-Ph), 4.56 
(1H, d, J 11.4, OCHA’’HB’’-C6H4OCH3), 4.49 (1H, d, J 11.4, OCHA’’HB’’-C6H4OCH3), 
4.42-4.31 (2H, m, OCHXHY-CH=CH2), 4.18-4.07 (3H, m, OCHX’HY’-CH=CH2 + 1 ( 
inositol ring, H-4), 4.03 (1H, dd, J 2.3, 2.3, inositol ring, H-2), 3.96 (1H, dd, J 9.5, 
9.5, inositol ring, H-6), 3.82 (3H, s, OCH2-C6H4OCH3), 3.26 (1H, dd, J 9.5, 2.3, 
inositol ring, H-1), 3.24 (1H, dd, J 9.5, 9.5, inositol ring, H-5), 3.18 (1H, dd, J 9.9, 
2.3, inositol ring, H-3), 2.57 (1H, br s, OH); )C (100 MHz; CDCl3) 159.3 (PMB – 
ArC), 138.9 (ArC) 138.9 (ArC), 135.4 (CHX=CHYHZ), 134.9 (CHX’=CHY’HZ’) 130.0 
(ArCH), 129.4 (ArCH), 128.3 (ArCH), 128.2 (ArCH), 127.8 (ArCH), 127.6 (ArCH), 
127.4 (ArCH), 116.7 (CHX=CHYHZ + CHX’=CHY’HZ’), 113.9 (PMB – ArCH), 82.9 
(inositol ring, C-5), 81.4 (inositol ring, C-6), 80.8 (inositol ring, C-1), 79.8 (inositol 
ring, C-3), 75.8 (OCH2-Ph), 74.2 (CH2-C=CH2), 74.0 (OCH2-Ph), 73.5 (inositol 
ring, C-2), 72.6 (inositol ring, C-4), 72.0 (OCH2-C6H4OCH3), 71.8 (CH2-C=CH2), 
55.3 (OCH2-C6H4OCH3); m/z (ES+) [Found: (M+Na)+ 583.2665. C34H40O7Na 
requires M+, 583.2666], m/z  (ES+) 662 ([M+HNEt3]+, 100%), 583 ([M+Na]+, 
60%), 578 ([M+NH4]+, 45%); Anal. Calcd. For C34H40O7: C, 72.8, H, 7.2; Found: 
C, 72.9, H, 7.3. 
 
 
(-)-5-O-Allyl-2,6-O-dibenzyl-myo-inositol 138 
 
BnO OH
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(-)-138 
 
(-)-1D-5-O-allyl-2,6-di-O-benzyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-
ylidine)-myo-inositol (-)-104 (2.86 g, 5.37 mmol, 1 eq) was dissolved in methanol 
(5 mL) and to this solution was added conc. hydrochloric acid (5 mL). The 
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solution was heated under reflux and stirred overnight. TLC analysis indicated 
the reaction had gone to completion, so the solution was cooled to 0 °C and the 
acid quenched by the cautious addition of solid sodium hydrogen carbonate 
(Note: copious effervescence is observed upon addition of sodium hydrogen 
carbonate) until pH 7 was achieved. The solid precipitate was removed by 
filtration and the filtrate concentrated under vacuum to give a crude colourless 
solid.  This solid was purified by silica gel column chromatography eluting with 
ethyl acetate and hexane (30:70, then 40:60) to give (-)-5-O-allyl-2,6-O-dibenzyl-
myo-inositol 138 (2.0 g 93% yield) as a colourless solid: Rf 0.45 (ethyl acetate); 
! 
"[ ]D
20  = -17.6 (c 1.00 in CHCl3); )H (400 MHz, CDCl3) 7.42-7.28 (10H, m, ArH), 
5.98 (1H, dddd, J 17.2, 10.4, 5.7, 5.7, CHX=CHYHZ), 5.31 (1H, dddd, J 17.2, 1.4, 
1.4, 1.4, CHX=CHYHZ), 5.20 (1H, dddd, J 10.4, 1.4, 1.4, 1.4, CHX=CHYHZ), 4.93 
(1H, d, J 11.2, OCHAHB-Ph), 4.89 (1H, d, J 11.6, OCHA’HB’-Ph), 4.78 (1H, d, J 
11.2, OCHAHB-Ph), 4.76 (1H, d, J 11.6, OCHA’HB’-Ph), 4.39 (1H, dddd, J 12.5, 
5.7, 1.4, 1.4, OCH2CH=CH2), 4.32 (1H, dddd, J 12.5, 5.7, 1.4, 1.4, 
OCH2CH=CH2), 4.03 (1H, dd, J 2.8, 2.8, inositol ring, H-2), 3.81 (1H, ddd, J 9.5, 
9.5, 2.3, inositol ring, H-4), 3.74 (1H, dd, J 9.5, 9.5, inositol ring, H-6), 3.58 (1H, 
ddd, J 9.5, 5.0, 2.8, inositol ring, H-1), 3.48 (1H, ddd, J 9.5, 7.1, 2.8, inositol ring, 
H-3), 3.23 (1H, dd, J 9.5, 9.5, inositol ring, H-5), 2.57 (1H, d, J 2.3, 4-OH), 2.36 
(1H, d, J 7.1, 3-OH), 2.33 (1H, d, J 5.0, 1-OH). The data are in good agreement 
with the literature values.89 
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(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (-)-139 
 
BnO OH
OBn
OAll
OH
PMBO
 
(-)-139 
 
Dibutyltin oxide (465 mg, 1.87 mmol, 1.5 eq) was added to a solution of (-)-1D-5-
O-allyl-2,6-bis-O-benzyl-myo-inositol (-)-138 (500 mg, 1.25 mmol, 1 eq) in dry 
toluene (30 mL). A Soxhlet apparatus containing 3 Å molecular sieves was 
attached and the mixture was heated under reflux overnight to pre-form the tin 
acetal complex. The mixture was cooled to room temperature and the volatile 
components removed under vacuum. The resulting residue was dissolved in dry 
DMF (30 mL) and TBAI (462 mg, 1.25 mmol, 1 eq), cesium fluoride (380 mg, 
2.50 mmol, 2 eq) and 4-(methoxy)benzyl chloride (391 mg, 339 µL, 2.50 mmol, 
2 eq) were added. The reaction was heated to 50 °C and left to stir overnight. 
The reaction was adjudged to be complete by TLC analysis and cooled to RT. 
The volatile components were removed under vacuum and the residue 
partitioned between ethyl acetate (50 mL) and water (50 mL), the layers were 
separated and the aqueous phase extracted with ethyl acetate (3 ( 30 mL). The 
combined organic components were dried (magnesium sulfate), filtered and the 
solvent removed under vacuum. The crude material was purified by silica gel 
column chromatography eluting with ethyl acetate and petroleum ether (20:80 
then 30:70). This gave (-)-1D-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-
inositol (-)-139 (325 mg, 50% yield) as a colourless solid:  Rf 0.48 (petroleum 
ether / ethyl acetate 60/40); mp 98-100 ºC (recrystallised from ethyl acetate), 
! 
"[ ]D
25  = -11.8 (c 0.70 in CHCl3); "max (KBr disc)/cm-1 3454 (s, broad), 3063 (w), 
3030 (w), 2962 (s), 2921 (s), 2853 (m), 1953 (w), 1722 (m), 1612 (s), 1514 (s), 
1259 (s), 1066 (s); )H (300 MHz, CDCl3) 7.42-7.26 (12H, m, ArH), 6.91 (2H, d, J 
8.7, OCH2C6H4OCH3), 6.01 (1H, dddd, J 17.2, 10.4, 5.7, 5.7, CHX=CHYHZ), 5.32 
(1H, dddd, J 17.2, 1.6, 1.4, 1.4, CHX=CHYHZ), 5.20 (1H, dddd, J 10.4, 1.6, 1.4, 
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1.4, CHX=CHYHZ), 4.94 (1H, d, J 11.5, OCHAHB-Ph), 4.93 (1H, d, J 11.1, 
OCHA’HB’-Ph), 4.77 (1H, d, J 11.1, OCHA’HB’-Ph), 4.72 (1H, d, J 11.5, OCHAHB-
Ph), 4.65 (1H, d, J 11.4, OCHAHB-C6H4OCH3), 4.55 (1H, d, J 11.4, OCHAHB-
C6H4OCH3), 4.40 (1H, dddd, J 12.5, 5.7, 1.4, 1.4, OCHVHW-CH=CH2), 4.35 (1H, 
dddd, J 12.5, 5.7, 1.4, 1.4, OCHVHW-CH=CH2), 4.09 (1H, ddd, J 9.5, 9.5, 1.9, 
inositol ring, H-4), 4.06 (1H, dd, J 2.6, 2.6, inositol ring, H-2), 3.84 (3H, s, OCH2-
C6H4OCH3), 3.75 (1H, dd, J 9.5, 9.5, inositol ring, H-6), 3.51 (1H, ddd, J 9.5, 6.3, 
2.6, inositol ring, H-1), 3.28 (1H, dd, J 9.5, 9.5, inositol ring, H-5), 3.27 (1H, dd, J 
9.5, 2.6, inositol ring, H-3), 2.54 (1H, d, J 1.9, 4-OH), 2.29 (1H, d, J 6.3, 1-OH). 
)C (75 MHz; CDCl3), 138.6 (ArC), 138.6 (ArC), 135.2 (CH2CH=CH2), 129.8 (ArC), 
129.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.8 
(ArCH), 127.7 (ArCH), 116.9 (CH2CH=CH2), 114.0 (ArCH), 82.9 (inositol ring, C-
5), 81.9 (inositol ring, C-6), 80.0 (inositol ring, C-3), 76.1 (inositol ring, C-2), 75.5 
(OCH2-Ph), 74.6 (OCH2-Ph), 74.1 (CH2CH=CH2), 73.0 (inositol ring, C-4), 72.6 
(inositol ring, C-1), 72.2 (OCH2-C6H4OCH3), 55.3 (OCH2-C6H4OCH3); m/z (ES+) 
[Found: (M+Na)+ 543.2358. C31H36O7Na requires M+, 543.2359], m/z (ES+) 543 
([M+Na]+, 100%); Anal. Calcd. For C31H36O7: C, 71.5, H, 7.0; Found: C, 71.7, H, 
6.9. 
 
 
(+)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-106 
 
BnO OH
OBn
OH
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(+)-106 
Method 1 
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (-)-139 
(300 mg, 0.58 mmol, 1 eq) was dissolved in absolute ethanol (20 mL) under a 
blanket of nitrogen, to this solution was added diisopropylethyl amine (75 mg, 
101 µL, 0.58 mmol, 1 eq). The solution was stirred at room temperature for 5 
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minutes and then Wilkinson’s catalyst (111 mg, 0.12 mmol, 0.2 eq) was added. 
The dark red slurry was heated under reflux for 3 h before being cooled to room 
temperature and filtered though Celite®. The filtrate was concentrated under 
vacuum and the residue analysed by 1H NMR to confirm complete isomerisation 
of the allylic ether to the enol ether. The crude residue was dissolved in 
methanol/CH2Cl2 (3:2, 20 mL) and acetyl chloride (27 mg, 24 +L, 0.35 mmol, 0.6 
eq) was added. The reaction was left to stir at room temperature for 4 h before 
the addition of triethylamine (2 mL) to quench the acid. The mixture was 
concentrated under vacuum and the residue purified by silica gel column 
chromatography, eluting with ethyl acetate and petroleum ether (50:50 then 
60:40) to afford a pale yellow solid. Recrystallisation from ethyl acetate and 
hexane gave (+)-1D-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-
106 (100 mg, 36% yield) as a colourless crystalline solid: Rf 0.56 (ethyl acetate); 
mp 126-128 ºC (recrystallised from ethyl acetate); 
! 
"[ ]D
20  = +10.5 (c 0.86 in 
CHCl3); "max (KBr disc)/cm-1 3395 (s, broad), 3084 (w), 3024 (m), 2943 (m), 2885 
(m), 1514 (s), 1249 (s), 1064 (s), 1023 (s); )H (300 MHz, CDCl3) 7.44-7.25 (12H, 
m, ArH), 6.91 (2H, d, J 8.7, OCH2C6H4OCH3), 4.97 (1H, d, J 11.6, OCHAHB-Ph), 
4.91 (1H, d, J 11.3, OCHA’HB’-Ph), 4.86 (1H, d, J 11.3, OCHA’HB’-Ph), 4.73 (1H, d, 
J 11.6, OCHAHB-Ph), 4.65 (1H, d, J 11.3, OCHAHB-C6H4OCH3), 4.53 (1H, d, J 
11.3, OCHAHB-C6H4OCH3), 4.08 (1H, dd, J 2.6, 2.6, inositol ring, H-2), 4.01 (1H, 
ddd, J 9.3, 9.3, 2.1, inositol ring, H-4), 3.84 (3H, s, OCH2-C6H4OCH3), 3.70 (1H, 
dd, J 9.3, 9.3, inositol ring, H-6), 3.55 (1H, ddd, J 9.3, 6.5, 2.6, inositol ring, H-1), 
3.50 (1H, ddd, J 9.3, 9.3, 2.2, inositol ring, H-5), 3.30 (1H, dd, J 9.3, 2.6, inositol 
ring, H-3), 2.62 (1H, d, J 2.2, 5-OH), 2.59 (1H, d, J 2.1, 4-OH), 2.36 (1H, d, J 6.5, 
1-OH); )C (125 MHz; CDCl3), 159.5 (PMB – ArC), 138.53 (ArC), 138.48 (ArC), 
129.6 (PMB – ArC), 129.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.0 (ArCH), 
127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 114.0 (PMB – ArCH), 81.7 (inositol 
ring, C-6), 79.8 (inositol ring, C-3), 76.3 (inositol ring, C-2), 75.0 (OCH2-Ph), 74.8 
(inositol ring, C-5), 74.7 (OCH2-Ph), 72.5 (inositol ring, C-1), 72.4 (inositol ring, C-
4), 72.1 (OCH2C6H4OCH3), 55.3 (OCH2C6H4OCH3); m/z (ES+) [Found: (M+Na)+ 
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503.2050. C28H32O7Na requires M+, 503.2046]; m/z (ES+) 503 ([M+Na]+, 100%); 
Anal. Calcd. For C28H32O7: C, 70.0, H, 6.7; Found: C, 70.0, H, 6.7. 
Method 2 
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol 139 
(540 mg, 1.04 mmol, 1 eq) was dissolved in AcOH (30 mL), with stirring at room 
temperature Pd(PPh3)4 (360 mg, 0.31 mmol, 0.3 eq) was added and the reaction 
monitored by TLC analysis.  After 18 h Pd(PPh3)4 (720 mg, 0.62 mmol, 0.6 eq) 
was added and the reaction stirred at room temperature for a further 24 h.  The 
reaction was adjudged complete by TLC analysis and quenched by the cautious 
addition of Na2CO3 (s) until pH 7 was achieved.  The reaction was then extracted 
with ethyl acetate (3 ( 30 mL) and the combined organic phases dried 
(magnesium sulfate), filtered and the solvent removed under vacuum. The crude 
material was purified by silica gel column chromatography eluting with ethyl 
acetate and petroleum ether (50:50).  This gave (-)-1D-2,6-bis-O-benzyl-3-O-(4-
methoxy)benzyl-myo-inositol (-)-106 (463 mg, 93% yield) as a colourless solid. 
The analysis of this material was consistent with that found for the method 1. 
 
 Method 3 
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol 139 
(60 mg, 0.12 mmol, 1 eq) was dissolved in AcOH (3 mL), Pd(PPh3)4 (40 mg, 35 
+mol, 0.3 eq) was added and the reaction heated to 80 °C.  After 4 h further 
Pd(PPh3)4 (40 mg, 35 +mol, 0.3 eq) was added and the reaction stirred at room 
temperature for a further 2 h.  The reaction was adjudged complete by TLC 
analysis and cooled to room temperature before being quenched by the cautious 
addition of Na2CO3 (s) until pH 7 was achieved.  The reaction was then extracted 
with ethyl acetate (3 ( 5 mL) and the combined organic phases dried 
(magnesium sulfate), filtered and the solvent removed under vacuum. The crude 
material was purified by silica gel column chromatography eluting with ethyl 
acetate and petroleum ether (50/50).  This gave (-)-1D-2,6-bis-O-benzyl-3-O-(4-
methoxy)benzyl-myo-inositol (-)-106 (49 mg, 89% yield) as a colourless solid. 
The analysis of this material was consistent with that found for the method 1. 
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Benzyloxy bis(N,N-diisopropylamino)phosphine 141 
 
P
NiPr2
BnO NiPr2
 
141 
 
Phosphorus trichloride (28 g, 18 mL, 206 mmol, 1 eq) was dissolved in dry 
diethyl ether (200 mL) under a nitrogen atmosphere.  To this solution was added 
dry pyridine (16 g, 17 mL, 206 mmol, 1 eq) and the mixture cooled to -78 °C. A 
solution of BnOH (22 g, 21 mL, 206 mmol, 1 eq) in dry diethyl ether (150 mL) 
was added dropwise over 1 h and the reaction warmed to room temperature and 
stirred for 1.5 h. The solid formed was removed by Schlenk filtration under 
nitrogen and washed with diethyl ether. The filtrate was cooled to -10 °C and dry 
diisopropyl amine (86 g, 118 mL, 845 mmol, 4.1 eq) added over 15 minutes 
before being warmed to room temperature and stirred for 20 h. The solid formed 
was removed by Schlenk filtration under a nitrogen atmosphere and washed with 
diethyl ether. The filtrate was concentrated under reduced pressure to give 
benzyloxy bis(N,N-diisopropylamino)phosphine 141 (56 g, 81% yield) as a pale 
yellow oil. !H (300 MHz, CDCl3) 7.43-7.31 (5H, m, ArH), 4.68 (2H, d, J 7.3, 
OCH2Ph), 3.68-3.51 [4H, m, NH(CH3)2], 1.21 (24H, dd, J 6.7, 3.4, NCH(CH3)2]; )p 
(121 MHz; CDCl3) 124.6. These data are in good agreement with the literature 
values.125 
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Bis(benzyloxy)-N,N-diisopropylamino phosphine 142 
 
P
NiPr2
BnO OBn
 
142 
 
Benzyloxy bis(N,N-diisopropylamino)phosphine 141 (5 g, 14.8 mmol, 1 eq) and 
1H-tetrazole (0.43 M solution in acetonitrile, 13 mL, 5.91 mmol, 0.4 eq) were 
dissolved in dry CH2Cl2 (50 mL) under a nitrogen atmosphere. Benzyl alcohol 
(1.6 g, 1.5 mL, 14.8 mmol, 1 eq) was added at RT, as a solution in dry CH2Cl2 
(25 mL), dropwise over 45 minutes. The reaction was stirred at RT and TLC 
analysis indicated the reaction had gone to completion after 3 h. The reaction 
was concentrated under reduced pressure and the crude material purified by 
silica gel column chromatography, eluting with triethyl amine, ethyl acetate and 
petroleum ether (5:15:80). This gave bis(benzyloxy)-N,N-diisopropylamino 
phosphine 142 (4.5 g, 88% yield) as a colourless oil. !H (300 MHz, CDCl3) 7.43-
7.27 (10H, m, ArH), 4.84 (2H, dd, J 12.7, 3JHP 8.2, 1 ( POCHAHB-Ph and 1 ( 
POCHA’HB’-Ph), 3.85-3.68 [2H, m, NCH(CH3)2], 1.21 (12H, d, J 6.8, NCH(CH3)2]; 
)p (121 MHz; CDCl3) 147.8. These data are in good agreement with the literature 
values.126 
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(-)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol 1,4,5-
tris(dibenzylphosphate) (-)-107 
 
BnO OPO(OBn)2
OBn
OPO(OBn)2
OPO(OBn)2
PMBO
 
(-)-107 
 
Bis(benzyloxy)-N,N-diisopropylamino phosphine (-)-142 (406 mg, 1.18 mmol, 
6 eq) was stirred under a nitrogen atomosphere with 1H-tetrazole (0.43 M 
solution in acetonitrile, 2.7 mL, 1.18 mmol, 6 eq) for 20 minutes. A solution of (+)-
1D-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-106 (94 mg, 0.2 
mmol, 1 eq) in dry CH2Cl2 (10 mL) was added via a cannular and the reaction left 
to stir at room temperature overnight. Further bis(benzyloxy)-N,N-
diisopropylamino phosphine (135 mg, 0.39 mmol, 2 eq) and 1H-tetrazole (0.43M 
solution in acetonitrile, 900 +L, 0.39 mmol, 2 eq) were added and the reaction 
stirred at RT for 2 h. The reaction was then cooled to -78 °C and 3-
chloroperoxybenzoic acid (60% w/w, 451 mg, 1.57 mmol, 8 eq) added before the 
solution was warmed to RT and stirred for 30 minutes. Sodium hydrogen sulfite 
(10% aq solution, 10 mL) was added and the layers separated and the aqueous 
layer further extracted with CH2Cl2 (3( 10 mL). The combined organic layers 
were washed with a saturated solution of sodium hydrogen carbonate and then 
dried (magnesium sulfate) and filtered. The filtrate was concentrated under 
vacuum and residue purified by silica gel column chromatography eluting with 
ethyl acetate and hexane (50:50 then 80:20) to give (-)-1D-2,6-bis-O-benzyl-3-O-
(4-methoxy)benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-107 (220 mg, 
89% yield) as a gum: Rf 0.48 (ethyl acetate); 
! 
"[ ]D
25  = -2.8 (c 1.00 in CHCl3); "max 
(KBr disc)/cm-1 3089 (m), 3064 (m), 2957 (m), 2934 (m), 1956 (w), 1888 (w), 
1812 (w), 1613 (w), 1514 (m), 1455 (m), 1273 (s), 1016 (s); !H (300 MHz, CDCl3) 
7.47-7.09 (40H, m, ArH), 7.03-6.97 (2H, m, ArH), 6.81 (2H, d, J 8.7, 
OCH2C6H4OCH3), 5.14-4.64 (17H, m, 6 ( POCH2-Ph + 2 ( OCH2-Ph + 1 ( 
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inositol ring, H-4), 4.59 (1H, ddd, J 9.5, 9.5, 3JHP 9.5, inositol ring, H-5), 4.51 (1H, 
d, J 11.1, OCHAHBC6H4OCH3), 4.45 (1H, d, J 11.1, OCHAHBC6H4OCH3), 4.38 
(1H, dd, J 2.1, 2.1, inositol ring, H-2), 4.31 (1H, ddd, J 9.5, 2.1, 3JHP 7.4, inositol 
ring, H-1), 4.15 (1H, dd, J 9.5, 9.5, inositol ring, H-6), 3.78 (3H, s, 
OCH2C6H4OCH3), 3.49 (1H, dd, J 9.9, 2.1, inositol ring, H-3); )C (125 MHz; 
CDCl3), 159.6 (PMB – ArC), 138.7 (ArC), 138.7 (ArC), 136.7 (d, 3JCP 7.8, ArC), 
136.6 (d, 3JCP 7.5, ArC), 136.6 (d, 3JCP 8.0, ArC), 136.3 (d, 3JCP 7.1, ArC), 136.0 
(d, 3JCP 7.2, ArC), 136.0 (d, 3JCP 6.9, ArC), 129.9 (ArCH), 129.8 (PMB – ArC), 
129.0 (ArCH), 129.0 (ArCH), 128.7 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.5 
(ArCH), 128.3 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 
127.6 (ArCH), 114.2 (PMB – ArCH), 79.6-79.4 (m, inositol ring, C-5), 78.6-78.2 
(m, inositol ring, C-1, 4 and 6), 77.9 (inositol ring, C-3), 75.7 (OCH2-Ph), 75.6 
(inositol ring, C-2), 75.0 (OCH2-Ph), 72.4 (OCH2C6H4OCH3), 70.0-69.8 (3 ( 
POCH2-Ph), 69.7 (d, 2JCP 5.7, POCH2-Ph), 69.6 (d, 2JCP 4.9, POCH2-Ph), 69.5 (d, 
2JCP 4.9, POCH2-Ph), 55.6 (OCH2C6H4OCH3); )p (121 MHz; CDCl3) -1.63, -1.83, 
-2.04; m/z  (ES+) [Found: (M+Na)+ 1283.3835. C70H71O16P3Na requires M+, 
1283.3847]; m/z (ES+) 1283 ([M+Na]+, 100%); Anal. Calcd. For C70H71O16P3: C, 
66.7, H, 5.7; Found: C, 66.8, H, 5.6. 
 
 
(-)-1D-2,6-bis-O-Benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-108 
 
BnO OPO(OBn)2
OBn
OPO(OBn)2
OPO(OBn)2
HO
 
(-)-108 
 
(-)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol 1,4,5-
tris(dibenzylphosphate) (-)-107 (53 mg, 42 +mol, 1 eq) was dissolved in CH2Cl2 
(10 mL). To this solution was added TMSCl (14 mg, 16 +l, 126 +mol, 3 eq) 
followed by anisole (7 mg, 7 +l, 63 +mol, 1.5 eq).  The reaction stirred at RT for 5 
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min before the addition of SnCl2·2H2O (catalytic, 0.1 eq) and monitored by TLC 
analysis.  The reaction was adjudged complete after 3 h.  The reaction was 
diluted with H2O (10 mL), the layers were separated and the aqueous layer 
further extracted with CH2Cl2 (3( 5 mL). The combined organic layers were then 
dried (magnesium sulfate) and filtered.  The filtrate was concentrated under 
vacuum and residue purified by silica gel column chromatography eluting with 
ethyl acetate and petroleum ether (50:50 then 60:40, 70:30, 80:20) to give (-)-1D-
2,6-bis-O-benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-108 (35 mg, 77% 
yield) as a colourless waxy solid: Rf 0.37 (3% MeOH in CH2Cl2); 
! 
"[ ]D
25  = -23.8 (c 
1.00 in CHCl3); "max (KBr disc)/cm-1 3330 (s, broad), 3089 (m), 3066 (m), 2925 
(s), 1497 (m), 1455 (m), 1260 (s), 1016 (s); !H (400 MHz, CDCl3) 7.44-7.12 (36H, 
m, ArH), 7.11-7.07 (2H, m, ArH), 7.00-6.96 (2H, m, ArH), 5.17-4.74 (15H, m, 
POCHAHB-Ph + 2 ( OCHAHB-Ph), 4.74-4.62 (2H, m, POCHAHB-Ph + inositol ring, 
H-4), 4.51 (1H, ddd, 3JHP 9.5, J 9.3, 9.3, inositol ring, H-5), 4.34 (1H, ddd, J 9.5, 
2.5, 3JHP 7.6, inositol ring, H-1), 4.29 (1H, dd, J 2.5, 2.5, inositol ring, H-2), 4.08 
(1H, dd, J 9.5, 9.5, inositol ring, H-6), 3.72 (1H, ddd, J 9.5, 3.7, 2.5, inositol ring, 
H-3); )C (75 MHz; CDCl3), 139.0 (ArC), 138.5 (ArC), 129.0 (ArCH), 128.9 (ArCH), 
128.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.2 (ArCH), 128.2 
(ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 
80.8 (dd, 2JCP 4.8, 3JCP 4.8, inositol ring, C-4), 79.1 (inositol ring, C-2), 79.1-78.9 
(m, inositol ring, C-5), 78.3 (d, 3JCP 8.2, inositol ring, C-6), 78.1 (d, 2JCP 5.9, 
inositol ring, C-1), 76.4 (OCH2-Ph), 75.0 (OCH2-Ph), 71.7 (inositol ring, C-3), 70.7 
(d, 2JCP 5.7, POCH2-Ph), 70.6 (d, 2JCP 5.7, POCH2-Ph), 69.9 (d, 2JCP 5.6, POCH2-
Ph), 69.8 (d, 2JCP 5.6, POCH2-Ph), 69.7 (d, 2JCP 5.7, POCH2-Ph), 69.6 (d, 2JCP 
5.0, POCH2-Ph);  )p (121 MHz; CDCl3) 0.8, -1.3, -1.6; m/z  (ES+) [Found: (M+H)+ 
1141.3447. C62H64O15P3 requires M+, 1141.3453]; m/z (ES+) 1141 ([M+H]+, 
100%); Anal. Calcd. For C62H64O15P3: C, 66.7, H, 5.7; Found: C, 66.6, H, 5.8. 
Further reactions on a large scale using the conditions described gave variable 
yield 19-40%. 
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(±)-1-O-Benzoyl-trans-cyclohexane-1,2-diol 147 
 
O
OH
O
Hc
Hc
Hb
Hb
Ha
Hd
He  
147 
 
Dibutyltin oxide (12.0 g, 51.69 mmol, 3 eq) was added to a solution of (±)-trans-
cyclohexane-1,2-diol 146 (2.0 g, 17.23 mmol, 1 eq) in dry toluene (50 mL). Dean 
and Stark apparatus was attached and the mixture was heated under reflux 
overnight to pre-form the tin acetal complex. The mixture was cooled to 0 °C and 
benzoyl chloride (3.6 mg, 3.0 mL, 25.84 mmol, 1.5 eq) was added. The reaction 
was stirred at RT and adjudged to be complete by TLC analysis after 6 h. The 
volatile components were removed under vacuum and the residue partitioned 
between ethyl acetate (50 mL) and water (50 mL), the layers were separated and 
the aqueous phase extracted with ethyl acetate (3 ( 30 mL). The combined 
organics were dried (magnesium sulfate), filtered and the solvent removed under 
vacuum. The crude material was purified by silica gel column chromatography 
eluting with ethyl acetate and petroleum ether (20:80, 30:70 then 50:50). This 
gave (±)-1-O-benzoyl-trans-cyclohexane-1,2-diol 147 (1.8 g, 47% yield) as a 
colourless crystalline solid:  Rf 0.48 (petroleum ether / ethyl acetate 60:40); mp 
98-100 °C (hexane/ethyl acetate); )H (300 MHz, CDCl3) 8.14-8.08 (2H, m, Hc), 
7.64-7.57 (1H, m, Ha ), 7.52-7.45 (2H, m, Hb), 4.94-4.84 (1H, m, Hd), 3.83-3.73 
(1H, m, He), 2.38 (1H, br s, -OH), 2.25-2.09 (2H, m, cyclohexane ring), 1.88-1.72 
(2H, m, cyclohexane ring), 1.57-1.28 (4H, m, cyclohexane ring).  These data are 
in agreement with the literature values.127 
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(±)-1-O-Dibenzylphosphate-2-O-benzoyl-2-trans-cyclohexane-1,2-diol 148 
 
O
O
P
OBn
OBn
O
O
Hc
Hc
Hb
Hb
Ha
Hd
He
 
148 
 
Bis(benzyloxy)-N,N-diisopropylamino phosphine (314 mg, 909 +mol, 2 eq) was 
stirred under a nitrogen atomosphere with 1H-tetrazole (0.43 M solution in 
acetonitrile, 2.1 mL, 909 +mol, 2 eq) for 20 minutes. A solution of (±)-1-O-
benzoyl-trans-cyclohexane-1,2-diol 147 (100 mg, 454 +mol, 1 eq) in dry CH2Cl2 
(10 mL) was added via a cannular and the reaction left to stir at room 
temperature overnight. Further bis(benzyloxy)-N,N-diisopropylamino phosphine 
(157 mg, 454 +mol, 1 eq) and 1H-tetrazole (0.43 M solution in acetonitrile, 1 mL, 
454 +mol, 1 eq) were added and the reaction stirred at RT for 2 h. The reaction 
was then cooled to -78 °C and 3-chloroperoxybenzoic acid (60% w/w, 393 mg, 
1363 +mol, 3 eq) added before being warmed to RT and stirred for 30 minutes.  
Sodium hydrogen sulfite (10% aq solution, 10 mL) was added and the layers 
separated and the aqueous layer further extracted with CH2Cl2 (3( 10 mL). The 
combined organic layers were washed with a saturated solution of sodium 
hydrogen carbonate and then dried (magnesium sulfate) and filtered. The filtrate 
was concentrated under vacuum and residue purified by silica gel column 
chromatography eluting with ethyl acetate and hexane (20:80 then 50:50) to give 
(±)-1-O-benzoyl-2-O-dibenzylphosphate-trans-cyclohexane-1,2-diol 148 (123 mg, 
56% yield) as a colourless gum:  Rf 0.42 (hexane / ethyl acetate 60:40); )H (300 
MHz, CDCl3) 8.03-7.94 (2H, m, Hc), 7.48-7.38 (1H, m, Ha ), 7.33-7.07 (10H, m, 
benzyl ArH), 7.01-6.90 (2H, m, Hb), 5.03-4.92 (1H, m, Hd), 4.92-4.82 (2H, m, 
benzylic CH2), 4.81-4.65 (2H, m, benzylic CH2), 4.56-4.43 (1H, m, He), 2.10-2.04 
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(2H, m, cyclohexane ring), 1.76-1.60 (2H, m, cyclohexane ring), 1.60-1.13 (4H, 
m, cyclohexane ring); )p (121 MHz; CDCl3) 1.9. 
 
 
(±)-1-O-Dibenzylphosphate-trans-cyclohexane-1,2-diol 149 
 
OH
O
P
OBn
OBn
O
Hb
Ha
 
149 
 
(±)-1-O-Benzoyl-2-O-dibenzylphosphate-trans-cyclohexane-1,2-diol 148 (76 mg, 
0.16 mmol, 1 eq) was dissolved in dry CH2Cl2 (3.5 mL) under a nitrogen 
atmosphere and cooled to -78 °C. With vigorous stirring diisobutylaluminium 
hydride (868 +L of a 1 M solution in hexane, 0.87 mmol, 5.5 eq) was added 
slowly dropwise. After 15 minutes TLC analysis indicated the full consumption of 
starting material. The DIBALH was quenched with the slow addition of methanol 
(5 ml) (CAUTION: copious effervescence and a slight exotherm is observed). 
The reaction mixture was warmed to RT and treated with Na2SO4·10H2O (Note: 
A thick gel formed, this was broken up with the addition of more Na2SO4·10H2O). 
The solid was removed by filtration through Celite® and washed with ethyl 
acetate. The filtrate was concentrated under vacuum and the crude material 
purified by silica gel column chromatography eluting with ethyl acetate and 
hexane (40:60) to give (±)-1-O-dibenzylphosphate-trans-cyclohexane-1,2-diol 
149 (52 mg, 87% yield) as a colourless solid: Rf 0.34 (ethyl acetate/hexane 4:6); 
)H (300 MHz, CDCl3) 7.51-7.02 (10H, m, benzyl ArH), 5.20-4.78 (4H, m, benzylic 
CH2), 4.02-3.92 (1H, m, Ha), 3.50-3.39 (1H, m, Hb), 3.34 (1H, br s –OH), 2.02-
1.87 (2H, m, cyclohexane ring), 1.66-1.50 (2H, m, cyclohexane ring), 1.38-1.02 
(4H, m, cyclohexane ring); )p (121 MHz; CDCl3) -0.3. 
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(±)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-benzoyl-myo-inositol 150 
 
BnO OH
OBn
OAll
OH
O
O
a
b
b
c
c
d
 
150 
 
Dibutyltin oxide (465 mg, 1.87 mmol, 1.5 eq) was added to a solution of (±)-1D-5-
O-allyl-2,6-bis-O-benzyl-myo-inositol 116 (500 mg, 1.25 mmol, 1 eq) in dry 
toluene (15 mL). A Soxhlet apparatus containing 3 Å molecular sieves was 
attached and the mixture was heated under reflux overnight to pre-form the tin 
acetal complex. The solution was cooled to RT and 4 Å molecular sieves added. 
The mixture was then cooled to -5 °C and benzoyl chloride (351 mg, 290 µL, 
2.50 mmol, 2 eq) was added. The reaction was allowed to stir at RT for 3 h. The 
molecular sieves were removed by filtration and the volatile components were 
removed under vacuum and the residue partitioned between ethyl acetate 
(30 mL) and water (30 mL), the layers were separated and the aqueous phase 
extracted with ethyl acetate (3 ( 30 mL). The combined organic layers were 
washed with a saturated solution of sodium hydrogen carbonate and then dried 
(magnesium sulfate) and filtered. The filtrate was concentrated under vacuum 
and residue purified by silica gel column chromatography eluting with ethyl 
acetate and hexane (10:90 then 30:70) to give (±)-1D-5-O-allyl-2,6-bis-O-benzyl-
3-O-benzoyl-myo-inositol 150 (366 mg, 60% yield) as a colourless gum:  Rf 0.60 
(hexane / ethyl acetate 50:50); "max (KBr disc)/cm-1 3519 (s, broad), 3385 (s, 
broad), 3089 (m), 3066 (m), 3032 (m), 2922 (s), 1712 (s), 1273 (s), 1112 (s); )H 
(400 MHz, CDCl3) 8.07 (2H, d, J 8.2, benzoyl ArH, Hc), 7.60 (1H, t, J 7.4, benzoyl 
ArH, Ha), 7.46 (2H, dd, J 8.2, 7.4, benzoyl ArH, Hb), 7.43-7.24 (10H, m, benzyl 
ArH), 5.99 (1H, dddd, J 17.1, 10.8, 5.8, 5.6, CHX=CHYHZ), 5.32 (1H, ddd, J 17.1, 
1.9, 1.9, CHX=CHYHZ), 5.20 (1H, ddd, J 10.8, 1.3, 1.3, CHX=CHYHZ), 5.05 (1H, 
dd, J 9.5, 2.5, inositol ring, H-3), 4.93 (1H, d, J 11.1, OCHAHB-Ph), 4.80 (1H, d, J 
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11.1, OCHAHB-Ph), 4.80 (1H, d, J 11.6, OCHA’HB’-Ph), 4.71 (1H, d, J 11.6, 
OCHA’HB’-Ph), 4.43 (1H, dddd, J 12.6, 5.6, 1.9, 1.3, OCHVHW-CH=CH2), 4.35 
(1H, dddd, J 12.6, 5.8, 1.9, 1.3, OCHVHW-CH=CH2), 4.27 (1H, ddd, J 9.5, 9.5, 
3.3, inositol ring, H-4), 4.18 (1H, dd, J 2.5, 2.5, inositol ring, H-2), 3.82 (1H, dd, J 
9.5, 9.5, inositol ring, H-6), 3.71 (1H, ddd, J 9.5, 6.0, 2.5, inositol ring, H-1), 3.36 
(1H, dd, J 9.5, 9.5, inositol ring, H-5), 2.41 (1H, d, J 3.3, 4-OH), 2.28 (1H, d, J 
6.0, 1-OH); )C (125 MHz; CDCl3), 166.1 (C=O), 138.4 (ArC), 138.2 (ArC), 134.9 
(OCH2-CH=CH2), 133.4 (benzoyl ArCH, Ca), 129.8 (benzoyl ArCH, Cb), 129.6 
(benzoyl ArC, Cd), 128.6 (benzoyl ArCH, Cc), 128.5 (ArCH), 128.4 (ArCH), 128.1 
(ArCH), 127.9 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 117.2 (OCH2-CH=CH2), 83.0 
(inositol ring, C-5), 81.6 (inositol ring, C-6), 77.8 (inositol ring, C-2), 75.5 (OCH2-
Ph), 75.3 (OCH2-Ph), 74.3 (OCH2-CH=CH2), 74.2 (inositol ring, C-3), 72.3 
(inositol ring, C-1), 71.6 (inositol ring, C-4); m/z (ES+) [Found: (M+Na)+ 527.2035. 
C30H32O7Na requires M+, 527.2040]; m/z (ES+) 606 ([M +HNEt3]+, 100%), 527 
([M+Na]+, 40%); Anal. Calcd. For C30H32O7: C, 71.4, H, 6.4; Found: C, 71.4, H, 
6.3. 
 
 
(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 151 
 
BnO OH
OBn
OH
OH
O
O
a
b
b
c
c
d
 
151 
(±)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-benzoyl-myo-inositol 150 (366 mg, 
0.73 mmol, 1 eq) was dissolved in AcOH (20 mL), with stirring at room 
temperature Pd(PPh3)4 (838 mg, 0.73 mmol, 1 eq) was added and the reaction 
monitored by TLC analysis.  After 18 h the reaction was adjudged complete by 
TLC analysis. The reaction mixture was concentrated by the azeotropic removal 
of AcOH with cyclohexane. The crude material was purified by silica gel column 
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chromatography eluting with ethyl acetate and petroleum ether (50:50).  This 
gave (±)-1D-2,6-bis-O-benzyl-3-O-benzoyl-myo-inositol 151 (290 mg, 86% yield) 
as a colourless solid: Rf 0.44 (ethyl acetate/petroleum ether 60:40); "max (KBr 
disc)/cm-1 3429 (s broad), 3063 (m), 3031 (m), 2927 (m), 1721 (s), 1317 (s), 1104 
(s); )H (300 MHz, CDCl3) 8.08 (2H, d, J 7.0 benzoyl ArH, Hc), 7.61 (1H, t, J 7.4, 
benzoyl ArH, Ha), 7.46 (2H, dd, J 7.4, 7.0, benzoyl ArH, Hb), 7.43-7.25 (10H, m, 
benzyl ArH), 5.03 (1H, dd, J 9.7, 2.4, inositol ring, H-3), 4.92 (1H, d, J 11.7, 
OCHAHB-Ph), 4.88 (1H, d, J 11.7, OCHAHB-Ph), 4.83 (1H, d, J 11.6, OCHA’HB’-
Ph), 4.72 (1H, d, J 11.6, OCHA’HB’-Ph), 4.20 (1H, ddd, J 9.7, 9.7, 3.9, inositol 
ring, H-4), 4.20 (1H, dd, J 2.4, 2.4, inositol ring, H-2), 3.81-3.69 (2H, m, 2 ( 
inositol ring, H-1 and H-6), 3.56 (1H, ddd, J 9.7, 9.7, 2.6, inositol ring, H-5), 2.96 
(1H, d, J 2.6, 5-OH), 2.75 (1H, d, J 3.9, 4-OH), 2.41 (1H, d, J 6.0, 1-OH); )C (125 
MHz; CDCl3), 166.6 (C=O), 139.5 (ArC), 139.0 (ArC), 133.4 (benzoyl ArCH, Ca), 
130.3 (benzoyl ArC, Cd), 129.9 (benzoyl ArCH, Cc), 128.5 (benzoyl ArCH, Cb), 
128.2 (ArCH), 128.2 (ArCH), 127.8 (ArCH), 127.5 (ArCH), 82.2 (inositol ring, C-
6), 79.2 (inositol ring, C-2), 75.7 (inositol ring, C-5), 75.3 (OCH2-Ph), 75.1 
(inositol ring, C-3), 75.1 (OCH2-Ph), 72.4 (inositol ring, C-1), 71.7 (inositol ring, C-
4); m/z (ES+) [Found: (M+Na)+ 487.1725. C27H28O7Na requires M+, 487.1727]; 
m/z (ES+) 566 ([M +HNEt3]+, 100%), 487 ([M+Na]+, 20%); Anal. Calcd. For 
C27H28O7: C, 69.8, H, 6.1; Found: C, 70.0, H, 6.1. 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 1,4,5-
tris(dibenzylphosphate) 145 
 
BnO OPO(OBn)2
OBn
OPO(OBn)2
OPO(OBn)2
O
O
a
b
b
c
c
d
 
145 
 
Bis(benzyloxy)-N,N-diisopropylamino phosphine (228 mg, 0.66 mmol, 6 eq) was 
stirred under a nitrogen atomosphere with 1H-tetrazole (0.43 M solution in 
acetonitrile, 1.5 mL, 0.66 mmol, 6 eq) for 20 minutes. A solution of (-)-1D-2,6-bis-
O-benzyl-3-O-benzoyl-myo-inositol 151 (51 mg, 0.11 mmol, 1 eq) in dry CH2Cl2 
(5 mL) was added to the phosphoramidite and tetrazole solution via a cannular 
and the reaction left to stir at room temperature overnight. More bis(benzyloxy)-
N,N-diisopropylamino phosphine (76 mg, 0.22 mmol, 2 eq) and 1H-tetrazole 
(0.43M solution in acetonitrile, 500 +L, 0.22 mmol, 2 eq) were added and the 
reaction mixture stirred at RT for 2 h. The reaction was then cooled to -78 °C and 
3-chloroperoxybenzoic acid (70% w/w, 152 mg, 0.88 mmol, 8 eq) added before 
being warmed to RT and stirred for 30 minutes.  Sodium hydrogen sulfite (10% 
aq solution, 5 mL) was added and the layers separated and the aqueous layer 
further extracted with CH2Cl2 (3 ( 5 mL). The combined organic layers were 
washed with a saturated solution of sodium hydrogen carbonate and then dried 
(magnesium sulfate) and filtered. The filtrate was concentrated under vacuum 
and residue purified by silica gel column chromatography eluting with ethyl 
acetate and hexane (50:50 then 80:20) to give (±)-1D-2,6-bis-O-benzyl-3-O-
benzoyl-myo-inositol 1,4,5-tris(dibenzylphosphate) 145 (96 mg, 70% yield) as a 
colourless gum: Rf 0.56 (ethyl acetate); !max (NaCl plate)/cm-1 3090 (m), 3064 
(m), 2955 (m), 2894 (m), 1956 (w), 1885 (w), 1814 (w), 1721 (s), 1314 (s), 1013 
(s); )H (500 MHz, CDCl3) 8.07 (2H, d, J 7.5, benzoyl ArH, Hc), 7.53 (1H, t, J 7.4, 
benzoyl ArH, Ha), 7.42-7.39 (2H, m, ArH), 7.37 (2H, dd, J 7.5, 7.4, benzoyl ArH, 
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Hb), 7.30-7.15 (28H, m, benzyl ArH), 7.14-7.08 (4H, m, ArH), 7.08-7.03 (2H, m, 
ArH), 7.03-6.98 (2H, m, ArH), 6.84-6.80 (2H, m, ArH), 5.26 (1H, ddd, J 9.5, 9.5, 
3JHP 9.5, inositol ring, H-4), 5.16 (1H, dd, J 9.5, 2.4, inositol ring, H-3), 5.02 (1H, 
dd, J 11.6, 3JHP 3.4, POCHXHY-Ph), 5.00 (1H, dd, J 11.1, 3JHP 4.1, POCHX’HY’-
Ph), 4.96-4.77 (9H, m, POCH2-Ph + OCH2-Ph), 4.73-4.65 (4H, m, POCH2-Ph + 
OCH2-Ph), 4.62 (1H, ddd, J 9.5, 9.5, 3JHP 9.5, inositol ring, H-5), 4.50-4.42 (2H, 
m, POCHXHY-Ph + inositol ring, H-1), 4.40 (1H, dd, J 2.4, 2.4, inositol ring, H-2), 
4.19 (1H, dd, J 9.5, 9.5, inositol ring, H-6); )C (125 MHz; CDCl3), 165.1 (C=O), 
138.1 (ArC), 137.6 (ArC), 135.9 (d, 3JCP 7.4, ArC), 135.8 (d, 3JCP 8.0, ArC), 135.8 
(d, 3JCP 7.3, ArC), 135.5 (d, 3JCP 6.6, ArC), 135.4 (d, 3JCP 6.6, ArC), 135.3 (d, 3JCP 
7.2, ArC), 133.3 (benzoyl ArCH, Ca), 130.2 (benzoyl ArCH, Cc), 129.1 (benzoyl 
ArC, Cd), 128.5 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.3 (ArCH), 128.2 
(ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 
128.0 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.6 
(ArCH), 127.4 (ArCH), 127.3 (ArCH), 127.2 (ArCH), 78.7 (dd, 2JCP 7.1, 3JCP 7.1, 
inositol ring, C-5), 77.8 (d, 2JCP 7.5, inositol ring, C-1), 77.5 (d, 3JCP 6.2, inositol 
ring, C-6), 76.5 (dd, 2JCP 5.2, 3JCP  5.2, inositol ring, C-4), 76.2 (inositol ring, C-2), 
75.6 (OCH2-Ph), 74.7 (OCH2-Ph), 71.5 (inositol ring, C-3), 69.6 (d, 2JCP 5.5, 
POCH2-Ph), 69.5 (d, 2JCP 5.9, POCH2-Ph), 69.4 (d, 2JCP 6.0, POCH2-Ph), 69.4 (d, 
2JCP 6.0, POCH2-Ph), 69.3 (d, 2JCP 5.0, POCH2-Ph), 68.9 (d, 2JCP 5.4, POCH2-
Ph); )p (161 MHz; CDCl3) -1.7, -1.8, -2.0; m/z (ES+) [Found: (M+Na)+ 1267.35 
(100.0%), 1238.36 (78.0%), 1269.36 (32.5%), 1270.36 (7.3%), 1271.36 (1.2%). 
C69H67O16P3Na calculated M+, 1267.35 (100.0%), 1268.36 (76.0%), 1269.36 
(31.8%), 1270.36 (9.5%), 1271.37 (2.3%)]; m/z (ES+) 1346 ([M +HNEt3]+, 100%), 
1267 ([M+Na]+, 40%); Anal. Calcd. For C69H67O16P3: C, 66.6, H, 5.4; Found: C, 
66.7, H, 5.4. 
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8.4. Synthesis of 5-O-position compounds 
 
(+)-1D-2,6-bis-O-Benzyl-5-O-allyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 
152 
BnO OPO(OBn)2
OBn
OAll
OPO(OBn)2
(BnO)2OPO
 
(+)-152 
 
To a solution of the triol 138 (1.0 g, 2.5 mmol, 1 eq) in dry CH2Cl2 (50 mL) under 
a nitrogen atomosphere was added 1H-tetrazole (0.43M solution in acetonitrile, 
33 mL, 15.0 mmol, 6 eq) followed by bis(benzyloxy)-N,N-diisopropylamino 
phosphine 142 (5.2 g, 15.0 mmol, 6 eq) the reaction left to stir at RT overnight. 
Further 1H-tetrazole (0.43M solution in acetonitrile, 11.1 mL, 5.0 mmol, 2 eq) 
followed by bis(benzyloxy)-N,N-diisopropylamino phosphine 142 (1.73 g, 5.0 
mmol, 2 eq) was added and the reaction stirred at RT for 2 h. Further 1H-
tetrazole (0.43 M solution in acetonitrile, 11.1 mL, 5.0 mmol, 2 eq) followed by 
bis(benzyloxy)-N,N-diisopropylamino phosphine 142 (1.73 g, 5.0 mmol, 2 eq) 
was added and the reaction mixture stirred at RT for another 2 h.  The reaction 
mixture was then cooled to -78 °C and 3-chloroperoxybenzoic acid (80% w/w, 5.5 
g, 25.0 mmol, 10 eq) added before being warmed to RT and stirred for 30 
minutes.  Sodium hydrogen sulfite (10% aq solution, 50 mL) was added and the 
layers separated and the aqueous layer further extracted with CH2Cl2 (3 ( 30 
mL). The combined organic layers were washed with a saturated solution of 
sodium hydrogen carbonate and then dried (magnesium sulfate) and filtered. The 
filtrate was concentrated under vacuum and residue purified by silica gel column 
chromatography eluting with Et2O (100%) then ethyl acetate and hexane (60:40, 
70:30, 80:20) to give (-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-
methylphosphate-3,4,5-tris(dibenzylphosphate) 152 (2.5 g, 86% yield) as a 
colourless gum: Rf 0.37 (4% MeOH in CHCl3); 
! 
"[ ]D
25= +2.00 (c 1.00 in CHCl3); 
"max (NaCl disc)/cm-1 3090 (w), 3064 (m), 3033 (m), 2961 (m), 2895 (m), 2360 
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(w), 2340 (w), 1956 (w), 1884 (w), 1814 (w), 1731 (w); !H (500 MHz, CDCl3) 
7.36-7.14 (40H, m, ArH), 5.85 (1H, dddd, J 17.0, 11.3, 5.7, 5.7, CHX=CHYHZ), 
5.16 (1H, dd, J 17.0, 1.6, CHX=CHYHZ), 5.09-4.71 (18H, m, 8 ( OCHAHB-Ph + 
CHX=CHYHZ + 1 ( inositol ring, H-4), 4.60 (1H, dd, J 2.3, 2.3, inositol ring, H-2), 
4.33-4.10 (4H, m, OCHVHW-CH=CH2 + 2 ( inositol ring, H-1 and H-3), 4.01 (1H, 
dd, J 9.5, 9.5, inositol ring, H-6), 3.23 (1H, dd, J 9.5, 9.5, inositol ring, H-5); )C 
(125 MHz; CDCl3), 138.3 (ArC), 138.1 (ArC), 136.1 (d, 3JCP 7.8, ArC), 136.0 (d, 
3JCP 7.6, ArC), 135.6 (d, 3JCP 6.7, ArC), 135.6 (d, 3JCP 7.0, ArC), 135.5 (d, 3JCP 
7.6, ArC), 134.6 (CH=CH2), 128.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 
(ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 
128.0 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.5 
(ArCH), 127.4 (ArCH), 127.2 (ArCH), 117.0 (CH=CH2), 80.1 (inositol ring, C-5), 
79.4 (d, 2JCP 6.5, inositol ring, C-6), 77.8 (dd, 2JCP 7.2, 3JCP 7.2, inositol ring, C-4), 
77.7 (inositol ring, C-2), 77.4 (d, 2JCP 6.4, inositol ring, C-1), 75.9 (dd, 2JCP 4.7, 
3JCP 4.0, inositol ring, C-3), 75.8 (OCH2-Ph), 75.6 (OCH2-Ph), 74.5 (OCH2-
CH=CH2), 69.8 (d, 2JCP 5.7, POCH2-Ph), 69.5 (d, 2JCP 5.2, POCH2-Ph), 69.4 (d, 
2JCP 5.7, POCH2-Ph), 69.4 (d, 2JCP 5.5, POCH2-Ph), 69.3 (d, 2JCP 5.1, POCH2-
Ph), 69.2 (d, 2JCP 5.2, POCH2-Ph); !p (161 MHz; CDCl3) -1.3, -1.5, -2.0; m/z 
(ES+) [Found: (M+Na)+ 1203.36 (100.0%), 1204.37 (72.8%), 1205.37 (28.8%), 
1206.37 (6.6%), 1207.37 (1.0%). C65H67NaO15P3 calculated M+, 1203.36 
(100.0%), 1204.36 (71.6%), 1205.37 (28.4%), 1206.37 (8.1%), 1207.37 (1.8%)]; 
m/z (ES+) 1193 ([M-Bn+HNEt3]+, 30%), 1203 ([M+Na]+, 40%), 1193 ([M +HNEt3]+, 
100%); Anal. Calcd. For C65H67O15P3: C, 66.1, H, 5.7; Found: C, 66.2, H, 5.6. 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 
 
BnO OPO(OBn)2
OBn
OPO(OBn)2
(BnO)2OPO OH
 
(+)-153 
 
 
Method 1 
To a solution of (+)-1D-2,6-bis-O-benzyl-5-O-allyl-myo-inositol 1,3,4-
tris(dibenzylphosphate) 152 (100 mg, 87 +mol, 1 eq) in AcOH (7 mL) under a 
nitrogen atomosphere was added Pd(PPh3)4 (60 mg, 52 +mol, 0.6 eq) the 
reaction left to stir at RT. After 2 h, further Pd(PPh3)4 (100 mg, 87 +mol, 1 eq) 
was added and the reaction stirred for a another 3 h. The reaction was 
concentrated by the azeotropic removal of AcOH with toluene.  The resulting 
residue was purified by silica gel column chromatography, eluting with 
ethylacetate and petroleum ether (30:70, 70:30, 100:0), then again with 
ethylacetate and petroleum ether (20:80, 40:60, 50:50, 70:30) and then finally 
with methanol and chloroform (3:97, 4:96, 5:95).  This afforded (+)-1D-2,6-bis-O-
benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 (55 mg, 55% yield) as a 
colourless gum:  Rf 0.28 (4% MeOH in CHCl3); 
! 
"[ ]D
25= +4.37 (c 1.26 in CHCl3); 
"max (NaCl disc)/cm-1 3385 (m), 3090 (m), 3063 (m), 3033 (m), 2956 (m), 1957 
(w), 1883 (w), 1814 (w), 1727 (w), 1631 (s), 1606 (s), 1264 (s), 1017 (s); !H (500 
MHz, CDCl3) 7.43-7.38 (2H, m, ArH), 7.35-7.16 (38H, m, ArH), 5.11-5.02 (4H, m, 
OCHAHB-Ph), 5.02-4.88 (9H, m, OCHAHB-Ph), 4.80-4.69 (4H, m, 3 ( OCHAHB-Ph 
+ 1 ( inositol ring, H-4), 4.53 (1H, dd, J 2.5, 2.5, inositol ring, H-2), 4.33-4.26 (2H, 
m, 2 ( inositol ring, H-1 and H-3), 3.98 (1H, dd, J 9.2, 9.2, inositol ring, H-6), 3.72 
(1H, dd, J 9.2, 9.2, inositol ring, H-5), 2.1 (1H, br s, OH); )C (125 MHz; CDCl3), 
138.4 (ArC), 138.2 (ArC), 135.7 (d, 3JCP 7.5, ArC), 135.6 (d, 3JCP 7.5, ArC), 135.5 
(d, 3JCP 7.6, ArC), 135.4 (d, 3JCP 7.6, ArC), 135.4 (d, 3JCP 6.3, ArC), 128.6 (ArCH), 
128.6 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 
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(ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 
128.0 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 127.5 (ArCH), 127.4 (ArCH), 127.3 (ArCH), 79.8 (dd, 2JCP 
6.2, 3JCP 6.2, inositol ring, C-4), 79.2 (d, 3JCP 6.7, inositol ring, C-6), 78.0 (inositol 
ring, C-2), 77.0* (inositol ring, C-1), 75.8 (OCH2-Ph), 75.6 (dd, 2JCP 6.0, 3JCP 6.0, 
inositol ring, C-3), 75.5 (OCH2-Ph), 74.2 (inositol ring, C-5), 70.1 (d, 2JCP 6.1, 
POCH2-Ph), 70.0 (d, 2JCP 6.0, POCH2-Ph), 69.7 (d, 2JCP 5.6, POCH2-Ph), 69.5 (d, 
2JCP 5.4, POCH2-Ph), 69.3 (d, 2JCP 5.5, POCH2-Ph); !p (161 MHz; CDCl3) 1.7, 
-0.5, -0.5; m/z (ES+) [Found: (M+Na)+ 1163.33 (100.0%), 1164.33 (68.5%), 
1165.33 (21.3%), 1166.34 (5.9%), 1167.35 (0.8%). C62H63NaO15P3 calculated 
M+, 1163.33 (100.0%), 1164.33 (68.4%), 1165.33 (26.1%), 1166.34 (7.2%), 
1167.34 (1.6%)]; m/z (ES+) 1199 ([M +NH4·MeCN]+, 100%), 1163 ([M+Na]+, 5%); 
Anal. Calcd. For C62H63O15P3: C, 65.3, H, 5.6; Found: C, 65.3, H, 5.5. 
*Signal was assigned from the HSQC NMR spectrum, as the solvent peak 
swamped the signal in the 1D 13C spectrum. 
 
Method 2 
To a solution of (+)-1D-2,6-bis-O-benzyl-5-O-allyl-myo-inositol 1,3,4-
tris(dibenzylphosphate) 152 (100 mg, 84 +mol, 1 eq) in AcOH (7 mL) under a 
nitrogen atomosphere was added Pd(PPh3)4 (49 mg, 42 +mol, 0.5 eq). The 
reaction was heated to 85 °C left to stir for 3 h before further Pd(PPh3)4 (49 mg, 
42 +mol, 0.5 eq) was added.  A further 30 min of stirring at 85 °C saw 
consumption of starting material. The reaction was therefore adjudged complete 
and cooled to RT and concentrated by the azeotropic removal of AcOH with 
toluene.  The resulting residue was purified by silica gel column chromatography, 
eluting with ethylacetate and petroleum ether (30:70, 70:30, 100:0), then again 
with ethylacetate and petroleum ether (20:80, 40:60, 50:50, 70:30) and then 
finally with methanol and chloroform (3:97, 4:96, 5:95).  This afforded (+)-1D-2,6-
bis-O-benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 (42 mg, 43% yield) 
as a colourless gum. The analysis of this material was in good agreement with 
the data given above. 
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Method 3 
To a solution of (+)-1D-2,6-bis-O-benzyl-5-O-allyl-myo-inositol 1,3,4-
tris(dibenzylphosphate) 152 (133 mg, 113 +mol, 1 eq) in dry MeOH (10 mL) 
under a nitrogen atomosphere was added PdCl2 (20 mg, 113 +mol, 1 eq) the 
reaction left to stir at RT. After 2 h, further PdCl2 (20 mg, 113 +mol, 1 eq) was 
added and the reaction stirred for another 1 h before the Pd residues were 
removed by filtration through Celite®. The filtrate was concentrated under 
vacuum and the residue partitioned between CH2Cl2 (20 mL) and a solution of 
H2O2 (15% w/w, 30 mL) the layers were stirred vigorously together for 30 min. 
The layers were separated and the aqueous extracted with CH2Cl2 (3( 10 mL). 
The combined organic layers were washed with brine then dried (magnesium 
sulfate) and filtered. The filtrate was concentrated under vacuum and the residue 
purified by silica gel column chromatography, eluting with methanol and 
chloroform (2:98) then with ethylacetate and petroleum ether (30:70, 70:30, 
100:0). This afforded (+)-1D-2,6-bis-O-benzyl-myo-inositol 1,3,4-
tris(dibenzylphosphate) 153 (84 mg, 65% yield) as a colourless gum. The 
analysis of this material was in good agreement with the data given above. 
 
Benzyloxy-N,N-diisopropylamino methoxy phosphoramidite 158 
 
P
OBnMeO
NiPr2  
158 
 
Benzyloxy bis(N,N-diisopropylamino)phosphine 141 (5 g, 14.77 mmol, 1.0 eq) 
and 1H-tetrazole (0.43 M solution in acetonitrile, 13.75 mL, 5.91 mmol, 0.4 eq) 
were dissolved in dry CH2Cl2 (50 mL) under a nitrogen atmosphere.  A solution of 
methanol (473 mg, 597 +L, 14.77 mmol, 1 eq) in dry CH2Cl2 (25 mL) was added 
dropwise via a dropping funnel at RT over 1 h. The reaction was stirred at RT 
and TLC analysis indicated the reaction had gone to completion after 3 h. The 
reaction was concentrated under vacuum and the residue purified by silica gel 
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column chromatography, eluting with triethyl amine, ethyl acetate and petroleum 
ether (5:5:90). This gave phophoramidite 158 (3 g, 76% yield) as a colourless oil:  
!H (300 MHz, CDCl3) 7.45-7.25 (5H, m, ArH), 4.70 (1H, dd, JAB 12.5, JHP 8.1, 
OCHAHB-Ph), 4.71 (1H, dd, JAB 12.5, JHP 8.4, OCHAHB-Ph), 3.76-3.61 (2H, m, 2 ( 
-N(CH(CH3)2), 3.47 (3H, d, JHP 13.2, -OCH3), 1.24 (6H, d, J 6.8, -NCH(CH3)2), 
1.23 (6H, d, J 6.8, -NC’H(CH3)2), )p (121 MHz; CDCl3) 149.0.  These data are in 
good agreement with the literature values.128 
 
 
(-)-1D-2,6-bis-O-Benzyl-myo-inositol 5-(O-benzyl-O-methyl)phosphate-1,3,4-
tris(dibenzylphosphate) 156 
 
BnO OPO(OBn)2
OBn
O
OPO(OBn)2
(BnO)2OPO P OMe
OBn
O
 
(-)-156 
 
To a solution of alcohol (+)-153 (100 mg, 87.6 +mol, 1 eq) in dry CH2Cl2 (10 mL) 
under a nitrogen atomosphere was added 1H-tetrazole (0.43 M solution in 
acetonitrile, 389 +L, 175.3 +mol, 2 eq) followed by phosphoramidite 158 (47 mg, 
175.3 +mol, 2 eq) the reaction left to stir at RT for 2 h.  After this time, further 1H-
tetrazole (0.43 M solution in acetonitrile, 389 +L, 175.3 +mol, 2 eq) and 
phosphoramidite 158 (47 mg, 175.3 +mol, 2 eq) were added and the reaction 
stirred at RT for a further 1 h. Complete consumption of the alcohol was seen by 
TLC analysis.  The reaction was cooled to -78 °C and 3-chloroperoxybenzoic 
acid (70% w/w, 87 mg, 350.0 +mol, 4 eq) added before the solution was warmed 
to RT and stirred for 30 minutes.  Sodium hydrogen sulfite (10% aq solution, 10 
mL) was added and the layers separated and the aqueous layer further extracted 
with CH2Cl2 (3 ( 10 mL). The combined organic layers were washed with a 
saturated solution of sodium hydrogen carbonate and then dried (magnesium 
sulfate) and filtered. The filtrate was concentrated under vacuum and residue 
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purified by silica gel column chromatography eluting with ethyl acetate and 
petroleum ether (50:50, 60:40, 70:30, 80:20, 90:10, 100:0) to give (-)-1D-2,6-bis-
O-benzyl-myo-inositol 5-(O-benzyl-O-methyl)-phosphate-1,3,4-
tris(dibenzylphosphate) 156 (91 mg, 79% yield) as a colourless gum: Rf 0.45 (4% 
MeOH in CHCl3); 
! 
"[ ]D
25= -1.02 (c 0.98 in CHCl3); "max (NaCl disc)/cm-1 3483 (w), 
3089 (m), 3064 (s), 3033 (s), 2954 (s), 2894 (m), 2732 (w), 2507 (w), 1956 (w), 
1887 (w), 1814 (w), 1734 (w), 1607 (s), 1587 (s); !H (500 MHz, CDCl3) 7.46-7.34 
(2H, m, ArH), 7.33-7.00 (43H, m, ArH), 5.15-4.58 (20H, m, 6 ( OCH2-Ph and 2 ( 
inositol ring, H-4 and H-2), 4.47 (1H, ddd, J 9.4, 9.4, 3JHP 9.4, inositol ring, H-5, 
minor diastereomer), 4.44 (1H, ddd, J 9.4, 9.4, 3JHP 9.4, inositol ring, H-5, major 
diastereomer), 4.37-4.30 (1H, m, inositol ring, H-1), 4.29-4.21 (1H, m, inositol 
ring, H-3), 4.08 (1H, dd, J 9.4, 9.4, inositol ring, H-6, major diastereomer), 4.06 
(1H, dd, J 9.4, 9.4, inositol ring, H-6, minor diastereomer), 3.55 (3H, d, 3JHP 11.4, 
POCH3, minor diastereomer), 3.33 (3H, d, 3JHP 11.4, POCH3, major 
diasteriomer); )C (125 MHz; CDCl3), 138.1 (ArC), 138.0 (ArC), 136.1 (d, 3JCP 7.1, 
ArC), 136.0 (d, 3JCP 6.7, ArC), 136.0 (d, 3JCP 7.7, ArC), 136.0 (d, 3JCP 7.6, ArC), 
135.9 (d, 3JCP 7.7, ArC), 135.8 (d, 3JCP 6.6, ArC), 135.6-135.4 (m, ArC), 128.6 
(ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 
128.3 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.1 
(ArCH), 128.1 (ArCH), 128.0 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 
127.8 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.5 (ArCH), 127.4 (ArCH), 127.4 
(ArCH), 127.3 (ArCH), 127.2 (ArCH), 127.2 (ArCH), 127.1 (ArCH), 78.1-77.8 (m, 
inositol ring, C-5), 77.8-77.6 (m, inositol ring, C-6), 77.2* (inositol ring, C-2), 77.1* 
(inositol ring, C-1), 76.2-75.9 (m, inositol ring, C-4), 75.9 (2 ( OCH2-Ph, major 
and minor diastereomers), 75.5-75.3 (m, inositol ring, C-3), 74.8 (OCH2-Ph, 
major diastereomer), 74.5 (OCH2-Ph, minor diastereomer), 69.8-69.7 (m, 31P 
coupled POCH2-Ph), 69.7-69.5 (m, 31P coupled POCH2-Ph), 69.4-69.2 (m, 31P 
coupled POCH2-Ph), 54.7 (d, 2JCP 6.5, POCH3, minor diastereomer), 54.2 (d, 2JCP 
5.2, POCH3, major diastereomer); )p (161 MHz; CDCl3) 1.0 (minor diastereomer), 
0.9 (major diastereomer), -0.0 (major diastereomer), -0.1 (minor diastereomer), -
0.4 (minor diastereomer), -0.5 (major diastereomer), -0.8 (minor and major 
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diastereomers); m/z (ES+) [Found: (M+Na)+ 1347.36 (100.0%), 1348.36 (74.3%), 
1349.36 (27.4%), 1350.37 (3.8%), 1351.36 (0.6%). C70H72NaO18P4 calculated 
M+, 1347.36 (100.0%), 1348.36 (77.2%), 1349.36 (33.1%), 1350.37 (10.2%), 
1351.37 (2.5%)]; m/z (ES+) 1426 ([M +HNEt3]+, 100%), 1347 ([M+Na]+, 50%); 
Anal. Calcd. For C70H72O18P4: C, 63.4, H, 5.5; Found: C, 63.5, H, 5.4.  *Signals 
were assigned from the HSQC NMR spectrum, as the solvent peak swamped the 
signal in the 1D 13C spectrum. 
 
 
(-)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 157 
 
HO OPO(ONa)2
OH
O
OPO(ONa)2
(NaO)2OPO P
O
ONa
OMe
 
(-)-157 
 
To a stirred solution of (-)-1D-2,6-bis-O-benzyl-myo-inositol 5-(O-benzyl-O-
methyl)phosphate-1,3,4-tris(dibenzylphosphate) 156 (44 mg, 33 +mol, 1 eq) in 
tBuOH (3 mL) and H2O (0.5 mL) was added Pd(black) (64 mg, 598 +mol, 16 eq) 
and NaHCO3 (19 mg, 232 +mol, 7 eq).  The mixture was stirred at 1 atm H2 and 
room temperature for 5 h.  The Pd was collected via filtration through Celite,, 
and washed with Et2O and the filtrate was collected.  The Et2O was removed 
under vacuum and the remaining tBuOH/H2O freeze dried.  The Pd residues 
were then washed with excess H2O.  The Pd washings were freeze-dried to give 
(-)-1D-myo-inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 157 (27 mg, 
83%) as a colourless solid: 
! 
"[ ]D
25= -1.53 (c 0.26 in H2O); "max (KBr disc)/cm-1 
3417 (s, OH), 2360 (s), 1669 (s); !H (500 MHz, D2O) 4.35 (1H, dd, J 2.2, 2.2, 
inositol ring, H-2), 4.31 (1H, ddd, J 9.6, 9.6, 3JHP 9.6, inositol ring, H-4) 4.01-3.79 
(4H, m, inositol ring, H-1, H-3, H-5, H-6), 3.58 (1H, d, 3JHP 10.9, POCH3); )C (125 
MHz; D2O) 79.2 (dd, 3JCP 5.7, 2JCP 5.7, inositol ring, C-5), 75.4-74.9 (m, inositol 
ring, C-4), 73.7 (d, 2JCP 4.6, inositol ring, C-3), 73.5 (d, 2JCP 5.0, inositol ring, C-
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1), 71.7 (d, 3JCP 4.9, inositol ring, C-6), 70.8 (inositol ring, C-2), 53.4 (d, 2JCP 5.6, 
POCH3); !P (101 MHz; D2O) 5.01, 4.55, 2.88, 2.46; HRMS m/z (ES-) [Found: (M-
4Na+3H)- 578.8833, (M-3Na+2H)- 600.8651, (M-2Na+H)- 622.8469. 
C7H12Na5O18P4 requires M-, 622.8469]. 
 
 
(+)-1D-2,6-bis-O-Benzyl-myo-inositol 5-O-sulfamoly-1,3,4-
tris(dibenzylphosphate) 159 
 
BnO OPO(OBn)2
OBn
O
OPO(OBn)2
(BnO)2OPO S O
O
NH2
 
(+)-159 
 
Alcohol 153 (88 mg, 77.1 +mol, 1 eq) was dissolved in dry DMA (1 mL) and 
placed under a nitrogen atomosphere and cooled to 0 °C.  To this solution of 
alcohol was added sulfamoly chloride (2.50 M solution in CH2Cl2, 62 +L, 154 
+mol, 2 eq) and the reaction was left to warm to RT and stir overnight.  After this 
time, the reaction was adjudged incomplete by TLC analysis.  Therefore, the 
reaction was cooled to 0 °C and sulfamoly chloride (2.50 M solution in CH2Cl2, 
31 +L, 77 +mol, 1 eq) was added before the reaction was warmed to RT and 
stirred for 1 h.  The reaction was poured onto brine (5 mL) at 0 °C and the 
aqueous layer extracted with ethyl acetate (3 ( 5 mL). The combined organic 
layers were washed with fresh brine and then dried (magnesium sulfate) and 
filtered. The filtrate was concentrated under vacuum and residue purified twice by 
silica gel column chromatography first eluting with MeOH and CHCl3 (4:96) and 
then second eluting with ethyl acetate and petroleum ether (70:30, 80:20, 90:10) 
to give (+)-1D-2,6-bis-O-benzyl-myo-inositol 5-O-sulfamoly-1,3,4-tris-
(dibenzylphosphate) 159 (91 mg, 50% yield) as a colourless gum: Rf 0.25 (4% 
MeOH in CHCl3); 
! 
"[ ]D
25= +2.60 (c 0.50 in CHCl3); "max (NaCl plate)/cm-1 3384 (m), 
3196 (m), 3065 (s), 3034 (s), 2960 (m), 1957 (w), 1886 (w), 1814 (w), 1740 (w), 
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1587 (s), 1498 (s); !H (400 MHz, CDCl3) 7.47-7.43 (2H, m, ArH), 7.33-7.20 (28H, 
m, ArH), 7.20-7.12 (10H, m, ArH), 5.92 (2H, S, NH2), 5.08-4.96 (5H, m, 
POCHAHB-Ph), 4.98* (1H, m, OCHAHB-Ph), 4.96-4.78 (9H, m, 4 ( POCHAHB-Ph 
+ 1 ( inositol ring, H-4), 4.75 (1H, d, J 11.4, OCHA’HB’-Ph), 4.70 (1H, d, J 11.4, 
OCHA’HB’-Ph), 4.65-4.60 (2H, m, 1 ( OCHAHB-Ph*, 1 ( inositol ring, H-2), 4.56 
(1H, dd, J 9.6, 9.6, inositol ring, H-5), 4.17 (1H, ddd, J 10.1, 2.1, 3JHP 8.2, inositol 
ring, H-1), 4.13 (1H, ddd, J 10.0, 2.0, 3JHP 8.1, inositol ring, H-3), 4.03 (1H, dd, J 
9.6, 9.6, inositol ring, H-6); )C (125 MHz; CDCl3), 139.0 (ArC), 137.4 (ArC), 135.4 
(d, 3JCP 7.6, ArC), 135.4 (d, 3JCP 6.7, ArC), 135.4 (d, 3JCP 6.7, ArC), 135.3 (d, 3JCP 
6.7, ArC), 135.3 (d, 3JCP 7.6, ArC), 128.6 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 
128.5 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 127.4 (ArCH), 
81.1 (inositol ring, C-5), 77.1* (inositol ring, C-2), 77.0* (inositol ring, C-6), 76.7* 
(inositol ring, C-1), 76.1* (inositol ring, C-4), 75.9 (OCH2-Ph), 75.7 (OCH2-Ph), 
75.2 (dd, 2JCP 4.8, 3JCP 4.8, inositol ring, C-3), 70.2 (d, 2JCP 5.7, POCH2-Ph), 70.2 
(d, 2JCP 5.7, POCH2-Ph), 69.8 (d, 2JCP 5.7, POCH2-Ph), 69.7 (d, 2JCP 5.8, POCH2-
Ph), 69.6 (d, 2JCP 5.5, POCH2-Ph), 69.4 (d, 2JCP 4.9, POCH2-Ph); )p (161 MHz; 
CDCl3) -0.58, -0.62, -0.67; m/z (ES+) [Found: (M+Na)+ 1242.29 (100.0%), 
1243.29 (67.7%), 1244.29 (30.4%), 1245.29 (11.5%), 1246.30 (3.1%). 
C70H72NaO18P4 calculated M+, 1242.30 (100.0%), 1243.30 (69.6%), 1244.30 
(31.9%), 1245.31 (10.9%), 1246.31 (3.0%)]; m/z (ES+) 1278 ([M+NH4·MeCN]+, 
100%), (ES-) 1218 ([M-H]-, 100%); Anal. Calcd. For C62H64NO17P3S: C, 61.0, H, 
5.3, N, 1.2, S, 2.6; Found: C, 61.1, H, 5.2, N, 1.2, S, 2.6. *Signals were assigned 
from the HSQC NMR spectrum. 
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(+)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-sulfamate 160 
 
HO OPO(ONa)2
OH
O
OPO(ONa)2
(NaO)2OPO S
O
NH2
O
 
(+)-160 
 
To a stirred solution of (+)-1D-2,6-bis-O-benzyl-myo-inositol 5-O-sulfamoly-1,3,4-
tris(dibenzylphosphate) 159 (45 mg, 37 +mol, 1 eq) in tBuOH (3 mL), MeOH 
(1 mL) and H2O (0.5 mL) was added Pd(black) (63 mg, 590 +mol, 16 eq) and 
NaHCO3 (18 mg, 221 +mol, 6 eq).  The mixture was stirred at 1 atm H2 and room 
temperature for 5 h.  The Pd was collected via filtration through Celite®, and 
washed with Et2O the filtrate was collected.  The Et2O was removed under 
vacuum and the remaining tBuOH/H2O freeze-dried.  The Pd residues were then 
washed with excess H2O.  The Pd washings were then freeze dried to give (+)-
1D-myo-inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 160 (20 mg, 
84%) as a colourless solid. 
! 
"[ ]D
25= +3.08 (c 0.20 in H2O); "max (KBr disc)/cm-1 
3418 (s, OH), 1632 (m), 1357 (s) 975 (s); !H (500 MHz, D2O) 4.47-4.37 (2H, m, 2 
( inositol ring, H-4 and H-2), 4.32 (1H, dd, J 9.0, 9.0, inositol ring, H-5), 4.00-3.87 
(3H, m, 3 ( inositol ring, H-1, H-3 and H-6); )C (125 MHz; CDCl3) 84.3 (inositol 
ring, C-5), 73.7-73.5 (m, inositol ring, C-4), 73.4 (d, 2JCP 3.0, inositol ring, C-3), 
73.3 (d, 2JCP 4.9, inositol ring, C-1), 70.3 (d, 3JCP 3.0, inositol ring, C-2), 70.2 (d, 
3JCP 3.3, inositol ring, C-6); !P (101 MHz; D2O) 5.4, 4.2, 3.9; HRMS m/z (ES+) 
[Found: (M-4Na+3H)- 541.8919, (M-3Na+2H)- 563.8740, (M-2Na+H)- 585.8559, 
(M-Na) 607.8376. C6H10NNa5O17P3S requires M-, 607.8376]. 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate)-5-O-
acetic acid 172 
BnO OPO(OBn)2
OBn
OCH2CO2H
OPO(OBn)2
(BnO)2OPO
 
(+)-172 
 
To a solution of (+)-1D-2,6-bis-O-benzyl-5-O-allyl-myo-inositol 1,3,4-
tris(dibenzylphosphate) 152 (150 mg, 127 +mol, 1 eq) in a CCl4 (3 mL), MeCN 
(3 mL) and H2O (5 mL) mixture, was added NaIO4 (111 mg, 521 +mol, 4.1 eq) 
followed RuCl3·H2O (substoichiometric). The reaction left to stir at RT and 
monitored by TLC and mass spec. analysis. After 2 h TLC showed traces of 
starting material and mass spec. showed M-H for the product and a possible M-H 
for the aldehyde intermediate.  Therefore further NaIO4 (27 mg, 127 +mol, 1 eq) 
was added. After 2 h, further NaIO4 (27 mg, 127 +mol, 1 eq) was added and the 
reaction stirred for another 2 h.  The reaction was adjudged complete after this 
time, so was diluted with CH2Cl2 (15 mL) and H2O (20 mL) the layers separated 
and the aqueous layer further extracted with CH2Cl2 (3 ( 10 mL). The combined 
organic layers were partitioned with the addition a solution of H2O2 (15% w/w, 
40 mL) the layers were stirred vigorously together for 30 min. The layers were 
separated and the aqueous extracted with CH2Cl2 (2( 10 mL). The combined 
organic layers were washed with brine then dried (magnesium sulfate) and 
filtered. The filtrate was concentrated under vacuum and the residue purified by 
silica gel column chromatography, eluting with ethyl acetate and acetic acid 
(100:0 then 99:1). This afforded (+)-1D-2,6-bis-O-benzyl-myo-inositol 1,3,4-
tris(dibenzylphosphate)-5-O-acetic acid 172 (60 mg, 40% yield) as a colourless 
gum: Rf 0.10 (100% ethyl acetate); 
! 
"[ ]D
25= +3.20 (c 0.97 in CHCl3); "max (NaCl 
plate)/cm-1 3500 (w br), 3089 (m), 3064 (s), 3034 (s), 2960 (m), 2922 (M) 1957 
(w), 1886 (w), 1750 (m), 1263 (s), 1018 (s); !H (500 MHz, CDCl3) 7.41-7.07 (40H, 
m, ArH), 5.09-4.85 (12H, m, 6 ( POCHAHB-Ph), 4.80 (1H, d, J 10.7, OCHAHB-
Ph), 4.78-4.68 (3H, m, OCHA’HB’-Ph + inositol ring, H-4), 4.63 (1H, d, J 10.7, 
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OCHAHB-Ph), 4.56 (1H, dd, J 2.4, 2.4, inositol ring, H-2), 4.51 (1H, d, J 14.7, 
OCHA’’HB’’-CO2H), 4.25-4.18 (2H, m, inositol ring, H-1 and H-3), 4.00 (1H, dd, J 
9.5, 9.5, inositol ring, H-6), 3.99 (1H, d, J 14.7, OCHA’’HB’’-CO2H), 3.16 (1H, dd, J 
9.5, 9.5, inositol ring, H-5); )C (125 MHz; CDCl3), 169.8 (C=O), 137.9 (ArC), 
136.9 (ArC), 135.4 (d, 2JCP 6.6, ArC), 135.3 (d, 2JCP 7.8, ArC), 135.2 (d, 2JCP 6.8, 
ArC), 135.0 (d, 2JCP 6.2, ArC), 128.8 (ArCH), 128.6 (ArCH), 128.6 (ArCH), 128.6 
(ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 
128.0 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 127.7 (ArCH), 127.3 (ArCH), 81.2 
(inositol ring, C-5), 79.2 (d, 3JCP 7.2, inositol ring, C-6), 77.5 (inositol ring, C-2), 
77.4 (d, 2JCP 6.1, inositol ring, C-1), 76.5 (dd, 2JCP 6.5, 3JCP 6.5, inositol ring, C-4), 
76.0 (OCH2-Ph), 75.6 (OCH2-Ph), 75.3 (dd, 2JCP 5.0, 3JCP 5.0, inositol ring, C-3), 
71.7 (OCH2CO2H), 70.4 (d, 2JCP 5.6, POCH2-Ph), 70.3 (d, 2JCP 5.6, POCH2-Ph), 
69.7 (d, 2JCP 5.6, POCH2-Ph), 69.7 (d, 2JCP 5.2, POCH2-Ph), 69.6 (d, 2JCP 5.2, 
POCH2-Ph), 69.5 (d, 2JCP 5.4, POCH2-Ph); !p (101 MHz; CDCl3) 0.95, -0.20, -
0.40; m/z (ES+) [Found: (M+Na)+ 1221.34 (100.0%), 1222.35 (70.1%), 1223.35 
(26.4%), 1224.36 (4.9%). C64H65O17P3Na calculated M+, 1221.33 (100.0%), 
1222.34 (70.6%), 1223.34 (28.1%), 1224.34 (8.1%), 1225.34 (1.9%)]; m/z (ES+) 
1199 ([M+H]+, 100%), 1221 ([M+Na]+, 95%), 1221 ([M+HNEt3]+, 40%), (ES-) 1197 
([M-H]-, 100%); Anal. Calcd. For C64H65NO17P3: C, 64.1, H, 5.5; Found: C, 64.1, 
H, 5.6. 
 
 
(-)-1D-myo-Inositol 1,3,4-trisphosphate-5-O-acetic acid 173 
 
HO OPO(ONa)2
OH
OCH2CO2Na
OPO(ONa)2
(NaO)2OPO
 
(-)-173 
 
To a stirred solution of (+)-1D-2,6-bis-O-benzyl-myo-inositol 1,3,4-
tris(dibenzylphosphate)-5-O-acetic acid 172 (37 mg, 31 +mol, 1 eq) in tBuOH 
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(3 mL) and H2O (0.5 mL) was added Pd(black) (53 mg, 501 +mol, 16 eq) and 
NaHCO3 (18 mg, 219 +mol, 7 eq).  The mixture was stirred at 1 atm H2 and room 
temperature for 5 h.  The Pd was collected via filtration through Celite®, and 
washed with Et2O the filtrate was collected.  The Et2O was removed under 
vacuum and the remaining tBuOH/H2O freeze-dried.  The Pd residues were then 
washed with excess H2O.  The Pd washings were then freeze-dried to give (-)-
1D-myo-inositol 1,3,4-trisphosphate-5-O-acetic acid 173 (17 mg, 85%) as a 
colourless solid. 
! 
"[ ]D
25= -1.76 (c 0.17 in H2O); "max (KBr disc)/cm-1 3450 (br s, 
OH), 1591 (s), 1455 (m), 1169 (s), 1080 (s), 993 (s); !H (500 MHz; D2O) 4.39-
4.21 (3H, m, 2 ( inositol ring + OCHAHBCO2Na), 4.09 (1H, d, J 17.4, 
CHAHBCO2Na), 3.96 (1H, dd, J 8.5, 8.5, inositol ring), 3.92-3.76 (2H, m, 2 ( 
inositol ring), 3.30 (1H, dd, J 7.9, 7.9, inositol ring); )C (125 MHz; CDCl3) 179.1 
(C=O), 83.2-83.0 (m, inositol ring), 76.3-75.9 (m, inositol ring), 73.9 (d, 2JCP 5.0, 
inositol ring), 73.8 (d, 2JCP 5.0, inositol ring), 71.3 (OCH2CO2Na), 71.2-70.9 (m, 
inositol ring), 70.8 (d, 2JCP 4.7, inositol ring); !P (101 MHz; D2O) 4.8, 4.2, 2.5; 
HRMS m/z (ES-) [Found: (M-4Na+3H)- 542.9073, (M-3Na+2H)- 564.8891, (M-
2Na+H)- 586.8704. C8H11Na5O17P3 requires M-, 586.8703]. 
 205 
8.5. Synthesis of 1-O-position compounds 
 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 
 
BnO OTIPS
OBn
OAll
O
O
 
(-)-121 
 
To a stirred solution of triisopropylsilane trifluoromethanesulfonate (2.26 g, 
1.66 mL, 7.98 mmol, 4 eq) in dry CH2Cl2 (3 mL) under an atmosphere of 
nitrogen, was added triethylamine (944 mg, 1.3 mL, 9.35 mmol, 5 eq). The 
solution was allowed to stir for 1 h at RT, turning a dark orange colour, to this 
solution was added a solution of (-)-1D-5-O-allyl-2,6-di-O-benzyl-3-O-exo-(L-
1',7',7'-trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-104 (3.0 g, 5.61 
mmol, 1 eq) in dry CH2Cl2 (30 mL). The reaction mixture was stirred at RT 
overnight. TLC analysis indicated the reaction was complete, so it was diluted 
with CH2Cl2 (20 mL) and partitioned with the addition of water (50 mL). The 
layers were separated and the aqueous phase extracted with CH2Cl2 (3 ( 
20 mL). The combined organic phases were dried over magnesium sulfate, 
filtered and the filtrate concentrated under vacuum to yield a dark brown oil. The 
oil was adsorbed onto silica gel and purified by silica gel column chromatography 
eluting with diethyl ether and petroleum ether (2:98) to give (-)-1D-5-O-allyl-2,6-
di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-
ylidine)-myo-inositol (-)-121 (1.12 g, 87%) as a colourless oil: Rf 0.51 (ethyl 
acetate and hexane 10/90); 
! 
"[ ]D
25= -1.54 (c 1.23 in CHCl3); "max (NaCl plate)/cm-1 
2943.5 (s), 2867.0 (s), 2362.9 (w), 1496.9 (w), 1454.2 (m), 1389.8 (m), 1369.4 
(w), 1308.9 (w), 1245.9 (w), 1202.3 (w), 1181.76 (m), 1113.7 (s), 1068.2 (s), 
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921.6 (w), 883.4 (m), 820.3 (m), 730.4 (m), 695.5 (m), 680.7 (w); )H (300 MHz, 
CDCl3) 7.38-7.12 (10H, m, ArH), 5.81 (1H, dddd, J 17.2, 10.4, 5.5, 5.5, 
CHX=CHYHZ), 5.17 (1H, dd, J 17.2, 1.5, CHX=CHYHZ), 5.03 (1H, d, J 10.4, 
CHX=CHYHZ), 4.92 (1H, d, J 11.5, OCHAHB-Ph), 4.85 (1H, d, J 11.1, OCHA’HB’-
Ph), 4.68 (1H, d, J 11.1, OCHA’HB’-Ph), 4.63 (1H, d, J 11.5, OCHAHB-Ph), 4.27 
(1H, dd, J 12.7, 5.5, OCHVHW-CH=CH2), 4.10 (1H, dd, J 2.7, 1.5, inositol ring, H-
2) 4.03 (1H, dd, J 12.7, 5.5, OCHVHW-CH=CH2), 3.94 (1H, dd, J 9.7, 9.7, inositol 
ring, H-6), 3.83 (1H, dd, J 9.0, 2.7, inositol ring, H-3), 3.67 (1H, dd, J 9.0, 9.0, 
inositol, H-4), 3.44 (1H, dd, J 9.7, 9.0, inositol ring, H-5), 3.21 (1H, dd, J 9.7, 1.5, 
inositol ring, H-1), 2.07 (1H, dt, J 13.4, 3.8, camphor ring), 1.89-1.77 (1H, m, 
camphor ring), 1.72-1.58 (2H, m, camphor ring), 1.43-1.36 (1H, m, camphor 
ring), 1.36-1.25 (1H, m, camphor ring), 1.18-1.09 (1H, m, camphor ring), 0.95-
0.93 (21H, m, Si-[CH(CH3)2]3), 0.93 (3H, s, CH-camphor ring), 0.77 (3H, s, CH3-
camphor bridge), 0.73 (3H, s, CH3-camphor bridge); )C (75 MHz; CDCl3), 139.9 
(ArC), 139.3 (ArC), 135.8 (CHX=CHYHZ), 128.5 (ArCH), 128.4 (ArCH), 127.9 
(ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.4 (ArCH), 120.7 (ketal carbon), 116.9 
(CHX=CHYHZ), 83.7 (inositol ring), 81.9 (inositol ring), 77.9 (inositol ring), 77.2 
(inositol ring), 76.4 (inositol ring), 76.3 (CH2), 75.3 (inositol ring), 74.2 (CH2), 72.1 
(CH2), 53.3 (Cq- camphor ring), 48.7 (Cq camphor ring), 46.7 (CH2), 45.3 (CH), 
29.3 (CH2), 27.1 (CH2), 20.7 (CH3), 20.5 (CH3), 18.6 (CH3), 13.3 (CH3), 10.0 
(CH); m/z (ES+) [Found: (M+Na)+ 713.4209. C42H62O6SiNa requires M+, 
713.4213], m/z (ES+) 713 ([M+Na]+, 100%); Anal. Calcd. For C42H62O6Si: C, 73.0, 
H, 9.0; Found: C, 72.7, H, 9.3. 
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(+)-D-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-myo-inositol 177 
 
BnO OTIPS
OBn
OH
OH
HO
 
(+)-177 
Method 1 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 (458 mg, 0.66 mmol, 1 
eq) was dissolved in absolute ethanol (20 mL), to this was added diisopropylethyl 
amine (86 mg, 115 µL, 0.66 mmol, 1 eq). The solution was stirred at room 
temperature for 5 minutes and then Wilkinson’s catalyst (123 mg, 0.13 mmol, 0.2 
eq) was added. The dark red slurry was heated under reflux for 3 h before being 
cooled to room temperature and filtered though Celite®. The filtrate was 
concentrated under vacuum and the residue analysed by 1H NMR to confirm 
complete isomerisation of the allylic ether to the enol ether. The crude residue 
was dissolved in MeOH and CH2Cl2 (3:2, 20 mL) and acetyl chloride (31 mg, 
26 +L, 0.40 mmol, 0.6 eq) was added. The reaction was left to stir at room 
temperature for 4 h before the addition of triethylamine (2 mL) to quench the 
acid. The volatile components were removed under vacuum and the residue 
partitioned between ethyl acetate (20 mL) and water (20 mL) the layers 
separated and the aqueous phase was further extracted with ethyl acetate (3 
( 10 mL). The combined organic layers were washed with brine, dried 
(magnesium sulfate) and filtered. The filtrate was concentrated under vacuum 
and the residue purified by silica gel column chromatography, eluting with ethyl 
acetate and petroleum ether (60:40). This afforded (+)-2,6-bis-O-benzyl-1-O-
triisopropylsilyl myo-inositol (+)-177 (128 mg, 37% yield) as a colourless sticky 
gum: Rf 0.30 (ethyl acetate); 
! 
"[ ]D
25= +14.80 (c 1.36, CHCl3); )H (400 MHz, CDCl3) 
7.31-7.17 (10H, m, ArH), 5.01 (1H, d, J 11.1, OCHAHB-Ph), 4.88 (1H, d, J 11.9, 
OCHA’HB’-Ph), 4.67 (1H, d, J 11.1, OCHAHB-Ph), 4.66 (1H, d, J 11.9, OCHA’HB’-
Ph), 3.83 (1H, dd, J 2.4, 2.4, inositol ring, H-2), 3.83 (1H, dd, J 9.1, 2.4, inositol 
 208 
ring, H-1), 3.71 (1H, dd, J 9.1, 9.1, inositol ring, H-6), 3.68 (1H, ddd, J 9.1, 9.1, 
2.4, inositol ring, H-4), 3.42 (1H, ddd, J 9.1, 7.8, 2.4, inositol ring, H-3), 3.30 (1H, 
ddd, J 9.1, 9.1, 2.4, inositol ring, H-5), 2.49 (1H, d, J 2.4, 4-OH), 2.30 (1H, d, J 
2.4, 5-OH), 2.26 (1H, d, J 7.8, 3-OH), 1.20-1.06 (21H, m, Si-[CH(CH3]2)3); m/z 
(ES+) 575 ([M+NH4·MeCN]+, 100%), (ES-) 515 ([M-H]-, 100%), 575 ([M+OAc]-, 
80%); Anal. Calcd. For C29H44O6Si: C, 67.4, H, 8.6; Found: C, 67.3, H, 8.5. 
These data are in good agreement with the literature values.31 
 
 
Method 2 
To a solution of (-)-1D-5-O-allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-
1',7',7'-trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 (292 mg, 
420 +mol, 1 eq) in AcOH (20 mL) under a nitrogen atmosphere was heated to 80 
°C.  Pd(PPh3)4 (244 mg, 210 +mol, 0.5 eq) was added and the reaction left to stir. 
After 1 h, the reaction was adjudged to be complete by TLC analysis and was 
cooled to RT. The AcOH was removed by azeotropic distillation with toluene in 
vacuo.  The resulting black residue was purified by silica gel column 
chromatography, eluting with ether and hexane (50:50, 60:40, 70:30, 80:20).  
This afforded (+)-D-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (+)-177 (71 
mg, 32% yield) as a colourless gum. The analysis of this material was in good 
agreement with the data given above. 
 
 
Method 3 
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol 121 (700 mg, 1.01 mmol, 1 eq) 
was dissolved in MeOH (70 mL), to this was added PdCl2 (179 mg, 1.01 mmol, 1 
eq). The reaction was left to stir at RT for 2 h before the palladium residues were 
removed by filtration through Celite®. The filtrate was concentrated under 
vacuum and the residue partitioned between CH2Cl2 (50 mL) and a solution of 
H2O2 (15% w/w, 60 mL). The layers were stirred vigorously together for 30 min. 
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The layers were separated and the aqueous extracted with CH2Cl2 (3 ( 20 mL). 
The combined organic layers were washed with sat. NaHCO3 solution then brine 
then dried over magnesium sulfate and filtered. The filtrate was concentrated 
under vacuum and the residue purified by silica gel column chromatography, 
eluting with MeOH in CHCl3 (1:99, 2:98 then 3:97), affording (+)-D-2,6-bis-O-
benzyl-1-O-triisopropylsilyl myo-inositol (+)-177 (426 mg, 81% yield) as a 
colourless gum. The analysis of this material was in good agreement with the 
data given above. 
 
 
(+)-1D-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-myo-inositol 3,4,5-
tris(dibenzylphosphate) 178 
 
BnO OTIPS
OBn
OPO(OBn)2
OPO(OBn)2
(BnO)2OPO
 
(+)-178 
 
Bis(benzyloxy)-N,N-diisopropylamino phosphine (1.6 g, 4.64 mmol, 6 eq) was 
stirred under a nitrogen atomosphere with 1H-tetrazole (0.43M solution in 
acetonitrile, 10.8 mL, 4.64 mmol, 6 eq) for 20 minutes. A solution of (+)-2,6-bis-
O-benzyl-1-O-triisopropylsilyl-myo-inositol 177 (400 mg, 0.77 mmol, 1 eq) in dry 
CH2Cl2 (40 mL) was added to the solution via cannular and the reaction left to stir 
at room temperature overnight. Further bis(benzyloxy)-N,N-diisopropylamino 
phosphine (535 mg, 1.55 mmol, 2 eq) and 1H-tetrazole (0.43M solution in 
acetonitrile, 3.6 mL, 1.55 mmol, 2 eq) were added and the reaction stirred at RT 
for 2 h. The reaction was then cooled to -78 °C and 3-chloroperoxybenzoic acid 
(60% w/w, 1.78 g, 6.19 mmol, 8 eq) added before being warmed to RT and 
stirred for 30 minutes.  Sodium hydrogen sulfite (10% aq solution, 40 mL) was 
added and the layers separated and the aqueous layer further extracted with 
CH2Cl2 (3 ( 20 mL). The combined organic layers were washed with a saturated 
 210 
solution of sodium hydrogen carbonate and then dried (magnesium sulfate) and 
filtered. The filtrate was concentrated under vacuum and residue purified by silica 
gel column chromatography eluting with ethyl acetate and hexane (40:60 then 
50:50 then 60:40) to give (+)-1D-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-
inositol 3,4,5-tris(dibenzylphosphate) 178 (700 mg, 70% yield) as a colourless 
gum. Rf 0.70 (ethyl acetate/petroleum ether 60:40); 
! 
"[ ]D
25= +4.9 (c 1.00, CHCl3); 
!H (400 MHz, CDCl3) 7.42-7.08 (38H, m, ArH), 6.85 (2H, d, J 7.2, ArH), 5.14-4.94 
(11H, m, OCHAHB-Ph + inositol ring, H-4), 4.92-4.81 (5H, m, OCHAHB-Ph), 4.78 
(1H, dd, J 11.8, 3JHP 7.3, POCHAHB-Ph), 4.54 (1H, ddd, J 9.4, 9.4, 3JHP 9.4, 
inositol ring, H-5), 4.50 (1H, dd, J 11.8, 3JHP 8.6, POCHAHB-Ph), 4.38 (1H, dd, J 
2.0, 2.0, inositol ring, H-2), 4.27 (1H, ddd, J 9.6, 2.0, 3JHP 7.2, inositol ring, H-3), 
3.99 (1H, dd, J 9.4, 9.4, inositol ring, H-6), 3.86 (1H, dd, J 9.4, 2.0, inositol ring, 
H-1), 1.04-0.94 (21H, m, Si-[CH(CH3]2)3); )p (121 MHz; CDCl3) -1.5, -1.5, -1.9; 
m/z (ES+) 1319 ([M+Na]+, 30%), 1398 ([M+HNEt3]+, 50%), 1680 
([M+Na+iPr2NPO(OBn)2]+, 100%). These data are in good agreement with the 
literature values.31 
 
 
(-)-1D-2,6-bis-O-Benzyl-myo-inositol 3,4,5-tris(dibenzylphosphate) 176 
 
BnO OH
OBn
OPO(OBn)2
OPO(OBn)2
(BnO)2OPO
 
(-)-176 
 
(+)-1D-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-myo-inositol-3,4,5-tris-
(dibenzylphosphate) 178 (1.3 g, 1.0 mmol, 1 eq) was dissolved in THF (20 mL).  
To this solution was added TBAF (1 M solution in THF, 1.2 mL, 1.2 mmol, 
1.2 eq), the mixture was stirred at room temperature and monitored by TLC 
analysis. After 3 h the reaction was adjudged complete by TLC analysis and so 
diluted with diethyl ether (40 mL) and water (40 mL). The layers separated and 
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the aqueous phase further extracted with diethyl ether (3 ( 20 mL). The 
combined organic layers were dried (magnesium sulphate), filtered and the 
filtrate concentrated under vacuum. The residue was purified by silica gel column 
chromatography eluting with ethyl acetate and petroleum ether (40:60, 60:40 
then 80:20). This gave (-)-1D-2,6-bis-O-benzyl-myo-inositol 3,4,5-
tris(dibenzylphosphate) 176 (912 mg, 80% yield) as a colourless gum: Rf 0.30 
(petroleum ether / ethyl acetate 40:60); 
! 
"[ ]D
25= -7.9 (c 1.00, CHCl3); )H (400 MHz, 
CDCl3) 7.27-7.01 (40H, m, ArH), 5.06-4.83 (12H, m, 11 ( POCHAHB-Ph + 1 ( 
inositol ring, H-4), 4.77 (1H, dd, J 11.8, 3JHP 8.5, POCHAHB-Ph), 4.77 (1H, d, J 
11.4, OCHAHB-Ph), 4.71 (1H, d, J 11.5, OCHA’HB’-Ph), 4.58 (1H, d, J 11.4, 
OCHAHB-Ph), 4.55 (1H, d, J 11.5, OCHA’HB’-Ph), 4.37 (1H, ddd, J 9.4, 9.4, 3JHP 
9.4, inositol ring, H-5), 4.21 (1H, dd, J 2.3, 2.3, inositol ring, H-2), 4.17 (1H, ddd, 
J 9.8, 2.3, 3JHP 7.5, inositol ring, H-3), 3.74 (1H, dd, J 9.4, 9.4, inositol ring, H-6), 
3.43 (1H, dd, J 9.4, 2.3, inositol ring, H-1); !p (161 MHz; CDCl3) -1.2, -1.3, -1.9. 
These data are in good agreement with the literature values.31 
 
 
(-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-methylphosphate-3,4,5-
tris(dibenzylphosphate) 199 
 
BnO O
OBn
OPO(OBn)2
OPO(OBn)2
(BnO)2OPO
P
O
OMe
OBn
 
(-)-199 
 
To a solution of alcohol 176 (50 mg, 43.8 +mol, 1 eq) in dry CH2Cl2 (5 mL) under 
a nitrogen atomosphere was added 1H-tetrazole (0.43 M solution in acetonitrile, 
204 +L, 87.6 +mol, 2 eq) followed by aminophosphine 158 (25 mg, 87.6 +mol, 
2 eq) the reaction left to stir at RT overnight. Further 1H-tetrazole (0.43 M 
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solution in acetonitrile, 204 +L, 87.6 +mol, 2 eq) followed by aminophosphine 158 
(25 mg, 87.6 +mol, 2 eq) were added and the reaction stirred at RT for 2 h. The 
reaction was then cooled to -78 °C and 3-chloroperoxybenzoic acid (70% w/w, 43 
mg, 175.3 +mol, 4 eq) added before being warmed to RT and stirred for 30 
minutes.  Sodium hydrogen sulfite (10% aq solution, 5 mL) was added and the 
layers separated and the aqueous layer further extracted with CH2Cl2 (3 ( 5 mL). 
The combined organic layers were washed with a saturated solution of sodium 
hydrogen carbonate and then dried (magnesium sulfate) and filtered. The filtrate 
was concentrated under vacuum and residue purified by silica gel column 
chromatography eluting with ethyl acetate and hexane (50:50, 60:40, 70:30, 
80:20) to give (-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-
methylphosphate-3,4,5-tris(dibenzylphosphate) 199 (50 mg, 86% yield) as a 
colourless gum. Rf 0.24 (petroleum ether / ethyl acetate 40:60); 
! 
"[ ]D
25= -2.13 (c 
0.80 in CHCl3); "max (NaCl plate)/cm-1 3090 (m), 3064 (m), 3033 (m), 2957 (m), 
2897 (m), 2852 (m), 1956 (w), 1886 (w), 1814 (w), 1754 (w), 1607 (s), 1587 (s), 
1278 (s), 1018 (s), 738 (s), 697 (s); !H (500 MHz, CDCl3) 7.49-7.09 (43H, m, 
ArH), 7.04-6.95 (2H, m, ArH), 5.11-4.73 (18H, m, POCHAHB-Ph + 2 ( OCHAHB-
Ph + inositol ring, H-4, major and minor diastereomers), 4.69-4.60 (2H, m, 
POCHAHB-Ph, inositol ring, H-2, major and minor diastereomers), 4.49 (1H, ddd, 
J 9.1, 9.1, 3JHP 9.1, inositol ring, H-5, major diastereomer), 4.48 (1H, ddd, J 9.0, 
9.0, 3JHP 9.0, inositol ring, H-5, minor diastereomer), 4.34 (1H, ddd, J 9.1, 2.2, 
3JHP 9.1, inositol ring, H-1, major diastereomer), 4.32 (1H, ddd, J 9.3, 2.0, 3JHP 
9.3, inositol ring, H-1, minor diastereomer), 4.30-4.24 (1H, m, inositol ring, H-3, 
major and minor diastereomers), 4.09 (1H, dd, J 9.5, 9.5, inositol ring, H-6, major 
diastereomer), 4.09 (1H, dd, J 9.5, 9.5, inositol ring, H-6, minor diastereomer), 
3.54 (3H, d, 3JHP 11.3, POCH3, minor diastereomer), 3.49 (3H, d, 3JHP 11.3, 
POCH3, major diastereomer); )C (125 MHz; CDCl3), 138.1 (ArC), 138.06 (ArC), 
136.06 (d, 3JCP 7.6, ArC), 136.04 (d, 3JCP 6.8, ArC), 135.9 (d, 3JCP 7.5, ArC), 
135.8 (d, 3JCP 7.5, ArC), 135.7 (d, 3JCP 7.1, ArC), 135.6 (d, 3JCP 6.6, ArC), 135.5 
(d, 3JCP 6.5, ArC), 128.57 (ArCH), 128.55 (ArCH), 128.52 (ArCH), 128.48 (ArCH), 
128.3 (ArCH), 128.28 (ArCH), 128.26 (ArCH), 128.16 (ArCH), 128.14 (ArCH), 
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128.11 (ArCH), 128.05 (ArCH), 128.03 (ArCH), 127.98 (ArCH), 127.92 (ArCH), 
127.87 (ArCH), 127.85 (ArCH), 127.80 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 
127.4 (ArCH), 127.3 (ArCH), 127.24 (ArCH), 127.20 (ArCH), 127.18 (ArCH), 
78.2-77.9 (m, inositol ring, C-5), 77.8-77.5 (m, inositol ring, C-6), 77.2* (inositol 
ring, C-1), 77.1 (inositol ring, C-2), 76.2-75.9 (m, inositol ring, C-4), 75.84 (OCH2-
Ph, minor diastereomer), 75.82 (OCH2-Ph, major diastereomer), 75.5-75.3 (m, 
inositol ring, C-3), 74.7 (OCH2-Ph, major diastereomer), 74.6 (OCH2-Ph, minor 
diastereomer), 69.8 (d, 2JCP 5.8, POCH2-Ph), 69.6 (d, 2JCP 5.2, POCH2-Ph), 
69.58-69.4 (m, POCH2-Ph), 69.3-69.2 (m, POCH2-Ph), 54.42 (d, 2JCP 6.0, 
POCH3, major diastereomer), 54.37 (d, 2JCP 7.1, POCH3, minor diastereomer); )p 
(161 MHz; CDCl3) -0.4 (minor diastereomer), -0.7 (major diastereomer), -1.3 
(major diastereomer), -1.3 (minor diastereomer), -1.5 (major diastereomer), -1.5 
(minor diastereomer), -2.1 (major diastereomer), -2.1 (minor diastereomer); m/z 
(ES+) [Found: (M+Na)+ 1347.36 (100.0%), 1348.36 (73.7%), 1349.36 (30.4%), 
1350.37 (8.6%), 1351.36 (1.2%). C70H72NaO18P4 calculated M+, 1347.36 
(100.0%), 1348.36 (77.2%), 1349.36 (33.1%), 1350.37 (10.2%), 1351.37 (2.5%)]; 
m/z (ES+) 1426 ([M +HNEt3]+, 100%), 1347 ([M+Na]+, 40%), 1342 ([M+NH4]+, 
25%); Anal. Calcd. For C70H72O18P4: C, 63.4, H, 5.5; Found: C, 63.5, H, 5.6. 
 
 
(-)-1D-myo-Inositol 1-O-methylphosphate-3,4,5-tris(phosphate) 198 
 
HO O
OH
OPO(ONa)2
OPO(ONa)2
(NaO)2OPO
P
O
OMe
ONa
 
(-)-198 
 
To a stirred solution of (-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-
methylphosphate-3,4,5-tris(dibenzylphosphate) 199 (45 mg, 34 +mol, 1 eq) in 
tBuOH (3 mL) and H2O (0.5 mL) was added Pd(black) (65 mg, 611 +mol, 18 eq) 
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and NaHCO3 (20 mg, 237 +mol, 7 eq).  The mixture was stirred at 1 atm of H2 
and at room temperature for 5 h.  The Pd was collected via filtration through 
Celite®, and washed with Et2O the filtrate was collected.  The Et2O was removed 
under vacuum and the remaining tBuOH/H2O freeze-dried.  The Pd residues 
were then washed with excess H2O.  The Pd washings were then freeze dried to 
give (-)-1D-myo-inositol 1-O-methylphosphate-3,4,5-tris(phosphate) 198 (22 mg, 
100% yield) as a colourless foam. 
! 
"[ ]D
25= -22.36 (c 0.16 in H2O); "max (KBr 
disc)/cm-1 3418 (broad, s, OH), 1667 (s), 1360 (m), 1100 (s), 971 (s);  !H (500 
MHz, D2O) 4.42 (1H, br s, inositol ring), 4.33-4.20 (1H, m, inositol ring), 4.02-3.88 
(2H, m, inositol ring), 3.88-3.79 (2H, m, inositol ring), 3.55 (3H, d, 3JHP 10.9, 
POCH3); !C (125 MHz; D2O), 77.2 (inositol ring), 75.5 (d, 2JCP 6.2, inositol ring), 
75.4-75.2 (m, inositol ring), 73.6 (inositol ring), 71.7 (d, 77.2 2JCP 7.5, inositol 
ring), 70.2 (inositol ring), 53.0 (d, 2JCP 5.8, POCH3); !p (121 MHz; D2O) 4.5, 3.4, 
2.1, 1.0; HRMS m/z (ES-) [Found: (M-4Na+3H)- 578.8833, (M-3Na+2H)- 
600.8648, (M-2Na+H)- 622.8463. C7H12Na5O18P4 requires M-, 622.8468]. 
 
 
Hydroxymethyl phosphonic acid dibenzyl ester 184 
 
P
O
BnO
BnO
OH
 
184 
 
Paraformaldehyde (572 mg, 19.06 mmol, 1 eq) and Et3N (193 mg, 265 +L, 1.91 
mmol, 0.1 eq) were added with stirring to dibenzyl phosphite (5 g, 4.2 mL, 
19.06 mmol, 1 eq).  The mixture was heated to 130 °C for 20 min before being 
cooled to RT.  The product was purified directly by silica gel column 
chromatography, eluting with Et2O / EtOH (100:0 then 99:1). This afforded 
hydroxymethyl-phosphonic acid dibenzyl ester 184 (1.4 g, 25% yield) as a 
colourless oil. Rf 0.25 (Et2O); !H (400 MHz, CDCl3) 7.38-7.32 (10H, m, ArH), 5.11 
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(2H, dd, J 11.9, 3JHP 8.8, 2 ( OCHAHB-Ph), 5.04 (2H, dd, J 11.9, 3JHP 8.1, 2 ( 
OCHAHB-Ph), 3.91 (2H, dd, J 6.8, 2JHP 6.1 PCH2OH), 3.47 (1H, dt, J 6.8, 3JHP 4.4 
OH); !p (162 MHz; CDCl3) 25.0. These data are in good agreement with the 
literature values.31 
 
Trifluoromethanesulfonic acid bisbenzyloxyphosphorylmethyl ester 185 
 
P
O
BnO
BnO
OTf
 
185 
 
To a solution of hydroxymethylphosphonic acid dibenzyl ester 184 (800 mg, 2.74 
mmol, 1 eq) in dry CH2Cl2 (7 mL), under a nitrogen atmosphere, and at -78 °C, 
was added 2,6-lutidine (352 mg, 383 +L, 3.28 mmol, 1.2 eq), followed by 
trifluromethane sulfonic anhydride (632 mg, 419 +L, 3.01, 1.1 eq). The reaction 
was stirred at -78 °C for 1 h before being warmed to -40 °C for 1 h and then at -
10 °C for a further 1 h.  The reaction was adjudged complete by TLC analysis 
and the reaction transferred via cannular into Et2O (50 mL), the resulting 
precipitate was removed by filtration.  The filtrate was washed with brine, dried 
(MgSO4), filtered and the filtrate concentrated under reduced pressure. The 
product was purified by silica gel column chromatography, eluting with Et2O and 
hexanes (50:50). This afforded trifluoromethanesulfonic acid 
bisbenzyloxyphosphorylmethyl ester 185 (870 mg, 75% yield) as a colourless oil: 
Rf 0.56 (Et2O); !H (400 MHz, CDCl3) 7.44-7.31 (10H, m, ArH), 5.14 (2H, dd, J 
11.6, 3JHP 9.6, 2 ( OCHAHB-Ph), 5.09 (2H, dd, J 11.6, 3JHP 9.6, 2 ( OCHAHB-Ph), 
4.47 (2H, d, 2JHP 8.8, PCH2OSO2CF3); !P (162 MHz; CDCl3) 13.4; !F (377 MHz; 
CDCl3) -73.8. These data are in good agreement with the literature values.31 
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Trichloroacetimidate bisbenzyloxyphosphorylmethyl ester 187 
 
P
O
BnO
BnO
O
CCl3
NH  
187 
 
To a solution of hydroxymethylphosphonic acid dibenzyl ester 184 (1.0 g, 
3.42 mmol, 1 eq) and trichloroacetonitrile (2.5 g, 1.7 mL, 17.11 mmol, 5 eq) in dry 
CH2Cl2 (35 mL) under nitrogen at 0 °C, was added DBU (208 mg, 205 +L, 
1.37 mmol, 0.4 eq). The reaction was allowed to warm to RT and adjudged 
complete by TLC analysis after 30 min.  The reaction was concentrated under 
reduced pressure and the resulting oily residue was purified directly by silica gel 
column chromatography, eluting with Et2O (100%). This afforded 
trichloroacetimidate bisbenzyloxyphosphorylmethyl ester 187 (865 mg, 58% 
yield) as a colourless oil. Rf 0.63 (Et2O); !H (400 MHz, CDCl3) 8.52 (1H, br s, 
NH), 7.40-7.31 (10H, m, ArH), 5.17 (2H, dd, J 11.8, 3JHP 8.4, 2 ( OCHAHB-Ph), 
5.13 (2H, dd, J 11.8, 3JHP 8.3, 2 ( OCHAHB-Ph), 4.62 (2H, d, 2JHP 8.2, PCH2-
TCA); !C (125 MHz; CDCl3) 128.61 (ArCH), 128.58 (ArCH), 127.9 (ArCH), 68.3 
(d, 2JCP 6.3, POCH2-Ph), 61.8 (d, 1JCP 168.6, PCH2-TCA); !P (162 MHz; CDCl3) 
18.6; m/z (ES+) 494 ([M + NH4·MeCN]+, 100%). 
 
 
Trifluoroacetimidate bis-benzyloxy-phosphorylmethyl ester 190 
 
P
O
BnO
BnO
O
CF3
NH  
190 
 
Trifluoroacetamide (618 mg, 5.47 mmol, 3.2 eq) was dissolved into dry CH2Cl2 
(12 mL) under nitrogen and to this solution was added DMSO (1.28 g, 1.2 mL, 
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16.42 mmol, 9.6 eq). The mixture was cooled to -78 °C and freshly distilled oxalyl 
chloride (651 mg, 434 µL, 5.13 mmol, 3 eq) followed by dry Et3N (1.31 g, 1.7 mL, 
13.00 mmol, 7.6 eq) were added (Note: That effervescence was observed upon 
the addition of the oxalyl chloride).  The reaction mixture was stirred at -78 °C for 
40 min before the addition of DBU (521 mg, 511 µL, 3.42 mmol, 2 eq) and 
hydroxymethylphosphonic acid dibenzyl ester 184 (500 mg, 1.71 mmol, 1 eq).  
The reaction mixture was stirred at RT overnight and was adjudged complete by 
TLC analysis after this time. The reaction was quenched by the addition of H2O 
(10 mL) and the resulting layers separated, the aqueous layer was extracted with 
with CH2Cl2 (3 ( 10 mL).  The combined organic fractions were dried (Na2SO4), 
filtered, and the filtrate concentrated under reduced pressure.  The product was 
purified by silica gel column chromatography, eluting with Et2O (100%). This 
afforded trifluoroacetimidate bisbenzyloxyphosphorylmethyl ester 190 (261 mg, 
40% yield) as a colourless oil. Rf 0.78 (Et2O) !H (400 MHz, CDCl3) 8.42 (1H, br s, 
NH), 7.42-7.31 (10H, m, ArH), 5.14 (2H, dd, J 11.7, 3JHP 8.8, 2 ( OCHAHB-Ph), 
5.10 (2H, dd, J 11.7, 3JHP 8.6, 2 ( OCHAHB-Ph), 4.54 (2H, d, 2JHP 8.5 PCH2O-
TFA); !P (162 MHz; CDCl3) 18.3; !F (377 MHz; CDCl3) -73.9; m/z (ES+) 446 ([M + 
NH4·MeCN]+, 100%). 
 
 
Bromomethylphosphonic acid dibenzyl ester 191 
 
P
O
BnO
BnO
Br
 
191 
 
To a solution of triphenylphosphine (449 mg, 1.71 mmol, 1 eq) in dry Et2O (5 mL) 
under nitrogen and at RT, was added CBr4 (567 mg, 1.71 mmol, 2 eq).  After 20 
min of stirring at RT hydroxymethylphosphonic acid dibenzyl ester 184 (250 mg, 
0.86 mmol, 1 eq) was added as a solution in Et2O (5 mL) via cannular to the 
yellow coloured reaction mixture.  The reaction was stirred overnight at RT and 
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after this time the now pink reaction was adjudged complete by TLC analysis. 
The reaction was clarified by filtration and the filtrate concentrated under reduced 
pressure.  The crude product was purified by silica gel column chromatography, 
eluting with Et2O (100%). This afforded bromomethylphosphonic acid dibenzyl 
ester 191 (89 mg, 29% yield) as a colourless oil. Rf 0.47 (Et2O); !H (400 MHz, 
CDCl3) 7.41-7.31 (10H, m, ArH), 5.14 (2H, dd, J 11.7, 3JHP 9.0, 2 ( OCHAHB-Ph), 
5.09 (2H, dd, J 11.7, 3JHP 8.6, 2 ( OCHAHB-Ph), 3.23 (2H, d, 2JHP 9.8 PCH2Br); !P 
(162 MHz; CDCl3) 19.7; m/z (ES+) 413 ([M + NH4·MeCN]+, 100%). 
 
 
6-Trifluoromethyl-N-hydroxybenzotriazole 168 
 
N
N
N
OH
F3C
1
2
34
5
6
7
8
9
 
168 
 
To a solution of 4-chloro-3-nitro-#,#,#-trifluorotoluene (25.0 g, 110 mmol, 1 eq) in 
ethanol (34 mL) was added hydrazine hydrate (16.6 g, 16.1 mL, 333 mmol, 3 eq). 
The reaction was heated to reflux and stirred for 18 h.  The reaction was cooled 
to RT and ethanol removed under reduced pressure.  The resulting solid residue 
was dissolved in an aqueous Na2CO3 solution (10% w/v 300 mL) and washed 
with Et2O (2 ( 100 mL).  The aqueous solution was acidified to pH 6 by the 
addition of conc. HCl.  The resulting solid was collected via filtration and washed 
with H2O (200 mL), the beige crystals were dried over P2O5 in a vacuum 
dessicator.  This gave 6-trifluoromethyl-N-hydroxybenzotriazole 168 (10.8 g, 48% 
yield) as a beige crystalline solid:  !H (400 MHz, D6-acetone) 8.19 (1H, d, J 8.8, 
H-7), 8.12 (1H, s, H-5), 7.71 (1H, d, J 8.8, H-8); m/z (ES-) 202.1 ([M-H]-, 80%), 
405.1 ([2M-H]-, 100%). These data are in good agreement with the literature 
values.108 
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Bis(6-trifluoromethyl-N-hydroxybenzotriazolyl)methylphosphonate 169 
 
NN
NO
CF3
P
O
Me
2  
169 
 
6-Trifluoromethyl-N-hydroxybenzotriazole 168 (1.53 g, 7.52 mmol, 2 eq) was 
dissolved in dry dioxane (20 mL) and placed under a nitrogen atmosphere.  To 
this solution was added dry pyridine (595 mg, 608 +L, 7.52 mmol, 2 eq) followed 
by the dropwise addition of a solution of methylphosphonic dichloride (500 mg, 
341 +L, 3.76 mmol, 1 eq) in dry dioxane (10 mL).  The reaction was stirred at 20 
°C for 2 h before the resulting pyridine salts were removed via Schlenk filtration.  
The filtrate was used as a 0.125 M stock solution of bis(6-trifluoromethyl-N-
hydroxybenzotriazolyl)methylphosphonate 169.  31P NMR was recorded using a 
D6-benzene capillary for internal deuterium lock.  !P (162 MHz; D6-benzene) 
47.4. These data are in good agreement with the literature values.108 
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8.6. Synthesis of Phosphatidylinositol 
 
(+)-D-2,3,4,5,6-Penta-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-205 
 
BnO OTIPS
OBn
OBn
OBn
BnO
 
(+)-205 
 
(-)-D-2,6-Bis-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-177 (128 mg, 
0.25 mmol, 1 eq) was dissolved in dry DMF (10 ml) under an atmosphere of 
nitrogen and cooled to 0°C. With vigorous stirring, sodium hydride (60% 
dispersion w/w in mineral oil, 40 mg, 0.99 mmol, 4 eq) was added. The resulting 
slurry was allowed to warm to RT and stirred for a further 2 h. The slurry was 
cooled to 0°C and benzyl bromide (170 mg, 117 +L, 0.99 mmol, 4 eq) was added 
with vigorous stirring. The reaction mixture was allowed to warm to RT and stir 
overnight. The reaction showed possible tris- and tetrakis- benzylated adducts by 
TLC analysis. Therefore the reaction was cooled to 0°C and additional sodium 
hydride (60% dispersion w/w in mineral oil, 40 mg, 0.99 mmol, 4 eq) and benzyl 
bromide (170 mg, 117 +L, 0.99 mmol, 4 eq) were added and stirred at RT for 5 h. 
The reaction was quenched with the addition of water (2 mL). The volatile 
components were removed under vacuum and the residue partitioned between 
ethyl acetate (20 mL) and water (20 mL). The layers were separated and the 
aqueous phase extracted with ethyl acetate (3 ( 15 mL). The combined organic 
coponents were dried over magnesium sulfate, filtered and the filtrate reduced 
under vacuum yielding an orange oil. The oil was adsorbed onto silica gel and 
purified by silica gel column chromatography, eluting with ethyl acetate and 
hexane (1:99, 2:98 and 3:97) giving (+)-D-2,3,4,5,6-penta-O-benzyl-1-O-
triisopropylsilyl myo-inositol 205 (77 mg, 68% yield) as a colourless oil: Rf 0.40 
(petroleum ether / diethyl ether 90/10); 
! 
"[ ]D
25= +1.80 (c 1.00 in CHCl3); "max (NaCl 
plate)/cm-1 3089 (w), 3064 (w), 3030 (m), 2925 (s), 2866 (s), 2361 (m), 2342 (m), 
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1947 (w), 1869 (w), 1808 (w), 1734 (w); )H (300 MHz, CDCl3) 7.38-7.05 (25H, m, 
ArH), 4.91-4.57 (10H, m, 5 ( OCHAHB-Ph), 3.99 (1H, dd, J 9.5, 9.5, inositol ring, 
H-4), 3.87 (1H, dd, J 9.5, 9.5, inositol ring, H-6), 3.83 (1H, dd, J 2.0, 2.0, inositol 
ring, H-2), 3.64 (1H, dd, J 9.5, 2.0, inositol ring, H-1), 3.38 (1H, dd, J 9.5, 9.5, 
inositol ring, H-5), 3.34 (1H, dd, J 9.5, 2.0, inositol ring, H-3), 0.99-0.93 (21H, m, 
Si-[CH(CH3)2]3); )C (100 MHz; CDCl3), 139.4 (ArC), 139.3 (ArC) 139.0 (ArC), 
138.7 (ArC), 138.4 (ArC), 128.4 (ArCH), 128.3 (ArCH), 128.2 (ArCH), 128.1 
(ArCH), 128.0 (ArCH), 129.97 (ArCH), 127.8 (ArCH), 127.79 (ArCH), 127.70 
(ArCH), 127.5 (ArCH), 127.4 (ArCH), 127.3 (ArCH), 127.28 (ArCH), 127.19 
(ArCH), 127.10 (ArCH), 126.9 (ArCH), 84.2 (inositol ring), 82.1 (inositol ring), 
81.9 (inositol ring), 80.9 (inositol ring), 79.9 (inositol ring), 75.9 (CH2), 75.7 (CH2), 
75.4 (CH2), 74.6 (CH2), 74.0 (inositol ring), 72.9 (CH2), 18.21 (Si-[CH(CH3)2]3), 
18.18 (Si-[CH(CH3)2]3), 12.8 (Si-[CH(CH3)2]3); HRMS m/z (ES+) [Found: (M+Na)+ 
809.4204. C50H62O6SiNa requires M+, 809.4208]; m/z (ES+) 804 ([M+NH4]+, 
45%), 809 ([M+Na]+, 50%), 845 ([M+NH4·MeCN]+, 100%); Anal. Calcd. For 
C50H62O6Si: C, 76.3, H, 7.9; Found: C, 76.4, H, 7.9. 
 
 
(-)-D-2,3,4,5,6-penta-O-benzyl myo-inositol (-)-201 
 
BnO OH
OBn
OBn
OBn
BnO
 
(-)-201 
 
(-)-D-2,3,4,5,6-penta-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-205 (136 mg, 
0.17 mmol, 1 eq) was dissolved in THF (15 mL).  To this solution was added 
TBAF (1 M solution in THF, 190 +L, 0.19 mmol, 1.1 eq), the mixture was stirred 
at room temperature and monitored by TLC analysis. After 3 h the reaction was 
adjudged complete by TLC analysis and so diluted with diethyl ether (40 mL) and 
water (40 mL). The layers separated and the aqueous phase further extracted 
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with diethyl ether (3 ( 20 mL). The combined organic layers were dried over 
magnesium sulfate, filtered and the filtrate concentrated under vacuum. The 
residue was purified by silica gel column chromatography eluting with ethyl 
acetate and petroleum ether (20:80 then 30:70). This gave (-)-D-2,3,4,5,6-penta-
O-benzyl myo-inositol (-)-201 (96 mg, 88% yield) as a colourless gum. Rf 0.46 
(petroleum ether / ethyl acetate 70:30); 
! 
"[ ]D
25= -10.9 (c 0.5 in CHCl3), {lit. 
! 
"[ ]D
18= -
10.0 (c 2.3 in CHCl3)}; )H (300 MHz, CDCl3) 7.42-7.27 (25H, m, ArH), 5.06-4.70 
(10H, m, 5 ( OCHAHB-Ph), 4.09 (1H, dd, J 9.5, 9.5, inositol ring), 4.06 (1H, dd, J 
2.5, 2.5, inositol ring), 3.84 (1H, dd, J 9.5, 9.5, inositol ring), 3.56-3.46 (3H, m, 
inositol ring), 2.22 (1H, d, J 6.3, 1-OH); m/z (ES+) 648 ([M+NH4]+, 30%), 653 
([M+Na]+, 100%), 732 ([M+HNEt3]+, 25%). These data are in good agreement 
with the literature values.89,129 
 
 
1,2-Dioctanoyl-sn-glycerol 209 
 
HO O
O
O
O  
209 
 
1,2-Dioctanoyl-3-O-benzyl-sn-glycerol 208 (500 mg, 1.15 mmol, 1 eq) was 
dissolved in dry THF (25 mL) and Pd(OH)2 (50 mg, 10% w/w of benzyl ether) 
added.  The mixture was degassed and placed under an atmosphere of 
hydrogen and stirred at room temperature for 36 h.  The reaction was filtered 
through a pad of Celite® and washed with THF.  The filtrate was concentrated 
under reduced pressure to give 1,2-dioctanoyl-sn-glycerol 209 (345 mg, 87% 
yield) as a colourless oil:  !H (300 MHz, CDCl3) 5.06-4.97 (1H, m, glycerol CH), 
4.25 (1H, dd, J 12.0 , 4.6, glycerol CHXHY), 4.17 (1H, dd, J 12.0, 5.6, glycerol 
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CHXHY), 3.66-5.57 (1H, m, glycerol CH2), 2.32-2.19 (4H, m, 2(#COCH2), 1.95 
(1H, t, J 6.5, OH), 1.62-1.50 (4H, m, 2(!COCH2CH2), 1.31-1.13 (16H, m, 
octanoyl CH2), 0.81 (6H, t, J 6.9, 2(octanoyl CH3). These data are in good 
agreement with the literature values.130 
 
 
Benzyloxy (1,2-Dioctanoyl-sn-glycerol) (N,N-diisopropylamino)phosphine 
203 
 
O O
O
O
O
P
BnO
NiPr2  
203 
 
Benzyloxy bis(N,N-diisopropylamino)phosphine 141 (540 mg, 1.60 mmol, 1.1 eq) 
and 1H-tetrazole (0.43 M solution in acetonitrile, 1.7 mL, 725 +mol, 0.5 eq) were 
dissolved in dry CH2Cl2 (10 mL) under a nitrogen atmosphere. Alcohol 209 
(500 mg, 1.45 mmol, 1 eq) as a solution dry CH2Cl2 (5 mL) was added dropwise, 
via cannula, over 1 h at RT. The reaction was stirred at RT and TLC analysis 
indicated the reaction had gone to completion after 3 h. The reaction was 
concentrated under reduced pressure and the crude material partitioned between 
CH2Cl2 (5 mL) and a saturated solution of NaHCO3 (5 mL) the layers separated 
and the aqueous phase was further extracted with CH2Cl2 (3 ( 5 mL). The 
combined organic layers dried over magnesium sulfate and filtered. The filtrate 
was concentrated under vacuum and the residue purified by silica gel column 
chromatography, eluting with triethyl amine, ethyl acetate and petroleum ether 
(5:15:80), gaving phophoramidite 203 (600 mg, 71% yield) as a colourless oil:  !H 
(300 MHz, CDCl3) 7.33-7.22 (5H, m, ArH), 5.19-5.06 (1H, m, glycerol CH), 4.72-
4.54 (2H, m, iPr-CH), 4.31-4.23 (1H, m, OCHAHB-Ph), 4.14-4.02 (1H, m, 
OCHAHB-Ph), 3.76-4.49 (4H, m, 2(glycerol CH2), 2.22 (4H, m, 2(#COCH2), 1.53 
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(4H, m, 2(!COCH2CH2), 1.25-1.16 (16H, m, octanoyl CH2), 1.15-1.08 (12H, m, 
4(iPr-CH3), 0.81 (6H, t, J 7.2, 2(octanoyl CH3). )p (121 MHz; CDCl3) 148.80, 
148.68. These data are in good agreement with the literature values.130 
 
 
(+)-D-1d-1-(1,2-Dioctanoyl-sn-glycerol-3-phospho)-2,3,4,5,6-penta-O-benzyl-
myo-inositol (+)-204 
 
BnO O
OBn
OBn
OBn
BnO
P
O
OBn
O O
O
O
O
 
(+)-204 
 
To a stirred solution of phosphoramidite 203 (120 mg, 0.206 mmol, 2 eq) in dry 
CH2Cl2 (5 mL) under an atmosphere of nitrogen was added 1H-tetrazole (0.43 M 
solution in acetonitrile, 479 +L, 206 +mol, 2 eq).  This mixture was stirred at RT 
for 10 minutes before the addition of (-)-D-2,3,4,5,6-penta-O-benzyl myo-inositol 
(-)-201 (65 mg, 103 +mol, 1 eq) as a solution in CH2Cl2 (2 mL).  The reaction was 
stirred at RT overnight. TLC analysis confirmed that further equivalents of 
phosphoramidite 203 (120 mg, 0.206 mmol, 2 eq) were required and the reaction 
stirred at RT for another 3 h before the addition of more phosphoramidite 203 
(120 mg, 0.206 mmol, 2 eq).  After 2 h the reaction was cooled to -78 °C.and 
mCPBA (60% purity, 178 mg, 618 +mol, 6 eq) added.  The reaction was stirred at 
RT for 20 min before being partitioned between sodium hydrogen sulfite (10% aq 
solution, 15 mL) and additional CH2Cl2 (5 mL), the layers separated and the 
aqueous layer further extracted with CH2Cl2 (3 ( 10 mL).  The combined organic 
layers were washed with a saturated solution of sodium hydrogen carbonate and 
then dried over magnesium sulfate and filtered.  The filtrate was concentrated 
 225 
under vacuum and residue purified by silica gel column chromatography eluting 
with ethyl acetate and hexane (20:80 then 40:60) to give (+)-D-1-(1,2-dioctanoyl-
sn-glycerol-3-phospho)-2,3,4,5,6-penta-O-benzyl-myo-inositol (+)-204 (60 mg, 
52% yield) as a colourless oil: Rf 0.66 (ethyl acetate/ petroleum ether 60:40); 
! 
"[ ]D
20= +3.17 (c 0.79 in CHCl3); "max (NaCl plate)/cm-1 3090 (s), 3064 (s), 2954 
(s), 2894 (s), 1956 (w), 1885 (w), 1721 (s), 1313 (s), 1008 (s); !H (300 MHz, 
CDCl3) 7.34-7.11 (30H, m, ArH), 5.06-4.54 (13H, m, 6 ( OCHAHB-Ph + glycerol 
CH), 4.28-4.24 (1H, m, inositol ring), 4.22-3.77 (7H, m, 3 ( inositol ring + 2 ( 
glycerol CH2), 3.47-3.34 (2H, m, 2 ( inositol ring), 2.26-2.06 (4H, m, 2(#COCH2), 
1.58-1.39 (4H, m, 2 ( !COCH2CH2), 1.27-1.10 (16H, m, octanoyl CH2), 0.85-0.75 
(6H, m, 2(octanoyl CH3); )C (126 MHz; CDCl3), 128.6 (ArCH), 128.5 (ArCH), 
128.34 (ArCH), 128.30 (ArCH), 128.27 (ArCH), 128.24 (ArCH), 128.19 (ArCH), 
128.15 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 127.77 (ArCH), 127.66 (ArCH), 
127.60 (ArCH), 127.57 (ArCH), 127.53 (ArCH), 127.47 (ArCH), 127.45 (ArCH), 
127.40 (ArCH), 83.1 (inositol ring), 81.2 (inositol ring), 80.4 (inositol ring), 79.9 
(inositol ring), 78.6 (inositol ring), 76.3 (inositol ring), 76.0 (CH2 benzylic), 75.9 
(CH2 benzylic), 75.5 (CH2 benzylic), 75.0 (CH2 benzylic), 72.7 (CH2 benzylic), 
69.4 (CH2 benzylic), 69.0 (CH glycerol), 65.5 (CH2 glycerol), 61.5 (CH2 glycerol), 
34.1 (#COCH2), 33.9 (#COCH2), 31.6 (octanoyl CH2), 29.0 (octanoyl CH2), 29.0 
(octanoyl CH2), 28.9 (octanoyl CH2), 24.7 !COCH2CH2), 22.5 (octanoyl CH2), 
14.0 (octanoly CH3); )p (121 MHz; CDCl3) 1.72, 1.69; m/z (ES+) [Found: 
(M+NH4)+ 1144.5918. C67H87O13N1P1 requires M+, 1144.5910], m/z (ES+) 1149 
([M+Na]+, 100%).  
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(+)-Phosphatidyl inositol 200 
 
HO O
OH
OH
OH
HO
P
O
ONa
O O
O
O
O
 
(+)-200 
 
To a stirred solution of (+)-D-1-(1,2-dioctanoyl-sn-glycerol-3-phospho)-2,3,4,5,6-
penta-O-benzyl-myo-inositol (+)-204 (23 mg, 20 +mol, 1 eq) in tBuOH (8 mL) and 
H2O (1.5 mL) was added Pd(black) (39 mg, 367 +mol, 18 eq) and NaHCO3 
(2.5 mg, 33 +mol, 1.6 eq).  The mixture was stirred at 1 atm H2 and RT for 24 h.  
The mixture was then filtered through Celite®, the solid washed with H2O and the 
filtrate lyophilised to give phosphatidyl inositol 200 (8 mg, 64% yield) as a 
colourless solid: 
! 
"[ ]D
25= +2.25 (c 0.20 in H2O, pH 10), {lit. 
! 
"[ ]D= +2.80 (c 1.0 in 
H2O, pH 9)}; !H (500 MHz, D2O) 5.29-5.20 (1H, m, glycerol CH), 4.37 (1H, d, J 
11.7, glycerol CHXHY-Oct), 4.24-4.12 (2H, m, glycerol CHXHY-Oct + inositol ring, 
H-2), 4.06-3.95 (2H, m, glycerol POCHX’HY’), 3.89 (1H, ddd, J 9.6, 3JHP 9.6, 1.9, 
inositol ring, H-1), 3.68 (1H, dd, J 9.6, 9.6, inositol ring, H-6), 3.58 (1H, dd, J 9.6, 
9.6, inositol ring, H-4), 3.48 (1H, dd, J 9.6, 1.9, inositol ring, H-3), 3.27 (1H, dd, J 
9.6, 9.6, inositol ring, H-5), 2.42-2.18 (4H, m, 2(#COCH2), 1.64-1.44 (4H, m, 
2(!COCH2CH2), 1.30-1.07 (16H, m, octanoyl chain, CH2), 0.83-0.76 (6H, m, 
2(octanoyl CH3); )C (126 MHz; CDCl3), 174.6 (C=O), 174.5 (C=O), 76.2 (d, 2JCP 
5.6, inositol ring, C-1), 73.9 (inositol ring, C-5), 72.2 (inositol ring, C-4), 71.4 
(inositol ring, C-6), 71.2 (inositol ring, C-2), 70.8-70.6 (m, glycerol POCH2 + 
inositol ring), 63.8 (d, 2JCP 3.8, glycerol POCH2), 63.2 (glycerol OCH2-Oct), 34.1 
(#COCH2) 34.0 (#COCH2), 31.8 (octanoyl chain, CH2), 29.1 (octanoyl chain, 
CH2), 29.09 (octanoyl chain, CH2), 29.0 (octanoyl chain, CH2), 28.9 (octanoyl 
chain, CH2), 24.8 (!COCH2CH2), 24.7 (!COCH2CH2) 22.6 (octanoyl chain, CH2), 
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22.5 (octanoyl chain, CH2), 13.8 (octanoyl chain, CH3), 13.7 (octanoyl chain, 
CH3); )p (121 MHz; D2O) -0.84; m/z (ES-) [Found: (M-Na)- 585.2690. C25H46O13P1 
requires M-, 585.2682]; m/z (ES-) 585 ([M-Na]-, 100%). These data are in good 
agreement with the literature values.131,132 
 228 
Bibliography 
 
(1) Biochem. J., 1989, 258, 1-2. 
(2) B. W. Agranoff, Trends Biochem. Sci., 1978, 3, N283-N285. 
(3) B. W. Agranoff, J. Biol. Chem., 2009, 284, 21121-21126. 
(4) J. Scherer, Ann. Chem. Pharm., 1850, 73, 322-328. 
(5) J. Folch, J. Biol. Chem., 1942, 146, 35-44. 
(6) M. R. Hokin and L. E. Hokin, J. Biol. Chem., 1953, 203, 967-977. 
(7) M. R. Hokin and L. E. Hokin, Metabolism and physiological significance of 
lipids 1964. 
(8) J. Durell and J. T. Garland, Ann. N. Y. Acad. Sci., 1969, 165, 743-&. 
(9) R. H. Michell, Biochim. Biophys. Acta, 1975, 415, 81-147. 
(10) R. F. Irvine, Nat. Rev. Mol. Cell Biol., 2003, 4, 586-590. 
(11) M. A. Lemmon, Nat. Rev. Mol. Cell Biol., 2008, 9, 99-111. 
(12) H. Streb, R. F. Irvine, M. J. Berridge and I. Schulz, Nature, 1983, 306, 67-
69. 
(13) M. A. De Matteis and A. Godi, Nat. Cell Biol., 2004, 6, 487-492. 
(14) S. Cockcroft, Biology of Phosphoinositides; Oxford University Press, 2000. 
(15) M. J. Berridge, Biochem. J., 1983, 212, 849-858. 
(16) G. Di Paolo, P. De Camilli, Nature, 2006, 443, 651-657. 
(17) M. G. Roth, Physiol. Rev., 2004, 84, 699-730. 
(18) Y. Takai, A. Kishimoto, U. Kikkawa, T. Mori and Y. Nishizuka, Biochem. 
Biophys. Res. Commun., 1979, 91, 1218-1224. 
(19) H. Brockerhoff and C. E. Ballou, J. Biol. Chem., 1961, 236, 1907-&. 
(20) Y. Nishizuka, Science, 1984, 225, 1365-1370. 
(21) S. E. Lietzke, S. Bose, T. Cronin, J. Klarlund, A. Chawla, M. P. Czech and 
D. G. Lambright, Mol. Cell, 2000, 6, 385-394. 
(22) C. P. Downes, A. Gray, and J. M. Lucocq, Trends Cell Biol., 2005, 15, 
259-268. 
(23) L. C. Cantley, Science, 2002, 296, 1655-1657. 
 229 
(24) R. H. Michell, V. L. Heath, M. A. Lemmon and S. K. Dove, Trends 
Biochem. Sci., 2006, 31, 52-63. 
(25) Nature, 2001, 409, 860-921. 
(26) R. J. Haslam, H. B. Koide and B. A. Hemmings, Nature, 1993, 363, 309-
310. 
(27) B. J. Mayer, R. B. Ren, K. L. Clark and D. Baltimore, Cell, 1993, 73, 629-
630. 
(28) I. Vivanco and C. L. Sawyers, Nat. Rev. Cancer, 2002, 2, 489-501. 
(29) A. P. Kozikowski, H. Y. Sun, J. Brognard and P. A. Dennis, J. Am. Chem. 
Soc., 2003, 125, 1144-1145. 
(30) Y. H. Hu, L. X. Qiao, S. M. Wang, S. B. Rong, E. J. Meuillet, M. Berggren, 
A. Gallegos, G. Powis and A. P. Kozikowski, J. Med. Chem., 2000, 43, 
3045-3051. 
(31) J. Nemeth, PhD Thesis, University of St Andrews, UK, 2008. 
(32) M. A. Lemmon, and K. M. Ferguson, Biochem. Soc. Trans. 2001, 29, 377-
384. 
(33) J. K. Klarlund, A. Guilherme, J. J. Holik, J. V. Virbasius, A. Chawla and M. 
P. Czech, Science 1997, 275, 1927-1930. 
(34) J. M. Lindvall, K. E. M. Blomberg, J. Valiaho, L. Vargas, J. E. Heinonen, A. 
Berglof, A. J. Mohamed, B. F. Nore, M. Vihinen and C. I. E. Smith, 
Immunol. Rev., 2005, 203, 200-215. 
(35) J. Valiaho, C. I. E. Smith and M. Vihinen, Hum. Mutat. 2006, 27, 1209-
1217. 
(36) P. Chardin, S. Paris, B. Antonny, S. Robineau, S. Beraud-Dufour, C. L. 
Jackson and M. Chabre, Nature 1996, 384, 481-484. 
(37) J. M. Kavran, D. E. Klein, A. Lee, M. Falasca, S. J. Isakoff, E. Y. Skolnik,  
and M. A. Lemmon, J. Biol. Chem., 1998, 273, 30497-30508. 
(38) C. C. Milburn, M. Deak, S. M. Kelly, N. C. Price, D. R. Alessi, D. M. F.  
Van Aalten, Biochem. J., 2003, 375, 531-538. 
(39) W. C. Shakespeare, Curr. Opin. Chem. Biol., 2001, 5, 409-415. 
(40) A. P. Combs, J. Med. Chem., 2009. 
 230 
(41) T. C. Myers, K. Nakamura, J. W. Flesher, J. Am. Chem. Soc., 1963, 85, 
3292-3295. 
(42) R. Engel, Chem. Rev., 1977, 77, 349-367. 
(43) R. G. Yount, D. Babcock, W. Ballanty and D. Ojala, Biochemistry, 1971, 
10, 2484-&. 
(44) G. M. Blackburn, D. E. Kent and F. Kolkmann, J. Chem. Soc., Chem. 
Commun., 1981, 1188-1190. 
(45) K. D. Grimes, Y. J. Lu, Y. M. Zhang, V. A. Luna, J. G. Hurdle, E. I. Carson, 
J. Qi, S. Kudrimoti,C. O. Rock and R. E. Lee, ChemMedChem, 2008, 3, 
1936-1945. 
(46) C. U. Kim, B. Y. Luh, P. F. Misco, J. J. Bronson, M. J. M. Hitchcock, I. 
Ghazzouli and J. C. Martin, J. Med. Chem., 1990, 33, 1207-1213. 
(47) R. S. Bohacek, D. C. Dalgarno, M. Hatada, V. A. Jacobsen, B. A. Lynch, 
K. J. Macek, T. Merry, C. A. Metcalf, S. S. Narula, T. K. Sawyer, W. C. 
Shakespeare, S. M. Violette and M. Weigele, J. Med. Chem., 2001, 44, 
660-663. 
(48) C. E. Dreef, J. P. Jansze, C. J. J. Elie, G. A. Vandermarel and J. H. 
Vanboom, Carbohydr. Res., 1992, 234, 37-50. 
(49) N. Keddie, PhD Thesis, University of St Andrews, 2009. 
(50) C. F. Xu, R. Hall, J. Cummings and F. M. Raushel, J. Am. Chem. Soc., 
2006, 128, 4244-4245. 
(51) S. U. Kang, Z. D. Shi, K. M. Worthy, L. K. Bindu, P. G. Dharmawardana, 
S. J. Choyke, D. P. Bottaro, R. J. Fisher and T. R. Burke, J. Med. Chem., 
2005, 48, 3945-3948. 
(52) A. M. Cooke, R. Gigg and B. V. L. Potter, J. Chem. Soc., Chem. 
Commun., 1987, 1525-1526. 
(53) Y. Xu, G. W. Jiang, R. Tsukahara, Y. Fujiwara, G. Tigyi, G. D. Prestwich, 
J. Med. Chem., 2006, 49, 5309-5315. 
(54) V. Nahum, G. Zundorf, S. A. Levesque, A. R. Beaudoin, G. Reiser and B. 
Fischer, J. Med. Chem., 2002, 45, 5384-5396. 
 231 
(55) V. Nahum, M. Tulapurkar, S. A. Levesque, J. Sevigny, G. Reiser and B. 
Fischer, J. Med. Chem., 2006, 49, 1980-1990. 
(56) A. G. McLennan, Pharmacology & Therapeutics, 2000, 87, 73-89. 
(57) R. A. Bambara, J. J. Crute and A. F. Wahl, Cancer Investigation 1985, 3, 
473-479. 
(58) E. F. Baril, S. A. Coughlin and P. C. Zamecnik, Cancer Investigation 1985, 
3, 465-471. 
(59) R. H. Hilderman and E. F. Christensen, Febs Letters, 1998, 427, 320-324. 
(60) P. C. Zamecnik, B. Kim, M. J. Gao, G. Taylor and G. M. Blackburn, Proc. 
Natl. Acad. Sci. USA, 1992, 89, 2370-2373. 
(61) S. R. Shaver, J. L. Rideout, W. Pendergast, J. G. Douglass, E. G. Brown, 
J. L. Boyer, R. I. Patel, C. C. Redick, A. C. Jones, M. Picher and B.R. 
Yerxa, Purinergic Signal, 2005, 1, 183-91. 
(62) S. D. Larsen, T. Barf, C. Liljebris, P. D. May, D. Ogg, T. J. O'Sullivan, B. J. 
Palazuk, H. J. Schostarez, F. C. Stevens and J. E. Bleasdale, J. Med. 
Chem., 2002, 45, 598-622. 
(63) M. Hussain, V. Ahmed, B. Hill, Z. Ahmed and S. D. Taylor, Bioorg. Med. 
Chem., 2008, 16, 6764-6777. 
(64) Y. T. Chen, J. Xie and C. T. Seto, J. Org. Chem. 2003, 68, 4123-4125. 
(65) P. Westerduin, H. A. M. Willems and C. A. A. Vanboeckel, Carbohydr. 
Res., 1992, 234, 131-140. 
(66) L. Y. Zhang, W. Huang, A. Tanimura, T. Morita, S. Harihar, D. B. DeWald 
and G. D. Prestwich, ChemMedChem, 2007, 2, 1281-1289. 
(67) T. R. Burke, B. Ye, X. J. Yan, S. M. Wang, Z. C. Jia, L. Chen, Z. Y. Zhang 
and D. Barford, Biochemistry, 1996, 35, 15989-15996. 
(68) C. P. Holmes, X. F. Li, Y. J. Pan, C. D. Xu, A. Bhandari, C. M. Moody, J. 
A. Miguel, S. W. Ferla, M. N. De Francisco, B. T. Frederick, S. Q. Zhou, N. 
Macher, L. Jang, J. D. Irvine and J. R. Grove, Bioorg. Med. Chem. Lett., 
2008, 18, 2719-2724. 
 232 
(69) F. Gao, X. X. Yan, T. Shakya, O. M. Baettig, S. Ait-Mohand-Brunet, A. M. 
Berghuis, G. D. Wright and K. J. Auclair, Med. Chem., 2006, 49, 5273-
5281. 
(70) T. Tomasic, N. Zidar, V. Rupnik, A. Kovac, D. Blanot, S. Gobec, D. Kikelj 
and L. P. Masic, Bioorg. Med. Chem. Lett., 2009, 19, 153-157. 
(71) D. C. Barnes, G. M. Stams, T. Topiol and S. Wolf, E. P. Office, Ed. 2007. 
(72) E. Black, J. Breed, A. L. Breeze, K. Embrey, R. Garcia, T. W. Gero, L. 
Godfrey, P. W. Kenny, A. D. Morley, C. A. Minshull, A. D. Pannifer, J. 
Read, A. Rees, D. J. Russell, D. Toader, J. Tucker, Bioorg. Med. Chem. 
Lett., 2005, 15, 2503-2507. 
(73) E. W. Yue, B. Wayland, B. Douty, M. L. Crawley, E. McLaughlin, A. 
Takvorian, Z. Wasserman, M. J. Bower, M. Wei, Y. L. Li, P. J. Ala, L. 
Gonneville, R. Wynn, T. C. Burn, P. C. C. Liu and A. P. Combs, Bioorg. 
Med. Chem., 2006, 14, 5833-5849. 
(74) Z. Yan, M. Kahn, M. Qabar, J. Urban, H. O. Kim and M. A. Blaskovich, 
Bioorg. Med. Chem. Lett., 2003, 13, 2083-2085. 
(75) A. R. Martin, K. Mohanan, D. Luvino, N. Floquet, C. Baraguey, M. 
Smietana and J. J. Vasseur, Org. Biol. Chem. 2009, 7, 4369-4377. 
(76) M. Abdo, S. Liu, B. Zhou, C. D. Walls, L. Wu, S. Knapp and Z. Y. Zhang, 
J. Am. Chem. Soc., 2008, 130, 13196-13197. 
(77) S. J. Conway, J. W. Thuring, S. Andreu, B. T. Kvinlaug, H. L. Roderick, M. 
D. Bootman and A. B. Holmes, Aust. J. Chem., 2006, 59, 887-893. 
(78) S. J. Conway and G. J. Miller, Nat. Prod. Rep. 2007, 24, 687-707. 
(79) B. V. L. Potter and L. Dethard, Angew. Chem. Int. Ed., 1995, 34, 1933-
1972. 
(80) V. A. Estevez and G. D. Prestwich, J. Am. Chem. Soc., 1991, 113, 9885-
9887. 
(81) B. R. Sculimbrene, S. J. Miller, J. Am. Chem. Soc., 2001, 123, 10125-
10126. 
(82) G. T. Copeland, S. J. Miller, J. Am. Chem. Soc., 2001, 123, 6496-6502. 
 233 
(83) E. R. Jarvo, G. T. Copeland, N. Papaioannou, P. J. Bonitatebus, S. J. 
Miller, J. Am. Chem. Soc., 1999, 121, 11638-11643. 
(84) C. M. Longo, Y. Wei, M. F. Roberts, S. J. Miller, Angew. Chem. Int. Ed., 
2009, 48, 4158-4161. 
(85) E. A. C. Davie, S. M. Mennen, Y. J. Xu, S. J. Miller, Chem. Rev., 2007, 
107, 5759-5812. 
(86) A. J. Morgan, S. Komiya, Y. J. Xu and S. J. Miller, J. Org. Chem., 2006, 
71, 6923-6931. 
(87) P. Andersch and M. P. Schneider, Tet. Asymm., 1993, 4, 2135-2138. 
(88) S. Ozaki, L. Ling, T. Ogasawara, Y. Watanabe and M. Hirata, Carbohydr. 
Res., 1994, 259, 307-310. 
(89) G. F. Painter, S. J. A. Grove, I. H. Gilbert, A. B. Holmes, P. R. Raithby, M. 
L. Hill, P. T. Hawkins and L. R. Stephens, J. Chem. Soc., Perkin Trans. 1, 
1999, 923-935. 
(90) S. W. Garrett, C. S. Liu, A. M. Riley and B. V. L. Potter, J. Chem. Soc. 
Perkin Trans. 1, 1998, 1367-1368. 
(91) D. Bello, PhD Thesis, University of St Andrews, UK, 2007. 
(92) D. Bello, T. Aslam, G. Bultynck, A. M. Z. Slawin, H. L. Roderick, M. D. 
Bootman and S. J. Conway, J. Org. Chem. 2007, 72, 5647-5659. 
(93) D. C. Billington, R. Baker, J. J. Kulagowski, I. M. Mawer, J. P. Vacca, S. J. 
Desolms and J. R. Huff, J. Chem. Soc. Perkin Trans. 1, 1989, 1423-1429. 
(94) I. H. Gilbert, A. B. Holmes and R. C. Young, Tet. Lett., 1990, 31, 2633-
2634. 
(95) I. H. Gilbert, A. B. Holmes, M. J. Pestchanker and R. C. Young, 
Carbohydr. Res., 1992, 234, 117-130. 
(96) S. J. Conway, J. Gardiner, S. J. A. Grove, M. K. Johns, Z.-Y. Lim, G. F. 
Painter, D. E. J. E. Robinson, C. Schieber, J. W. Thuring, L. S. M. Wong, 
M.-X. Yin, A. W. Burgess, B. Catimel, P. T. Hawkins, N. T. Ktistakis, L. R. 
Stephens and A. B. Holmes, Org. Biol. Chem., 2010, 8, 66-76. 
(97) S. David, Selective O-substitution using stannylene acetal and stannyl 
ethers, in Preparative Carbohydrate Chemistry; Marcel Dekker, Inc., 1997. 
 234 
(98) G. J. Boons, A. Burton and S. Isles, Chem. Comm., 1996, 141-142. 
(99) N. S. Keddie, G. Bultynck, T. Luyten, A. M. Z. Slawin and S. J. Conway, 
Tet. Asymm., 2009, 20, 857-866. 
(100) K. Nakayama, K. Uoto, K. Higashi, T. Soga and T. Kusama, Chem. 
Pharm. Bull., 1992, 40, 1718-1720. 
(101) T. Akiyama, H. Shima and S. Ozaki, Synlett., 1992, 415-416. 
(102) H. L. Zhang, N. Markadieu, R. Beauwens, C. Erneux and G. D. Prestwich, 
J. Am. Chem. Soc., 2006, 128, 16464-16465. 
(103) H. Mandai and T. Mukaiyama, Bull. Chem. Soc. Jpn, 2006, 79, 479-488. 
(104) T. Ogawa and S. Nakabayashi, Carbohydr. Res., 1981, 93, C1-C5. 
(105) D. Arosio, I. Vrasidas, P. Valentini, R. M. J. Liskamp, R. J. Pieters and A. 
Bernardi, Org. Biol. Chem., 2004, 2, 2113-2124. 
(106) B. Willi and T. Arnold, Helv. Chim. Acta, 1987, 70, 175-186. 
(107) M. Okada, S. Iwashita and N. Koizumi, Tet. Lett., 2000, 41, 7047-7051. 
(108) C. E. Dreef, R. J. Tuinman, A. W. M. Lefeber, C. J. J. Elle, G. A. 
Vandermarel and J. H. Vanboom, Tetrahedron, 1991, 47, 4709-4722. 
(109) C. E. Dreef, M. Douwes, C. J. J. Elie, G. A. Vandermarel and J. H. 
Vanboom, Synthesis-Stuttgart, 1991, 443-447. 
(110) C. Liu and B. V. L. Potter, J. Org. Chem., 1997, 62, 8335-8340. 
(111) H. Ikeda, E. Abushanab and V. E. Marquez, Bioorg. Med. Chem. Lett., 
1999, 9, 3069-3074. 
(112) L. Czollner, J. Kuszmann and A. Vasella, Helv. Chim. Acta, 1990, 73, 
1338-1358. 
(113) N. Nakajima, M. Saito and M. Ubukata, Tetrahedron, 2002, 58, 3561-
3577. 
(114) N. Nakajima, M. Saito and M. Ubukata, Tet. Lett., 1998, 39, 5565-5568. 
(115) L. Van Hijfte and R. D. J. Little, J. Org. Chem., 1985, 50, 3940-3942. 
(116) R. Appel, Angew. Chem. Int. Ed., 1975, 14, 801-811. 
(117) K. K. Reddy, M. Saady, J. R. Falck and G. J. Whited, J. Org. Chem., 1995, 
60, 3385-3390. 
 235 
(118) S. F. Martin, J. A. Josey, Y. L. Wong and D. W. Dean, J. Org. Chem., 
1994, 59, 4805-4820. 
(119) M. K. Johns, M. -X. Yin, S. J. Conway, D. E. J. E. Robinson, L. S. M. 
Wong, R. Bamert, R. E. H. Wettenhall, A. B. Holmes, Org. Biomol. Chem., 
2009, 7, 3691-7. 
(120) Z. Y. Lim, J. W. Thuring, A. B. Holmes, M. Manifava, N. T. Ktistakis, J. 
Chem. Soc., Perkin Trans. 1, 2002, 1067-1075. 
(121) T. S. Elliott, J. Nemeth, S. A. Swain, S. J. Conway, Tet. Asymm., 2009, 
20, 2809-2813. 
(122) D. C. Billington, R. Baker, J. J. Kulagowski, I. M. Mawer, J. P. Vacca, S. J. 
deSolms and J. R. Huff, J. Chem. Soc., Perkin Trans. 1, 1989, 1423 - 
1429. 
(123) G. F. Painter, S. J. A. Grove, I. H. Gilbert, A. B. Holmes, P. R. Raithby, M. 
L. Hill, P. T. Hawkins and L. R. Stephens, J. Chem. Soc., Perkin Trans. 1, 
1999, 923-936. 
(124) K. B. Wiberg and W. C. Cunningham, J. Org. Chem., 1990, 55, 679-684. 
(125) R. C. Buijsman, J. E. M. Basten, T. G. van Dinther, G. A. van der Marel, C. 
A. A. van Boeckel and J. H. van Boom, Bioorg. Med. Chem. Lett., 1999, 9, 
2013-2018. 
(126) W. Bannwarth and A. Trzeciak, Helv. Chim. acta, 1987, 70, 175-186. 
(127) O. Mitsunobu, J. Kimura, K. Iiizumi and N. Yanagida, Bull. Chem. Soc. 
Jpn, 1976, 49, 510-513. 
(128) J. R. Falck, K. K. Reddy, J. Ye, M. Saady, C. Mioskowski, S. B. Shears, Z. 
Tan and S. Safrany, J. Am. Chem. Soc., 1995, 117, 12172-12175. 
(129) R. Aneja, S. Aneja, V. P. Pathak and P. T. Ivanova, Tett. Lett. 1994, 35, 
6061-6062. 
 (130) Y. Xu, B. R. Sculimbrene and S. J. Miller, J. Org. Chem., 2006, 71, 4919-
4928. 
(131) R. Aneja and S. G. Aneja, Tett. Lett., 2000, 41, 847-850. 
 
 
 236 
 
 237 
Appendix 1 – Selected NMR Spectra 
 (-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2’-ylidine)-myo-inositol (-)-121 
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(-)-5-O-Allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl myo-inositol 105 
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(-)-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl myo-inositol (-)-122 
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(-)-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-1-O-triisopropylsilyl myo-inositol (-)-122 
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(+)-1D-1,5-bis-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-131 
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(+)-1D-1,5-bis-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-131 
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(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (-)-139 
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(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-(4-methoxy)benzyl-myo-inositol (-)-139 
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(+)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-106 
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(+)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol (+)-106 
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(-)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-107 
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(-)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-107 
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(-)-1D-2,6-bis-O-Benzyl-3-O-(4-methoxy)benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-107 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-108 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-108 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 1,4,5-tris(dibenzylphosphate) (-)-108 
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(±)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-benzoyl-myo-inositol 150 
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(±)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-benzoyl-myo-inositol 150 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 151 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 151 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 1,4,5-tris(dibenzylphosphate) 145 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 1,4,5-tris(dibenzylphosphate) 145 
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(±)-1D-2,6-bis-O-Benzyl-3-O-benzoyl-myo-inositol 1,4,5-tris(dibenzylphosphate) 145 
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(+)-1D-2,6-bis-O-Benzyl-5-O-allyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 152 
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(+)-1D-2,6-bis-O-Benzyl-5-O-allyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 152 
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(+)-1D-2,6-bis-O-Benzyl-5-O-allyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 152 
 
 
BnO OPO(OBn)2
OBn
OAll
OPO(OBn)2
(BnO)2OPO
 266 
 
(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate) 153 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 5-(O-benzyl-O-methyl)phosphate-1,3,4-tris(dibenzylphosphate) 156 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 5-(O-benzyl-O-methyl)phosphate-1,3,4-tris(dibenzylphosphate) 156 
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(-)-1D-2,6-bis-O-Benzyl-myo-inositol 5-(O-benzyl-O-methyl)phosphate-1,3,4-tris(dibenzylphosphate) 156 
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(-)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 157 
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(-)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 157 
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(-)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-methylphosphate ester 157 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 5-O-sulfamoly-1,3,4-tris(dibenzylphosphate) 159 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 5-O-sulfamoly-1,3,4-tris(dibenzylphosphate) 159 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 5-O-sulfamoly-1,3,4-tris(dibenzylphosphate) 159 
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(+)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-sulfamate 160 
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(+)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-sulfamate 160 
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(+)-1D-myo-Inositol-1,3,4-trisphosphate-5-O-sulfamate 160 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate)-5-O-acetic acid 172 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate)-5-O-acetic acid 172 
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(+)-1D-2,6-bis-O-Benzyl-myo-inositol 1,3,4-tris(dibenzylphosphate)-5-O-acetic acid 172 
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(-)-1D-myo-Inositol 1,3,4-trisphosphate-5-O-acetic acid 173 
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OH
OCH2CO2Na
OPO(ONa)2
(NaO)2OPO
 285 
 
(-)-1D-myo-Inositol 1,3,4-trisphosphate-5-O-acetic acid 173 
 
 
 
HO OPO(ONa)2
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(-)-1D-myo-Inositol 1,3,4-trisphosphate-5-O-acetic acid 173 
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(-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-methylphosphate-3,4,5-tris(dibenzylphosphate) 199 
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(-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-methylphosphate-3,4,5-tris(dibenzylphosphate) 199 
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(-)-1D-2,6-bis-O-benzyl-myo-inositol 1-O-benzyl-O-methylphosphate-3,4,5-tris(dibenzylphosphate) 199 
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(-)-1D-myo-Inositol 1-O-methylphosphate-3,4,5-tris(phosphate) 198 
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(-)-1D-myo-Inositol 1-O-methylphosphate-3,4,5-tris(phosphate) 198 
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(-)-1D-myo-Inositol 1-O-methylphosphate-3,4,5-tris(phosphate) 198 
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(+)-1D-1-(1,2-Dioctanoyl-sn-glycerol-3-phospho)-2,3,4,5,6-penta-O-benzyl-myo-inositol (+)-204 
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(+)-1D-1-(1,2-Dioctanoyl-sn-glycerol-3-phospho)-2,3,4,5,6-penta-O-benzyl-myo-inositol (+)-204 
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(+)-1D-1-(1,2-Dioctanoyl-sn-glycerol-3-phospho)-2,3,4,5,6-penta-O-benzyl-myo-inositol (+)-204 
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(+)-1D-Phosphatidylinositol 200 
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(+)-1D-Phosphatidylinositol 200 
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(+)-1D-Phosphatidylinositol 200 
 
 
 
HO O
OH
OH
OH
HO
P
O
ONa
O O
O
O
O
 299 
Appendix 2 – Crystallographic Data 
 
 
X-Ray crystal structure of compound X 
Table 1.  Crystal data and structure refinement for compound X. 
Identification code - tesc1 
Empirical formula  C40 H56 O7 Si Theta range for data 
collection 
1.78 to 25.32!. 
Formula weight  676.94 Index ranges -13<=h<=12, -
15<=k<=12, -
34<=l<=32 
Temperature  93(2) K Reflections collected 24698 
Wavelength  0.71073 " Independent 
reflections 
7017 [R(int) = 0.0674] 
Crystal system  Monoclinic Completeness to 
theta = 25.00! 
99.9 %  
Space group  P2(1)/n Absorption correction Multiscan 
Unit cell dimensions a = 10.8233(15) "   a= 
90!. 
b = 12.5013(17) "   b= 
90.238(4)!. 
c = 28.564(4) "  g = 
90!. 
 
Max. and min. 
transmission 
1.0000 and 0.9733 
Volume 3864.8(9) "3 Refinement method Full-matrix least-
squares on F2 
Z 4 Data / restraints / 
parameters 
7017 / 1 / 439 
Density (calculated) 1.163 Mg/m3 Goodness-of-fit on F2 0.964 
Absorption coefficient 0.107 mm-1 Final R indices 
[I>2sigma(I)] 
R1 = 0.0656, wR2 = 
0.1696 
F(000) 1464 R indices (all data) R1 = 0.1015, wR2 = 
0.1991 
Crystal size 0.1500 x 0.0300 x 
0.0300 mm3 
Largest diff. peak and 
hole 
0.761 and -0.372 e."-3 
 
 
1 
2 
3 4 
5 
6 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters ("2x 
103) for tesc1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
Si(1) 3399(1) 1243(1) 3148(1) 26(1) 
O(1) 4325(2) 2005(1) 3470(1) 28(1) 
C(1) 4273(3) 2190(2) 3962(1) 25(1) 
O(2) 4721(2) 4032(1) 3820(1) 28(1) 
C(2) 3847(3) 3344(2) 4048(1) 25(1) 
O(3) 3451(2) 4678(1) 4638(1) 31(1) 
C(3) 3810(3) 3586(2) 4568(1) 28(1) 
O(4) 5010(2) 3601(2) 5286(1) 33(1) 
C(4) 5072(3) 3412(2) 4793(1) 27(1) 
O(5) 6727(2) 2142(2) 4892(1) 33(1) 
C(5) 5512(3) 2275(2) 4703(1) 28(1) 
O(6) 5875(2) 905(1) 4127(1) 28(1) 
C(6) 5542(2) 2005(2) 4185(1) 25(1) 
C(7) 3568(3) -195(2) 3347(1) 36(1) 
C(8) 4783(3) -696(2) 3184(1) 48(1) 
C(9) 2462(3) -915(2) 3218(1) 46(1) 
C(10) 3960(3) 1555(2) 2540(1) 31(1) 
C(11) 5356(3) 1495(3) 2466(1) 43(1) 
C(12) 3274(3) 922(2) 2155(1) 39(1) 
C(13) 1720(3) 1639(2) 3187(1) 29(1) 
C(14) 1424(3) 2733(2) 2973(1) 39(1) 
C(15) 1172(3) 1561(2) 3681(1) 36(1) 
C(16) 4211(3) 4981(2) 3612(1) 36(1) 
C(17) 4980(3) 5274(2) 3194(1) 30(1) 
C(18) 5111(3) 4541(2) 2829(1) 37(1) 
C(19) 5816(3) 4788(3) 2445(1) 48(1) 
C(20) 6385(3) 5767(3) 2412(1) 53(1) 
C(21) 6266(3) 6504(3) 2765(1) 55(1) 
C(22) 5568(3) 6253(2) 3161(1) 42(1) 
C(23) 2299(3) 4841(2) 4879(1) 32(1) 
C(24) 1204(3) 4466(2) 4597(1) 29(1) 
C(25) 891(3) 4974(2) 4180(1) 33(1) 
C(26) -99(3) 4630(2) 3907(1) 34(1) 
O(27) -1777(2) 3345(2) 3811(1) 42(1) 
C(27) -804(3) 3767(2) 4057(1) 31(1) 
C(28) -511(3) 3260(2) 4473(1) 33(1) 
C(29) 476(3) 3607(2) 4741(1) 31(1) 
C(30) -2146(3) 3859(3) 3387(1) 48(1) 
C(31) 6808(3) 1354(3) 5255(1) 54(1) 
C(32) 8104(4) 1201(4) 5385(1) 72(1) 
C(33) 8672(5) 263(5) 5317(2) 100(2) 
C(34) 7117(3) 775(2) 3972(1) 33(1) 
C(35) 7496(3) -388(2) 3984(1) 28(1) 
C(36) 6762(3) -1187(2) 4172(1) 31(1) 
C(37) 7163(3) -2243(2) 4176(1) 37(1) 
C(38) 8295(3) -2513(2) 3997(1) 37(1) 
C(39) 9043(3) -1726(2) 3810(1) 40(1) 
C(40) 8643(3) -672(2) 3808(1) 32(1) 
 
 
 
 302 
Table 3.   Bond lengths ["] and angles [!] for  tesc1. 
Si(1)-O(1)  1.6585(19) O(6)-C(6)-C(1) 108.9(2) 
Si(1)-C(10)  1.881(3) C(5)-C(6)-C(1) 110.4(2) 
Si(1)-C(13)  1.887(3) O(6)-C(6)-H(6A) 109.40 
Si(1)-C(7)  1.894(3) C(5)-C(6)-H(6A) 109.40 
O(1)-C(1)  1.427(3) C(1)-C(6)-H(6A) 109.40 
C(1)-C(6)  1.528(4) C(8)-C(7)-C(9) 110.9(2) 
C(1)-C(2)  1.534(3) C(8)-C(7)-Si(1) 112.3(2) 
C(1)-H(1A)  1.0000 C(9)-C(7)-Si(1) 114.1(2) 
O(2)-C(2)  1.435(3) C(8)-C(7)-H(7A) 106.30 
O(2)-C(16)  1.436(3) C(9)-C(7)-H(7A) 106.30 
C(2)-C(3)  1.516(4) Si(1)-C(7)-H(7A) 106.30 
C(2)-H(2A)  1.0000 C(7)-C(8)-H(8A) 109.50 
O(3)-C(3)  1.433(3) C(7)-C(8)-H(8B) 109.50 
O(3)-C(23)  1.441(3) H(8A)-C(8)-H(8B) 109.50 
C(3)-C(4)  1.523(4) C(7)-C(8)-H(8C) 109.50 
C(3)-H(3A)  1.0000 H(8A)-C(8)-H(8C) 109.50 
O(4)-C(4)  1.428(3) H(8B)-C(8)-H(8C) 109.50 
O(4)-H(4O)  0.939(19) C(7)-C(9)-H(9A) 109.50 
C(4)-C(5)  1.522(4) C(7)-C(9)-H(9B) 109.50 
C(4)-H(4A)  1.0000 H(9A)-C(9)-H(9B) 109.50 
O(5)-C(5)  1.429(3) C(7)-C(9)-H(9C) 109.50 
O(5)-C(31)  1.434(4) H(9A)-C(9)-H(9C) 109.50 
C(5)-C(6)  1.520(4) H(9B)-C(9)-H(9C) 109.50 
C(5)-H(5A)  1.0000 C(11)-C(10)-C(12) 110.4(2) 
O(6)-C(34)  1.426(3) C(11)-C(10)-Si(1) 116.1(2) 
O(6)-C(6)  1.432(3) C(12)-C(10)-Si(1) 113.3(2) 
C(6)-H(6A)  1.0000 C(11)-C(10)-H(10A) 105.30 
C(7)-C(8)  1.531(4) C(12)-C(10)-H(10A) 105.30 
C(7)-C(9)  1.541(4) Si(1)-C(10)-H(10A) 105.30 
C(7)-H(7A)  1.0000 C(10)-C(11)-H(11A) 109.50 
C(8)-H(8A)  0.9800 C(10)-C(11)-H(11B) 109.50 
C(8)-H(8B)  0.9800 H(11A)-C(11)-H(11B) 109.50 
C(8)-H(8C)  0.9800 C(10)-C(11)-H(11C) 109.50 
C(9)-H(9A)  0.9800 H(11A)-C(11)-H(11C) 109.50 
C(9)-H(9B)  0.9800 H(11B)-C(11)-H(11C) 109.50 
C(9)-H(9C)  0.9800 C(10)-C(12)-H(12A) 109.50 
C(10)-C(11)  1.528(4) C(10)-C(12)-H(12B) 109.50 
C(10)-C(12)  1.543(4) H(12A)-C(12)-H(12B) 109.50 
C(10)-H(10A)  1.0000 C(10)-C(12)-H(12C) 109.50 
C(11)-H(11A)  0.9800 H(12A)-C(12)-H(12C) 109.50 
C(11)-H(11B)  0.9800 H(12B)-C(12)-H(12C) 109.50 
C(11)-H(11C)  0.9800 C(14)-C(13)-C(15) 110.0(2) 
C(12)-H(12A)  0.9800 C(14)-C(13)-Si(1) 114.2(2) 
C(12)-H(12B)  0.9800 C(15)-C(13)-Si(1) 114.4(2) 
C(12)-H(12C)  0.9800 C(14)-C(13)-H(13A) 105.80 
C(13)-C(14)  1.532(4) C(15)-C(13)-H(13A) 105.80 
C(13)-C(15)  1.538(4) Si(1)-C(13)-H(13A) 105.80 
C(13)-H(13A)  1.0000 C(13)-C(14)-H(14A) 109.50 
C(14)-H(14A)  0.9800 C(13)-C(14)-H(14B) 109.50 
C(14)-H(14B)  0.9800 H(14A)-C(14)-H(14B) 109.50 
 303 
C(14)-H(14C)  0.9800 C(13)-C(14)-H(14C) 109.50 
C(15)-H(15A)  0.9800 H(14A)-C(14)-H(14C) 109.50 
C(15)-H(15B)  0.9800 H(14B)-C(14)-H(14C) 109.50 
C(15)-H(15C)  0.9800 C(13)-C(15)-H(15A) 109.50 
C(16)-C(17)  1.505(4) C(13)-C(15)-H(15B) 109.50 
C(16)-H(16A)  0.9900 H(15A)-C(15)-H(15B) 109.50 
C(16)-H(16B)  0.9900 C(13)-C(15)-H(15C) 109.50 
C(17)-C(22)  1.383(4) H(15A)-C(15)-H(15C) 109.50 
C(17)-C(18)  1.394(4) H(15B)-C(15)-H(15C) 109.50 
C(18)-C(19)  1.375(4) O(2)-C(16)-C(17) 108.5(2) 
C(18)-H(18A)  0.9500 O(2)-C(16)-H(16A) 110.00 
C(19)-C(20)  1.374(5) C(17)-C(16)-H(16A) 110.00 
C(19)-H(19A)  0.9500 O(2)-C(16)-H(16B) 110.00 
C(20)-C(21)  1.372(5) C(17)-C(16)-H(16B) 110.00 
C(20)-H(20A)  0.9500 H(16A)-C(16)-H(16B) 108.40 
C(21)-C(22)  1.398(5) C(22)-C(17)-C(18) 118.9(3) 
C(21)-H(21A)  0.9500 C(22)-C(17)-C(16) 121.7(3) 
C(22)-H(22A)  0.9500 C(18)-C(17)-C(16) 119.4(3) 
C(23)-C(24)  1.504(4) C(19)-C(18)-C(17) 120.5(3) 
C(23)-H(23A)  0.9900 C(19)-C(18)-H(18A) 119.80 
C(23)-H(23B)  0.9900 C(17)-C(18)-H(18A) 119.80 
C(24)-C(25)  1.390(4) C(20)-C(19)-C(18) 120.3(3) 
C(24)-C(29)  1.395(4) C(20)-C(19)-H(19A) 119.90 
C(25)-C(26)  1.392(4) C(18)-C(19)-H(19A) 119.90 
C(25)-H(25A)  0.9500 C(21)-C(20)-C(19) 120.4(3) 
C(26)-C(27)  1.389(4) C(21)-C(20)-H(20A) 119.80 
C(26)-H(26A)  0.9500 C(19)-C(20)-H(20A) 119.80 
O(27)-C(27)  1.370(3) C(20)-C(21)-C(22) 119.8(3) 
O(27)-C(30)  1.427(4) C(20)-C(21)-H(21A) 120.10 
C(27)-C(28)  1.383(4) C(22)-C(21)-H(21A) 120.10 
C(28)-C(29)  1.380(4) C(17)-C(22)-C(21) 120.2(3) 
C(28)-H(28A)  0.9500 C(17)-C(22)-H(22A) 119.90 
C(29)-H(29A)  0.9500 C(21)-C(22)-H(22A) 119.90 
C(30)-H(30A)  0.9800 O(3)-C(23)-C(24) 112.4(2) 
C(30)-H(30B)  0.9800 O(3)-C(23)-H(23A) 109.10 
C(30)-H(30C)  0.9800 C(24)-C(23)-H(23A) 109.10 
C(31)-C(32)  1.462(5) O(3)-C(23)-H(23B) 109.10 
C(31)-H(31A)  0.9900 C(24)-C(23)-H(23B) 109.10 
C(31)-H(31B)  0.9900 H(23A)-C(23)-H(23B) 107.90 
C(32)-C(33)  1.339(6) C(25)-C(24)-C(29) 117.9(3) 
C(32)-H(32A)  0.9500 C(25)-C(24)-C(23) 120.3(3) 
C(33)-H(33A)  0.9500 C(29)-C(24)-C(23) 121.8(3) 
C(33)-H(33B)  0.9500 C(24)-C(25)-C(26) 121.6(3) 
C(34)-C(35)  1.510(4) C(24)-C(25)-H(25A) 119.20 
C(34)-H(34A)  0.9900 C(26)-C(25)-H(25A) 119.20 
C(34)-H(34B)  0.9900 C(27)-C(26)-C(25) 119.3(3) 
C(35)-C(36)  1.386(4) C(27)-C(26)-H(26A) 120.30 
C(35)-C(40)  1.388(4) C(25)-C(26)-H(26A) 120.30 
C(36)-C(37)  1.389(4) C(27)-O(27)-C(30) 118.3(2) 
C(36)-H(36A)  0.9500 O(27)-C(27)-C(28) 115.9(2) 
C(37)-C(38)  1.373(4) O(27)-C(27)-C(26) 124.3(3) 
C(37)-H(37A)  0.9500 C(28)-C(27)-C(26) 119.7(3) 
C(38)-C(39)  1.382(4) C(29)-C(28)-C(27) 120.4(3) 
C(38)-H(38A)  0.9500 C(29)-C(28)-H(28A) 119.80 
C(39)-C(40)  1.388(4) C(27)-C(28)-H(28A) 119.80 
C(39)-H(39A)  0.9500 C(28)-C(29)-C(24) 121.1(3) 
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C(40)-H(40A)  0.9500 C(28)-C(29)-H(29A) 119.50 
  C(24)-C(29)-H(29A) 119.50 
O(1)-Si(1)-C(10) 101.31(11) O(27)-C(30)-H(30A) 109.50 
O(1)-Si(1)-C(13) 113.34(11) O(27)-C(30)-H(30B) 109.50 
C(10)-Si(1)-C(13) 108.32(13) H(30A)-C(30)-H(30B) 109.50 
O(1)-Si(1)-C(7) 108.74(12) O(27)-C(30)-H(30C) 109.50 
C(10)-Si(1)-C(7) 116.29(13) H(30A)-C(30)-H(30C) 109.50 
C(13)-Si(1)-C(7) 108.83(13) H(30B)-C(30)-H(30C) 109.50 
C(1)-O(1)-Si(1) 127.88(17) O(5)-C(31)-C(32) 109.3(3) 
O(1)-C(1)-C(6) 110.3(2) O(5)-C(31)-H(31A) 109.80 
O(1)-C(1)-C(2) 108.8(2) C(32)-C(31)-H(31A) 109.80 
C(6)-C(1)-C(2) 110.3(2) O(5)-C(31)-H(31B) 109.80 
O(1)-C(1)-H(1A) 109.20 C(32)-C(31)-H(31B) 109.80 
C(6)-C(1)-H(1A) 109.20 H(31A)-C(31)-H(31B) 108.30 
C(2)-C(1)-H(1A) 109.20 C(33)-C(32)-C(31) 121.2(5) 
C(2)-O(2)-C(16) 115.4(2) C(33)-C(32)-H(32A) 119.40 
O(2)-C(2)-C(3) 110.1(2) C(31)-C(32)-H(32A) 119.40 
O(2)-C(2)-C(1) 107.0(2) C(32)-C(33)-H(33A) 120.00 
C(3)-C(2)-C(1) 110.6(2) C(32)-C(33)-H(33B) 120.00 
O(2)-C(2)-H(2A) 109.70 H(33A)-C(33)-H(33B) 120.00 
C(3)-C(2)-H(2A) 109.70 O(6)-C(34)-C(35) 111.0(2) 
C(1)-C(2)-H(2A) 109.70 O(6)-C(34)-H(34A) 109.40 
C(3)-O(3)-C(23) 115.9(2) C(35)-C(34)-H(34A) 109.40 
O(3)-C(3)-C(2) 109.5(2) O(6)-C(34)-H(34B) 109.40 
O(3)-C(3)-C(4) 108.7(2) C(35)-C(34)-H(34B) 109.40 
C(2)-C(3)-C(4) 111.0(2) H(34A)-C(34)-H(34B) 108.00 
O(3)-C(3)-H(3A) 109.20 C(36)-C(35)-C(40) 118.1(2) 
C(2)-C(3)-H(3A) 109.20 C(36)-C(35)-C(34) 123.2(3) 
C(4)-C(3)-H(3A) 109.20 C(40)-C(35)-C(34) 118.7(2) 
C(4)-O(4)-H(4O) 105(2) C(35)-C(36)-C(37) 120.6(3) 
O(4)-C(4)-C(5) 109.7(2) C(35)-C(36)-H(36A) 119.70 
O(4)-C(4)-C(3) 110.3(2) C(37)-C(36)-H(36A) 119.70 
C(5)-C(4)-C(3) 110.0(2) C(38)-C(37)-C(36) 120.7(3) 
O(4)-C(4)-H(4A) 108.90 C(38)-C(37)-H(37A) 119.70 
C(5)-C(4)-H(4A) 108.90 C(36)-C(37)-H(37A) 119.70 
C(3)-C(4)-H(4A) 108.90 C(37)-C(38)-C(39) 119.6(3) 
C(5)-O(5)-C(31) 114.0(2) C(37)-C(38)-H(38A) 120.20 
O(5)-C(5)-C(6) 108.5(2) C(39)-C(38)-H(38A) 120.20 
O(5)-C(5)-C(4) 109.4(2) C(38)-C(39)-C(40) 119.7(3) 
C(6)-C(5)-C(4) 112.4(2) C(38)-C(39)-H(39A) 120.20 
O(5)-C(5)-H(5A) 108.80 C(40)-C(39)-H(39A) 120.20 
C(6)-C(5)-H(5A) 108.80 C(39)-C(40)-C(35) 121.4(3) 
C(4)-C(5)-H(5A) 108.80 C(39)-C(40)-H(40A) 119.30 
C(34)-O(6)-C(6) 112.56(19) C(35)-C(40)-H(40A) 119.30 
O(6)-C(6)-C(5) 109.4(2)   
Symmetry transformations used to generate equivalent atoms: 
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Table 4.   Anisotropic displacement parameters  ("2x 103) for tesc1.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 U11 U22  U33 U23 U13 U12 
Si(1) 28(1)  24(1) 27(1)  -4(1) -4(1)  2(1) 
O(1) 31(1)  28(1) 23(1)  -7(1) -3(1)  1(1) 
C(1) 27(2)  26(1) 23(1)  -6(1) -1(1)  -1(1) 
O(2) 25(1)  26(1) 32(1)  1(1) -2(1)  1(1) 
C(2) 21(2)  26(1) 29(2)  -5(1) -4(1)  -2(1) 
O(3) 27(1)  27(1) 40(1)  -11(1) 6(1)  -2(1) 
C(3) 28(2)  27(1) 28(2)  -7(1) 4(1)  -4(1) 
O(4) 40(1)  37(1) 22(1)  -6(1) 4(1)  -15(1) 
C(4) 27(2)  34(1) 20(1)  -4(1) 0(1)  -7(1) 
O(5) 27(1)  46(1) 28(1)  5(1) -7(1)  -3(1) 
C(5) 22(2)  33(1) 30(2)  -2(1) -2(1)  -5(1) 
O(6) 24(1)  24(1) 36(1)  -2(1) 0(1)  2(1) 
C(6) 26(2)  24(1) 26(1)  -1(1) -2(1)  1(1) 
C(7) 47(2)  24(1) 35(2)  -3(1) -8(2)  1(1) 
C(8) 48(2)  34(2) 63(2)  -9(2) -16(2)  13(1) 
C(9) 57(2)  30(2) 50(2)  -4(2) 0(2)  -4(2) 
C(10) 32(2)  31(1) 30(2)  -4(1) -4(1)  2(1) 
C(11) 39(2)  53(2) 38(2)  -3(2) -1(2)  -2(2) 
C(12) 43(2)  45(2) 29(2)  -8(1) -5(1)  2(1) 
C(13) 27(2)  29(1) 33(2)  -5(1) -3(1)  -1(1) 
C(14) 38(2)  33(2) 45(2)  4(1) -4(2)  10(1) 
C(15) 29(2)  39(2) 40(2)  -2(1) 1(1)  -2(1) 
C(16) 44(2)  31(1) 33(2)  1(1) 0(1)  11(1) 
C(17) 27(2)  31(1) 32(2)  1(1) -4(1)  6(1) 
C(18) 34(2)  45(2) 31(2)  -2(1) -5(1)  1(1) 
C(19) 43(2)  66(2) 35(2)  -3(2) 0(2)  6(2) 
C(20) 37(2)  71(2) 53(2)  22(2) 7(2)  3(2) 
C(21) 41(2)  46(2) 77(3)  20(2) -1(2)  -6(2) 
C(22) 40(2)  33(2) 53(2)  -2(2) -6(2)  -1(1) 
C(23) 26(2)  37(2) 34(2)  -10(1) 5(1)  -2(1) 
C(24) 26(2)  29(1) 34(2)  -9(1) 4(1)  2(1) 
C(25) 29(2)  29(1) 42(2)  -1(1) 7(1)  0(1) 
C(26) 31(2)  31(1) 40(2)  7(1) 4(1)  6(1) 
O(27) 31(1)  47(1) 46(1)  5(1) -10(1)  -6(1) 
C(27) 26(2)  29(1) 38(2)  -1(1) -1(1)  4(1) 
C(28) 30(2)  31(1) 39(2)  -3(1) 7(1)  -3(1) 
C(29) 29(2)  34(1) 30(2)  -4(1) 5(1)  0(1) 
C(30) 34(2)  58(2) 53(2)  10(2) -16(2)  -2(2) 
C(31) 37(2)  87(3) 39(2)  27(2) 0(2)  8(2) 
C(32) 46(3)  114(4) 55(2)  27(2) -2(2)  -4(2) 
C(33) 106(4)  139(4) 55(3)  36(3) 8(3)  72(4) 
C(34) 26(2)  34(2) 38(2)  2(1) 4(1)  4(1) 
C(35) 24(2)  33(1) 27(2)  3(1) -2(1)  1(1) 
C(36) 27(2)  32(1) 33(2)  4(1) 3(1)  2(1) 
C(37) 44(2)  31(2) 36(2)  7(1) 2(1)  -7(1) 
C(38) 42(2)  25(1) 44(2)  2(1) 5(2)  8(1) 
C(39) 36(2)  36(2) 47(2)  -3(1) 6(2)  8(1) 
C(40) 30(2)  31(1) 35(2)  0(1) 4(1)  -1(1) 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters ("2x 10 3) for 
tesc1. 
 x  y  z  U(eq) 
H(1A) 3664 1686 4105 30 
H(2A) 3008 3453 3908 30 
H(3A) 3193 3106 4721 33 
H(4O) 5520(30) 4200(20) 5340(13) 72(12) 
H(4A) 5675 3924 4652 32 
H(5A) 4941 1766 4864 34 
H(6A) 6166 2467 4026 30 
H(7A) 3607 -176 3697 43 
H(8A) 4834 -1435 3297 72 
H(8B) 5479 -283 3310 72 
H(8C) 4813 -690 2841 72 
H(9A) 2610 -1641 3335 69 
H(9B) 2362 -933 2877 69 
H(9C) 1709 -628 3361 69 
H(10A) 3736 2321 2486 37 
H(11A) 5548 1680 2141 65 
H(11B) 5645 768 2533 65 
H(11C) 5770 2000 2677 65 
H(12A) 3601 1122 1848 59 
H(12B) 2390 1089 2167 59 
H(12C) 3395 154 2206 59 
H(13A) 1257 1105 2993 35 
H(14A) 539 2879 3004 58 
H(14B) 1648 2733 2641 58 
H(14C) 1896 3288 3137 58 
H(15A) 301 1774 3672 54 
H(15B) 1628 2038 3893 54 
H(15C) 1239 823 3794 54 
H(16A) 4218 5573 3842 43 
H(16B) 3345 4850 3515 43 
H(18A) 4710 3866 2847 44 
H(19A) 5911 4279 2201 57 
H(20A) 6862 5935 2144 64 
H(21A) 6657 7182 2741 66 
H(22A) 5498 6757 3409 50 
H(23A) 2202 5611 4949 38 
H(23B) 2322 4449 5180 38 
H(25A) 1365 5571 4080 40 
H(26A) -291 4981 3621 40 
H(28A) -992 2670 4576 40 
H(29A) 662 3254 5027 37 
H(30A) -2348 4609 3451 72 
H(30B) -2874 3497 3257 72 
H(30C) -1469 3825 3160 72 
H(31A) 6454 669 5144 65 
H(31B) 6332 1592 5531 65 
H(32A) 8551 1778 5521 86 
H(33A) 8233 -318 5182 120 
H(33B) 9515 179 5404 120 
H(34A) 7677 1197 4175 40 
H(34B) 7194 1050 3648 40 
H(36A) 5977 -1012 4299 37 
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H(37A) 6649 -2783 4305 44 
H(38A) 8562 -3237 4000 44 
H(39A) 9826 -1907 3684 48 
H(40A) 9165 -133 3683 38 
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Table 6.  Torsion angles [!] for tesc1. 
C(10)-Si(1)-O(1)-C(1) 173.7(2) C(13)-Si(1)-C(10)-C(12) -62.1(2) 
C(13)-Si(1)-O(1)-C(1) 57.9(2) C(7)-Si(1)-C(10)-C(12) 60.8(2) 
C(7)-Si(1)-O(1)-C(1) -63.3(2) O(1)-Si(1)-C(13)-C(14) 66.8(2) 
Si(1)-O(1)-C(1)-C(6) 129.44(19) C(10)-Si(1)-C(13)-C(14) -44.8(2) 
Si(1)-O(1)-C(1)-C(2) -109.5(2) C(7)-Si(1)-C(13)-C(14) -172.1(2) 
C(16)-O(2)-C(2)-C(3) -95.5(3) O(1)-Si(1)-C(13)-C(15) -61.2(2) 
C(16)-O(2)-C(2)-C(1) 144.2(2) C(10)-Si(1)-C(13)-C(15) -172.79(18) 
O(1)-C(1)-C(2)-O(2) -58.6(3) C(7)-Si(1)-C(13)-C(15) 59.9(2) 
C(6)-C(1)-C(2)-O(2) 62.4(3) C(2)-O(2)-C(16)-C(17) -149.3(2) 
O(1)-C(1)-C(2)-C(3) -178.5(2) O(2)-C(16)-C(17)-C(22) -121.0(3) 
C(6)-C(1)-C(2)-C(3) -57.5(3) O(2)-C(16)-C(17)-C(18) 58.6(3) 
C(23)-O(3)-C(3)-C(2) 116.4(2) C(22)-C(17)-C(18)-C(19) 0.2(5) 
C(23)-O(3)-C(3)-C(4) -122.1(2) C(16)-C(17)-C(18)-C(19) -179.5(3) 
O(2)-C(2)-C(3)-O(3) 60.0(3) C(17)-C(18)-C(19)-C(20) -1.0(5) 
C(1)-C(2)-C(3)-O(3) 178.1(2) C(18)-C(19)-C(20)-C(21) 0.8(5) 
O(2)-C(2)-C(3)-C(4) -60.0(3) C(19)-C(20)-C(21)-C(22) 0.3(5) 
C(1)-C(2)-C(3)-C(4) 58.0(3) C(18)-C(17)-C(22)-C(21) 0.9(5) 
O(3)-C(3)-C(4)-O(4) 61.8(3) C(16)-C(17)-C(22)-C(21) -179.4(3) 
C(2)-C(3)-C(4)-O(4) -177.62(19) C(20)-C(21)-C(22)-C(17) -1.2(5) 
O(3)-C(3)-C(4)-C(5) -177.0(2) C(3)-O(3)-C(23)-C(24) -67.1(3) 
C(2)-C(3)-C(4)-C(5) -56.5(3) O(3)-C(23)-C(24)-C(25) -65.6(3) 
C(31)-O(5)-C(5)-C(6) -119.2(3) O(3)-C(23)-C(24)-C(29) 114.2(3) 
C(31)-O(5)-C(5)-C(4) 117.9(3) C(29)-C(24)-C(25)-C(26) -1.3(4) 
O(4)-C(4)-C(5)-O(5) -62.0(3) C(23)-C(24)-C(25)-C(26) 178.5(2) 
C(3)-C(4)-C(5)-O(5) 176.5(2) C(24)-C(25)-C(26)-C(27) 1.0(4) 
O(4)-C(4)-C(5)-C(6) 177.4(2) C(30)-O(27)-C(27)-C(28) 177.9(3) 
C(3)-C(4)-C(5)-C(6) 55.8(3) C(30)-O(27)-C(27)-C(26) -4.0(4) 
C(34)-O(6)-C(6)-C(5) -104.9(2) C(25)-C(26)-C(27)-O(27) -178.3(3) 
C(34)-O(6)-C(6)-C(1) 134.3(2) C(25)-C(26)-C(27)-C(28) -0.3(4) 
O(5)-C(5)-C(6)-O(6) 63.0(3) O(27)-C(27)-C(28)-C(29) 178.3(2) 
C(4)-C(5)-C(6)-O(6) -175.8(2) C(26)-C(27)-C(28)-C(29) 0.1(4) 
O(5)-C(5)-C(6)-C(1) -177.1(2) C(27)-C(28)-C(29)-C(24) -0.5(4) 
C(4)-C(5)-C(6)-C(1) -56.0(3) C(25)-C(24)-C(29)-C(28) 1.1(4) 
O(1)-C(1)-C(6)-O(6) -63.7(3) C(23)-C(24)-C(29)-C(28) -178.7(3) 
C(2)-C(1)-C(6)-O(6) 176.1(2) C(5)-O(5)-C(31)-C(32) 173.9(3) 
O(1)-C(1)-C(6)-C(5) 176.11(19) O(5)-C(31)-C(32)-C(33) -115.9(4) 
C(2)-C(1)-C(6)-C(5) 55.9(3) C(6)-O(6)-C(34)-C(35) 171.5(2) 
O(1)-Si(1)-C(7)-C(8) -74.4(2) O(6)-C(34)-C(35)-C(36) -6.5(4) 
C(10)-Si(1)-C(7)-C(8) 39.1(3) O(6)-C(34)-C(35)-C(40) 174.7(2) 
C(13)-Si(1)-C(7)-C(8) 161.7(2) C(40)-C(35)-C(36)-C(37) -0.8(4) 
O(1)-Si(1)-C(7)-C(9) 158.4(2) C(34)-C(35)-C(36)-C(37) -179.6(3) 
C(10)-Si(1)-C(7)-C(9) -88.1(3) C(35)-C(36)-C(37)-C(38) 0.2(4) 
C(13)-Si(1)-C(7)-C(9) 34.5(3) C(36)-C(37)-C(38)-C(39) 0.1(5) 
O(1)-Si(1)-C(10)-C(11) 49.1(2) C(37)-C(38)-C(39)-C(40) 0.2(5) 
C(13)-Si(1)-C(10)-C(11) 168.5(2) C(38)-C(39)-C(40)-C(35) -0.8(5) 
C(7)-Si(1)-C(10)-C(11) -68.6(2) C(36)-C(35)-C(40)-C(39) 1.2(4) 
O(1)-Si(1)-C(10)-C(12) 178.5(2) C(34)-C(35)-C(40)-C(39) 180.0(3) 
Symmetry transformations used to generate equivalent atoms: 
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Table 7.  Hydrogen bonds for tesc1  [" and !]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(4)-H(4O)...O(3)#1 0.939(19) 1.797(19) 2.730(3) 172(3) 
Symmetry transformations used to generate equivalent atoms: 
#1 -x+1,-y+1,-z+1 
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X-Ray crystal structure of compound X 
 
Table 1.  Crystal data and structure refinement for X. 
Identification code - tesc2 
Empirical formula  C28 H32 O7 Theta range for data 
collection 
2.97 to 25.40!. 
Formula weight  480.54 Index ranges -7<=h<=7, -
27<=k<=26, -
20<=l<=20 
Temperature  93(2) K Reflections collected 24997 
Wavelength  0.71073 " Independent 
reflections 
8888 [R(int) = 0.0851] 
Crystal system  Monoclinic Completeness to 
theta = 25.00! 
99.8 %  
Space group  P2(1) Absorption correction Multiscan 
Unit cell dimensions 
a = 6.500(2) " a= 
90!. 
b = 22.510(8) " b= 
93.104(5)!. 
c = 16.801(6) " g = 
90!. 
 
Max. and min. 
transmission 
1.0000 and 0.9749 
Volume 2454.8(15) "3 Refinement method Full-matrix least-
squares on F2 
Z 4 Data / restraints / 
parameters 
8888 / 7 / 659 
Density (calculated) 1.300 Mg/m3 Goodness-of-fit on F2 1.077 
Absorption coefficient 0.093 mm-1 Final R indices 
[I>2sigma(I)] 
R1 = 0.0736, wR2 = 
0.1636 
F(000) 1024 R indices (all data) R1 = 0.0903, wR2 = 
0.1757 
Crystal size 0.3000 x 0.0300 x 
0.0100 mm3 
Absolute structure 
parameter 
1.2(10) 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters ("2x 103) 
for tesc2.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
O(1) 4816(4) 4369(1) 4369(2) 40(1) 
C(1) 3265(6) 4168(2) 3789(2) 36(1) 
O(2) 279(4) 4340(1) 4605(2) 36(1) 
C(2) 1260(6) 4504(2) 3890(2) 33(1) 
O(3) -2218(4) 4634(1) 3261(2) 36(1) 
C(3) -317(5) 4322(2) 3218(2) 33(1) 
O(4) -2215(4) 3476(1) 2667(2) 36(1) 
C(4) -771(6) 3667(2) 3301(2) 34(1) 
O(5) 617(4) 2692(1) 3502(2) 37(1) 
C(5) 1159(6) 3288(2) 3289(2) 34(1) 
O(6) 4775(4) 3197(1) 3714(2) 37(1) 
C(6) 2888(5) 3506(2) 3871(2) 32(1) 
C(7) 1142(6) 4582(2) 5343(2) 39(1) 
C(8) 837(6) 5244(2) 5395(2) 40(1) 
C(9) -1103(7) 5486(2) 5477(3) 52(1) 
C(10) -1374(8) 6090(2) 5545(3) 59(1) 
C(11) 279(8) 6468(2) 5528(3) 54(1) 
C(12) 2225(8) 6238(2) 5433(3) 62(1) 
C(13) 2495(7) 5632(2) 5366(3) 51(1) 
C(14) -2043(6) 5259(2) 3090(3) 44(1) 
C(15) -4131(6) 5539(2) 2985(2) 38(1) 
C(16) -5542(6) 5368(2) 2372(3) 41(1) 
C(17) -7389(6) 5664(2) 2245(2) 38(1) 
O(18) -9723(4) 6411(1) 2557(2) 45(1) 
C(18) -7858(6) 6135(2) 2737(3) 38(1) 
C(19) -6504(6) 6304(2) 3354(3) 43(1) 
C(20) -4660(6) 6003(2) 3478(3) 43(1) 
C(21) -10236(7) 6899(2) 3057(4) 64(1) 
C(22) 5274(6) 2686(2) 4212(2) 40(1) 
C(23) 5717(6) 2839(2) 5075(2) 39(1) 
C(24) 4216(7) 2791(2) 5631(3) 45(1) 
C(25) 4619(7) 2968(2) 6417(3) 48(1) 
C(26) 6523(8) 3200(2) 6654(3) 53(1) 
C(27) 8034(7) 3235(2) 6118(3) 52(1) 
C(28) 7635(6) 3059(2) 5334(3) 45(1) 
O(15) -8475(4) 3744(1) 7889(2) 47(1) 
C(30) 7436(7) 7110(2) 10197(3) 52(1) 
O(31) 5697(4) 6058(1) 8903(2) 41(1) 
C(31) 4041(6) 6251(2) 8361(3) 39(1) 
O(32) 1511(4) 5789(1) 9193(2) 42(1) 
C(32) 2254(6) 5823(2) 8406(2) 36(1) 
O(33) -1361(4) 5657(1) 7937(2) 40(1) 
C(33) 416(6) 6025(2) 7869(2) 36(1) 
O(34) -1865(4) 6857(1) 7557(2) 37(1) 
C(34) -235(6) 6653(2) 8095(2) 36(1) 
O(35) 876(4) 7648(1) 8380(2) 39(1) 
C(35) 1566(6) 7087(2) 8089(2) 34(1) 
O(36) 5140(4) 7263(1) 8514(2) 38(1) 
C(36) 3418(5) 6871(2) 8603(2) 34(1) 
C(37) 2592(6) 5386(2) 9734(3) 47(1) 
C(38) 1043(6) 5027(2) 10164(2) 38(1) 
C(39) 1603(7) 4478(2) 10493(3) 47(1) 
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C(40) 243(8) 4148(2) 10918(3) 57(1) 
C(41) -1722(7) 4364(2) 11025(3) 54(1) 
C(42) -2281(7) 4904(2) 10692(3) 52(1) 
C(43) -920(6) 5239(2) 10260(3) 43(1) 
C(44) -1006(6) 5039(2) 7793(3) 48(1) 
C(45) -3015(6) 4704(2) 7842(3) 42(1) 
C(46) -3347(6) 4348(2) 8500(3) 43(1) 
C(47) -5163(6) 4024(2) 8547(3) 45(1) 
C(48) -6649(6) 4050(2) 7923(2) 39(1) 
C(49) -6333(6) 4413(2) 7274(2) 44(1) 
C(50) -4520(6) 4736(2) 7242(3) 43(1) 
C(51) -8834(7) 3354(2) 8541(3) 56(1) 
C(52) 5489(7) 7708(2) 9133(2) 43(1) 
C(53) 5677(7) 7438(2) 9955(3) 44(1) 
C(54) 4055(7) 7471(2) 10467(3) 52(1) 
C(55) 4157(9) 7172(3) 11186(3) 68(2) 
C(56) 5861(10) 6844(3) 11411(3) 70(2) 
C(57) 7512(10) 6812(2) 10923(3) 66(2) 
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Table 3.   Bond lengths ["] and angles [!] for  tesc2. 
O(1)-C(1)  1.437(4) C(10)-C(9)-C(8) 121.1(4) 
O(1)-H(1O)  0.961(19) C(10)-C(9)-H(9A) 119.4000 
C(1)-C(6)  1.517(5) C(8)-C(9)-H(9A) 119.4000 
C(1)-C(2)  1.524(5) C(11)-C(10)-C(9) 120.5(4) 
C(1)-H(1A)  1.0000 C(11)-C(10)-H(10A) 119.8000 
O(2)-C(2)  1.438(4) C(9)-C(10)-H(10A) 119.8000 
O(2)-C(7)  1.439(5) C(10)-C(11)-C(12) 119.4(4) 
C(2)-C(3)  1.538(5) C(10)-C(11)-H(11A) 120.3000 
C(2)-H(2A)  1.0000 C(12)-C(11)-H(11A) 120.3000 
O(3)-C(3)  1.427(4) C(13)-C(12)-C(11) 120.0(5) 
O(3)-C(14)  1.442(5) C(13)-C(12)-H(12A) 120.0000 
C(3)-C(4)  1.511(5) C(11)-C(12)-H(12A) 120.0000 
C(3)-H(3A)  1.0000 C(12)-C(13)-C(8) 121.0(4) 
O(4)-C(4)  1.447(4) C(12)-C(13)-H(13A) 119.5000 
O(4)-H(4O)  0.97(2) C(8)-C(13)-H(13A) 119.5000 
C(4)-C(5)  1.519(5) O(3)-C(14)-C(15) 110.6(3) 
C(4)-H(4A)  1.0000 O(3)-C(14)-H(14A) 109.5000 
O(5)-C(5)  1.436(5) C(15)-C(14)-H(14A) 109.5000 
O(5)-H(5O)  0.97(2) O(3)-C(14)-H(14B) 109.5000 
C(5)-C(6)  1.531(5) C(15)-C(14)-H(14B) 109.5000 
C(5)-H(5A)  1.0000 H(14A)-C(14)-H(14B) 108.1000 
O(6)-C(6)  1.447(4) C(20)-C(15)-C(16) 118.3(4) 
O(6)-C(22)  1.449(5) C(20)-C(15)-C(14) 119.9(4) 
C(6)-H(6A)  1.0000 C(16)-C(15)-C(14) 121.7(4) 
C(7)-C(8)  1.507(6) C(17)-C(16)-C(15) 120.8(4) 
C(7)-H(7A)  0.9900 C(17)-C(16)-H(16A) 119.6000 
C(7)-H(7B)  0.9900 C(15)-C(16)-H(16A) 119.6000 
C(8)-C(9)  1.387(6) C(16)-C(17)-C(18) 119.7(4) 
C(8)-C(13)  1.390(6) C(16)-C(17)-H(17A) 120.2000 
C(9)-C(10)  1.377(7) C(18)-C(17)-H(17A) 120.2000 
C(9)-H(9A)  0.9500 C(18)-O(18)-C(21) 116.6(3) 
C(10)-C(11)  1.373(7) C(19)-C(18)-O(18) 123.9(4) 
C(10)-H(10A)  0.9500 C(19)-C(18)-C(17) 120.4(4) 
C(11)-C(12)  1.384(7) O(18)-C(18)-C(17) 115.6(3) 
C(11)-H(11A)  0.9500 C(18)-C(19)-C(20) 119.5(4) 
C(12)-C(13)  1.382(7) C(18)-C(19)-H(19A) 120.2000 
C(12)-H(12A)  0.9500 C(20)-C(19)-H(19A) 120.2000 
C(13)-H(13A)  0.9500 C(19)-C(20)-C(15) 121.3(4) 
C(14)-C(15)  1.498(5) C(19)-C(20)-H(20A) 119.4000 
C(14)-H(14A)  0.9900 C(15)-C(20)-H(20A) 119.4000 
C(14)-H(14B)  0.9900 O(18)-C(21)-H(21A) 109.5000 
C(15)-C(20)  1.388(6) O(18)-C(21)-H(21B) 109.5000 
C(15)-C(16)  1.396(6) H(21A)-C(21)-H(21B) 109.5000 
C(16)-C(17)  1.380(5) O(18)-C(21)-H(21C) 109.5000 
C(16)-H(16A)  0.9500 H(21A)-C(21)-H(21C) 109.5000 
C(17)-C(18)  1.388(6) H(21B)-C(21)-H(21C) 109.5000 
C(17)-H(17A)  0.9500 O(6)-C(22)-C(23) 113.6(3) 
O(18)-C(18)  1.381(4) O(6)-C(22)-H(22A) 108.8000 
O(18)-C(21)  1.433(6) C(23)-C(22)-H(22A) 108.8000 
C(18)-C(19)  1.377(6) O(6)-C(22)-H(22B) 108.8000 
C(19)-C(20)  1.383(6) C(23)-C(22)-H(22B) 108.8000 
C(19)-H(19A)  0.9500 H(22A)-C(22)-H(22B) 107.7000 
C(20)-H(20A)  0.9500 C(28)-C(23)-C(24) 117.9(4) 
C(21)-H(21A)  0.9800 C(28)-C(23)-C(22) 120.4(4) 
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C(21)-H(21B)  0.9800 C(24)-C(23)-C(22) 121.6(4) 
C(21)-H(21C)  0.9800 C(25)-C(24)-C(23) 120.8(4) 
C(22)-C(23)  1.503(6) C(25)-C(24)-H(24A) 119.6000 
C(22)-H(22A)  0.9900 C(23)-C(24)-H(24A) 119.6000 
C(22)-H(22B)  0.9900 C(26)-C(25)-C(24) 120.1(4) 
C(23)-C(28)  1.389(6) C(26)-C(25)-H(25A) 119.9000 
C(23)-C(24)  1.391(6) C(24)-C(25)-H(25A) 119.9000 
C(24)-C(25)  1.390(6) C(27)-C(26)-C(25) 119.6(4) 
C(24)-H(24A)  0.9500 C(27)-C(26)-H(26A) 120.2000 
C(25)-C(26)  1.382(7) C(25)-C(26)-H(26A) 120.2000 
C(25)-H(25A)  0.9500 C(26)-C(27)-C(28) 120.3(4) 
C(26)-C(27)  1.371(7) C(26)-C(27)-H(27A) 119.8000 
C(26)-H(26A)  0.9500 C(28)-C(27)-H(27A) 119.8000 
C(27)-C(28)  1.386(6) C(27)-C(28)-C(23) 121.1(4) 
C(27)-H(27A)  0.9500 C(27)-C(28)-H(28A) 119.4000 
C(28)-H(28A)  0.9500 C(23)-C(28)-H(28A) 119.4000 
O(15)-C(48)  1.371(5) C(48)-O(15)-C(51) 116.9(3) 
O(15)-C(51)  1.431(5) C(57)-C(30)-C(53) 119.9(5) 
C(30)-C(57)  1.389(7) C(57)-C(30)-H(30A) 120.1000 
C(30)-C(53)  1.402(6) C(53)-C(30)-H(30A) 120.1000 
C(30)-H(30A)  0.9500 C(31)-O(31)-H(31O) 106(4) 
O(31)-C(31)  1.439(5) O(31)-C(31)-C(32) 109.0(3) 
O(31)-H(31O)  0.98(2) O(31)-C(31)-C(36) 108.1(3) 
C(31)-C(32)  1.514(6) C(32)-C(31)-C(36) 110.8(3) 
C(31)-C(36)  1.516(6) O(31)-C(31)-H(31A) 109.6000 
C(31)-H(31A)  1.0000 C(32)-C(31)-H(31A) 109.6000 
O(32)-C(32)  1.434(5) C(36)-C(31)-H(31A) 109.6000 
O(32)-C(37)  1.439(5) C(32)-O(32)-C(37) 116.1(3) 
C(32)-C(33)  1.527(5) O(32)-C(32)-C(31) 112.2(3) 
C(32)-H(32A)  1.0000 O(32)-C(32)-C(33) 105.6(3) 
O(33)-C(33)  1.431(4) C(31)-C(32)-C(33) 111.1(3) 
O(33)-C(44)  1.432(5) O(32)-C(32)-H(32A) 109.3000 
C(33)-C(34)  1.529(6) C(31)-C(32)-H(32A) 109.3000 
C(33)-H(33A)  1.0000 C(33)-C(32)-H(32A) 109.3000 
O(34)-C(34)  1.430(4) C(33)-O(33)-C(44) 114.3(3) 
O(34)-H(34O)  0.962(19) O(33)-C(33)-C(32) 112.9(3) 
C(34)-C(35)  1.525(5) O(33)-C(33)-C(34) 106.3(3) 
C(34)-H(34A)  1.0000 C(32)-C(33)-C(34) 110.3(3) 
O(35)-C(35)  1.436(5) O(33)-C(33)-H(33A) 109.1000 
O(35)-H(35O)  0.98(2) C(32)-C(33)-H(33A) 109.1000 
C(35)-C(36)  1.522(5) C(34)-C(33)-H(33A) 109.1000 
C(35)-H(35A)  1.0000 C(34)-O(34)-H(34O) 112(2) 
O(36)-C(36)  1.438(4) O(34)-C(34)-C(35) 109.4(3) 
O(36)-C(52)  1.454(5) O(34)-C(34)-C(33) 110.2(3) 
C(36)-H(36A)  1.0000 C(35)-C(34)-C(33) 111.6(3) 
C(37)-C(38)  1.506(6) O(34)-C(34)-H(34A) 108.5000 
C(37)-H(37A)  0.9900 C(35)-C(34)-H(34A) 108.5000 
C(37)-H(37B)  0.9900 C(33)-C(34)-H(34A) 108.5000 
C(38)-C(43)  1.380(6) C(35)-O(35)-H(35O) 110(4) 
C(38)-C(39)  1.395(6) O(35)-C(35)-C(36) 109.8(3) 
C(39)-C(40)  1.383(6) O(35)-C(35)-C(34) 107.9(3) 
C(39)-H(39A)  0.9500 C(36)-C(35)-C(34) 112.1(3) 
C(40)-C(41)  1.388(7) O(35)-C(35)-H(35A) 109.0000 
C(40)-H(40A)  0.9500 C(36)-C(35)-H(35A) 109.0000 
C(41)-C(42)  1.378(7) C(34)-C(35)-H(35A) 109.0000 
C(41)-H(41A)  0.9500 C(36)-O(36)-C(52) 116.1(3) 
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C(42)-C(43)  1.395(6) O(36)-C(36)-C(31) 108.4(3) 
C(42)-H(42A)  0.9500 O(36)-C(36)-C(35) 110.0(3) 
C(43)-H(43A)  0.9500 C(31)-C(36)-C(35) 110.8(3) 
C(44)-C(45)  1.514(6) O(36)-C(36)-H(36A) 109.2000 
C(44)-H(44A)  0.9900 C(31)-C(36)-H(36A) 109.2000 
C(44)-H(44B)  0.9900 C(35)-C(36)-H(36A) 109.2000 
C(45)-C(50)  1.369(6) O(32)-C(37)-C(38) 108.9(3) 
C(45)-C(46)  1.390(6) O(32)-C(37)-H(37A) 109.9000 
C(46)-C(47)  1.394(6) C(38)-C(37)-H(37A) 109.9000 
C(46)-H(46A)  0.9500 O(32)-C(37)-H(37B) 109.9000 
C(47)-C(48)  1.388(6) C(38)-C(37)-H(37B) 109.9000 
C(47)-H(47A)  0.9500 H(37A)-C(37)-H(37B) 108.3000 
C(48)-C(49)  1.387(6) C(43)-C(38)-C(39) 118.9(4) 
C(49)-C(50)  1.389(6) C(43)-C(38)-C(37) 121.2(4) 
C(49)-H(49A)  0.9500 C(39)-C(38)-C(37) 119.9(4) 
C(50)-H(50A)  0.9500 C(40)-C(39)-C(38) 121.4(4) 
C(51)-H(51A)  0.9800 C(40)-C(39)-H(39A) 119.3000 
C(51)-H(51B)  0.9800 C(38)-C(39)-H(39A) 119.3000 
C(51)-H(51C)  0.9800 C(39)-C(40)-C(41) 119.7(4) 
C(52)-C(53)  1.508(6) C(39)-C(40)-H(40A) 120.1000 
C(52)-H(52A)  0.9900 C(41)-C(40)-H(40A) 120.1000 
C(52)-H(52B)  0.9900 C(42)-C(41)-C(40) 118.8(4) 
C(53)-C(54)  1.398(6) C(42)-C(41)-H(41A) 120.6000 
C(54)-C(55)  1.382(7) C(40)-C(41)-H(41A) 120.6000 
C(54)-H(54A)  0.9500 C(41)-C(42)-C(43) 121.8(4) 
C(55)-C(56)  1.367(8) C(41)-C(42)-H(42A) 119.1000 
C(55)-H(55A)  0.9500 C(43)-C(42)-H(42A) 119.1000 
C(56)-C(57)  1.388(8) C(38)-C(43)-C(42) 119.4(4) 
C(56)-H(56A)  0.9500 C(38)-C(43)-H(43A) 120.3000 
C(57)-H(57A)  0.9500 C(42)-C(43)-H(43A) 120.3000 
  O(33)-C(44)-C(45) 109.1(3) 
C(1)-O(1)-H(1O) 105(3) O(33)-C(44)-H(44A) 109.9000 
O(1)-C(1)-C(6) 111.0(3) C(45)-C(44)-H(44A) 109.9000 
O(1)-C(1)-C(2) 109.9(3) O(33)-C(44)-H(44B) 109.9000 
C(6)-C(1)-C(2) 109.5(3) C(45)-C(44)-H(44B) 109.9000 
O(1)-C(1)-H(1A) 108.8000 H(44A)-C(44)-H(44B) 108.3000 
C(6)-C(1)-H(1A) 108.8000 C(50)-C(45)-C(46) 118.7(4) 
C(2)-C(1)-H(1A) 108.8000 C(50)-C(45)-C(44) 121.1(4) 
C(2)-O(2)-C(7) 117.0(3) C(46)-C(45)-C(44) 120.2(4) 
O(2)-C(2)-C(1) 112.7(3) C(45)-C(46)-C(47) 121.0(4) 
O(2)-C(2)-C(3) 103.7(3) C(45)-C(46)-H(46A) 119.5000 
C(1)-C(2)-C(3) 109.1(3) C(47)-C(46)-H(46A) 119.5000 
O(2)-C(2)-H(2A) 110.4000 C(48)-C(47)-C(46) 119.5(4) 
C(1)-C(2)-H(2A) 110.4000 C(48)-C(47)-H(47A) 120.3000 
C(3)-C(2)-H(2A) 110.4000 C(46)-C(47)-H(47A) 120.3000 
C(3)-O(3)-C(14) 113.1(3) O(15)-C(48)-C(49) 115.4(4) 
O(3)-C(3)-C(4) 107.5(3) O(15)-C(48)-C(47) 125.1(4) 
O(3)-C(3)-C(2) 112.2(3) C(49)-C(48)-C(47) 119.5(4) 
C(4)-C(3)-C(2) 108.5(3) C(48)-C(49)-C(50) 120.1(4) 
O(3)-C(3)-H(3A) 109.5000 C(48)-C(49)-H(49A) 119.9000 
C(4)-C(3)-H(3A) 109.5000 C(50)-C(49)-H(49A) 119.9000 
C(2)-C(3)-H(3A) 109.5000 C(45)-C(50)-C(49) 121.1(4) 
C(4)-O(4)-H(4O) 127(6) C(45)-C(50)-H(50A) 119.4000 
O(4)-C(4)-C(3) 110.2(3) C(49)-C(50)-H(50A) 119.4000 
O(4)-C(4)-C(5) 109.0(3) O(15)-C(51)-H(51A) 109.5000 
C(3)-C(4)-C(5) 112.4(3) O(15)-C(51)-H(51B) 109.5000 
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O(4)-C(4)-H(4A) 108.4000 H(51A)-C(51)-H(51B) 109.5000 
C(3)-C(4)-H(4A) 108.4000 O(15)-C(51)-H(51C) 109.5000 
C(5)-C(4)-H(4A) 108.4000 H(51A)-C(51)-H(51C) 109.5000 
C(5)-O(5)-H(5O) 103(3) H(51B)-C(51)-H(51C) 109.5000 
O(5)-C(5)-C(4) 107.9(3) O(36)-C(52)-C(53) 112.2(3) 
O(5)-C(5)-C(6) 108.8(3) O(36)-C(52)-H(52A) 109.2000 
C(4)-C(5)-C(6) 112.9(3) C(53)-C(52)-H(52A) 109.2000 
O(5)-C(5)-H(5A) 109.1000 O(36)-C(52)-H(52B) 109.2000 
C(4)-C(5)-H(5A) 109.1000 C(53)-C(52)-H(52B) 109.2000 
C(6)-C(5)-H(5A) 109.1000 H(52A)-C(52)-H(52B) 107.9000 
C(6)-O(6)-C(22) 116.2(3) C(54)-C(53)-C(30) 118.6(4) 
O(6)-C(6)-C(1) 108.2(3) C(54)-C(53)-C(52) 121.0(4) 
O(6)-C(6)-C(5) 109.2(3) C(30)-C(53)-C(52) 120.2(4) 
C(1)-C(6)-C(5) 111.9(3) C(55)-C(54)-C(53) 120.7(5) 
O(6)-C(6)-H(6A) 109.1000 C(55)-C(54)-H(54A) 119.7000 
C(1)-C(6)-H(6A) 109.1000 C(53)-C(54)-H(54A) 119.7000 
C(5)-C(6)-H(6A) 109.1000 C(56)-C(55)-C(54) 120.2(5) 
O(2)-C(7)-C(8) 112.2(3) C(56)-C(55)-H(55A) 119.9000 
O(2)-C(7)-H(7A) 109.2000 C(54)-C(55)-H(55A) 119.9000 
C(8)-C(7)-H(7A) 109.2000 C(55)-C(56)-C(57) 120.4(5) 
O(2)-C(7)-H(7B) 109.2000 C(55)-C(56)-H(56A) 119.8000 
C(8)-C(7)-H(7B) 109.2000 C(57)-C(56)-H(56A) 119.8000 
H(7A)-C(7)-H(7B) 107.9000 C(56)-C(57)-C(30) 120.1(5) 
C(9)-C(8)-C(13) 118.0(4) C(56)-C(57)-H(57A) 119.9000 
C(9)-C(8)-C(7) 121.1(4) C(30)-C(57)-H(57A) 119.9000 
C(13)-C(8)-C(7) 120.9(4)   
Symmetry transformations used to generate equivalent atoms: 
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Table 4.   Anisotropic displacement parameters  ("2x 103) for tesc2.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 U11 U22  U33 U23 U13 U12 
O(1) 30(1)  43(2) 48(2)  -1(1) -2(1)  -1(1) 
C(1) 28(2)  37(2) 42(2)  2(2) -1(2)  2(2) 
O(2) 34(1)  36(2) 38(1)  -1(1) 4(1)  -1(1) 
C(2) 30(2)  28(2) 41(2)  2(2) 8(2)  -4(2) 
O(3) 28(1)  30(1) 49(2)  1(1) 6(1)  2(1) 
C(3) 29(2)  30(2) 42(2)  1(2) 2(2)  1(2) 
O(4) 31(1)  34(2) 41(1)  -2(1) -5(1)  -3(1) 
C(4) 30(2)  34(2) 37(2)  -2(2) -1(2)  1(2) 
O(5) 40(2)  28(2) 43(2)  1(1) 5(1)  -2(1) 
C(5) 26(2)  35(2) 41(2)  -1(2) 5(2)  -1(2) 
O(6) 28(1)  38(2) 47(2)  7(1) 3(1)  5(1) 
C(6) 24(2)  30(2) 41(2)  -1(2) 4(2)  8(2) 
C(7) 44(2)  38(2) 36(2)  -2(2) 2(2)  -3(2) 
C(8) 40(2)  41(2) 39(2)  -5(2) 2(2)  0(2) 
C(9) 38(2)  54(3) 65(3)  -14(2) -1(2)  4(2) 
C(10) 51(3)  55(3) 72(3)  -16(3) 7(2)  14(2) 
C(11) 64(3)  37(3) 61(3)  -8(2) 4(2)  2(2) 
C(12) 58(3)  48(3) 81(4)  -18(3) 8(3)  -8(2) 
C(13) 42(2)  47(3) 65(3)  -12(2) 7(2)  -2(2) 
C(14) 34(2)  34(2) 63(3)  6(2) 7(2)  1(2) 
C(15) 35(2)  32(2) 47(2)  6(2) 3(2)  3(2) 
C(16) 33(2)  35(2) 55(2)  -2(2) 11(2)  5(2) 
C(17) 33(2)  36(2) 46(2)  1(2) 2(2)  -4(2) 
O(18) 35(2)  34(2) 66(2)  -1(1) -4(1)  5(1) 
C(18) 28(2)  32(2) 52(2)  4(2) 0(2)  4(2) 
C(19) 39(2)  41(2) 49(2)  -9(2) 1(2)  1(2) 
C(20) 35(2)  47(3) 47(2)  1(2) -2(2)  4(2) 
C(21) 42(2)  49(3) 102(4)  -23(3) 2(3)  9(2) 
C(22) 36(2)  34(2) 49(2)  8(2) 3(2)  6(2) 
C(23) 40(2)  33(2) 43(2)  4(2) 2(2)  2(2) 
C(24) 39(2)  41(2) 57(3)  5(2) 5(2)  3(2) 
C(25) 43(2)  55(3) 47(2)  4(2) 11(2)  4(2) 
C(26) 63(3)  45(3) 51(3)  2(2) -2(2)  9(2) 
C(27) 48(3)  54(3) 54(3)  13(2) -10(2)  -11(2) 
C(28) 38(2)  48(3) 50(2)  13(2) 3(2)  0(2) 
O(15) 36(2)  47(2) 57(2)  4(1) 1(1)  -2(1) 
C(30) 52(3)  54(3) 49(3)  -9(2) -2(2)  6(2) 
O(31) 28(1)  46(2) 48(2)  2(1) 2(1)  1(1) 
C(31) 34(2)  40(2) 44(2)  0(2) 2(2)  3(2) 
O(32) 36(2)  41(2) 48(2)  12(1) 5(1)  3(1) 
C(32) 32(2)  37(2) 41(2)  1(2) 6(2)  3(2) 
O(33) 33(1)  30(2) 56(2)  0(1) 5(1)  -4(1) 
C(33) 30(2)  36(2) 41(2)  2(2) 5(2)  -4(2) 
O(34) 27(1)  38(2) 46(2)  4(1) 3(1)  0(1) 
C(34) 27(2)  38(2) 42(2)  3(2) 2(2)  1(2) 
O(35) 37(2)  30(2) 50(2)  -1(1) 4(1)  2(1) 
C(35) 28(2)  33(2) 41(2)  0(2) 2(2)  -3(2) 
O(36) 33(1)  39(2) 43(2)  0(1) 3(1)  -6(1) 
C(36) 28(2)  35(2) 39(2)  4(2) 2(2)  -3(2) 
C(37) 37(2)  50(3) 53(3)  11(2) 2(2)  4(2) 
C(38) 38(2)  39(2) 37(2)  6(2) 2(2)  3(2) 
C(39) 45(2)  45(3) 52(2)  4(2) 5(2)  6(2) 
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C(40) 61(3)  47(3) 62(3)  19(2) 12(2)  6(2) 
C(41) 50(3)  63(3) 50(3)  17(2) 8(2)  -3(2) 
C(42) 40(2)  70(3) 46(2)  14(2) 6(2)  5(2) 
C(43) 38(2)  43(3) 49(2)  6(2) 4(2)  2(2) 
C(44) 35(2)  35(2) 75(3)  -9(2) 7(2)  -3(2) 
C(45) 34(2)  31(2) 61(3)  -3(2) 3(2)  -5(2) 
C(46) 37(2)  34(2) 58(3)  -2(2) -2(2)  4(2) 
C(47) 39(2)  46(3) 50(2)  1(2) 1(2)  1(2) 
C(48) 34(2)  36(2) 48(2)  0(2) 5(2)  0(2) 
C(49) 40(2)  50(3) 42(2)  0(2) 1(2)  0(2) 
C(50) 41(2)  43(3) 48(2)  8(2) 10(2)  0(2) 
C(51) 47(3)  47(3) 75(3)  12(2) 5(2)  -12(2) 
C(52) 47(2)  34(2) 46(2)  -2(2) -2(2)  -6(2) 
C(53) 48(2)  35(2) 48(2)  -1(2) -4(2)  -5(2) 
C(54) 46(3)  62(3) 48(3)  -7(2) -1(2)  -8(2) 
C(55) 64(3)  91(4) 47(3)  4(3) -1(2)  -27(3) 
C(56) 95(4)  64(4) 51(3)  9(3) -9(3)  -27(3) 
C(57) 92(4)  44(3) 60(3)  -3(2) -23(3)  9(3) 
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Table 5.  Hydrogen coordinates ( x 104) and isotropic  displacement parameters ("2x 10 3) for 
tesc2. 
 x  y  z  U(eq) 
H(1O) 6070(50) 4380(20) 4090(20) 55(14) 
H(1A) 3743 4248 3243 43 
H(2A) 1506 4942 3877 39 
H(3A) 271 4398 2690 40 
H(4O) -3690(40) 3420(40) 2700(60) 180(40) 
H(4A) -1415 3603 3821 40 
H(5O) 1090(80) 2460(20) 3060(20) 79(17) 
H(5A) 1664 3287 2737 41 
H(6A) 2514 3419 4429 38 
H(7A) 2635 4492 5391 47 
H(7B) 488 4388 5793 47 
H(9A) -2263 5230 5487 63 
H(10A) -2715 6246 5605 71 
H(11A) 89 6885 5582 65 
H(12A) 3375 6497 5414 74 
H(13A) 3835 5477 5299 61 
H(14A) -1294 5313 2597 52 
H(14B) -1243 5457 3532 52 
H(16A) -5227 5044 2037 49 
H(17A) -8334 5547 1824 46 
H(19A) -6833 6624 3692 52 
H(20A) -3737 6116 3909 52 
H(21A) -10300 6761 3608 97 
H(21B) -11578 7062 2873 97 
H(21C) -9182 7209 3030 97 
H(22A) 6492 2484 4009 47 
H(22B) 4107 2403 4170 47 
H(24A) 2900 2635 5472 55 
H(25A) 3585 2928 6792 58 
H(26A) 6782 3335 7186 64 
H(27A) 9360 3380 6284 63 
H(28A) 8692 3090 4967 54 
H(30A) 8573 7092 9866 62 
H(31O) 6820(80) 5940(30) 8570(40) 130(30) 
H(31A) 4521 6259 7805 47 
H(32A) 2698 5419 8236 44 
H(33A) 815 6024 7302 43 
H(34O) -3020(40) 7006(16) 7830(20) 33(10) 
H(34A) -751 6641 8645 43 
H(35O) 1410(90) 7970(20) 8060(30) 100(20) 
H(35A) 1980 7137 7529 40 
H(36A) 3058 6867 9174 41 
H(37A) 3479 5613 10124 56 
H(37B) 3481 5119 9435 56 
H(39A) 2947 4328 10424 57 
H(40A) 652 3774 11135 68 
H(41A) -2665 4145 11322 65 
H(42A) -3629 5052 10758 62 
H(43A) -1341 5610 10035 52 
H(44A) 26 4882 8194 58 
H(44B) -465 4986 7258 58 
H(46A) -2321 4326 8923 52 
H(47A) -5382 3787 9003 54 
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H(49A) -7359 4440 6850 53 
H(50A) -4320 4984 6795 52 
H(51A) -7726 3059 8593 84 
H(51B) -10157 3152 8442 84 
H(51C) -8864 3586 9034 84 
H(52A) 4331 7995 9107 51 
H(52B) 6766 7930 9035 51 
H(54A) 2870 7700 10318 62 
H(55A) 3039 7195 11527 81 
H(56A) 5914 6636 11904 85 
H(57A) 8697 6586 11084 79 
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Table 6.  Torsion angles [!] for tesc2. 
C(7)-O(2)-C(2)-C(1) 76.8(4) C(37)-O(32)-C(32)-C(31) -84.2(4) 
C(7)-O(2)-C(2)-C(3) -165.4(3) C(37)-O(32)-C(32)-C(33) 154.7(3) 
O(1)-C(1)-C(2)-O(2) -70.3(4) O(31)-C(31)-C(32)-O(32) 59.4(4) 
C(6)-C(1)-C(2)-O(2) 51.8(4) C(36)-C(31)-C(32)-O(32) -59.4(4) 
O(1)-C(1)-C(2)-C(3) 175.0(3) O(31)-C(31)-C(32)-C(33) 177.3(3) 
C(6)-C(1)-C(2)-C(3) -62.8(4) C(36)-C(31)-C(32)-C(33) 58.5(4) 
C(14)-O(3)-C(3)-C(4) -172.6(3) C(44)-O(33)-C(33)-C(32) -55.4(4) 
C(14)-O(3)-C(3)-C(2) 68.1(4) C(44)-O(33)-C(33)-C(34) -176.4(3) 
O(2)-C(2)-C(3)-O(3) 61.4(4) O(32)-C(32)-C(33)-O(33) -53.9(4) 
C(1)-C(2)-C(3)-O(3) -178.2(3) C(31)-C(32)-C(33)-O(33) -175.7(3) 
O(2)-C(2)-C(3)-C(4) -57.2(4) O(32)-C(32)-C(33)-C(34) 64.9(4) 
C(1)-C(2)-C(3)-C(4) 63.1(4) C(31)-C(32)-C(33)-C(34) -57.0(4) 
O(3)-C(3)-C(4)-O(4) 59.8(4) O(33)-C(33)-C(34)-O(34) -61.2(4) 
C(2)-C(3)-C(4)-O(4) -178.6(3) C(32)-C(33)-C(34)-O(34) 176.0(3) 
O(3)-C(3)-C(4)-C(5) -178.3(3) O(33)-C(33)-C(34)-C(35) 177.0(3) 
C(2)-C(3)-C(4)-C(5) -56.8(4) C(32)-C(33)-C(34)-C(35) 54.3(4) 
O(4)-C(4)-C(5)-O(5) -66.9(4) O(34)-C(34)-C(35)-O(35) 63.2(4) 
C(3)-C(4)-C(5)-O(5) 170.6(3) C(33)-C(34)-C(35)-O(35) -174.5(3) 
O(4)-C(4)-C(5)-C(6) 172.9(3) O(34)-C(34)-C(35)-C(36) -175.8(3) 
C(3)-C(4)-C(5)-C(6) 50.3(4) C(33)-C(34)-C(35)-C(36) -53.5(4) 
C(22)-O(6)-C(6)-C(1) 141.0(3) C(52)-O(36)-C(36)-C(31) -140.3(3) 
C(22)-O(6)-C(6)-C(5) -97.0(4) C(52)-O(36)-C(36)-C(35) 98.4(4) 
O(1)-C(1)-C(6)-O(6) -62.7(4) O(31)-C(31)-C(36)-O(36) 63.2(4) 
C(2)-C(1)-C(6)-O(6) 175.8(3) C(32)-C(31)-C(36)-O(36) -177.4(3) 
O(1)-C(1)-C(6)-C(5) 176.9(3) O(31)-C(31)-C(36)-C(35) -176.0(3) 
C(2)-C(1)-C(6)-C(5) 55.4(4) C(32)-C(31)-C(36)-C(35) -56.5(4) 
O(5)-C(5)-C(6)-O(6) 71.2(4) O(35)-C(35)-C(36)-O(36) -65.9(4) 
C(4)-C(5)-C(6)-O(6) -169.0(3) C(34)-C(35)-C(36)-O(36) 174.1(3) 
O(5)-C(5)-C(6)-C(1) -168.9(3) O(35)-C(35)-C(36)-C(31) 174.2(3) 
C(4)-C(5)-C(6)-C(1) -49.2(4) C(34)-C(35)-C(36)-C(31) 54.3(4) 
C(2)-O(2)-C(7)-C(8) 68.0(4) C(32)-O(32)-C(37)-C(38) -134.5(4) 
O(2)-C(7)-C(8)-C(9) 69.7(5) O(32)-C(37)-C(38)-C(43) -25.0(6) 
O(2)-C(7)-C(8)-C(13) -110.7(4) O(32)-C(37)-C(38)-C(39) 157.0(4) 
C(13)-C(8)-C(9)-C(10) -1.3(7) C(43)-C(38)-C(39)-C(40) -0.6(7) 
C(7)-C(8)-C(9)-C(10) 178.3(4) C(37)-C(38)-C(39)-C(40) 177.5(4) 
C(8)-C(9)-C(10)-C(11) 0.4(8) C(38)-C(39)-C(40)-C(41) -0.3(7) 
C(9)-C(10)-C(11)-C(12) 0.7(8) C(39)-C(40)-C(41)-C(42) 0.9(8) 
C(10)-C(11)-C(12)-C(13) -0.8(8) C(40)-C(41)-C(42)-C(43) -0.7(8) 
C(11)-C(12)-C(13)-C(8) -0.2(8) C(39)-C(38)-C(43)-C(42) 0.8(6) 
C(9)-C(8)-C(13)-C(12) 1.2(7) C(37)-C(38)-C(43)-C(42) -177.3(4) 
C(7)-C(8)-C(13)-C(12) -178.4(4) C(41)-C(42)-C(43)-C(38) -0.2(7) 
C(3)-O(3)-C(14)-C(15) 168.9(3) C(33)-O(33)-C(44)-C(45) -177.3(3) 
O(3)-C(14)-C(15)-C(20) 120.7(4) O(33)-C(44)-C(45)-C(50) 74.9(5) 
O(3)-C(14)-C(15)-C(16) -62.9(5) O(33)-C(44)-C(45)-C(46) -106.1(4) 
C(20)-C(15)-C(16)-C(17) 1.9(6) C(50)-C(45)-C(46)-C(47) 0.7(6) 
C(14)-C(15)-C(16)-C(17) -174.6(4) C(44)-C(45)-C(46)-C(47) -178.3(4) 
C(15)-C(16)-C(17)-C(18) -0.5(6) C(45)-C(46)-C(47)-C(48) 1.0(6) 
C(21)-O(18)-C(18)-C(19) -0.2(6) C(51)-O(15)-C(48)-C(49) 178.7(4) 
C(21)-O(18)-C(18)-C(17) -179.9(4) C(51)-O(15)-C(48)-C(47) -2.0(6) 
C(16)-C(17)-C(18)-C(19) -0.7(6) C(46)-C(47)-C(48)-O(15) 178.6(4) 
C(16)-C(17)-C(18)-O(18) 179.0(3) C(46)-C(47)-C(48)-C(49) -2.1(6) 
O(18)-C(18)-C(19)-C(20) -179.2(4) O(15)-C(48)-C(49)-C(50) -179.0(4) 
C(17)-C(18)-C(19)-C(20) 0.4(6) C(47)-C(48)-C(49)-C(50) 1.6(6) 
C(18)-C(19)-C(20)-C(15) 1.0(7) C(46)-C(45)-C(50)-C(49) -1.3(6) 
C(16)-C(15)-C(20)-C(19) -2.1(6) C(44)-C(45)-C(50)-C(49) 177.7(4) 
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C(14)-C(15)-C(20)-C(19) 174.4(4) C(48)-C(49)-C(50)-C(45) 0.2(7) 
C(6)-O(6)-C(22)-C(23) -65.3(4) C(36)-O(36)-C(52)-C(53) 54.4(5) 
O(6)-C(22)-C(23)-C(28) -80.1(5) C(57)-C(30)-C(53)-C(54) 1.9(6) 
O(6)-C(22)-C(23)-C(24) 97.2(4) C(57)-C(30)-C(53)-C(52) -173.5(4) 
C(28)-C(23)-C(24)-C(25) 1.1(6) O(36)-C(52)-C(53)-C(54) -103.7(5) 
C(22)-C(23)-C(24)-C(25) -176.2(4) O(36)-C(52)-C(53)-C(30) 71.6(5) 
C(23)-C(24)-C(25)-C(26) 0.6(7) C(30)-C(53)-C(54)-C(55) -1.8(7) 
C(24)-C(25)-C(26)-C(27) -2.4(7) C(52)-C(53)-C(54)-C(55) 173.5(4) 
C(25)-C(26)-C(27)-C(28) 2.5(7) C(53)-C(54)-C(55)-C(56) 0.6(8) 
C(26)-C(27)-C(28)-C(23) -0.7(7) C(54)-C(55)-C(56)-C(57) 0.7(8) 
C(24)-C(23)-C(28)-C(27) -1.1(6) C(55)-C(56)-C(57)-C(30) -0.6(8) 
C(22)-C(23)-C(28)-C(27) 176.3(4) C(53)-C(30)-C(57)-C(56) -0.7(7) 
Symmetry transformations used to generate equivalent atoms: 
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Table 7.  Hydrogen bonds for tesc2  [" and !]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 O(1)-H(1O)...O(3)#1 0.961(19) 1.92(3) 2.815(4) 154(4) 
 O(4)-H(4O)...O(6)#2 0.97(2) 2.08(8) 2.773(4) 127(8) 
 O(5)-H(5O)...O(34)#3 0.97(2) 1.79(2) 2.742(4) 164(5) 
 O(31)-H(31O)...O(33)#1 0.98(2) 1.75(2) 2.729(4) 173(7) 
 O(34)-H(34O)...O(36)#2 0.962(19) 1.80(2) 2.748(4) 169(3) 
 O(35)-H(35O)...O(4)#4 0.98(2) 1.77(2) 2.737(4) 170(6) 
Symmetry transformations used to generate equivalent atoms: 
#1 x+1,y,z    #2 x-1,y,z    #3 -x,y-1/2,-z+1    #4 -x,y+1/2,-z+1 
